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Copper dyshomeostasis has been identified as a pathological feature of Alzheimer’s disease 
(AD) and Niemann-Pick disease type C1 (NPC1), as well as other neurological disorders. 
However, the nature of copper dysregulation in these conditions as well as its impact on 
disease severity and progression remain poorly understood. The growing availability of high-
resolution Positron Emission Tomography (PET) systems and copper radionuclides encourages 
the use of copper radiotracers to measure copper fluxes in a variety of disease states with PET 
imaging.  
 
In this thesis, we investigated copper trafficking at brain and whole-body levels with 64Cu-PET in 
preclinical models of AD and NPC1 disease. The blood-brain barrier-permeable copper-64 
bis(thiosemicarbazone) complex 64Cu-GTSM was used to monitor the retention, efflux and 
redistribution of radiocopper within the brain, while 64Cu-acetate was used to visualise copper 
uptake into organs from blood plasma. In addition to these imaging studies, a new library of 
copper bis(thiosemicarbazone) complexes for potential use in molecular imaging applications, 
including measurement of copper trafficking, was generated. 
 
64Cu-GTSM-PET revealed significant differences in 64Cu brain uptake, regional distribution and 
biokinetics between TASTPM transgenic AD mice and wildtype controls. Interestingly, although 
64Cu-GTSM was taken up by the entire brain, the regions showing the most prominent 64Cu 
accumulation in TASTPM brain tissue did not coincide with the areas most affected by Aβ 
plaque pathology, suggesting that additional metabolic/pathological factors besides Aβ plaque 
deposition influence brain regional 64Cu distribution. 64Cu-acetate-PET indicated subtle but 
significant differences in whole-body 64Cu trafficking between TASTPM transgenic mice and 
healthy controls. Furthermore, 64Cu-GTSM-PET detected substantial differences in brain and 
blood 64Cu concentration between symptomatic NPC1 knockout mice and wildtype controls that 
may have added value for the diagnosis of this disorder. Taken together, these results 
demonstrate the potential of 64Cu-PET as a useful tool to delineate copper trafficking 
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1. Chapter 1- Copper radiopharmaceuticals in nuclear 




The essential nature of copper for most living organisms has long been established. First 
experimental evidence of the biological necessity for copper was provided in 1925 by J. S. 
McHargue in a series of studies on the role of various trace metals in the nutrition, growth and 
development of plants and animals (1, 2). Over the years, the participation of copper in a wide 
range of vital metabolic processes, such as cellular respiration, iron mobilisation, 
neurotransmission, oxygen transport or radical scavenging, has been demonstrated. However, 
many aspects of copper trafficking and metabolism in health and disease remain to be fully 
understood.  
 
The aim of this review is to assess the current state of knowledge on copper biochemistry in 
order to identify important areas of uncertainty that need to be addressed. This is particularly 
critical for the characterisation of changes in the transport and metabolism of copper associated 
with disease. This article will then review the current uses of copper radionuclides and 
radiopharmaceuticals in nuclear medicine and will discuss future directions for application.   
 
1.2 CHEMISTRY OF COPPER 
 
The physicochemical behaviour of copper is governed by many of the characteristics of 
transition metals, such as a high melting point, paramagnetism in compounds with an 
incomplete d sub-shell and the formation of coloured species due to charge transfer or d-d 
electronic transitions. However, the coordination chemistry of this element remains relatively 
straightforward when compared to that of other d-block metals since it is mainly dominated by 




Copper is capable of existing in five different oxidation states (0-IV), with cuprous and cupric 
species predominating. Oxidation states 0 and IV are extremely rare, but the syntheses of 
several stabilised copper (0) and (IV) complexes have been reported (3, 4). Stable copper (III) 
complexes exist only with strong π-donor anionic ligands (e.g. F-, O2-, R2N-, RO-) and exhibit 
very high Cu (III)/Cu (II) redox potentials, which may explain why the copper (III) oxidation state 
has not yet been assigned to any biological redox process (5).  
 
The equilibrium between the most common oxidation states of copper is strongly influenced by 
the medium and may be summarised by the following equation: 
 
                                                  
 
The presence of polarisable, “soft” bases will favour the formation of cuprous compounds, 
whereas the interaction of copper with weakly coordinating, “harder” donor groups will lead to 
the disproportionation of copper (I) into metallic copper and copper (II) species (6). The choice 
of solvent may also affect the relative stability of the copper (I) and (II) oxidation states. 
Because of the higher hydration energy of the copper (II) ion, copper (II) compounds show a 
greater stability in aqueous environments compared to copper (I) complexes. Conversely, 
copper (I) complexes exhibit a higher stability in some non-aqueous solvents (e.g. acetonitrile) 
than copper (II) species (7). In this manner, the nature of the chemical environment influences 
the stability of the copper (I) and (II) oxidation states and ultimately modulates the reducing or 
oxidising power of copper-dependent enzymes. 
 
1.2.1 Copper (I) 
Copper (I) ions display diamagnetic behaviour due to a completely filled 3d sub-shell. The lack 
of d-d electronic transitions renders most copper (I) compounds colourless, except when colour 
results from charge-transfer transitions or from the ligand itself. 
 
Copper (I) exhibits a marked class b Lewis acid behaviour, readily complexing with “soft”, 
coordinating ligands of negligible basicity (e.g. CN-, Cl-, I-, R2S, RS-, R3P) (6). Due to the lack of 
ligand field effects, the copper (I) state is characterised by a flexible coordination geometry, with 
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the preferred coordination number ranging from two to four. Copper (I) complexes can adopt 
linear (e.g. Cu2O, CuCl2), trigonal planar (e.g. KCu(CN)2, [Cu(SPMe3)3]ClO4) and tetrahedral 
(e.g. CuI, [Cu(CN)4]3-) geometries and may even exhibit octahedral coordination (e.g. 
Cu6[S2P(OEt)2]6•2H2O) on rare occasions (7, 8). Since copper (I) complexes show little 
preference for a particular coordination geometry, ligand exchange processes are generally 
rapid, unless they are sterically blocked by the ligand itself.  
 
Copper in the monovalent form is essential in all biological systems, either alone or as the 
copper (II)/copper (I) redox pair. However, the low kinetic stability of copper (I) complexes limits 
considerably their use as radiopharmaceuticals. 
 
1.2.2 Copper (II) 
Copper (II) ions have an unsaturated d9 configuration and, consequently, behave 
paramagnetically, except when the magnetism is quenched by metal-metal interactions. The 
electronic transitions between the d sub-orbitals of the metal ion give most copper (II) 
compounds a blue-green colour. However, intense ligand-to-metal charge transfer transitions 
can cause some copper (II) complexes to appear brown coloured. 
 
Copper (II) complexes strongly favour tetra-, penta- and hexa-coordinate geometries, and are 
characterised by pronounced Jahn-Teller distortion due to the unfilled 3d sub-shell of the metal 
ion. In order to decrease the overall energy of the system resulting from the asymmetric 
distribution of electronic density, the symmetry of copper (II) complexes is reduced by 
elongation of the metal-ligand bonds lying along the z-axis in the case of octahedral 
arrangements, or by tetragonal compression in tetrahedral geometries. As a result, the most 
commonly encountered structures for copper (II) complexes are distorted octahedral (e.g. 
CuCl2, K2[Cu(EDTA)]) and tetrahedral (e.g. Cs2[CuCl4]), as well as square pyramidal (e.g. 
[Cu(NH3)5]2+) and square planar (e.g. CuO) (7).  
 
Copper (II) ions are classified as borderline Lewis acids on the Pearson scale and therefore 
show a preference for weakly polarisable anionic ligands, such as halides (e.g. CuF2, CuCl2), 
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oxoanions (e.g. CuSO4•5H2O, CuCO3) and nitrogen donor groups  (e.g. [Cu(py)4]2+, 
[Cu(NH3)5]2+) (6). 
 
Despite showing higher kinetic stability than copper (I) species, copper (II) complexes are still 
considerably reactive when compared to kinetically inert d3/d6 transition metal chelates.  Non-
bridged and cross-bridged macrocyclic chelators as well as sarcophagine ligands have been 
used to enhance the stability to decomplexation of bioconjugate-based copper 
radiopharmaceuticals (9). However, alternatively, the accessible reduction potential and lability 
of some copper (II) complexes can be exploited to tailor the tissue targeting properties of copper 
radiopharmaceuticals and even to deposit radiocopper into cells to monitor its trafficking (10). 
 
1.3 BIOCHEMISTRY OF COPPER 
 
Copper is the third most abundant trace metal in the human body, after iron and zinc. Ever 
since the generation of an oxidising biosphere, copper has served as an essential catalytic and 
structural cofactor in a wide range of important enzyme-mediated biochemical processes in both 
aerobic and anaerobic organisms.  The redox activity of copper, in the oxidation states I and II, 
has been exploited in catalysis by an array of metalloenzymes that play essential roles in 
energy metabolism, antioxidant protection, blood clotting, signal transduction, iron transport, 
pigmentation, cellular metabolism, oxygen transport, hormone formation and regulation and 
other biochemical functions (11). In proteins and enzymes, copper (I) tends to coordinate to 
cysteine- or methionine-rich domains, whereas copper (II) prefers to bind to aminoacids such as 
histidine, glutamate or aspartate, which contain harder donor groups (N, O) (12). 
 
The importance of copper in many biological functions requires the maintenance of 
physiological copper levels through dietary intake. However, the ability of “free” copper ions to 
displace other metals from their enzymes and their involvement in the generation of reactive 
oxygen species (ROS) demands tight regulation of the copper homeostasis machinery (13, 14). 
The mechanisms that regulate the delicate balance between the essentiality and toxicity of 
copper have been increasingly investigated over the years but are not yet fully understood. 
Copper metabolism imbalance is a key pathological hallmark in a number of human diseases, 
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including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease 
(PD) and Wilson’s (WD) and Menkes (MD) genetic disorders. Therefore, it is essential to 
summarise our current understanding of copper biochemistry in order to identify gaps in our 
knowledge that could provide critical information for detecting and treating diseases associated 
with copper dyshomeostasis.  
 
Figure 1.1 illustrates the mechanisms underlying the intestinal absorption and peripheral 
distribution of copper ions. Dietary copper is initially taken up by intestinal epithelial cells (IECs) 
and incorporated into copper-dependent proteins and enzymes, or transported from the 
intestinal lumen into portal circulation. Copper can be then delivered to the liver for incorporation 
into ceruloplasmin or excreted through the kidneys. From the liver, copper can be mobilised into 
peripheral circulation to be transported to other organs or removed from the body through the 
bile. These biochemical pathways will be described in greater detail in the following sections. 
 
Figure 1.1: Physiological pathways followed by dietary copper. After reduction of dietary copper (II) by an 
unidentified metalloreductase, copper (I) is transported across the apical membrane of IECs by copper (I) 
transporter, Ctr1. Once inside the cell, copper (I) is pumped into the secretory compartments for 
incorporation into copper-dependent enzymes or mobilised across the basolateral membrane into portal 
circulation by copper (I) transporter ATP7A. Once in the bloodstream, excess copper is excreted in urine, 
whereas the rest of the absorbed copper is transported into the liver. In the liver, copper is mainly 
incorporated into the copper-carrier protein ceruloplasmin and mobilized to peripheral tissues. Excess 
hepatic copper is removed through the bile (10, 12).  
 
1.3.1 Dietary copper and gastrointestinal absorption 
Copper is acquired mainly through diet and absorbed by the small intestine after digestion. The 
average amount of copper in the adult human body is approximately 110 mg, most of which is 
found in the liver (10 mg), brain (8.8 mg), blood (6 mg), skeleton (46 mg) and skeletal muscle 
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(26 mg) (15). Dietary copper is mainly found in the cupric state and is tightly bound to specific 
proteins and, to a minor extent, small nutrient molecules. The efficiency of gastrointestinal 
absorption of copper in an adult human oscillates between 55 % and 75 % of the total amount 
ingested and is barely altered by aging (16).  
 
The gastrointestinal absorption of dietary copper and its mobilisation across the intestinal lumen 
into portal circulation occur via different mechanisms. On one hand, the transfer of copper into 
the absorptive cells of the intestinal mucosa is a non-energy-dependent diffusive process. On 
the other hand, the transfer of the absorbed copper across the basolateral membrane of the 
IECs into the bloodstream occurs by saturable, energy-dependent mechanisms, which are 
influenced by dietary copper intake and cellular concentration of other transition metal ions (e.g. 
iron, zinc). The localisation and activity of copper transporters and chaperones varies 
depending on the amount of copper initially absorbed by the IECs (17). 
   
1.3.2 Intracellular copper trafficking 
In humans, dietary copper is transported into cells as copper (I) by the Ctr1 transmembrane 
transporter. This high-affinity copper transporter is generally located in the plasma membrane 
and intracellular vesicles of all cells. A second member of the Ctr family, low-affinity copper-
binding protein Ctr2, has been identified both in yeast and humans but its role in copper 
homeostasis has not yet been defined (11, 18).  
 
The Ctr1 transporter imports copper (I) ions across the apical membrane of intestinal cells into 
the cytosol in association with an unidentified metalloreductase, which is responsible for the 
reduction of dietary copper (II) salts. Once inside the cell, copper (I) ions are transferred from 
Ctr1 to different members of a family of soluble copper handling proteins called copper 
chaperones. The main function of these proteins is to deliver copper (I) ions to specific target 
proteins via direct protein-protein interactions and prevent the metal cargo from accumulating in 
the potentially toxic free ionic form (19).  
 
There are four major copper trafficking pathways in mammalian cells (Figure 1.2). Firstly, the 
Ctr1 transporter can deliver copper (I) ions to the copper chaperone for superoxide dismutase-1 
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(CCS), which in turn shuttles the copper cargo to the free radical-scavenging enzyme Cu/Zn 
superoxide dismutase-1 (Cu/Zn SOD-1). Ctr1 can also transfer its copper payload to the Atox1 
copper chaperone, which subsequently delivers copper (I) to the copper-transporting ATPases 
ATP7B (expressed mainly in the liver and brain) and ATP7A (expressed in all extrahepatic 
tissues) in the trans-Golgi network. ATP7A and ATP7B are responsible for both the 
incorporation of copper (I) ions into copper-dependent enzymes under normal physiological 
copper levels, and the efflux of copper from cells into the bloodstream (ATP7A) or bile (ATP7B) 
in the presence of elevated copper concentrations (20). Furthermore, copper (I) ions can also 
be delivered by copper chaperones into the mitochondrion for incorporation into the electron 
transport chain enzyme cytochrome c oxidase (CCO) and Cu/Zn SOD-1. The underlying 
molecular mechanism by which copper (I) is transferred from Ctr1 into the intermembrane space 
(IMS) of the mitochondrion has yet to be resolved. Once inside the IMS, copper (I) binds to the 
Cox17 metallochaperone and subsequently to the Sco1 and Cox11 proteins, which facilitate the 
formation of the copper centres within each structural subunit of CCO (21). Finally, copper (I) 
ions can be transported by Atox1 and other unknown copper chaperones to the nucleus (22). 
This pathway is particularly important to understand the cytotoxic mode of action of many 
copper-based anticancer drugs. However, very little is known about the identity of the nuclear 
metallochaperones and the regulatory mechanisms involved in the mobilisation of copper ions 
to, from and within the nucleus.  
 




In order to prevent intracellular oxidative stress, unbound copper (I) ions are typically 
sequestered by glutathione or metallothioneins (MTs), which serve as short-term intracellular 
storage sites for excess copper. Glutathione, which is present in high concentrations in the 
cytoplasm, has also been suggested to play a role in copper handling at the entry step since 
depletion of intracellular glutathione stores was found to substantially decrease the initial rate of 
copper uptake into cells (23). 
 
1.3.2.1 Copper entry into cells 
The Ctr1 high affinity copper transporter is the only system responsible for the entry of copper 
ions into eukaryotic cells that has been studied in depth. Electron crystallography studies have 
determined that human Ctr1 is a homotrimer with a cone-shaped pore along its central three-
fold axis where the translocation of copper (I) ions occurs. Each subunit of the trimeric human 
Ctr1 transporter consists of three transmembrane domains (TM1, TM2 and TM3), tightly packed 
in a three-helix bundle. The methionine residues of the MxxxM motif on MT2 have been 
suggested to mediate directly the movement of copper (I) ions across the membrane by 
providing two neighbouring three-coordinate binding sites for the metal (24, 25).  
 
The specificity of the Ctr1 transport system for copper (I) ions suggests the participation of a 
metalloreductase in the process responsible for the reduction of dietary copper (II). Lee et al. 
demonstrated that the uptake of 64Cu in Hek293 mammalian cells increased by 2-fold in the 
presence of the reducing agent ascorbate (26). The mechanism by which the +I oxidation state 
of copper is maintained in the presence of oxygen before the metal ion is transferred to the Ctr1 
transporter has not yet been deciphered. Copper (I) could be stabilised by a specific ligand after 
reduction and the complex could be then transported by Ctr1 across the cell membrane. 
Another mechanism to ensure the efficient delivery of copper (I) ions to the cytosol could involve 
the direct interaction of a cupric reductase with the Ctr1 transporter.    
 
Despite showing a very high specificity for copper (I) ions, it has been shown that Ctr1 also 
mediates the uptake of the chemotherapy drug cisplatin. In a study by Ishida and co-workers, 
Ctr1-knockout mouse and yeast cell lines exhibited enhanced cisplatin resistance and reduced 
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cellular accumulation of the drug. Furthermore, copper was shown to compete with cisplatin for 
Ctr1 in vitro, resulting in reduced absorbed dose of the drug and enhanced cell survival (27).  
 
The nature of the regulatory process that controls the entry of copper (I) ions into cells has not 
yet been resolved. The movement of cuprous ions across the plasma membrane could be 
driven by a concentration gradient, the need for maintenance of metalloenzymatic activity 
(CCO, Cu/Zn SOD-1) or higher copper (I)-binding affinities exhibited by specific intracellular 
components. Petris and co-workers reported a decrease in human Ctr1 surface levels and an 
increased rate of endocytosis of the transporter in HEK293 cells when these were exposed to 
elevated copper levels, indicating the existence of post-translational mechanisms able to 
modulate Ctr1-mediated copper (I) uptake (28).  
 
Ctr1 is thought to be the major factor driving the transport of copper (I) ions across the plasma 
membrane into the cytoplasm but the existence of alternative copper import mechanisms has 
also been suggested. In a study by Nose et al., copper content in IECs was found to be eight 
times greater in IEC-specific Ctr1-knockout mice compared to that in wildtype controls, 
evidencing the existence of alternative copper transport pathways activated under conditions of 
Ctr1 deficiency. However, the fact that significantly reduced copper-dependent enzymatic 
activity was also observed in the IECs of Ctr1-knockout mice seemed to indicate that Ctr1 not 
only mediates gastrointestinal copper absorption but also prevents the hyperaccumulation of 
copper in an unidentified biologically unavailable copper pool in IECs (29).  
 
The divalent metal transporter 1 (DMT1), which plays a major role in intestinal iron uptake, is 
also thought to facilitate copper uptake into cells in specific organ systems (e.g. small intestine) 
and under certain circumstances (e.g. iron deficiency) (30, 31). For example, DMT1 was found 
to increase duodenal copper transport in iron-deficient rats and to enhance copper uptake into 
HEK-293 cells in the presence of an iron chelator (32). Lin et al. recently reported that Ctr1 
levels decreased in umbilical vein endothelial cells in response to increasing concentrations of 
extracellular copper, whereas DMT1 expression increased, suggesting a compensatory role for 




Another member of the Ctr protein family, Ctr2, has been found to mediate copper transport 
from vacuolar stores into the cytosol for subsequent delivery to copper chaperones in yeast 
cells (12). Rees and co-workers demonstrated that the S. cerevisiae Ctr2 protein functions in 
concert with metalloreductase Fre6 and facilitates vacuolar export of copper (I) ions into the 
cytosol (34). Van den Berghe et al. identified the mammalian Ctr2 homologue in the endosomal 
and lysosomal compartments of human cells and showed that the protein stimulated the 
delivery of copper (I) ions to the cytosol at relatively high copper concentrations. In addition to 
this role, it has been suggested that human Ctr2 might also facilitate copper import into cells but 
with a lower affinity compared to Ctr1 (35). 
 
1.3.2.2 Copper delivery into the mitochondria 
Copper is delivered to the mitochondrion primarily for incorporation into CCO, an essential 
metalloenzyme that acts as an electron acceptor in the last step of the respiratory electron 
transport chain. Cox1 and Cox2 are the two mitochondrial-encoded subunits of CCO that 
contain the copper centres that form the CuA and CuB enzymatic sites. Copper (I) ions are also 
transferred by CCS to the Cu/Zn SOD-1 enzyme, which is present in small amounts within the 
IMS in order to protect the mitochondrion from superoxide radicals generated from incomplete 
reduction of oxygen in the electron transport chain (36). However, only a small fraction of the 
total mitochondrial copper content is associated with these metalloenzymes. A stable and 
dynamic copper pool is located within the mitochondrial matrix, mostly in the form of a 
structurally undefined anionic complex. This mitochondrial copper fraction is responsive to 
changes in cytosolic copper levels and guarantees the availability of copper for the metallation 
of CCO and mitochondrial Cu/Zn SOD-1 (37). 
 
The mechanism by which Ctr1-imported copper (I) is transferred from the cytosol to the IMS of 
the mitochondrion is not yet clear. Metallochaperone Cox17 is present both in the cytosol and 
mitochondrial IMS and therefore was initially suggested as a potential candidate for shuttling 
copper (I) ions into the IMS. Nevertheless, Wang and co-workers recently revealed that Cox17 
deficiency in cultured cells significantly increased mitochondrial copper concentration, thus 
precluding this possibility. Interestingly, it was found that CCS-deficient cells showed a 
significant decrease in copper concentration in the mitochondria, suggesting a potential role for 
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this chaperone in the transport of copper (I) ions from the cytosol into the mitochondria. The 
authors additionally reported that although Cox17 appeared not to be responsible for the 
transfer of copper to the mitochondrion, Cox17 deficiency significantly reduced CCO activity in 
cultured cells, evidencing the essential role that this transporter plays in the metallation of CCO 
(38). Cox17 has been shown to act as a specific copper donor to accessory proteins Sco1 and 
Cox11 for the assembly of the CuA and CuB sites of yeast CCO (39). 
 
1.3.2.3 Copper transfer into the trans-Golgi network 
A portion of cytosolic copper (I) is also guided towards the trans-Golgi network, where the 
metallation of several copper-dependent proteins and enzymes occurs. These metalloproteins 
are subsequently directed towards other intracellular organelles for storage or cleared out from 
cells.  
 
The Atx1-like family of copper chaperones plays an essential role in the delivery of Ctr1-
imported copper to the secretory pathway in eukaryotic organisms. The human Atx1 
homologue, Atox1, is a 68-aminoacid polypeptide that contains a conserved cysteine CXXC 
motif for metal binding in the N-terminus. Two Atox-1 molecules are required to coordinate a 
single copper (I) ion, resulting in a distorted tetrahedral metal-protein complex. 
 
Copper (I) ions transported by Atox1 are delivered to the metal-binding domains of the N-
terminus of copper-transporting ATPases ATP7A and ATP7B. In eukaryotic cells, these proteins 
are responsible for the delivery of copper to copper-dependent enzymes, as well as for the 
modulation of cellular copper levels. In elevated copper conditions, ATP7A has been found to 
traffic from the trans-Golgi network to the plasma membrane to mediate copper efflux (40). 
ATP7B has been reported to relocate to vesicular compartments under elevated copper levels 
and might therefore facilitate vesicular sequestration of excess intracellular copper (41).  
 
Human copper (I) ATPases ATP7A (expressed in all extrahepatic tissues) and ATP7B 
(expressed mainly in the liver and brain) consist of eight transmembrane helices, a nucleotide-
binding domain (N-domain), a phosphorylation domain (P-domain) and an actuator domain (A-
domain), that functions to couple ATP hydrolysis with metal ion transport. The N-terminus of 
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human ATP7A and ATP7B is composed of six metal-binding domains, which enclose conserved 
cysteine CXXC sequences, to which copper (I) ions are coordinated (18). Once copper is bound 
to the copper-transporting ATPases, the metal can be transferred into the secretory 
compartment for subsequent incorporation into copper-binding proteins (e.g.lysyl oxidase, 
tyrosinase), transported across the basolateral membrane into portal circulation (ATP7A) or 
excreted into the bile (ATP7B) under elevated copper levels in the case of hepatocytes.  
 
The MT family of proteins can also be found in the membrane of the Golgi apparatus. These 
low-molecular-weight, cysteine-rich proteins exhibit great heavy metal binding capacity and play 
an essential role in copper homeostasis by sequestering and storing copper (I) ions, especially 
under conditions of high intracellular copper levels. The expression of MTs is dependent on 
stress conditions such as heavy metal overload, oxidative stress or exposure to ionising 
radiation. Four MT protein types (MT-1, MT-2, MT-3 and MT-4) predominate in vertebrates, 
acting mainly as short-term stores for excess copper. However, MTs have not been shown to be 
capable of transporting excess copper out of the cell (42).  
 
1.3.2.4 Copper incorporation into Cu/Zn superoxide dismutase-1 
The main function of Cu/Zn SOD-1 is to protect the cell against ROS production, which can 
cause irreversible damage to DNA, lipids and proteins. In eukaryotic organisms, the transport 
protein CCS is responsible for the incorporation of copper (I) into Cu/Zn SOD-1. The CCS 
protein is mainly composed of an N-terminal Atox1-like domain containing a metal-binding site 
(Domain I), a middle domain structurally similar to Cu/Zn SOD-1 (Domain II) that facilitates 
target recognition, and a C-terminus (Domain III) that has not been structurally characterised yet 
(43). The Cu/Zn SOD-1 enzyme possesses a highly conserved intramolecular disulfide bond in 
its structure which is critical for the regulation of enzymatic activity and prevention of protein 
misfolding and aggregation. Furukawa et al. reported that the formation of this disulfide bond in 
yeast Cu/Zn SOD-1 was an oxygen-dependent process, catalysed by the copper-bound form of 
CCS (44). After the formation of the disulfide bond, it has been suggested that the Cu-CCS 
complex forms a heterodimeric complex with the zinc-metallated form of Cu/Zn SOD-1 via the 
Domain III of the CCS protein, from which copper (I) ions are shuttled from Domain I of CCS to 
the Cu/Zn SOD-1 active site (43).  
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CCS expression has been found to be strongly regulated by intracellular copper levels. 
Bertinato and co-workers revealed an increase in CCS levels under conditions of copper 
deficiency in different rodent and human cell lines, as well as a slower rate of protease-
mediated degradation of CCS in copper-deficient cells compared to cells cultured in copper-rich 
medium (45).  
 
The CCS transporter is thought to be predominantly responsible for the incorporation of copper 
into Cu/Zn SOD-1. However, a study performed on tissues from CCS-knockout mice reported 
residual levels of Cu/Zn SOD-1 activity, thus revealing the existence of a CCS-independent 
copper metallation pathway for Cu/Zn SOD-1. The identity of the metallochaperones that 
participate in this CCS-independent mechanism has not yet been established. Carroll et al. 
demonstrated the involvement of the reduced form of glutathione in the CCS-independent 
activation of human Cu/Zn SOD-1 (46). An unidentified CCS-independent metallation pathway 
could also be responsible for the incorporation of copper into the extracellular superoxide 
dismutase (EC-SOD) enzyme, which plays an essential role in the regulation of ROS levels in 
the extracellular space. It has been demonstrated that copper metallation of EC-SOD requires 
the participation of the Atox1/ATP7A pair, which is probably responsible for the transport of 
copper (I) ions across the trans-Golgi network. However, the identity of the chaperone that 
directly transfers copper into the EC-SOD enzyme remains unknown (47).  
 
1.3.3 Copper transport into circulation 
Endogenous copper metabolism is thought to involve two different phases of blood copper 
transport: a first wave, in which, following gastrointestinal absorption, copper binds to serum 
proteins (e.g. albumin, α2-macroglobulin) and aminoacids (e.g. histidine, glutamine, threonine) 
and is transported through the bloodstream into the liver and kidneys; and a second phase, in 
which, after being incorporated into the multi-copper ferroxidase ceruloplasmin in the liver, 
copper re-emerges in the blood plasma to be transported into other tissues (15). A similar fate 
to that of dietary copper has been observed for injected radiocopper. A study conducted by 
Weiss et al. in adult rats injected with copper-67 chloride (67CuCl2) showed immediate 
localisation of ionic radiocopper in the plasma protein fractions (albumin and α2-macroglobulin)  
after injection, followed by an increase in liver and kidney radioactivity at approximately 6 hours 
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and finally the incorporation of 67Cu into ceruloplasmin at 18 hours post-injection (48). A 
different distribution pattern for injected radiocopper was observed in lactating rats, in which 
almost 60 % of a 64Cu/67Cu mixture was taken up by the mammary gland and incorporated into 
milk ceruloplasmin and the exchangeable milk copper pool (49).  
 
The mechanism by which absorbed copper is transferred into hepatocytes is not yet fully 
understood. After its entry into portal circulation, copper is incorporated into an exchangeable 
copper pool, in which the metal is predominantly bound to plasma proteins albumin (68 kDa) 
and α2-macroglobulin (270 kDa). This labile copper pool is in equilibrium with tissue copper and 
is characterised by rapid transfer of copper ions between serum proteins and copper delivery 
from proteins to cells via low molecular-weight intermediates (15). Little is known about how 
copper is transferred from albumin and α2-macroglobulin into cells. Moriya and co-workers 
examined the uptake of albumin- and α2-macroglobulin-bound 64Cu in cultured hepatic and 
mammary epithelial cells and observed that uptake kinetics were different depending on the cell 
type. For example, the delivery of α2-macroglobulin-bound 64Cu into hepatocytes was found to 
involve the Ctr1 transporter, whereas a different transport system was shown to mediate the 
uptake of 64Cu from α2-macroglobulin into mammary epithelial cells (50).  
 
Albumin is the most abundant protein present in the blood plasma and interstitial fluids of 
mammals and participates in the transport of a wide range of substances, from metal ions to 
fatty acids. This plasma protein has a high affinity binding site for copper (II) at the N-terminus, 
as well as a low affinity multi-metal binding site (51). Most of plasma copper is readily 
exchanged between albumin and α2-macroglobulin, leaving a very small fraction bound to 
aminoacids and small peptides. This implies that copper uptake into the liver might be mediated 
by one or both of these proteins. Nevertheless, early research suggested that albumin might not 
play a central role in the delivery of copper from blood plasma to hepatocytes. A study by 
McArdle and co-workers on cultured rodent and human fibroblasts and hepatocytes treated with 
64Cu showed inhibitory effects of albumin on the cellular uptake of radiocopper in the absence 
and presence of histidine (52). Vargas et al. additionally reported that tissue uptake of 67Cu was 
unaffected in analbuminemic rats (53). Albumin could therefore participate in the regulation of 
copper toxicity in blood plasma by binding copper ions and minimising the amount of ionic 
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copper in the “free” form.  
 
Plasma α2-macroglobulin is another protein with high affinity for newly absorbed copper. Despite 
being present in a smaller concentration, this protein exhibits a greater affinity for copper (II) 
than albumin and histidine-rich peptides (54). Copper ions bound to α2-macroglobulin are 
delivered into hepatocytes through a number of small carriers and plasma protein receptors. 
However, the identity of these molecules has not yet been determined.  
 
1.3.4 In the liver 
The second phase of distribution of absorbed copper starts with the entry of the metal ion into 
the liver, where the multi-copper ferroxidase ceruloplasmin is primarily synthesised. After the 
incorporation of copper into ceruloplasmin, this enzyme is released into the bloodstream to 
deliver copper ions to extrahepatic tissues.  
 
As previously mentioned the mechanism by which copper is delivered from blood plasma 
proteins into hepatocytes has not yet been deciphered. Ctr1 is thought to be directly involved in 
the transfer of copper from α2-macroglobulin (but not from other blood proteins) into 
hepatocytes. Kim and co-workers evaluated the contribution of Ctr1 to hepatic copper transport 
using a transgenic mouse model in which Ctr1 was deleted specifically in the liver. Ctr1-
deficient mice exhibited significant growth deficits and reduced hepatic copper concentration. 
Although the activity of copper-dependent enzymes was substantially reduced in the liver, 
copper levels in extrahepatic organs were found to be unaltered, indicating the existence of 
compensatory mechanisms that facilitate copper uptake and retention in the liver under 
conditions of Ctr1 deficiency (55).    
 
The distribution of copper in hepatocytes resembles that observed in IECs. Once inside the cell, 
copper binds to various metallochaperones that deliver the metal  to specific target molecules, 
such as Cu/Zn SOD-1 or CCO. The intracellular concentration of ionic copper is controlled by 




The ATP7B transporter plays a pivotal role in hepatic copper metabolism. A functional 
deficiency of this ATPase in hepatocytes is responsible for the accumulation of copper in the 
liver, which may lead to the development of WD, cirrhosis or other pathological conditions. Both 
ATP7B and Atox1 are components of the transport system that exports copper into the bile 
under conditions of copper overload. The COMMD1 protein is also thought to be involved in this 
mechanism by regulating the activity of ATP7B and its trafficking from the trans-Golgi network to 
vesicular compartments in the cytosol from which copper is thought to be excreted out of the 
cell (56).  
 
ATP7B also facilitates copper incorporation into ceruloplasmin, which is predominantly 
synthesised in the liver but is also expressed in other tissues (e.g. mammary glands, lungs, 
brain, spleen). This enzyme was first discovered and characterised as a copper-containing 
protein by Holmberg and Laurell, who reported the isolation of a 151-kDa blue protein from pig 
serum containing 6-8 atoms of copper per molecule (57). Further research revealed that the 
concentration of ceruloplasmin in human blood plasma and hepatocytes oscillates in a number 
of diseases and hormonal states. Ceruloplasmin deficiency in serum has been observed in 
patients suffering from WD as a consequence of impaired ATP7B-mediated copper trafficking. 
Furthermore, specific mutations in the ceruloplasmin gene are the cause of an autosomal 
recessive disorder known as aceruloplasminemia. This genetic condition exemplifies the 
importance of the ferroxidase activity of ceruloplasmin, which is essential to enable the 
incorporation of iron into transferrin. The absence of ceruloplasmin in the bloodstream leads to 
the accumulation of iron in organs such as the liver, pancreas, spleen or brain (58).  
 
Ceruloplasmin utilises the redox chemistry of copper ions to couple substrate oxidation with the 
complete reduction of dioxygen to water. Human ceruloplasmin has a single polypeptide chain 
structure composed of six compact domains separated by large loop insertions and six tightly 
bound copper atoms. Three copper atoms (type II and type III centres) in the form of a trinuclear 
cluster are coordinated at the interface between the first and the sixth domain of ceruloplasmin 
and constitute the oxygen-binding site of the protein. Additionally, the enzyme contains three 
type I copper centres located at the intra-domain sites along the polypeptide chain which confer 
the blue colour to the protein through ligand-to-metal charge transfer interactions (59).  
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A role for ceruloplasmin in copper transport from the liver to other organs was first supported by 
the discovery of ceruloplasmin plasma membrane receptors in chick aortic and heart tissue (60). 
Ceruloplasmin accounts for 95 % of blood plasma copper and has been shown to deliver 
copper to various cell types (61, 62) However, copper transport to extrahepatic tissues is not an 
exclusive function of this protein. Plasma copper can also be taken up into cells from non-
ceruloplasmin sources, as evidenced by the nearly-unchanged copper levels in extrahepatic 
organs observed in patients suffering from aceruloplasminemia. Research conducted by 
Percival et al. on the uptake of 67Cu-labeled ceruloplasmin by cultured erythroleukemic K-562 
cells revealed the stimulatory effect of ascorbate on the cellular uptake of copper from 
ceruloplasmin. In this study, it was also observed that 67Cu dissociated from ceruloplasmin 
before its entry into the cells since the protein fragment was not detected intracellularly. These 
results suggest that ceruloplasmin might bind to specific protein receptors in the plasma 
membrane which might in turn deliver the copper cargo into cells (63).  
 
Copper delivery from the liver to other tissues is only one of the many biological functions of 
ceruloplasmin. This protein also exhibits ferroxidase activity and plays an essential role in the 
maintenance of iron homeostasis. Osaki et al. first showed that ceruloplasmin stimulated the 
oxidation rate of iron (II), allowing its incorporation into blood plasma transferrin for subsequent 
delivery to extrahepatic organs (64). The importance of ceruloplasmin in iron metabolism was 
also demonstrated by Ragan and co-workers, who reported the effects of injected ceruloplasmin 
on the levels of blood plasma iron in copper-deficient swine. In this study, the intravenous 
administration of ceruloplasmin resulted in a marked increase in plasma iron concentration in 
these animals, suggesting a role for this protein in the transfer of iron from hepatocytes to blood 
plasma (65). The oxidation of ferrous ions and their subsequent transfer into transferrin is 
thought to occur on the surface of ceruloplasmin, which is negatively charged in order to attract 
cationic species. The identity of the iron chaperone proteins that deliver ferrous ions to 
ceruloplasmin remains unknown (66). It has been suggested that iron (II) initially displaces a 
copper atom from a labile metal-binding site on the surface of the protein. After oxidation, ferric 




In addition to the copper-binding sites on the surface of ceruloplasmin associated with its 
ferroxidase activity, this enzyme has another catalytic site involving a cysteine residue (Cys699) 
that displays copper-independent glutathione peroxidase activity. Through this site, 
ceruloplasmin catalyses the reduction of lipid hydroperoxides into alcohols and hydrogen 
peroxide into water in an effort to protect the cell against oxidative damage. Furthermore, 
ceruloplasmin is also capable of oxidising nitric oxide and various aromatic amines and biogenic 
amines, as well as regulating their concentration in blood plasma (59).  
 
1.3.5 Copper-dependent enzymes 
Copper is a key functional component of many enzymes involved in fundamental biological 
processes, such as energy metabolism or ROS scavenging. Some of these cuproenzymes are 
found in all types of cells (Cu/Zn SOD-1, CCO), whereas others are characteristic of specific cell 
types (dopamine β-hydroxylase). The structure and function of the most important copper-
dependent enzymes will be examined in detail in the following sections. 
 
1.3.5.1 Cu/Zn superoxide dismutase-1 
In 1969, McCord et al. first isolated Cu/Zn SOD-1 from bovine erythrocytes and reported its 
inhibiting effect on superoxide-mediated cellular toxicity (67). Further research confirmed that 
Cu/Zn SOD-1 catalysed the dismutation of superoxide radicals into oxygen and hydrogen 
peroxide, which, in turn, was detoxified by the iron-dependent catalase enzyme. Superoxide 
radicals are generated within the cell as a result of the incomplete reduction of oxygen into 
water during aerobic respiration. Uncontrolled generation of ROS can cause irreversible 
oxidative damage to lipids, proteins and DNA, as well as the disruption of several cellular 
signalling mechanisms. Consequently, the superoxide radical scavenging activity of Cu/Zn 
SOD-1 is vital for the protection of most cellular components in aerobic organisms.  
 
In eukaryotic cells, Cu/Zn SOD-1 is a dimeric protein whose active site consists of one catalytic 
copper ion and one structural zinc atom per subunit coordinated by the deprotonated 
imidazolate ring of a histidine residue. The remaining coordination sites for copper are occupied 
by three histidine residues and a water molecule, whereas zinc is coordinated to two histidines 
and one aspartate residue. The characterisation of bovine Cu/Zn SOD-1 purified from 
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erythrocytes revealed that the active copper sites of the enzyme were buried at the bottom of 
two narrow channels within the protein respectively. The positively charged side-chain of an 
arginine residue in the lining of the channel generates an electrostatic gradient that is thought to 
facilitate the diffusion of the superoxide anions through the channel (68, 69). Another structural 
characteristic of mature Cu/Zn SOD-1 is the formation of a kinetically stable disulfide bond 
between cysteine residues Cys-57 and Cys-146 after the incorporation of copper into the zinc-
metallated form of the enzyme. This conserved intramolecular disulfide bond is essential for the 
stabilisation of the structure of Cu/Zn SOD-1 but is also thought to have functional significance 
(70).  
          Figure 1.3: Proposed mechanism of action for Cu/Zn SOD-1 (71). 
 
The proposed mechanism of action for Cu/Zn SOD-1 relies mainly on the redox properties of 
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the copper active site (Figure 1.3). The superoxide radicals are initially directed through the 
narrow channels of the enzyme by the guanidinium groups of the channel-lining arginine 
residues towards the catalytic copper (II) centre, where the radical is oxidised to molecular 
oxygen.  The resulting copper (I) centre dissociates from the protonated imidazolate ring but 
remains bound to the protein. In the second part of the mechanism, the copper (I) complex is 
reoxidised to copper (II) by a second superoxide radical, resulting in the reassembly of the 
enzymatic structure and the production of hydrogen peroxide (71).  
 
The zinc centre in Cu/Zn SOD-1 plays essentially a structural role but its absence severely 
affects the functionality of the enzyme. Roberts and co-workers demonstrated that the loss of 
zinc in Cu/Zn SOD-1 causes a series of structural changes to the enzyme that promote protein 
aggregation and allow better access to the catalytic copper (II) centre to intracellular reductants 
(e.g. glutathione, ascorbate), causing an increase in the production of free radicals. 
 
Cu/Zn SOD-1 malfunction is associated with ineffective management of oxidative stress, which 
is one of the main pathological hallmarks in neurodegenerative disorders. More than 130 
mutations to the Cu/Zn SOD-1 gene resulting in impaired or decreased antioxidant function of 
the enzyme have been linked to the pathogenesis of ALS (72). Moreover, Murakami et al. 
reported significantly increased oxidative stress-mediated Aβ peptide oligomerisation and 
cognitive deficits in a Cu/Zn SOD-1-deficient mouse model of AD when compared to control AD 
mice. In this study it was also revealed that cytoplasmic Cu/Zn SOD-1 levels were significantly 
reduced in brain tissue samples from patients suffering from AD compared to healthy 
individuals, which may indicate a role for cytosolic Cu/Zn SOD-1 in the development and course 
of this disorder (73).  
 
1.3.5.2 Cytochrome c oxidase 
CCO is a transmembrane cuproenzyme found in the mitochondria of eukaryotic cells. This 
enzyme plays an essential role in the last stage of the respiratory electron transport chain by 
catalysing the safe reduction of molecular oxygen to water using electrons delivered by the 
cytochrome c  electron donor. This electron transfer process involves the translocation of four 
protons across the mitochondrial membrane using a proton pumping system to form a water 
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molecule. The exact mechanism underlying this proton pumping process driven by electron 
transfer still remains to be elucidated (74). 
 
CCO is a metalloenzyme of great structural complexity, composed of thirteen different protein 
subunits. The metal content of CCO includes three copper atoms, two iron complexes, one 
magnesium ion and one zinc ion per monomer. A mixed-valence copper dimer (CuA), a 
mononuclear copper (II) centre (CuB) coordinated to a redox-active tyrosine residue, and two 
heme-iron complexes (a/a3) consitute the active site of the enzyme. Electrons are initially 
transferred from the cytochrome c protein to CuA and subsequently delivered to the heme-iron a 
centre, where they are used to reduce the heme-iron a3 complex and CuB. Molecular oxygen is 
then coordinated to the iron (II) and Cu (I) centres, which constitute the oxygen reduction site of 
the enzyme, leading to the formation of a [Fe3+-(OOH-) Cu+] complex. The cleavage of the O-O 
bond through electron transfer from the redox-active tyrosine residue induces the formation of 
[Fe4+=O] and [Cu2+ (H2O)] complexes and the generation of a tyrosyl radical. Finally, four 
reduction steps (tyrosine radical to tyrosine, Fe (IV) to Fe (III), Fe (III) to Fe(II) and Cu (II) to 
Cu(I)) take place coupled to the pumping of four protons across the mitochondrial membrane, 
yielding two water molecules (71, 75). CCO is located on the inner mitochondrial membrane 
and contains two aqueous-exposed surfaces facing the mitochondrial matrix and the IMS, 
respectively. The oxygen reduction site of the enzyme is coordinated to the IMS hydrophilic 
surface by a number of hydrogen bonds through which protons are delivered for the formation 
of water molecules (76). 
 
Research conducted by Pan et al. on isolated bovine CCO revealed that zinc plays mainly a 
structural role since removal of the metal by mercuric chloride treatment did not alter the steady-
state activity of CCO (77). Further research is required in order to determine the role of the 
magnesium centre in the mechanism of action of CCO. 
 
The vital role of CCO in the last part of aerobic respiration makes this metalloenzyme 
indispensable for cell survival. A rare autosomal recessive disorder known as CCO deficiency 
characterised by degeneration of the brain stem and basal ganglia and lactic acidosis has been 
identified (78). Reduced CCO activity has been observed in isolated mitochondria from platelets 
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of AD patients when compared to healthy individuals, and this decrease has been correlated 
with reduced ATP levels and enhanced ROS concentration (79).     
 
1.3.5.3 Lysyl oxidase  
Cuproenzyme lysyl oxidase (LOX) plays an essential role in the biosynthesis of collagen and 
elastin, which are the main structural components of the extracellular matrix of connective tissue 
in vertebrate organisms. The main biological function of LOX is the catalysis of the post-
translational oxidative deamination of peptidyl lysine to generate peptidyl aminoadipic 
semialdehyde, ammonia and hydrogen peroxide (Figure 1.4) (17).  
 
Figure 1.4: LOX-catalysed oxidative deamination of lysine ε-amino groups. 
 
The aldehyde group of the resulting product can subsequently condense with the amino group 
of a neighbouring lysine residue or react with another peptidyl aminoadipic semialdehyde to 
form essential cross-linkages for the stabilisation of collagen fibres and the insolubilisation of 
elastin. The deamination of lysine ε-amino groups can also be catalysed by other amine 
oxidases but LOX-mediated catalysis is specific for lysine side-chains in collagen and elastin 
substrates. A number of studies have reported the participation of LOX in other cellular 
processes, such as cell signalling, proliferation or migration. 
 
Pro-protein LOX is secreted in the extracellular space and activated upon proteolytic cleavage. 
The catalytic cofactors of this cuproenzyme are a copper (II) ion and a lysine tyrosylquinone 
prosthetic group. LOX has been principally detected in the extracellular space of different tissue 
cells (e.g. epithelial, cardiac, hepatic) but it has also been localised inside the nuclei of vascular 
smooth muscle cells and fibroblasts (80). 
 
LOX expression has been reported to be regulated by hypoxia-inducible factors in various 
cancer cell lines. Research conducted by Erler et al. with patients affected by breast and head 
and neck cancer showed a significant correlation between the level of LOX expression in cancer 
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cells and the degree of tumour hypoxia. In the same study, it was also demonstrated that 
enhanced levels of LOX expression in cancer cells were associated with decreased distant 
metastasis-free survival and poor prognosis. Furthermore, Erler and co-workers also 
demonstrated that treatment of breast tumour-bearing mice with LOX inhibitor β-
aminopropionitrile reduced significantly the formation of metastases (81). Nonetheless, other 
studies have linked LOX expression to tumour suppression. Kaneda et al. revealed the 
presence of silenced forms of LOX genes in gastric cancer cells that promoted an increase in 
tumour growth in vivo when compared with tumour-bearing mice expressing activated LOX 
genes (82). The role of LOX in tumorigenesis and its potential as a molecular target for cancer 
therapy remain to be further investigated. 
 
1.3.5.4 Dopamine β-hydroxylase 
Dopamine β-hydroxylase (DβH) is one of the most important cuproenzymes in the human brain, 
although little is known about its mechanism of action. This copper-dependent enzyme 
catalyses the monooxygenation of neurotransmitter dopamine to noradrenaline, which is the 
precursor of adrenaline (Figure 1.5). The synthesis of noradrenaline requires also the 
participation of molecular oxygen as electron acceptor and ascorbic acid as an electron donor. 
Secondary products of this reaction are a water molecule and dehydroascorbic acid.  
 
Figure 1.5: Synthesis of noradrenaline catalysed by DβH (83). 
 
The structure of DβH consists mainly of four subunits stabilised by intermolecular disulfide 
linkages into two dimers. Each protein subunit contains two copper atoms, giving a total number 
of eight copper atoms per enzyme molecule. The enzyme is mainly found in the chromaffin 




Noradrenaline depletion in the CNS is the main pathological feature of a rare genetic disorder 
known as DβH deficiency. Although DβH deficiency does not cause significant cognitive 
impairment, DβH-deficient patients show acute hypotension, noradrenergic failure and drooping 
or falling of the eyelids (85). Reduced DβH activity has also been detected in patients suffering 
from AD (86). 
 
1.3.5.5 Tyrosinase 
Tyrosinase is a multi-copper oxygenase that plays an essential role in the biosynthesis of the 
melanin pigment. Tyrosinase catalyses the hydroxylation of monophenols into o-diphenols and, 
subsequently the conversion of o-diphenols into o-quinones, using in both cases molecular 
oxygen as the electron acceptor. The catalytic domain of tyrosinase consists of two copper 
centres, each bound to three histidine residues. The remaining coordination sites for both 
copper atoms are occupied during the catalytic process by the molecular oxygen molecule and 
the phenolic substrate. The structure of the metalloenzyme is stabilised by a number of disulfide 
bonds. Mutant forms of human tyrosinase have been linked to genetic disorders, such as 
oculocutaneous albinism (87).  
 
1.4 RADIOCHEMISTRY OF COPPER 
 
1.4.1 Copper radionuclides: physical properties and production methods 
The wide range of half-lives and decay modes of copper radioisotopes along with their 
accessible coordination chemistry offer many opportunities for the development of 
radiopharmaceuticals for a variety of diagnostic and therapeutic applications. Table 1.1 lists the 







Table 1.1: Physical properties of copper radioisotopes used for diagnostic imaging and therapy (10, 88, 
89) 
 
a β+= Positron emission, EC = Electron capture, β- = Beta decay; b Average energy of radiation; c Average range of 
radiation in tissue; PET = positron emission tomography; SPECT = single-photon emission computed tomography 
 
 
Each of these copper radionuclides displays a unique set of physical properties (half-life, decay 
mode, positron range) that make it more or less suitable for a given nuclear medicine 
application. Long-lived 67Cu (t1/2 = 2.6 d) and 64Cu (t1/2 = 12.7 h) are attractive candidates for the 
radiolabelling of biomolecules with slow targeting kinetics (e.g. peptides, proteins, antibodies) 
for both diagnostic and therapeutic purposes, whereas the shorter half-lives of 60Cu (t1/2= 23.7 
min) and 62Cu (t1/2= 9.8 min) make them more suitable as labels of smaller tracer molecules 
(90). The rapid physical decay of 60Cu and 62Cu considerably restricts the duration of the 
radiosynthesis process but also allows the possibility of performing repeated scans on the same 
individual and even dual tracer imaging. The 3.3-h half-life of 61Cu provides the flexibility to 
image both small tracers and moderately large biological molecules, as well as native copper 
transport processes (91, 92). 
 
Although physical half-life remains a major limiting factor, other decay characteristics also have 
an impact on the imaging performance of copper radionuclides and their use in medical imaging 
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resolution that becomes more severe for higher-energy positron emitters. PET imaging with 
60Cu and 62Cu radiotracers will consequently result in a poorer spatial resolution when 
compared to 64Cu radiopharmaceuticals, which provide a positron range effect similar to that of 
18F. Conversely, 64Cu has the lowest positron yield (18 %) among all copper radioisotopes, 
which contributes to a loss in image contrast due to poorer counting. However, the long half-life 
of this radionuclide allows for extended imaging time windows to compensate for its lower 
counting statistics. Short-lived radioisotopes 60Cu and 62Cu have positron decay fractions close 
to unity (0.93 and 0.98, respectively) and therefore require lower activity doses and shorter scan 
times than 64Cu tracer molecules. From all copper PET radionuclides, 61Cu achieves the best 
balance between spatial resolution and sensitivity, with moderate positron energy and a 62 % 
positron yield. The radiation burden associated with this radioisotope is comparable with that of 
the widely used PET radiotracer 18F‐fluorodeoxyglucose (18F-FDG), but is considerably higher 
when compared to the effective dose resulting from PET imaging with shorter-lived 60Cu and 
62Cu. 64Cu provides the highest radiation dose from all copper PET radionuclides, mainly due to 
its prolonged half-life and beta particle emissions (93).  
 
Of all copper radionuclides, 64Cu is considered the most versatile since it combines three 
different types of physical decay – positron emission (18 %), beta decay (39 %) and electron 
capture (43 %) – and can therefore be used both for diagnostic imaging (positron emission) and 
targeted radiotherapy (beta particle and Auger electron emission). This singular characteristic 
offers the possibility of using PET imaging in the assessment of radiation dosimetry when 
planning targeted radionuclide therapies with 64Cu radiopharmaceuticals. The decay scheme of 
the longest-lived copper radioisotope 67Cu (beta particle and gamma emission) also allows pre-
therapy diagnostic imaging (by SPECT), and was initially regarded as well suited for 
radioimmunotherapy applications (10). Nevertheless, despite the large number of cyclotron- and 
reactor-based production methods reported (94), the development and clinical use of 67Cu 
radiopharmaceuticals is still hindered by unreliable supply, low production yields and a wide 
variety of radionuclide impurities (e.g. 62Zn, 67Ga, 65Zn, 55Co, 58Co, 57Ni) (95). 
 
Despite the long-lasting interest of the nuclear medicine community in the development of 
copper radiopharmaceuticals, the clinical translation of these agents is often hampered by 
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limited radionuclide supply, which still relies mostly on academic institutions. The availability of 
the majority of copper radionuclides (60Cu, 61Cu, 64Cu and 67Cu) is principally restricted by 
access to cyclotron or reactor facilities and overall production cost. In this scenario, the 
62Zn/62Cu generator has the potential to provide widespread and cost-effective clinical access to 
the short-lived 62Cu radionuclide, thus enabling the clinical evaluation of a range of small 
molecule radiotracers with relatively low radiation doses to patients (96-98). The 9.3-h half-life 
of the 62Zn parent isotope allows delivery of the generator system to clinical sites without an in-
house cyclotron and the possibility of performing multiple elutions per day. Nonetheless, the 
rapid physical decay of 62Cu makes cyclotron/reactor-based production of longer-lived copper 
radioisotopes a necessity.  
 
Non-carrier added 60Cu, 61Cu, 62Cu and 64Cu can be produced in high yield and specific activity 
via proton (p,n) or deuteron (d,2n) bombardment of nickel-enriched solid targets (60Ni, 61Ni, 62Ni 
and 64Ni, respectively) (91, 99-101). In the case of 61Cu and 64Cu, the elevated cost of the 
parent radionuclide has led to the investigation of different cyclotron-based production routes, 
such as proton or deuteron irradiation of zinc solid targets (e.g. 64Zn, 66Zn, 68Zn) (102-105). High 
specific activity 64Cu can alternatively be produced by the 64Zn(n,p)64Cu reaction in a nuclear 
reactor. Although good yields are reported using this production method, the limited availability 
of nuclear reactors along with the co-production of high amounts of 65Zn restrict large-scale 
production of 64Cu via this route (106). Therapeutic quantities of 67Cu can be produced on high 
energy accelerators by the 68Zn(p,2p)67Cu reaction or bombardment of 67Zn with neutrons in 
high flux reactors. However, both of these routes are economically unfeasible and produce a 
large number of radionuclidic impurities, thus requiring long and complex purification processes. 
67Cu can additionally be produced in high radionuclidic purity by the 70Zn(p,α)67Cu reaction 
using a low energy proton beam or the photonuclear reaction 68Zn(γ,p)67Cu on electron 
accelerators. Nevertheless, the product yields of these routes need to be further validated to 
determine whether the proposed methods are viable production options for 67Cu (90, 94, 107, 
108). In addition to cost and accessibility, the extensive presence of copper in the environment 
remains a major challenge in the production of all copper radioisotopes since it frequently 




1.4.2 Copper radiopharmaceuticals in nuclear medicine 
Copper radionuclides were first used as research tools to investigate the uptake, biodistribution 
and trafficking of endogenous copper in living organisms (109-111). However, these 
radioisotopes soon became increasingly attractive to the nuclear medicine community due to 
their wide array of half-lives and decay schemes, amenable coordination chemistry and 
potential for application in the development of diagnostic, therapeutic and theranostic 
radiopharmaceuticals. Interest in copper radionuclides has peaked in recent years mostly due to 
the development of the 62Zn/62Cu generator system and the versatility of the copper 
bis(thiosemicarbazone) (Cu-BTSC) family of radiotracers, which have demonstrated great 
potential for delineating blood flow and tissue hypoxia. This last section of the review 
summarises current developments in copper radiopharmaceuticals in the field of diagnostic 
imaging, ranging from copper-labelled bioconjugates to small tracer molecules and plain copper 
salts. 
 
1.4.2.1 Copper-labelled bioconjugates 
The long-lived 64Cu and 67Cu radioisotopes are well suited to the slow kinetics of many 
molecular targeting agents (e.g. peptides, antibodies, proteins), and have been therefore 
extensively utilised for radiolabelling biological molecules with a variety of bifunctional chelators. 
The primary focus of the development of copper-labelled bioconjugates is on oncology 
applications, with most radiopharmaceuticals targeting somatostatin, integrin, bombesin and 
epidermal growth factor receptors (112).  
 
The principal challenge in the design of copper-labelled bioconjugates is to achieve sufficient 
kinetic stability to prevent copper decomplexation in vivo, since the most common oxidation 
states for copper (I and II) are relatively labile and consequently the ligand may not be able to 
retain the metal ion in the presence of endogenous copper-binding proteins. Transchelation of 
copper by native proteins generally results in prolonged recirculation of the radiocopper in 
blood, increased non-specific uptake and retention of copper in the liver and excretion of 
radiocopper by the gut, which is problematic when imaging the abdomen. Moreover, copper-
labelled bioconjugates should also exhibit high thermodynamic stability and form under mild 
reaction conditions, compatible with the biomolecule of choice. Figure 1.6 shows the chemical 
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Figure 1.6: Structures of bifunctional chelators for copper radiopharmaceuticals. A) 
diethylenetriaminepentaacetic acid (DTPA); B) ethylenediaminetetraacetic acid (EDTA); C) diacetyl bis(N4-
methylthiosemicarbazone) (H2-ATSM); D)  1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA); E) 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA); F) 1,4,7-
triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA); G) 1,4,7-triazacyclononane-1,4,7-triacetic 
acid (NOTA); H) 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A); I) 11-
carboxymethyl-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4-methanephosphonic acid (CB-TE1A1P); J) 1-
N-(4-aminobenzyl)-3,6,10,13,16,19-hexaaza-bicyclo-[6.6.6]eicosane-1,8-diamine (sarAr); K) (1-NH2-8-
NHCO(CH2)3CO2H)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane (sar-CO2H); L) 3,6,9,15-




Acyclic polyaminocarboxylate ligands, such as DTPA (Figure 1.6.A) or EDTA (Figure 1.6.B), 
were initially evaluated for use in the radiolabelling of biological molecules but the resulting 
radiochelates demonstrated poor serum stability in vitro (113, 114). The potential of 
bis(thiosemicarbazone) (BTSC) ligands as bifunctional chelators has also been investigated, 
although these chelators are more frequently used for the development of copper-based small-
molecule radiotracers (see section 1.2.2.4). Hueting et al. reported the synthesis and 64Cu 
radiolabelling of a carboxylate functionalised BTSC ligand conjugated to a bombesin derivative 
with high affinity for the gastrin-releasing peptide receptor, which is overexpressed in many 
cancers. The radiolabelled bioconjugate exhibited good tumour uptake in nude mice with PC-3 
xenografts at early imaging time points but also high kidney and liver accumulation, probably 
indicating some extent of demetallation in vivo (115). Paterson and co-workers synthesised a 
series of bifunctional derivatives of the H2-ATSM ligand (Figure 1.6.C) and used these for the 
radiolabelling of the tumour targeting BBN(7-14)-NH2 bombesin derivative with 64Cu. Although 
the radiolabelled conjugates proved to be stable in the presence of excess cysteine and 
histidine in aqueous solution, no in vivo biodistribution data was reported (116).  
 
To date, the most widely used chelators for the radiolabelling of biomolecules with copper 
radioisotopes are tetraazamacrocyclic ligands with functionalised pendant arms (e.g. DOTA 
[Figure 1.6.D], TETA [Figure 1.6.E]). Because of their ability to adopt pre-organised 
conformations in the free form, these chelators form kinetically and thermodynamically more 
stable copper (II) complexes than acyclic ligands. DOTA remains the most frequently used 
copper chelator, mainly due to its mild reaction conditions, commercial availability and Food and 
Drug administration approval (9). Although copper-labelled DOTA bioconjugates generally 
display good pharmacokinetics and imaging properties (117), the stability of these complexes in 
vivo has been questioned. McQuade and co-workers reported a higher degree of non-specific 
uptake of the 64Cu-DOTA-ReCCMSH(Arg11) conjugate relative to its 86Y-labelled analogue in 
mice implanted with B16/F1 murine melanoma cells (118). When comparing the in vivo imaging 
performance of 64Cu-radiolabelled DOTA and NODAGA-immunoconjugates (NODAGA: Figure 
1.6.F) for the detection of epithelial cell adhesion molecule expression in a prostate cancer 
model, Ghosh et al. found lower blood retention and increased liver, prostate and pancreas 
accumulation of the DOTA bioconjugate, indicating some extent of 64Cu transchelation (119). 
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Copper-radiolabelled TETA bioconjugates have also proved to be susceptible to copper (II) 
exchange processes in vivo. Bass and co-workers demonstrated the formation of [64Cu] Cu/Zn 
SOD-1 in the liver of Sprague-Dawley rats 20 h after injection of 64Cu-TETA-D-Phe1-octreotide 
(120). Among all non-bridged macrocyclic bifunctional chelators, NOTA (Figure 1.6.G) is 
possibly the most promising for the radiolabelling of biological molecules with radiocopper (117). 
Prasanphanich et al. developed the 64Cu-NOTA-8-Aoc-BBN(7-14)NH(2) targeting vector which 
showed very high affinity for the gastrin-releasing peptide receptor overexpressed in tumour-
bearing PC-3 mice and excellent in vivo stability at 1 h post-injection (121). Liu and co-workers 
compared the in vivo stability of a 64Cu-radiolabelled E. coli heat-stable enterotoxin analogue 
conjugated to DOTA, TETA and NOTA chelating moieties. Results from PET imaging and ex 
vivo biodistribution in SCID mice bearing T84 human colorectal cancer xenografts demonstrated 
significantly higher tumour/non-target tissue ratios at 1 h post-injection for the 64Cu-labelled 
NOTA conjugate when compared to the DOTA and TETA analogues (122). 
 
In order to improve the in vivo stability of copper-labelled bioconjugates, cross-bridged 
macrocyclic chelators have been increasingly investigated. The CB-TE2A ligand (Figure 1.6.H) 
is able to form copper (II) complexes of exceptional in vivo stability, and has been used to 
radiolabel bombesin, somatostatin and RGD analogues (123-126). Nevertheless, the 
preparation of copper-labelled CB-TE2A conjugates requires relatively harsh reaction conditions 
(e.g. 2 h at 95 °C) that are generally not compatible with most molecular targeting agents (127). 
The CB-TE1A1P chelator (I) has emerged as an effective alternative to CB-TE2A since it 
enables 64Cu radiolabelling with high specific activity under mild reaction conditions (e.g. 1 h at 
40 °C). 64Cu-labeled CB-TE1A1P somatostatin and integrin α4β1-targeting peptides 
demonstrated faster blood clearance, higher tumour-to-blood ratios and lower uptake in non-
target tissues in tumour-bearing small animals than their corresponding CB-TE2A analogues 
(128, 129). 
 
The potential of hexaaminemacrobicyclic cage amine ligands -also known as sarcophagines- as 
bifunctional chelators for the radiolabelling of biomolecules with copper isotopes was first 
explored by Bartolo and co-workers. This group reported that the sarAr chelator (Figure 1.6.J) 
allowed rapid 64Cu radiolabelling of whole and fragmented B72.3 antibody with high specific 
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activity under mild reaction conditions (5 min at 20 °C). Ex vivo biodistribution in nude mice 
bearing LS174t tumours additionally demonstrated high target specificity and in vivo stability for 
all the investigated sarAr-radioimmunoconjugates (130). Moreover, Cooper et al. reported a 
good balance between mild 64Cu labelling conditions (20 min at room temperature) and 
excellent in vivo stability for the sar-CO2H-Rituximab conjugate (sar-CO2H: Figure 1.6.K), which 
outperformed that of its DOTA, DTPA and PCTA (Figure 1.6.L) analogues (117). The 
development of sarcophagine-based chelators for the radiolabelling of molecular targeting 
agents with copper radioisotopes remains a highly productive research area (131-133). 
 
1.4.2.2 Copper-labelled nanoparticles 
The long half-life and suitable imaging properties of 64Cu have also been exploited to develop 
multifunctional nanoparticles for targeted drug delivery and dual-modality imaging (e.g. PET/ 
magnetic resonance imaging [MRI], PET/ near-infrared fluorescence [NIRF]). The high surface 
area per unit volume of nanoparticulate materials allows the conjugation of a large number of 
targeting ligands and bifunctional chelators, thus enhancing the affinity and specific activity of 
the tracer (112). As with 64Cu-radiolabelled bioconjugates, the choice of the bifunctional chelator 
is essential to reduce copper transchelation to native copper-binding proteins and ensure 
sufficient delivery of the probe to the target site. Size and lipophilicity are also critical for tuning 
the biodistribution and pharmacokinetics of nanoparticles in vivo, and in particular, for 
minimising early clearance of the agent by the mononuclear phagocyte system. The latter 
difficulty is exemplified by a study by Cai et al. who evaluated a novel 64Cu-radiolabelled 
quantum dot probe, modified with arginine-glycine-aspartic acid peptides and DOTA ligands, 
targeting αvβ3 integrin receptors. Although the probe exhibited selective targeting of the 
vasculature of αvβ3 positive tumours, minimal extravasation into solid tumour tissue was 
observed and most of the tracer was taken up by the liver, spleen and bone marrow (134). 
Rossin and co-workers conjugated DOTA chelators to nanoparticles targeting the pulmonary 
endothelium with monoclonal antibodies, and observed high lung uptake of the 64Cu-
radiolabelled probe in wildtype mice even at late imaging time-points. However, the results of 
this study revealed increasing loss of the radiometal over time as well as prominent early tracer 
uptake in spleen and liver (135). In order to improve the in vivo stability of nanoparticle-based 
probes, de Rosales et al. suggested direct labelling of the inorganic surface of the particle 
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instead of its polymeric coating using dithiocarbamate-bisphosphonate ligands. The dual 
modality PET/MR agent radiolabelled with 64Cu following this methodology showed excellent in 
vivo stability and targeting properties and great potential to image draining lymph nodes (136). 
Petersen and co-workers reported an alternative method to reduce copper transchelation in vivo 
consisting in remote 64Cu loading into pre-formed DOTA-containing liposomes using 2-
hydroxyquinoline chelators. The probe was evaluated in a mouse model of colon 
adenocarcinoma and demonstrated great kinetic inertness, prolonged blood circulation and 
good tumour-to-muscle ratios (137). 
 
1.4.2.3 Copper dithiocarbamates 
Although the chemistry and biological activity of copper (II) dithiocarbamate (Cu-DTC) 
complexes have been extensively investigated, their use as radiopharmaceuticals for medical 
diagnosis has been somewhat neglected when compared to other copper-based small-molecule 
radiotracers. The reason for this is that, although dithiocarbamate ligands are able to form 
neutral copper (II) chelates (2:1, ligand-metal) in high yield under mild reaction conditions, the 
resulting complexes exhibit relatively poor in vivo stability, which considerably limits their use as 
imaging agents (138). 
                                     
 
        
Figure 1.7: Structures of Cu-DTC complexes. A) copper (II) diethyldithiocarbamate (Cu-(DEDTC)2); B) 
copper(II) dimethyldithiocarbamate (Cu-(DMDTC)2); C) copper (II) diisopropyldithiocarbamate (Cu-
(DPDTC)2). 
 
Because of their lipophilic nature and small size, Cu-DTCs are able to enter the cell by passive 
diffusion. Once inside the cell, these copper (II) complexes are thought to undergo bioreduction 
and metal-ligand dissociation in a similar manner as Cu-BTSC complexes (see section 1.4.2.4) 
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(139). Intracellular trapping of Cu-DTCs offers the possibility of using these complexes to 
incorporate non-selectively a 64Cu label into cells for cell-tracking applications. Charoenphun et 
al. evaluated the feasibility of this approach by testing the cell labelling efficiency of a series of 
64Cu-DTC complexes (64Cu-(DEDTC)2, 64Cu-(DMDTC)2 and 64Cu-(DPDTC)2; Figure 1.7) in a 
J774 mouse macrophage cell line. Although the complexes exhibited different cellular uptake 
kinetics, the washout rate for all of them was found to be very similar, with ~65 % of 64Cu 
radioactivity clearing out of cells over 20 h. This behaviour was also observed for several non-
selective 64Cu-BTSC radiotracers (e.g. 64Cu-GTSM, 64Cu-PTSM). The similarity of the washout 
profiles supports the notion that the investigated 64Cu-DTC complexes underwent dissociation 
inside the cell and released their metal cargo, which became subject to native copper transport 
processes. Charoenphun and co-workers concluded that active efflux of 64Cu ions from cells 
would only allow the use of 64Cu-DTCs as cell-tracking agents on a very short time-scale, 
making the use of non-biological radioelements as cell labels (e.g. 111In, 89Zr) more preferable 
(140). 
 
The rapid degradation of Cu-DTCs in vivo may limit the use of these complexes as cell-tracking 
agents but could be exploited to deliver copper into cells for other molecular imaging purposes. 
A preliminary biodistribution study by Matsumoto et al. demonstrated high brain uptake of 
62Cu(DEDTC)2 and 62Cu(DMDTC)2 chelates by 15 min post-injection, unveiling the potential of 
these complexes as brain perfusion imaging agents (141). The utility of Cu-DTC complexes as 
imaging agents for the delineation of perfusion and whole-body copper fluxes remains largely 
unexplored.  
 
1.4.2.4 Copper bis(thiosemicarbazone) complexes 
The lability of copper (I)/(II) centres represents a major difficulty when designing bioconjugate- 
or nanoparticle-based probes with sufficient kinetic inertness for in vivo use. Nonetheless, the 
bioreduction of copper (II) to copper (I) and subsequent metal-ligand dissociation can also be 
exploited as a mechanism to selectively deposit radiocopper within cells for various imaging 
purposes. Cu-BTSC radiotracers have been engineered as vehicles for the selective delivery of 




Cu-BTSCs are a versatile family of copper (II) complexes that have been investigated as 
metallodrugs and PET imaging agents for many years. The main characteristic of these 
compounds is that their physicochemical properties can be tailored by subtle modification of the 
ligand structure, prompting the complex to release its copper payload intracellularly only under 
specific physiological conditions. For example, the number of alkyl groups attached to the 
diimine backbone of the ligand has been found to significantly affect the redox potential of the 
resulting copper (II) complex and consequently the conditions under which the latter undergoes 
bioreduction and metal-ligand dissociation. Meanwhile, alkylation at the terminal nitrogen atoms 
of the ligand is thought to alter the lipophilicity and cell permeability of the metal complex, thus 
affecting its tissue biodistribution, clearance rate and plasma protein binding. Controlled tuning 
of these two ligand sites facilitates the development of a library of Cu-BTSC complexes with 
distinct biological behaviours. Examples of investigated Cu-BTSC radiotracers, along with their 
physicochemical properties and intended application, are shown in Table 1.2. 
 
Table 1.2: Structure, physicochemical properties and potential application of Cu-BTSC complexes 
(142, 143). A) copper (II) glyoxal-bis(N4-methyl-3-thiosemicarbazone)  (Cu-GTSM); B)  copper (II) 
pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM); C) copper (II) diacetyl-bis(N4-
methylthiosemicarbazone) (Cu-ATSM); D) copper (II) 2,3-butanedione-bis(thiosemicarbazone) (Cu-ATS); 
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The most accepted uptake mechanism for this family of radiotracers suggests that Cu-BTSCs 
freely diffuse into cells, where they become reduced to Cu(I)-BTSC complexes by bioavailable 
reducing agents (e.g. ascorbate, glutathione, NADH) and dissociate, releasing their radiocopper 
payload into the intracellular copper pool. Bioreduction and subsequent metal-ligand 
dissociation of Cu-BTSCs may occur slowly (Cu-ATSM, Cu-ATS, Cu-CTS) or rapidly (Cu-
GTSM, Cu-PTSM), depending on the reduction potential and in vivo stability of the Cu (I) 
complexes. If sufficient oxygen is available, slowly-dissociating Cu-BTSC complexes are 
reoxidised and washed out of the cell intact, whereas that when exposed to lower physiological 
oxygen conditions, these become irreversibly reduced and dissociate, giving rise to a hypoxia-
dependent PET signal. On the other hand, rapidly-dissociating Cu-BTSC complexes release 
their copper payload into cells irrespective of their redox status and are therefore good 
radiotracers to delineate tissue perfusion. 
 
The effect of the backbone alkyl groups on the redox potential of Cu-BTSC complexes and the 
reversibility of the reduction process has been examined in some detail. Maurer and co-workers 
reported that the two patterns of chemical behaviour observed for Cu-BTSCs (hypoxia-selective 
and non-selective metal release) could be predicted by density functional theory calculations 
from the energy order of the lowest unoccupied molecular orbital (LUMO) and the next lowest 
unoccupied orbital on the electronic structure of the complexes. This group also suggested that 
intracellular pH might be a key factor influencing the reversibility of the copper (II) reduction 
process, since reduced Cu-PTSM and other non-selective Cu-BTSC complexes were shown to 
dissociate immediately in the presence of small amounts of weak acid by cyclic voltammetry, 
while hypoxia-selective analogues such as Cu-ATSM remained unaltered (144). Blower et al. 
studied the structures of eight Cu-BTSC complexes with different alkylation patterns by X-ray 
crystallography and found that alkylation at the diimine backbone of the ligand induced a 
lengthening of the C-C bond and a significant shortening of the Cu-S bonds, allowing a better 
metal-ligand fit and subsequently enhancing the overall stability of the hypoxia-selective 
complexes under normoxia (145). Although the redox potential of Cu-BTSCs is usually modified 
by varying the alkylation pattern of the diimine backbone of the ligand, McQuade et al. proposed 
to vary the reduction potential of the complexes by alternatively replacing sulfur with selenium 
as the donor atom. However, the resulting copper bis(selenosemicarbazone) complexes 
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showed very poor in vitro and in vivo stability which precluded their application as hypoxia 
imaging agents (146).  
 
Over the years, several overlapping theories have attempted to elucidate the mechanisms 
underlying the cellular uptake, hypoxia selectivity, intracellular distribution and efflux of Cu-
BTSC complexes, particularly focusing on the prototype hypoxia imaging agent Cu-ATSM. In 
1997, Fujibayashi et al. first suggested that Cu(II)-ATSM was reduced to Cu(I)-ATSM only under 
hypoxic conditions and subsequently underwent metal-ligand dissociation and intracellular 
sequestration (147). An alternative mechanism proposed by Dearling and co-workers postulated 
that the reduction of Cu(II)-ATSM to Cu(I)ATSM occurred to some extent both in normoxic and 
hypoxic cellular environments, but that under sufficient  oxygen concentrations Cu(I)-ATSM was 
reoxidised and cleared out of the cell (142). Burgman et al. inferred that copper (I) ions released 
from Cu-ATSM under hypoxia were incorporated into the intracellular copper pool by 
association with endogenous copper chaperones. This group also suggested that the 
differences observed in radiocopper retention and efflux after 64Cu-ATSM dissociation between 
tumour cell lines might be caused by different levels of expression of copper transporters (148). 
In 2010, Dearling and co-workers proposed a detailed mechanism for the cellular uptake of Cu-
ATSM, which they described as “biphasic”. The first phase is the bioreduction of Cu(II)-ATSM to 
Cu(I)-ATSM potentially by thiol groups or redox-active proteins with NADH as an enzymatic 
cofactor. NADH is a particularly abundant species in the mitochondria under hypoxic conditions 
due to the metabolic switch to anaerobic respiration. The resulting [Cu(I)-ATSM]- complex is a 
considerably less lipophilic species than Cu(II)-ATSM, and therefore is less likely to diffuse out 
of the cell. In the presence of sufficient oxygen, [Cu(I)-ATSM]- can be reoxidised back to Cu(II)-
ATSM and diffuse out of the cell. In hypoxic cells, where intracellular pH is more acidic, [Cu(I)-
ATSM]- might be protonated at the N3 and N6 sites of the ligand and subsequently dissociate, 
releasing the copper (I) ion into the endogenous copper pool. The group concluded that the 
bioreduction, dissociation and intracellular trapping of Cu-ATSM were mainly dependent on 
cellular oxygen levels, pH and NADH concentration (149).  
 
The identity of the endogenous reducing agent responsible for the intracellular reduction of Cu-
BTSCs is yet to be elucidated. Xiao et al. reported that in aqueous media and in the presence of 
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higher affinity copper-binding proteins (Atx1 and Ctr1) both glutathione and ascorbate were able 
to reduce the non-selective complex Cu-GTSM, but not the hypoxia-selective Cu-ATSM (150). A 
recently published study showed that glutathione status was not altered under hypoxia in the 
Langendorff-perfused rat heart model and that modulation of glutathione levels did not affect the 
retention and pharmacokinetics of 64Cu-ATSM under either hypoxia or normoxia. However, this 
study did not preclude glutathione acting as a cofactor in the bioreduction of the tracer (151).  
 
Besides the identity of the intracellular reductant, other aspects of the proposed mechanism of 
action of Cu-BTSCs remain unclear. Further research is needed to clarify the fate of “free” 
copper (I) ions and ligand molecules after dissociation, as well as the effect of pH, NADH and 
oxygen levels on the mechanism of hypoxia selectivity of some of these complexes. The 
influence of copper metabolism on the uptake, dissociation and efflux of Cu-BTSCs should also 
be assessed. This point is particularly relevant in the context of tumour hypoxia imaging since 
many cancer types exhibit altered copper trafficking and distribution (152).   
 
The possibility of tuning the physicochemical properties of Cu-BTSCs by modification of their 
ligand structure allows controlled radiocopper release in different cellular environments, which 
can be exploited in broad range of imaging applications. Hypoxia imaging remains the main 
focus of Cu-BTSC radiopharmaceutical development, although the use of Cu-BTSCs for the 
monitoring of blood flow has also been extensively investigated. In recent years, the use of Cu-
BTSC radiotracers to study disease-related changes in the transport and metabolism of copper 
has also been explored with promising outcomes (153-155). These three main areas of 
research will be discussed in further detail in the following sections. 
 
1.4.2.4.1  Delineation of hypoxia 
The antitumour activity of the family of Cu-BTSCs was first discovered by Petering et al. in 
1964. The 2-keto-3-ethoxybutyraldehyde-bis(thiosemicarbazone) (KTS) ligand was reported to 
exhibit carcinostatic and carcinolytic activity against advanced rat tumours. The therapeutic 
capacity of the Cu-KTS complex proved to be superior to that of ligand itself and Cu-BTSCs 




In 1997, Fujibayashi and co-workers reported the synthesis of the first hypoxia-selective Cu-
BTSC radiotracer, 62Cu-ATSM, which was successfully tested in the Langendorff-perfused rat 
heart model (147). Ever since it was reported that Cu-ATSM was retained selectively under 
hypoxic conditions, the complex became a candidate to replace the current gold standard for 
hypoxia imaging 18F-fluoromisonidazole (18F-FMISO), which suffered from slow uptake, low 
specificity and slow clearance from normoxic tissue (157). Lewis et al. conducted a comparative 
study between the two radiotracers in cultured EMT6 breast cancer cells and EMT6 tumour-
bearing mice, in which 64Cu-ATSM showed a higher retention under hypoxic conditions and a 
faster clearance from normoxic tissue than [18F]-FMISO (158). Burgman and co-workers 
suggested that the hypoxia-selective accumulation of 64Cu-ATSM could be cell-line dependent 
after observing considerable variation in the uptake, efflux and hypoxic/anoxic-to normoxic 
uptake ratios of 64Cu among different tumour cell lines (R3327-AT, FSaII, MDA468, MCF7, 
DU145 and FaDu) incubated with 64Cu-ATSM (148). 
 
Despite showing promise in vitro, in vivo evaluation of Cu-ATSM has produced variable results. 
In a study to assess the intratumoral distribution and oxygen concentration dependence of 64Cu-
ATSM and [18F]-FMISO in vivo, it was shown that the tumour distribution of the two tracers in 
rats bearing R3327-AT prostate tumours only correlated well at late imaging time-points (16-20 
h post-injection), whereas that in rats inoculated with FaDu tumour cells 64Cu-ATSM showed a 
good correlation with [18F]-FMISO and tumour hypoxia both at early and late time-points (159). 
Tumour-specific dependence of 64Cu-ATSM uptake was also observed by Yuan et al. in mice 
inoculated with different tumour cell lines (R3230 mammary adenocarcinomas, fibrosarcomas 
and 9L gliomas). This study also revealed an inconsistent correlation between 64Cu-ATSM 
intratumoral distribution and standard hypoxia markers EF5, pimonidazole and carbonic 
anhydrase, indicating the influence of other factors in the retention of the tracer (160).  
 
In 2000, Takahashi and co-workers conducted a small PET imaging study with 62Cu-ATSM in 6 
patients with lung cancer. The study demonstrated high tumour uptake of 62Cu-ATSM in all 
cancer patients but did not provide any evidence of correlation between tracer distribution and 
tumour hypoxia (161). Dehdashti et al. assessed the performance of 60Cu-ATSM and its 
relationship with treatment response in patients with cervical cancer (n = 14) and non-small-cell 
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lung carcinoma (n = 19). In patients with cervical cancer, 60Cu-ATSM tumour uptake (expressed 
as tumour-to-muscle ratio) showed an inverse correlation with progression-free survival and 
overall survival after radiotherapy and chemotherapy (162). Tumour-to-muscle ratios of 60Cu-
ATSM in patients suffering from lung cancer demonstrated a similar predictive value in tumour 
response to treatment, although no significant difference in mean tumour 60Cu-ATSM 
standardised uptake value (SUV) was found between responders and non-responders (163).  
 
Although clinical evaluation of the tracer has so far shown a good correlation between Cu-
ATSM tumour accumulation and prognosis, the cell-line dependence of Cu-ATSM uptake along 
with the inconsistent correlation between tumour tracer distribution and hypoxia-related markers 
suggest that there may be other factors besides tumour hypoxia governing the biodistribution 
and tumour uptake of Cu-ATSM. Hueting et al. suggested in a recent publication that copper 
metabolism may also play a role in the mechanism of accumulation of 64Cu-ATSM in hypoxic 
tumour tissue. This group compared 64Cu retention in cultured EMT6 and CaNT cells and 
tumour-bearing mice after administration of 64Cu-ATSM and 64Cu-acetate, and observed a very 
similar biodistribution of the two tracers in vivo and only colocalisation with the EF5 hypoxia 
marker at late imaging time-points (16 h post-injection). Hueting and co-workers suggested that 
64Cu-ATSM dissociated in blood and was subsequently taken up by the tumour as ionic copper 
in vivo. Although this study raises some valid points, it seems unlikely that the in vivo 
biodistribution of all Cu-BTSC complexes, particularly at early imaging time-points, mirrors that 
of ionic copper, given the wide range of biodistribution profiles of Cu-BTSC radiotracers. 
Nevertheless, the results of this study should be taken into consideration especially in the 
context of tumour hypoxia imaging, where slow clearance rates from normoxic tissue may 
require long imaging times and tracer distribution may be affected by altered copper metabolism 
in tumour tissue. 
 
Although poor in vivo stability of Cu-ATSM in blood may not be a concern for cardiac imaging, 
where tracer kinetics are generally fast, the utility of Cu-ATSM as an imaging agent for the 
delineation of cardiac hypoxia has been questioned. The radiotracer was only clinically 
evaluated for this purpose in 7 patients with coronary artery disease with ambiguous results 
(164). The main disadvantage of Cu-ATSM as a cardiac hypoxia imaging agent is that the tracer 
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gets selectively trapped in hypoxic environments that are more severe than is experienced in 
hypoxically compromised but salvageable myocardium. Handley and co-workers identified two 
alternative Cu-BTSC agents, Cu-ATS and Cu-CTS, characterised by a lower lipophilicity than 
Cu-ATSM and a similar redox potential, which exhibited significantly improved hypoxic:normoxic 
retention ratios (14:1 and 17:1, respectively) in the Langendorff-perfused rat heart model when 
compared to the 8:1 contrast shown by 64Cu-ATSM (143). Subsequently, Medina et al. 
performed a series of perfusion buffer oxygen titrations to identify the oxygen concentration 
threshold that caused a degree of low grade hypoxia in the perfused rat heart model that 
correlated with the moderately compromised cardiac energetics characteristic of hypoxic but 
salvageable myocardium. At this key threshold (30 % oxygen concentration), 64Cu-CTS was the 
only tracer that showed hypoxia-selective retention, providing a hypoxic:normoxic contrast of 
>3:1, whereas that the rest of the Cu-BTSC complexes (64Cu-ATS, 64Cu-ATSE and 64Cu-ATSM) 
exhibited selective trapping only below 20 % oxygen concentration (165). 64Cu-CTS therefore 
holds great promise as an imaging agent for the delineation of pathophysiologically relevant 
degrees of cardiac hypoxia.  
 
1.4.2.4.2  Perfusion imaging 
Unlike Cu-ATSM, Cu-PTSM is readily reduced and intracellularly trapped in most tissues, 
regardless of their oxygen levels, and consequently has been extensively investigated as a 
marker of tissue perfusion. Cu-PTSM has one less methyl backbone substituent than Cu-ATSM, 
which results in an increase in redox potential, making the complex more susceptible to 
bioreduction and metal release (142, 166).  
 
 In the 1980s, Green et al. conducted a number of preclinical studies to explore the 
biodistribution profile of Cu-PTSM and evaluate its potential for perfusion imaging applications. 
An initial study revealed rapid blood clearance of the tracer (within 1 minute post-injection) and 
high accumulation of 64Cu radioactivity in the brain (2 ± 0.4 %ID/g) and heart (4.7 ± 1.2 %ID/g) in 
Sprague-Dawley rats. Although the relationship between 64Cu-PTSM uptake and regional blood 
flow could not be demonstrated, it was suggested that the uptake of Cu-PTSM in tissue was so 
rapid that it roughly reflected the pattern of blood distribution (167). Green and co-workers 
subsequently evaluated the in vivo distribution of 67Cu-PTSM and derivatives 67Cu-PTS and 
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67Cu-PTSM2 (R3=R4=H and R3=R4=CH3, respectively) in Sprague-Dawley rats to assess their 
potential as cerebral and myocardial perfusion imaging agents. Lipophilic 67Cu-PTSM and 67Cu-
PTSM2 complexes exhibited rapid blood clearance and excellent brain uptake (~2 %ID/g) within 
1 minute post-injection, although brain concentration of 67Cu-PTSM2 dropped by half after 15 
min. 67Cu-PTSM showed prolonged “microsphere-like” retention both in the heart and brain, 
where 67Cu concentration remained constant over 2 h. This difference in tracer kinetics could be 
attributed to the considerably higher lipophilicity of Cu-PTSM2 (logP = 2.35) compared to Cu-
PTSM (logP = 1.45), which may prompt rapid washout of the complex from cells before 
bioreduction and metal-ligand dissociation take place. Contrary to its lipophilic analogues, 67Cu-
PTS (logP = 0.53) crossed the blood-brain barrier less efficiently (~0.3 %ID/g) but showed a 
similar myocardial 67Cu concentration (~4.7 %ID/g). In the same study, a dual-tracer 
biodistribution experiment in a gerbil stroke model revealed an excellent correlation between the 
regional brain distribution of 67Cu-PTSM and that of SPECT cerebral blood flow tracer [125I]-
iodoantipyrine (142, 168). Further studies by this group additionally demonstrated the utility of 
Cu-PTSM for measuring myocardial, renal and tumour perfusion in vivo (169-171).  
 
These preclinical results encouraged the evaluation of Cu-PTSM as a blood flow imaging agent 
in living patients. Okazawa et al. first evaluated the pharmacokinetic properties and clinical 
applicability of 62Cu-PTSM as a cerebral blood flow tracer in 10 human subjects. Arterial 
sampling showed rapid blood clearance of 62Cu-PTSM within 3 minutes post-injection. Time-
activity curves extracted from PET images revealed maximal brain uptake of the tracer within 2 
minutes after injection and stable tissue activity during the following 8 minutes of scan. 62Cu-
PTSM brain distribution showed an excellent correlation with that of regional blood flow tracer 
15O-H2O (172). Cu-PTSM also showed promising results in a pharmacological study aimed at 
assessing angiotensin II-induced changes in hepatic perfusion to elucidate the role of vascular 
manipulation applied to chemotherapy in subjects suffering from colorectal liver metastases (n = 
9). 62Cu-PTSM imaging before and after angiotensin II infusion revealed significant blood flow 
changes in the liver in 7 out of 9 patients (173). 62Cu-PTSM imaging also proved effective in 
identifying perfusion abnormalities in 91 % of patients suffering from occlusive coronary artery 
disease (n = 28) (174). However, 62Cu-PTSM has been shown to interact strongly with human 
serum albumin which may result in the attenuation of first-pass extraction of the tracer into 
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tissue at high flow rates (175). Further evaluation of the characteristics of 62Cu-PTSM and direct 
comparison of the tracer with other established perfusion imaging agents will determine the 
extent of its clinical use.  
 
1.4.2.4.3 Imaging of copper trafficking 
Copper is an essential trace element in all living organisms but can be harmful to health if not 
tightly regulated. Abnormal copper metabolism has been associated with the pathophysiology of 
many diseases, particularly of neurological nature, and is therefore a potentially attractive 
diagnostic and therapeutic target (176). Radioactive copper (II) salts have traditionally been 
used to investigate whole-body copper metabolism in health and disease but are subject to 
active copper transport mechanisms, which deliver copper ions to the brain in quantities that are 
insufficient for meaningful imaging.  
 
The Cu-BTSC complex Cu-GTSM has a low molecular weight and a moderate lipophilicity (logP 
= 0.84), both properties that enable its transfer across the blood-brain barrier (BBB), allowing in 
vivo measurement of copper trafficking within the brain. In addition, Cu-GTSM has two 
hydrogens instead of methyl groups on its backbone, which results in a relatively positive redox 
potential (-0.43 V (vs. Ag/AgCl)) that promotes rapid bioreduction of the complex and non-
selective release of copper ions into cells (142). The ability of Cu-GTSM to penetrate the BBB 
and supply radiocopper to the intracellular copper pool offers the possibility to study changes in 
copper ion trafficking associated with various neurological disorders (e.g. AD, ALS, PD) and 
evaluate the potential of copper metabolism imbalance as a diagnostic and/or therapeutic 
marker. To date, this approach has only been explored in a mouse model of AD plaque 
pathology. Fodero-Tavoletti and co-workers showed that when 64Cu-radiolabeled Cu-GTSM 
was administered intravenously, 64Cu brain uptake as measured by ex vivo gamma-counting 
was 2-fold higher in APP/PS1 mice at 9-12 months of age (3.0 ± 0.25 %ID/g) than in age-
matched controls (1.58 ± 0.14 %ID/g) at 60 min post-injection (155). Interestingly, this group 
found no correlation between the distribution of 64Cu in human frontal cortex slices after 
incubation of the tissue with 64Cu-GTSM and amyloid-β plaque deposition in the APP/PS1 
mouse model, which contradicts the generally accepted notion of amyloid-β plaques acting as 
“sinks” for metal ions, at least in the acute time scale. The results of this study encourage further 
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evaluation of 64Cu-GTSM-PET as a tool to investigate brain copper trafficking in various 
neurological disorders in order to determine its diagnostic potential. 
 
1.4.2.5  Radioactive copper salts 
PET imaging of ionic radiocopper provides an excellent opportunity to noninvasively measure 
copper trafficking in vivo to understand better the physiology of copper metabolism in health and 
disease. Radioactive copper (II) salts and copper-binding proteins labelled with radiocopper 
have been used to investigate the mechanisms underlying absorption, transport, distribution 
and excretion of endogenous copper in living organisms (16, 48, 177). However, in recent 
years, PET imaging of ionic radiocopper has also gained recognition as a useful tool to identify 
copper metabolism abnormalities, particularly in the context of the Wilson’s and Menkes genetic 
disorders. 
 
WD is a fatal autosomal recessive disorder characterised by excessive copper accumulation in 
the liver, brain, kidneys and other tissues arising from loss-of-function mutations in the gene 
encoding the ATP7B copper efflux transporter. Bahde et al. assessed the feasibility of imaging 
disrupted copper trafficking in WD in the ATP7B-deficient Long-Evans Cinnamon rat model 
using a 64Cu-histidine complex. ATP7B-deficient rats exhibited increased accumulation of 64Cu 
radioactivity in the liver and no hepatobiliary excretion compared to their wildtype counterparts 
as a result of the functional impairment of ATP7B. Interestingly, ATP7B-deficient rodents 
transplanted with healthy hepatocytes showed reduced liver uptake of 64Cu and restored biliary 
excretion, which demonstrates the importance of ATP7B in the maintenance of copper 
homeostasis and the potential of this approach to monitor response to transplantation therapy 
(178). Subsequently, Peng and co-workers evaluated the utility of copper-64 chloride (64CuCl2) 
as a radiotracer for the non-invasive measurement of copper metabolism imbalance in WD. PET 
imaging of copper trafficking was performed in ATP7B knockout mice and wildtype littermates 
using a hybrid PET/CT scanner, which allowed real-time quantitative analysis of 64Cu 
distribution at the whole-body level. As expected, intravenous administration of 64CuCl2 resulted 
in enhanced deposition of radiocopper in the liver and impaired biliary excretion in the WD 
model. Moreover, 64Cu concentration in extrahepatic tissues (heart, lungs, kidneys and brain) 
was found to be significantly lower at 24 h post-injection in ATP7B knockout mice compared to 
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controls, probably due to hepatic sequestration of the radiocopper (153). Peng et al. conducted 
a similar study to assess gastrointestinal absorption and whole-body distribution of dietary 
copper in WD in ATP7B knockout mice orally treated with 64CuCl2. The group revealed 
significantly higher hepatic concentration of 64Cu in the disease group compared to wildtype 
mice, but no significant differences in tracer uptake between the two groups were detected in 
the kidneys, heart, brain and blood at 24 h post-injection (179). Lutsenko and co-workers used 
64CuCl2 PET/CT imaging to investigate the mechanisms underlying urinary copper elevation at 
late-stages of hepatic copper accumulation in WD. The study demonstrated an age-dependent 
decrease in copper hepatic retention in ATP7B-knockout mice associated with the activation of 
a renal copper export pathway. It was additionally found that this secondary efflux pathway 
involves a decrease in Ctr1 transporter levels in the liver and the upregulation of small copper 
carrier protein in the urine (180).  
 
64CuCl2 PET imaging has also been used to study copper metabolism imbalance in MD, another 
genetic disorder of copper trafficking caused by mutations in the gene encoding the ATP7A 
transporter. ATP7A dysfunction in MD causes accumulation of dietary copper in the intestines 
and kidneys and concomitant copper deficiency in the remaining organs. To date, the most 
successful treatment to correct systemic copper deficiency in MD consists of subcutaneous 
injections of a copper-histidine complex. However, this therapy is only effective at early stages 
of disease development during infancy, when the BBB is still immature and allows the complex 
to pass through. To ensure sufficient copper delivery to the brain in the presence of a maturing 
blood-brain barrier, the use of lipophilic Cu-BTSC complexes and the combination of CuCl2 and 
brain-permeable chelators have been suggested (181, 182). In this context, Nomura and co-
workers evaluated the trafficking efficacy of the copper-chelating agent 1,1',1'',1'''-
[disulfanediylbis(carbonothioylnitrilo)]tetraethane (disulfiram) in a mouse model of MD by 
64CuCl2-PET. Non-treated macular mice showed increased concentration of 64Cu radioactivity in 
the kidneys and reduced 64Cu uptake in the liver and brain when compared to healthy controls. 
By contrast, animals pre-treated with disulfiram exhibited lower accumulation of 64Cu in the 
kidneys and higher tracer uptake in the liver and brain than non-treated mice (154). This study 




Numerous studies in the literature have reported that copper metabolism is also dysregulated in 
a variety of human carcinomas. Both serum and tumour copper levels have been found to be 
significantly increased in ovarian, breast, cervical, lung, prostate, colorectal, blood and gastric 
cancers, and this elevation in copper concentration has been shown to be directly correlated 
with disease progression (183). The discovery of abnormal copper accumulation in cancer cells 
has led to the development of copper-chelating strategies as potential treatment options and the 
use of 64CuCl2-PET as a tool to delineate tumour tissue and investigate the role of copper 
metabolism in carcinogenesis. Peng and co-workers first evaluated 64CuCl2 as an imaging agent 
for the visualisation of solid tumours in athymic mice transplanted with extrahepatic hepatoma 
cells. The group hypothesised that 64Cu accumulation in hepatoma grafts might be mediated by 
endogenous copper transporter Ctr1, which is highly expressed in hepatocytes and whose 
expression might therefore be strong in hepatoma cells. Extrahepatic hepatomas were 
successfully visualised by 64CuCl2-PET at 1 h post-injection of the tracer (3.68 ± 0.42 SUV), 
indicating the potential utility of this technique for detecting extrahepatic hepatocellular 
carcinoma metastasis in tissues with low uptake of 64CuCl2 (e.g. muscle, brain). Ctr1 
immunoreactivity in extrahepatic hepatoma grafts was found to be approximately 70 % of that in 
the liver but was significantly more intense compared to that in soft tissue and brain (184). Peng 
et al. conducted a similar imaging study in athymic mice bearing human prostate cancer 
xenografts and reported good tumour visualisation using 64CuCl2 at 24 h post-injection of the 
tracer but not at 1h, in contrast to mice bearing extrahepatic hepatoma grafts. The authors 
suggested that this difference in 64Cu accumulation might be due to lower expression of mouse 
Ctr1 and more active copper efflux mechanisms in prostate cancer cells compared to 
extrahepatic hepatoma cells (185). Subsequently, Jørgensen et al. assessed 64Cu uptake in five 
different mouse tumour models (colorectal cancer, glioblastoma, head and neck cancer, 
neuroendocrine lung cancer and ovarian cancer) and compared it to gene expression of mCtr1 
in tumour tissue. Tumour uptake of 64Cu was found to be both time and tumour-type dependent, 
with 64Cu accumulation in tumour tissue increasing in three out of five tumour types from 1 h to 
22 h post-injection of the tracer. Surprisingly, no correlation was found between tumour 64Cu 
concentration and mouse Ctr1 gene expression levels, which indicate the existence of a second 
copper influx system or the relocation of Ctr1 between intracellular vesicles and the cell 
membrane as a regulatory mechanism of Ctr1 activity (186). In a recent study, Qin et al. 
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evaluated the potential of 64CuCl2 as a theranostic probe for both PET imaging and radionuclide 
therapy of malignant melanoma in B16F10 and A375M tumour-bearing mice. 64CuCl2-PET 
showed excellent 64Cu tumour uptake in the B16F10 group already at 1h post-injection of the 
tracer, whereas 64Cu accumulation in A375M tumours was more gradual, reaching its peak 
value by 24 h. Additionally, the authors demonstrated that 64CuCl2 treatment slowed down 
tumour growth in both melanoma models compared to the non-treated groups (187). In the first 
and only clinical study to date, Capasso and co-workers evaluated 64CuCl2-PET as a tool for 
primary staging of patients with prostate cancer (n = 7). Preliminary results of this study 
demonstrated high accumulation of 64Cu in tumour tissue and regional lymph nodes, 
demonstrating the potential of increased copper metabolism as a diagnostic and therapeutic 
biomarker for prostate cancer (188). Further research is needed to shed some light into the 
mechanisms underlying abnormal copper metabolism in neoplastic disease and its impact on 
disease progression and survival rates. 
 
1.5 CONCLUDING REMARKS 
 
Copper is an essential bioelement in the human body but can become harmful if not tightly 
regulated. Significant progress has been made in describing the key molecular players and 
pathways involved in the trafficking and regulation of copper metabolism but many aspects of 
these mechanisms remain elusive. Disrupted copper homeostasis has been identified as a 
pathological feature in a variety of inherited and acquired disorders, including WD, MD, AD and 
various types of cancer. There is therefore an urgent need to improve our understanding of the 
mechanisms governing copper transport, distribution and regulation in order to be able to 
identify and fully characterise abnormalities in copper metabolism associated with specific 
disease states and evaluate their impact on disease progression and prognosis. 
 
Many of the early efforts to investigate copper biochemistry relied on the use of copper 
radioisotopes. Copper absorption, distribution and excretion were studied by administering 
radioactive copper salts into small animals and measuring the radioactivity present in organs 
and tissues.  Over the last decade, the advent of proteomics has provided new insights into the 
study of copper metabolism, allowing the investigation of specific trafficking pathways and 
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protein structures, and thus the use of radiocopper has been relegated to the development of 
traditional radiopharmaceuticals.  
 
Copper radionuclides have attracted considerable attention in radiopharmaceutical development 
due to the wide selection of half-lives and decay schemes they offer as well as their amenable 
radiochemistry. Over the years, this family of radioisotopes has been used in the construction of 
a wide array of radiopharmaceuticals, ranging from bioconjugate-based agents to small-
molecule radiotracers, with various degrees of success. The choice of radiocopper as a label to 
monitor the distribution of bioconjugates and nanoparticles is not ideal since the resulting 
probes generally exhibit low stability in vivo due to competition with endogenous copper-binding 
species. The susceptibility of copper to native trafficking mechanisms also hampers the use of 
radiocopper complexes as cell-tracking imaging agents, making preferable the use of “non-
biological” radioisotopes.  
 
The continuous improvement in the resolution and sensitivity of PET systems along with the 
increasing availability of PET copper radionuclides provide the opportunity to use these isotopes 
to measure copper fluxes in vivo in a non-invasive manner, in both animals and humans. The 
administration of radiocopper at sub-pharmacological concentrations would allow the dynamic 
study of native metabolic pathways without perturbing them. This is a unique feature of PET 
copper radioisotopes that could be exploited not only to provide a better understanding of the 
physiology of copper metabolism but also to determine the potential  of copper dyshomeostasis 















The brain is one of the most copper-demanding organs in the body. In the brain, copper plays 
an indispensable role in normal cell physiology but is also an important contributor to brain-
specific functions such as neuropeptide production or synaptic transmission. Paradoxically, the 
brain is also one of the most vulnerable organs to oxidative stress induced by uncontrolled 
redox-active metals and, as a result, copper trafficking in the central nervous system (CNS) is 
maintained under very tight control. Brain copper dysregulation is the main driving force for 
neurodegeneration in the Wilson’s and Menkes genetic disorders but has also been linked to 
the pathophysiology of many other neurological diseases. However, despite the importance of 
brain copper homeostasis in neurological health and disease, very little is known about the 
mechanisms underlying the trafficking and distribution of copper within the CNS. 
 
In this chapter, we aim to give an overview of our current knowledge on the metabolism and 
functions of copper in the CNS, as well as the mechanisms regulating brain copper 
homeostasis. The role of copper in a growing list of neurological disorders will also be 
discussed in order to identify potential opportunities for application of PET as a tool to study 
copper metabolism abnormalities associated with neurodegeneration and monitor the effects of 
copper-modulating therapies. 
 
2.2  COPPER METABOLISM IN THE CNS 
 
2.2.1 Copper content and distribution in the CNS 
Copper is an essential bioelement for the normal development and function of the brain. The 
brain is one of the main sites of copper accumulation (second only to the liver) and utilises the 
metal for both general (e.g. antioxidative defence, energy metabolism, iron transport) and brain-
specific metabolic functions (e.g. neuropeptide and neurotransmitter synthesis) (15). Due to the 
high rate of cerebral oxidative metabolism and relatively low abundance of brain-resident 
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antioxidants, brain copper trafficking is tightly regulated in order to minimise metal-catalysed 
production of ROS. The average concentration of copper in the human brain is approximately 
80 μM, with the intracellular availability of free copper ions kept at extraordinarily low levels 
(189). Copper levels in the cerebrospinal fluid (CSF) are comparatively much lower (~ 0.3 μM) 
than those in the brain parenchyma and differ from plasma copper concentration (~ 15 μM) by 
1.5 orders of magnitude (190).  
 
The distribution of copper within the human brain is heterogeneous, as reflected by two- to 
three-fold higher copper levels in the grey matter compared to the white matter. Regional 
distribution of copper in the brain is dictated by region-specific metabolic demands but is also 
influenced by factors such as species or age. The area in the human brain containing the 
highest concentration of copper is the locus coeruleus, which is the principal site for 
noradrenaline production. The substantia nigra, dentate nucleus and cerebellum are other 
structures in the human brain with high copper levels, which reveals an enhanced metabolic 
requirement for copper in these regions. Interestingly, in the mouse brain, copper is most 
abundant along the ventricles and in the hypothalamus, which is the region responsible for the 
maintenance of body homeostasis (191-194).  
 
Several studies have demonstrated that copper content in the rodent brain increases with age. 
Massie and co-workers first reported an increase in brain copper levels in wildtype mice from 50 
to 600 days of age which was inversely correlated with cerebral Cu/Zn SOD-1 activity (195). 
Similarly, Wang et al. found increased cerebral copper content in 14-month-old wildtype mice 
when compared to 7-9- and 2-month-old mice, as well as significantly decreased Cu/Zn SOD-1 
levels, particularly in the striatum and ventral cortex. Paradoxically, Wang and co-workers also 
reported an age-dependent reduction in active 67CuCl2 brain uptake (as measured by digital 
autoradiography), which may depict a regulatory mechanism associated with total copper 
content to maintain brain copper homeostasis at a constant level (196).  
 
2.2.2 Functions of copper in the CNS 
In the CNS, copper acts as a cofactor for two essential enzymes that are ubiquitously present in 
all mammalian tissues, CCO and Cu/Zn SOD-1. These metalloenzymes are particularly crucial 
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for brain function since the brain has a high rate of oxidative metabolism which enhances its 
vulnerability to oxidative stress. The critical role of these proteins in the maintenance of brain 
homeostasis is illustrated by the Menkes genetic disorder, in which brain copper deficiency 
arising from mutations in the gene encoding the ATP7A copper transporter leads to a significant 
reduction in CCO and Cu/Zn SOD-1 activities, which in turn contributes to the 
neurodegenerative phenotype of the disease (197). 
 
Copper is also a fundamental cofactor for a number of CNS-specific enzymes, including DβH, 
peptidylglycine α-amidating monooxygenase (PAM) and various copper amine oxidases. DβH is 
a component of the catecholamine biosynthetic pathway which catalyses the side-chain 
hydroxylation of dopamine into noradrenaline, while PAM is a bifunctional enzyme with two 
catalytic domains, copper-dependent peptidylglycine α-hydroxylating monooxygenase (PHM) 
and peptidyl-α-hydroxyglycine α-amidating lyase (PAL), responsible for the post-translational α-
amidation of peptidylglycine bioactive substrates (Figure 2.1).  
 
Figure 2.1: A) Synthesis of noradrenaline catalysed by DβH; B) Two-step α-amidation reaction catalysed 
by PAM consisting of stereospecific hydroxylation of peptidylglycine substrate catalysed by PHM (top), and 
N-dealkylation of peptidyl α-hydroxyglycine intermediate to produce α-amidated peptide and glyoxylate 




Although their substrate specificities are grossly different, these two cuproenzymes catalyse a 
similar type of reaction (i.e. oxygen- and ascorbate-dependent hydroxylation) and share up to 
28 % structural identity throughout a common 270 aminoacid sequence (199). PAM is highly 
expressed in most neuronal and endocrine cells as well as glial cells and atrial myocytes, 
whereas DβH is found almost exclusively in chromaffin cells of the adrenal medulla and 
synaptic vesicles of noradrenergic neurons (200, 201). Impaired DβH activity, as observed in 
the rare genetic DβH deficiency disorder, has been associated with symptoms such as 
hypotension, hypotonia or hypoglycaemia, but surprisingly does not have severe consequences 
for CNS function (202). On the other hand, deletion of the PAM gene, which results in complete 
absence of peptide amidation activity, has been shown to induce fatal cardiovascular deficits 
during embryonic development in PAM null mutant mice but has not been found to alter 
neuroblast proliferation (203). 
 
Copper-dependent ferroxidase ceruloplasmin is known to play a critical role in the regulation of 
mammalian iron homeostasis. Although this enzyme carries up to 95 % of the copper found in 
blood, the main physiological role of ceruloplasmin does not seem to be copper transport, as 
evidenced by normal copper metabolism in patients suffering from aceruloplasminemia, but 
plasma iron transport and efflux from mammalian cells. Despite being a systemic iron 
metabolism disorder, lack of ceruloplasmin activity in aceruloplasminemic patients has 
particularly severe manifestations for the CNS resulting from regional iron accumulation in the 
retina and basal ganglia (204). The presence of these neurological abnormalities suggests an 
essential role for ceruloplasmin in iron homeostasis in the CNS. Nonetheless, it has been 
shown that serum ceruloplasmin does not cross the blood-brain barrier under normal conditions, 
which implies the existence of local expression mechanisms of the protein within the brain 
(205). Klomp and co-workers first detected abundant ceruloplasmin gene expression in the 
epithelial cells of the choroid plexus as well as in specific subpopulations of astrocytes 
surrounding the brain microvasculature and retina (206). Subsequently, research by Patel et al. 
revealed that astrocytic ceruloplasmin was anchored to the cell surface via a 
glycosylphosphatidylinositol (GPI) motif and that this GPI-anchored form of the protein 
predominated in the CNS. Except for the GPI anchor, astrocyte-expressed ceruloplasmin was 
found to be structurally and functionally similar to the form of the protein produced by the liver 
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and choroid plexus (207, 208). The proximity of ceruloplasmin expression sites to blood-CNS 
barriers (BBB and blood-cerebrospinal fluid barrier [BCSFB]) along with the increased iron 
deposition observed in the brains of aceruloplasminemic patients support a role for 
ceruloplasmin in the efflux of ferrous ions from CNS cells, potentially through interaction with an 
iron transport protein. 
 
In addition to its role as an enzymatic cofactor, copper is also thought to modulate synaptic 
transmission. Colburn et al. first reported a greater concentration of copper in synaptosomes 
and synaptic vesicles isolated from mouse brain tissue compared to magnesium, iron and zinc 
(209). In 1988, Hartter and co-workers proposed a role for copper as a neuromodulator after 
observing radiocopper release into the extracellular space in response to potassium-induced 
depolarisation in rat hypothalamic tissue incubated with a 67Cu-histidine complex (210). Since 
then, a great number of studies have explored the effects of copper at brain synapses and its 
importance for synaptic plasticity. For example, it has been shown that exposure to micromolar 
concentrations of copper (~18-30 μM) produces an inhibitory effect on N-methyl-D-aspartate 
(NMDA), γ-aminobutyric acid (GABA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors in cultured neurons, and suppresses long-term potentiation in rat 
hippocampal slices (211-214). Contrarily, prolonged incubation of neuronal cultures with lower 
concentrations of CuCl2 (~10 μM) has been found to enhance AMPA receptor-mediated 
synaptic activity. This increase in AMPAergic neurotransmission was suggested to derive from 
AMPA receptor anchorage in post-synaptic membranes as a result of a copper-induced 
increase in the levels of scaffolding protein PSD95 (215). Although these studies are 
informative, they only report effects of exogenously applied copper on synaptic activity and 
therefore further research is required to elucidate the exact role of synaptically released 
endogenous copper in neurotransmission. 
 
Copper has been reported to have an inhibitory effect on long-term potentiation but has also 
been suggested to play a neuroprotective role against glutamate-induced excitotoxicity. Schlief 
and co-workers showed that NMDA receptor activation resulted in rapid and reversible 
trafficking of the ATP7A copper transporter from the trans-Golgi network followed by copper 
efflux in cultured hippocampal neurons. ATP7A translocation was found to depend on calcium 
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entry through the NMDA receptor but not on intracellular copper concentration (216). Further 
research revealed that CuCl2 addition (200 μM) decreased cell death after NMDA receptor 
activation in cultured neurons exposed to excitotoxic levels of glutamate/glycine, and that this 
protective effect was dependent on endogenous nitric oxide production (217). From this 
evidence, Schlief et al. suggested that ATP7A-related copper efflux might promote the S-
nitrosylation of NMDA receptors in order to reduce excitotoxic cell death after glutamate 
synaptic release. Thus, ATP7A loss-of-function in MD could lead to increased neuronal 
excitotoxicity, which in turn could be responsible for the rapid neuronal degeneration and high 
seizure occurrence characteristic of this disorder (218).   
 
2.2.3 Copper uptake into the CNS 
Although many advances in the understanding of systemic copper metabolism have been 
made, copper processing within the CNS has not been widely investigated. Most of the current 
knowledge on brain copper metabolism derives from studies in yeast and extracerebral 
mammalian cell models. However, the importance of copper in the development and function of 
the CNS as well as the vulnerability of the brain to metal-induced oxidative stress imply the 
existence of system-specific copper handling mechanisms.  
 
Plasma copper can enter the CNS through the BBB and/or BCSFB, which respectively separate 
the brain interstitial fluid and the CSF from blood. The exact role of these barrier systems in the 
maintenance of brain copper homeostasis is still unknown but it has been suggested that 
circulating copper may enter the brain mainly through the BBB, while the BCSF may act as a 
regulatory site of copper levels in the CSF. Choi and co-workers first provided evidence in 
support of this possibility in a study that evaluated the uptake kinetics of three radiocopper 
species (64CuCl2, 64Cu-albumin and 64Cu-ceruloplasmin) into brain vessels, parenchyma, 
choroid plexus and CSF using an in situ brain perfusion method. This study showed that the 
highest copper uptake in barrier tissues and brain parenchyma was achieved when the brain 
was perfused with ionic radiocopper, thus demonstrating that copper is transported into the 
brain and CSF as a free copper ion and not as a protein-bound species. Furthermore, it was 
found that the uptake rate of 64CuCl2 by the choroid plexus was 3.2-fold faster compared to the 
transport rate for copper in cerebral capillaries but that the rate of copper entering the brain 
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parenchyma from brain vessels was higher than the rate of copper entering the CSF from the 
choroid plexus (219). Using a two-chamber in vitro BCSFB model system, Monnot et al. 
revealed that copper efflux from the CSF to blood across a layer of primary choroidal epithelial 
cells was almost 2-fold higher than copper transport in the opposite direction. Taken together, 
these findings suggest that copper may enter the brain primarily through the BBB and that 
excess copper may be transferred from the brain parenchyma into the CSF and exported back 
into the bloodstream via the BCSFB. The high copper sequestration capacity exhibited by 
choroid plexus epithelial cells and the low concentration of copper in CSF compared to copper 
levels in plasma may support a role for the BCSFB as a regulatory site of copper levels in the 
CSF (220).  
 
Copper transporters Ctr1, DMT1, ATP7A and ATP7B are strongly expressed in brain barrier 
tissues and consequently are thought to mediate copper transport into and out of the CNS. The 
levels of gene expression of Ctr1 and ATP7A have been reported to be significantly greater 
(1.2- and 3.4-fold, respectively) in the choroid plexus compared to those in the BBB, whereas 
ATP7B has been found to be more abundant in cerebral capillaries than in the choroid plexus. 
Gene expression of non-specific metal transporter DMT1 at the BBB has been found to be 
equivalent to that at the choroid plexus but almost 3-fold higher when compared to that in the 
brain parenchyma (219).  
 
The importance of Ctr1 in copper transport into the CNS is underlined by the nearly 50 % 
decrease in brain copper levels exhibited by Ctr1-deficient mice (221). The involvement of 
ATP7A in the mobilisation of copper ions from blood to brain seems also irrefutable as depicted 
by severe copper deficiency resulting from ATP7A loss-of-function observed in the brains of MD 
patients. However, ATP7A might play a dual role in copper transport since functional analysis 
has demonstrated that treatment with p-chloromercuribenzoate, a potent inhibitor of ATP7A 
function, markedly reduced copper efflux from mouse cerebrovascular endothelial cells (222). 
This possibility is further supported by the significant decrease in brain copper concentration 
observed in transgenic mice overexpressing ATP7A (223). Although ATP7B is also highly 
expressed in brain endothelial cells, its functional role in the BBB remains largely undefined. 
However, brain copper overload arising from ATP7B loss-of-function in WD seems to suggest 
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that this transporter might play a role in the export of excess copper to blood across the BBB 
(224). 
 
While Ctr1, ATP7A and ATP7B are located in the cytoplasm in most brain regions, the choroid 
plexus epithelium (BCSFB) exhibits distinct patterns of distribution, which illustrates the unique 
role that this region plays in brain copper homeostasis. Immunohistochemistry of copper 
transport proteins showed that Ctr1 and ATP7B were primarily located along the apical 
membrane of the choroidal epithelium, whereas that ATP7A was mostly concentrated at the 
basolateral surface. This distribution pattern might indicate that Ctr1 mediates the transport of 
excess copper from the CSF into the choroid plexus and that ATP7A facilitates its export back 
into circulation across the basolateral membrane. The localisation and slow kinetics of ATP7B 
(with respect to ATP7A) seem to suggest that this transporter could participate in the transfer of 
copper ions from the choroid plexus into the CSF (225).  
 
Figure 2.2: Proposed copper uptake and export mechanisms at the BBB and BCSFB. Copper transport 
across the BBB to the brain parenchyma is thought to be mediated by Ctr1 and ATP7A, whereas ATP7B 
might facilitate copper efflux back into circulation. Ctr1 has also been suggested to play a role in the 
transport of excess copper from the CSF into the choroid plexus. ATP7A is thought to facilitate the transfer 
of copper ions from the BCSFB to blood, while ATP7B has been proposed to mediate copper delivery from 
the choroid plexus to the CSF (221, 224, 225). 
 
2.2.4 Astrocyte regulation of brain copper homeostasis 
Astrocytes are the most abundant cell type in the CNS and perform multiple essential functions, 
including regulation of cerebral blood flow, glycogen storage, BBB preservation, modulation of 
synaptic function and maintenance of CNS homeostasis of neurotransmitters, metabolites and 
redox-active metal ions (226). Although this cell type is present throughout most of the CNS, 
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some astrocytes have been found in close association with brain endothelial cells and are 
thought to contribute to the development and regulation of the BBB phenotype. The strategic 
localisation of perivascular astrocytes between capillary endothelial cells and neuronal bodies 
has led to the suggestion that these cells additionally regulate the supply of metabolic 
substrates, oxygen and trace metals to neurons (227). It is therefore thought that astrocytes are 
the first brain parenchymal cells that take up copper ions after they cross the BBB.  
 
Several studies have demonstrated that astrocytes efficiently accumulate copper ions and show 
a greater resistance to copper-induced toxicity when compared to other brain cells (228-231). 
This feature implies that astrocytes may not only supply copper to neurons but also serve as 
depots for copper in the brain to protect neurons and other cell types against metal-induced 
oxidative damage. Brown et al. revealed that cultured astrocytes inhibited copper toxicity in 
cerebellar neurons exposed to 100 μM of copper (II) sulphate. This protective effect was shown 
to be dependent on the expression of the copper-binding prion protein (PrP), which was 
released from neurons upon exposure to copper and taken up by astrocytes (230). The ability of 
astrocytes to sequester copper from neurons may be associated with the biological activity of 
PrP but is also supported by the high levels of glutathione and MTs present in these cells (229, 
231-234). Scheiber and co-workers observed a concentration-dependent increase in glutathione 
synthesis in cultured astrocytes after copper treatment. Interestingly, this elevation of cellular 
glutathione content as a result of increased intracellular copper concentration does not occur in 
most cell types, which highlights the unique capacity of astrocytes to store and detoxify copper 
ions (229).  
 
Astrocytes have been suggested to play a central role in the maintenance of brain copper 
homeostasis since they are involved both in the supply of copper ions to neurons, and the 
storage and detoxification of excess copper exported from neurons and other brain cells. 
Nevertheless, little is known about the molecular mechanisms that control astrocytic copper 
trafficking. Transport protein Ctr1 has been found to be expressed in cultured astrocytes and is 
thought to the primary contributor to cellular copper uptake (228). Copper export from 
astrocytes has been proposed to be mediated by ATP7A, although ATP7A-independent 
transport mechanisms are also thought to operate (235). Evidence for the involvement of 
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ATP7A in copper efflux from astrocytes was first provided by Kodama et al., who reported 
increased astrocytic copper content in a mouse model of MD as a result of ATP7A dysfunction 
(236).  
 
Considering the importance of astrocytes in brain copper metabolism, the mechanisms 
underlying astrocytic copper trafficking require further investigation in order to understand better 
the consequences of their malfunction for global copper homeostasis in the CNS.  
 
2.2.5 Copper trafficking in the CNS 
Despite the essential contribution of copper to the development and function of the CNS, the 
molecular mechanisms involved in copper trafficking within the brain and spinal cord remain 
poorly understood. Additionally, little is known about the differences in copper transport systems 
existing between the main CNS cell types. However, many cuproenzymes and copper 
chaperones commonly expressed in other body tissues have been also identified in the CNS 
(e.g. Cu/Zn SOD-1, CCO, Ctr1, Atox1, CCS, Cox17) (237-241).  
 
Similar to copper entry into enterocytes (see Chapter I, section 1.3.2.1), copper transporter 
Ctr1, in conjunction with an unidentified metalloreductase, is the main transporter responsible 
for copper uptake into brain cells. Loss of Ctr1 function has been shown to particularly affect 
neural tissue, leading to abundant cell death and embryonic lethality in knockout zebra fish and 
mouse models (221, 242). The identity of the protein that facilitates the reduction of copper (II) 
to copper (I) and subsequent copper (I) uptake into brain cells is still under discussion, but it has 
been suggested that cupric reductase Steap2, which is highly expressed in the epithelial layers 
of the choroid plexus, could be a potential candidate (243). A synthetic peptide representing the 
copper-binding site of the amyloid precursor protein (APP) has been shown to be capable of 
reducing copper (II) to copper (I) in vitro, suggesting a potential role for this protein in the Ctr1-
mediated copper uptake process (244). The non-specific DMT1 metal transporter is also 
thought to contribute to neuronal copper uptake, although it seems to play a more significant 




Despite the established role of Ctr1 in cellular copper uptake, Davies et al. surprisingly showed 
that the distribution of the transporter in several regions of the human brain (visual cortex, 
anterior cingulate cortex, caudate putamen, substantia nigra and cerebellum) was mainly 
cytoplasmic, except in barrier tissues where it was found closer to the apical cell surface. The 
authors suggested that in copper-sufficient cells Ctr1 might exist as an internalised protein pool, 
rather than as a membrane-bound transporter, and move back to the plasma membrane under 
conditions of copper deficiency. Furthermore, immunohistochemical staining of Ctr1 revealed 
that this transporter was mainly concentrated in neuronal cells in the cerebral cortex and 
caudate putamen, whereas in the cerebellum it was strongly expressed in Bergmann glia but 
not in Purkinje neurons (225). 
 
Once inside brain cells, copper (I) ions are chaperoned by various copper-binding proteins and 
incorporated into specific cuproenzymes, or form transient complexes with glutathione or 
metallothioneins for storage purposes. Atox1 is a ubiquitously expressed copper chaperone 
whose function consists in transferring the metal to copper ATPases ATP7A and ATP7B for 
subsequent delivery to copper-dependent enzymes or efflux from cells. In the rat brain, the 
highest concentrations of Atox1 have been detected in the pyramidal neurons of the cerebral 
cortex and hippocampus as well as in the neuronal cells of the locus coeruleus, which might 
indicate a higher need for copper in these regions in the rodent brain (225, 245).  
 
Copper ATPases ATP7A/B are crucial components of the copper homeostasis machinery since 
they facilitate the incorporation of copper into essential copper-dependent enzymes and also 
exert a tight control over intracellular copper levels, which is of particular importance for the 
CNS. The faster kinetics of copper transport by ATP7A compared to ATP7B seem to suggest 
that ATP7B might be mainly responsible for the delivery of copper ions to cuproenzymes (e.g. 
ceruloplasmin), while ATP7A might be more inclined to play a regulatory role in the 
maintenance of cellular copper content. Both transporters are ubiquitously expressed in the 
brain but are especially abundant in barrier tissues, cerebellum, olfactory bulb, hippocampus 
and cerebral cortex (246, 247). In the CNS, the levels of expression of ATP7A/B seem to be 
inversely correlated to those of Ctr1, although the significance of this difference in expression 
patterns still needs to be fully elucidated. It has been proposed that cells that express high 
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levels of Ctr1 and relatively low levels of ATP7A/B might have greater metabolic requirements 
than other cell types, whereas that cells that exhibit greater levels of expression of copper 
ATPases relative to Ctr1 might be more sensitive to copper-induced cellular toxicity. For 
example, in the human brain, abundant expression of ATP7A/B was observed in Purkinje 
neurons in the cerebellum but not in Bergmann glia, while Ctr1 showed the inverse pattern of 
expression. Copper-transporting ATPases were also present at high levels in the proximal fibers 
of the anterior cingulate cortex and in the striosomes of the caudate putamen complex, while 
Ctr1 expression was reported to be low in these regions (225). 
 
ATP7A has been reported to release copper ions into the synaptic cleft in order to reduce 
neuronal excitotoxicity after NMDA receptor-mediated neurotransmission in hippocampal 
neurons (216, 217). In view of this, the lack of ATP7A expression observed in the axons of 
neurons of the substantia nigra, the brain region with the highest concentration of dopaminergic 
neurons, seems rather surprising (225). However, it has been suggested that copper might be 
released into the synaptic cleft by ATP7A-mediated vesicle exocytosis and not necessarily 
pumped out of the cell across the plasma membrane directly by ATP7A (235).  
 
The copper transporter CCS is the main transporter responsible for activating the copper-
dependent antioxidant enzyme Cu/Zn SOD-1 through the insertion of copper, although the 
existence of CCS-independent Cu/Zn SOD-1 metalation mechanisms has also been reported 
(46). The distribution of CCS within the brain mirrors that of Cu/Zn SOD-1, which implies that 
CCS might have a role in CNS disorders characterised by Cu/Zn SOD-1 dysfunction, such as 
ALS. In the CNS, CCS expression was reported to be similar across all brain and spinal cord 
regions and was detected throughout the neuropil, primarily in neurons and some astrocytes. 
Although CCS was found to be present in most brain regions (e.g. cerebellum, cerebral cortex, 
hippocampus), it was reported to be largely absent from white matter tracts in both mouse and 
human brain (239). Angeletti et al. revealed that CCS was able to interact with the cytoplasmic 
domain of β-secretase 1 (BACE1), one of the enzymes involved in the production of the AD-
associated amyloid-β peptide (Aβ). This group demonstrated that overexpression of BACE1 led 
to a significant decrease in Cu/Zn SOD-1 activity in cultured rat cortical neurons, thus revealing 
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a competitive copper (I)-binding mechanism between CCS and BACE1 that might contribute to 
increased vulnerability to oxidative stress in AD (248). 
 
Another essential copper chaperone is Cox17, which mediates the incorporation of copper into 
the cellular respiration enzyme CCO along with accessory proteins Sco1 and Cox11. Little is 
known about the cellular functions of this copper transporter in the CNS. Detailed examination 
of the expression pattern of Cox17 in the mouse brain revealed that this chaperone was 
ubiquitously expressed in all brain regions, with highest levels of expression observed in the 
pituitary gland. Abundant expression of Cox17 was also detected in the cerebral cortex, brain 
stem and cerebellum, while the lowest expression levels were measured in the hippocampus 
and hypothalamus. High expression of Cox17 in pituitary tissue strongly suggests that this 
transporter might not only be involved in cellular respiration but might also play a role in 
neuroendocrine function (240).  
 
The APP and PrP, which are commonly associated with the pathogenesis of AD and prion 
diseases, have been reported to bind copper ions and are therefore thought to play a role in 
normal copper metabolism (249, 250). It was initially suggested that PrP could play a role in the 
uptake of copper into brain cells since PrP-knockout mice were found to exhibit severely 
reduced copper levels in the brain as well as decreased Cu/Zn SOD-1 activity (251). Pauly and 
co-workers later observed that exposure to copper (II) sulphate (> 200 μM) reversibly stimulated 
the endocytosis of PrP in cultured neuroblastoma cells, suggesting the possibility of PrP-
mediated copper uptake by endocytosis (252). PrP has also been proposed to act as a buffer 
for copper (II) ions at the presynaptic terminal, mediating both the release of copper into the 
synaptic cleft after neurotransmission and the redistribution of copper into the presynaptic 
cytosol (253). Moreover, Brown and co-workers reported that copper-bound PrP had Cu/Zn 
SOD-1-like activity, suggesting a potential neuroprotective role for PrP against oxidative stress 
(254).  
 
The physiological function of APP in copper metabolism remains equally unresolved. Multhaup 
and co-workers reported that a synthetic peptide representing the copper-binding site of APP 
was capable of reducing copper (II) to copper (I) in vitro (244). Suazo et al. demonstrated that 
85 
 
APP overexpression induced an increase in copper (II) reduction capacity and intracellular 
copper levels in HEK293 cell cultures exposed to 10 μM of copper, suggesting that APP could 
act as a metalloreductase in the Ctr1-mediated copper uptake mechanism (255). Nevertheless, 
an earlier study by Treiber et al. provided conflicting evidence that showed that expression of 
human APP in cultured yeast cells incubated in media supplemented with 0.5 μM and 1 mM of 
copper resulted in a significant reductions in intracellular copper levels compared to control cells 
(256). These findings were consistent with previous transgenic mouse studies that 
demonstrated that APP overexpression also resulted in a decrease in brain copper content in 
vivo (257, 258), suggesting a potential role for this protein as a copper efflux transporter.  
 
Copper trafficking in the CSF differs considerably from that in blood plasma. In the CSF, copper 
is not predominantly bound to ceruloplasmin but to a low-molecular-weight protein or ligand not 
yet identified (259). The concentration of copper in the CSF may be indicative of BCSFB 
integrity or abnormal copper metabolism. For example, elevated copper concentration in the 
CSF in patients suffering from WD results from the accumulation of copper in the brain due to 
ATP7B loss-of-function (260).  
 
2.2.6 Copper buffering in the CNS 
Due to its elevated copper content and high oxygen demand, the brain is particularly vulnerable 
to copper-induced oxidative stress. It is therefore crucial that the intracellular concentration of 
free copper ions in all brain cells is maintained at very low levels.  
 
MT proteins are an essential component of the metal homeostasis machinery since they are 
able to buffer several heavy metals (e.g. Cd, Pb, Zn, Co, Hg, Cu), thus minimising metal-
induced cellular toxicity. MTs bind excess copper (I) ions for detoxification purposes but also 
serve as a copper depot in the event of intracellular copper deficiency (261). The role of MTs in 
the maintenance of copper homeostasis is supported by reported increases in MT content in 
response to cellular copper overload. Wake et al. observed 16- and 6-fold increases in hepatic 
and renal MT mRNA in rats intraperitoneally injected with CuCl2 (1.5 mg/kg) (262). In the CNS, 
elevation of intracellular MT levels upon exposure to copper was also reported. Hidalgo and co-
workers demonstrated that MT expression levels increased up to 5-fold in neurons and up to 
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15-fold in astrocytes in response to exposure to a range of copper concentrations (0-50 μM) 
(263). The difference in MT content observed between neurons and astrocytes might illustrate 
the greater resistance of astrocytes against copper toxicity compared to other cell types. 
 
The localisation of MT expression within the CNS remains unclear, probably due to the different 
specificities and sensitivities of the antibodies used in immunohistochemical studies. For 
example, Hidalgo et al. reported elevated MT immunoreactivity in glial cells in most regions of 
the rat brain as well as in neuronal cell subsets of the cerebral cortex, hippocampus, 
hypothalamus, brain stem and cerebellum. However, in an earlier study, Nishimura and co-
workers detected almost no MT expression in the adult rat brain and intense MT 
immunostaining in glial cells, arachnoid and pia mater of the mouse brain but not in neurons. 
Both studies revealed strong MT expression in the ependymal cells of the ventricular system 
and choroid plexus, underlining the potential role of the BCSFB as a site for copper homeostatic 
regulation (263, 264). 
 
MT-I and -II are protein isoforms ubiquitously expressed in most organ systems, while MT-III is 
predominantly expressed in the CNS. In addition to its role in heavy metal detoxification and 
intracellular copper storage, MT-III is thought to be involved in the utilisation of zinc as a 
neuromodulator since a direct correlation has been established between neurons with high 
expression levels of MT-III and neurons that store zinc at their presynaptic terminals (265). This 
possibility is further supported by the increased susceptibility to seizures and hippocampal 
neuron injury observed in MT-III-deficient mice (266).  
 
The cellular antioxidant glutathione has also been shown to form stable complexes with copper 
(I) ions. This tripeptide is present intracellularly at millimolar concentrations and is therefore 
considered the primary contributor to the exchangeable cytosolic copper pool (267). Freedman 
and co-workers reported that over 60 % of the cytoplasmic copper isolated from wildtype 
hepatoma and copper resistant cell lines was in the form of copper (I)-glutathione complex 
(268). Glutathione plays a crucial role in copper storage and detoxification but is also thought to 
be involved in intracellular copper trafficking. Carroll et al. demonstrated that the reduced form 
of glutathione mediates the CCS-independent incorporation of copper into mammalian Cu/Zn 
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SOD-1 in both yeast and murine cells deficient for CCS (46). Moreover, glutathione is also 
thought to transfer copper (I) ions to MT proteins after they enter the cell. Freedman et al. 
revealed that inhibition of glutathione synthesis led to a 55 % decrease in 67Cu-MT 
concentration in cultured wildtype hepatoma cells (268). A role for glutathione in the early steps 
of cellular copper uptake was further corroborated by Maryon and co-workers, who reported a 
significant reduction in the initial rate of copper uptake as a result of glutathione depletion in 
HEK293 cells (23). Whether glutathione exerts this function also within the CNS remains 
unknown. 
 
2.3 COPPER IN NEUROLOGICAL DISORDERS 
 
Copper is an essential nutrient for CNS development and function but has also been shown to 
promote molecular processes associated with aging and age-related diseases, such as ROS 
production and the formation of protein aggregates. Hence, copper homeostasis in the CNS 
needs to be tightly regulated, as even a slight imbalance may have deleterious consequences. 
Copper (I) can react with molecular oxygen to produce superoxide radicals and subsequently 
hydrogen peroxide (Figure 2.3.a). Copper (II) ions can be then reduced by superoxide radicals 
to copper (I), which in turn can react with hydrogen peroxide to produce hydroxyl radicals via 
the Fenton mechanism (Figure 2.3.b). The formation of these ROS species may lead to lipid 
and protein oxidation, oxidative inactivation of specific enzymes and irreversible DNA damage, 
and is a common pathological hallmark in most neurodegenerative disorders (269). 
 
Figure 2.3: Copper-catalysed production of ROS. 
 
Copper has also been reported to bind to a number of proteins associated with 
neurodegenerative diseases (e.g. Aβ, APP, PrP, α-synuclein) and subsequently promote their 
aggregation process. In addition to the accumulation of neurotoxic aggregates in the brain, 
copper binding to these molecular entities may lead to the disruption of normal copper 
metabolism pathways and to a further increase in the level of oxidative stress. 
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Copper dyshomeostasis in the CNS is thought to contribute either directly or indirectly to the 
pathophysiology of various neurological diseases, including AD, WD, ALS, MD, prion disease, 
Huntington’s disease (HD) and PD. Although multiple reports have evidenced a role for copper 
in these disorders, the causes and consequences of copper dysregulation as well as its 
significance in disease severity and progression are not fully understood. The following sections 
of this review will evaluate the current state of knowledge on copper dyshomeostasis in the 
above mentioned neurological diseases and discuss its potential as a diagnostic and 
therapeutic biomarker.  
 
2.3.1 Menkes disease 
Mutations in the gene encoding the copper transporter ATP7A are the main cause of the X-
linked recessive Menkes syndrome. Symptoms manifested by patients suffering from MD 
include sparse and fragile hair, progressive neurodegeneration and connective tissue 
abnormalities (270). ATP7A loss-of-function results in altered copper gastrointestinal absorption 
and hyperaccumulation in intestinal and renal tissues, which in turn leads to severe copper 
deficiency in peripheral organs, including brain. Due to decreased brain copper bioavailability, 
the activities of essential cuproenzymes (e.g. Cu/Zn SOD-1, ceruloplasmin, CCO, LOX, DβH) 
are significantly reduced in MD, resulting in impaired antioxidant activity, decreased 
neurotransmitter synthesis, enhanced sensitivity to glutamate-mediated NMDA receptor-
dependent excitotoxicity and reduced axon outgrowth. Brain copper deficiency is therefore the 
primary contributor to the neurodegenerative phenotype of MD, which is characterised by 
profound developmental delay and mental retardation (271).  
 
Among the available therapeutic strategies for the treatment of MD, intravenous administration 
of copper complexes (e.g. copper-histidine) has shown some degree of success in restoring 
physiological copper levels and improving neurodevelopmental outcomes. However, the 
efficacy of this treatment has been found to be highly dependent on early diagnosis, residual 
ATP7A activity and ATP7A mutation type (272, 273). Copper replacement treatment is thought 
to be less effective if initiated after two months of age since the injected copper is sequestered 
by mature BBB endothelial cells and is not transported to neurons. In order to improve copper 
delivery to neuronal cells, the combination of intravenous copper injections and oral 
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administration of lipophilic chelator disulfiram was evaluated in a mouse model of MD. 
Combination therapy resulted in increased copper concentration (as measured by atomic 
absorption spectroscopy) in the cerebellum, liver and serum of macular mice and improved 
CCO and DBH activities, thus suggesting that the administration of disulfiram facilitated copper 
transfer across the BBB (274). Nomura et al. also investigated the effects of disulfiram pre-
treatment on copper biodistribution in MD mice injected with 64CuCl2 by PET imaging. PET 
imaging showed significantly reduced renal 64Cu concentration and enhanced liver and brain 
64Cu uptake in macular mice pretreated with disulfiram compared to untreated controls at 4 h 
post-injection of 64CuCl2 (kidneys: 14.54 vs. 25.56 %ID/g; liver: 29.42 vs. 13.83 %ID/g; brain: 
5.12 vs. 0.96 %ID/g). Moreover, ex vivo brain autoradiography demonstrated that disulfiram 
pretreatment in macular mice led to increased 64Cu accumulation in the cerebral cortex and 
thalamus and decreased ventricular uptake (154). Despite promising preclinical outcomes, 
combination therapy has produced mixed results in patients with MD and is still under 
investigation (275). 
 
ATP7A gene addition has emerged as a very promising treatment option for MD sufferers since 
it is likely to improve the outcome of patients that remain unresponsive to conventional 
therapies. Combined injection of human ATP7A complementary DNA and CuCl2 into the lateral 
cerebral ventricles of neonatal MD mice was reported to significantly enhance survival rates and 
brain copper content as well as CCO and DβH activities. Nevertheless, although the 
combination of ATP7A gene addition and copper treatment restored myelination to normal 
levels and prevented cortical ultrastructural abnormalities, this type of treatment was not able to 
decrease the loss of Purkinje neurons in MD mice, which is thought to impact significantly upon 
motor coordination function (276).  
 
2.3.2 Wilson’s disease 
WD is an autosomal recessive disorder caused by mutations in the gene encoding the ATP7B 
transporter. Copper-transporting ATP7B is predominantly expressed in the liver but can also be 
found in the kidneys, intestines, mammary glands, eyes and brain (277). The main biological 
function of ATP7B is the incorporation of copper into ceruloplasmin, a copper-dependent 
ferroxidase that mediates the transfer of iron into transferrin. In addition to its role in the copper 
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metalation of ceruloplasmin, ATP7B is also involved in the excretion of excess hepatic copper 
into the biliary tract and the efflux of copper ions from the brain. Defective ATP7B activity in WD 
therefore results in copper and iron hyperaccumulation in the liver, kidneys and brain, which in 
turn leads to liver disease, oxidative damage and neuronal degeneration. Brain copper overload 
in WD may give rise to several neuropsychiatric symptoms, including body tremors, dystonia, 
depression or psychosis (278).  
 
Unlike MD, WD is a relatively treatable condition. The use of copper chelating agents (e.g. D-
(−)-2-amino-3-mercapto-3-methylbutanoic acid [D-Penicillamine], N,N'-bis(2-aminoethyl)ethane-
1,2-diamine [Triethylenetetramine]) has been shown to be effective in promoting urinary copper 
excretion, thus reducing excess copper in specific organs. D-Penicillamine is most commonly 
used for this purpose but its clinical application is somewhat limited by high incidence of side 
effects. An alternative option for the treatment of WD is the administration of zinc salts. 
Ingestion of zinc salts has been found to block gastrointestinal copper absorption and to 
enhance the expression of MT proteins in intestinal epithelial cells, which in turn leads to the 
trapping of copper in the intestinal mucosa and its subsequent excretion. In addition, zinc 
therapy is also thought to increase MT levels in hepatocytes, thus decreasing copper-induced 
toxicity in the liver. The combination of zinc and chelation therapies for the treatment of WD has 
been proposed but so far no significant improvements compared to the individual treatments 
have been reported (279, 280). 
 
The most common pathological hallmark found among WD patients is the formation of Kayser-
Fleischer rings due to copper deposition in the periphery of the cornea. The presence of the 
latter together with lower-than-normal ceruloplasmin levels in blood plasma and elevated urinary 
copper is typically sufficient for a positive diagnosis. Nonetheless, additional diagnostic 
approaches are required for cases in which these symptoms are absent. MRI has been used 
with some success to examine brain abnormalities in WD sufferers (281). Another non-invasive 
diagnostic method that has shown great promise for clinical application is 64CuCl2-PET. Peng et 
al. demonstrated the feasibility and utility of imaging the trafficking of both intravenously and 
orally administered 64CuCl2 with PET in an ATP7B knockout mouse model of WD. This group 
revealed significantly increased hepatic 64Cu accumulation in ATP7B knockout mice orally 
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treated with 64CuCl2 compared to healthy controls at 24 h post-ingestion of the tracer (179). 
Peng and co-workers also reported significantly increased hepatic 64Cu concentration in ATP7B 
knockout mice intravenously injected with 64CuCl2 relative to controls at 24 h post-injection of 
the tracer, as well as significantly reduced 64Cu uptake in the kidneys, heart and brain of the 
transgenic mice compared to wildtype controls (153). Alternatively, Gray et al. used 64CuCl2-
PET to characterise the mechanism underlying urinary copper elevation in WD. This group 
revealed an age-dependent decrease in the capacity of ATP7B-knockout livers to accumulate 
copper, resulting in increased renal copper excretion. This decrease in hepatic 64Cu 
accumulation was found to occur due to age-dependent downregulation of the Ctr1 copper 
transporter in the liver of ATP7B-knockout mice (180). Taken together, these preclinical findings 
demonstrate the potential of 64CuCl2-PET as a tool to detect and monitor WD as well as to 
understand better its pathophysiology in vivo. 
 
2.3.3 Amyotrophic Lateral Sclerosis 
ALS or Lou Gehrig disease is a fatal neurodegenerative disorder that affects primarily the motor 
neuron system. The main pathological hallmarks of the disease include degeneration and death 
of motor neurons and gliosis. Most ALS cases are sporadic, while 5-10 % are due to genetic 
causes. 20-25 % of familial ALS cases derive from mutations in the gene encoding the copper-
dependent enzyme Cu/Zn SOD-1. Over 155 mutations in this gene have been identified so far, 
although only some of these have been described as pathogenic (282, 283).  
 
The mechanism by which mutant Cu/Zn SOD-1 induces motor neuron death remains unclear. It 
has been proposed that mutations in the Cu/Zn SOD-1 gene could enhance the pro-oxidative 
capacity of the enzyme, thus leading to oxidative damage and motor neuron degeneration. 
Conversely, it has been suggested that mutations near the metal-binding sites of Cu/Zn SOD-1 
could result in loss of function of the enzyme, deeply affecting the antioxidant defence system of 
motor neurons. Finally, it has also been proposed that the deleterious effects of mutant Cu/Zn 
SOD-1 could be due to the formation of intracellular mutant Cu/Zn SOD-1 aggregates. This is 
supported by the detection of protein inclusions rich in mutant Cu/Zn SOD-1 in the spinal cord of 
familial ALS sufferers (284). However, the formation of these insoluble protein aggregates has 
been found to occur in advanced stages of the disorder and is therefore unlikely to be 
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responsible for progressive motor neuron loss. Instead, mutant Cu/Zn SOD-1 oligomers, which 
have been shown to stimulate ROS production, have been postulated to be the main neurotoxic 
species involved in familial ALS pathology (285). 
 
Symptoms displayed by ALS patients reflect neuronal cell death at all levels of the motor 
system. Upper motor neuron degeneration causes bulbar symptoms such as slurred speech, 
emotional lability, muscular atrophy or respiratory dysfunction, while motor neuron loss in the 
cervical and lumbar regions of the spinal cord results in muscle weakness and spasms in upper 
and lower extremities. To date, there are no effective treatments to halt and reverse the course 
of ALS and most therapeutic approaches are focused on slowing the progression of the disease 
and improving the quality of life of patients. The only approved treatment for ALS is the oral 
administration of 6-(trifluoromethoxy)benzothiazol-2-amine (Riluzole). This drug is thought to 
exert a neuroprotective effect in some ALS patients by preventing excessive glutamate release 
into the synaptic cleft through the inactivation of voltage-dependent sodium channels. Although 
Riluzole has been shown to attenuate glutamate-mediated excitotoxicity in motor neurons, the 
treatment results in only a modest increase in patient survival and does not significantly improve 
muscle deterioration. Other therapeutic substances, including vitamin E, creatine and various 
antioxidant, antiapoptotic and antiexcitotoxic agents, have been evaluated but none has 
demonstrated substantial efficacy in human clinical trials (286, 287). 
 
In recent years, the potential of the Cu-ATSM complex (see Chapter I, section 1.4.2.4) as a 
therapeutic agent for the treatment of ALS has been extensively investigated. Soon et al. first 
reported that Cu-ATSM behaved as an effective scavenger for peroxynitrite, a powerful 
antioxidant resulting from the reaction of nitric oxide and superoxide radicals (288). Peroxynitrite 
has been shown to form a neurotoxic intermediate with Cu/Zn SOD-1 that is capable of nitrating 
tyrosine residues in critical cellular targets, profoundly altering their structure and function (289). 
Soon and co-workers also demonstrated that oral treatment of transgenic mice expressing low 
levels of mutant Cu/Zn SOD-1 with Cu-ATSM at presymptomatic and symptomatic stages of the 
disease significantly delayed onset of paralysis and increased survival rate. Cu-ATSM treatment 
was found to reduce protein nitration and motor neuron loss and enhance the antioxidant 
activity of Cu/Zn SOD-1 in the spinal cord (288). McCallum et al. subsequently showed that Cu-
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ATSM administration prolonged lifespan and improved locomotor function in transgenic mice 
expressing elevated levels of mutant Cu/Zn SOD-1 at early stages of the disease compared to 
Riluzole treatment (290). Roberts et al. used the same mouse model of ALS to examine the 
therapeutic effects of Cu-ATSM in further detail and found that Cu-ATSM treatment surprisingly 
increased the levels of mutant Cu/Zn SOD-1 in the spinal cord of transgenic mice. Mass 
spectrometry analysis revealed that most mutant Cu/Zn SOD-1 present in the spine of ALS mice 
was copper deficient and that Cu-ATSM was capable of improving its metal content in vivo, 
resulting in a decrease of its cellular toxicity (291). Treatment of transgenic mice overexpressing 
mutant Cu/Zn SOD-1 with Zn-ATSM also improved the phenotype of the disease potentially 
through the transmetallation of Zn-ATSM to Cu-ATSM and subsequent delivery of copper ions 
from the complex to Cu/Zn SOD-1 (292). 
 
Due to the high variability in disease phenotype and the overlap between ALS and other 
neurodegenerative disorders, no definitive diagnostic methods currently exist for ALS. For 
patients with a clear-cut family history of ALS, genetic testing is applied. Routine evaluation of 
patients with suspected sporadic ALS includes serum, urine and CSF analysis, and 
electromyography to detect loss of lower motor neurons. However, these diagnostic techniques 
mainly serve to exclude other conditions that mimic ALS features and cannot be used to monitor 
disease progression and response to treatment. MRI of the brain and spinal cord has the 
potential to become a more specific diagnostic tool for ALS. A variety of MRI techniques aimed 
at detecting structural (e.g. grey/white matter volumetric changes, motor cortex atrophy) and 
functional (e.g. cortical activation, neuronal connectivity) abnormalities associated with ALS are 
currently under development (293).  
 
The encouraging results obtained from the preclinical assessment of Cu-ATSM as a therapeutic 
agent along with the hypoxia selectivity exhibited by this complex recently prompted its 
evaluation as a diagnostic tool to delineate cerebral oxidative stress based on an over-reductive 
state caused by mitochondrial dysfunction in ALS. In a relatively small PET clinical study (12 
ALS patients vs. 9 age-matched healthy individuals), Ikawa et al. reported significantly greater 
62Cu concentration in the motor cortex of ALS patients compared to controls at 20 min post-
injection of 62Cu-ATSM. 62Cu accumulation in the motor cortex correlated well with the severity 
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of the disease, which suggests that 62Cu-ATSM-PET could be a useful tool to monitor ALS 
progression (294).  
 
2.3.4 Parkinson’s disease 
PD is another progressive neurodegenerative disorder characterised by the disruption of motor 
function. Patients suffering from PD generally experience slowness of movements, muscle 
rigidity, resting tremors, problems with balance and sensorial alterations. The key 
pathophysiological characteristics of this disorder are dopaminergic neuron loss, particularly in 
the substantia nigra, and the formation of intracellular protein inclusions known as Lewy bodies 
whose main component is the presynaptic protein α-synuclein. In some patients the 
development of PD has been linked to mutations in the gene encoding α-synuclein but in the 
majority of cases the causes of PD remain unknown. It has been suggested that the dysfunction 
of the mitochondrial complex I of the electron transport chain could play a key role in the 
pathogenesis of PD. Impaired mitochondrial metabolism has been evidenced in some PD 
patients through autopsy and in vitro studies. Impaired functioning of complex I has been shown 
to enhance the production of ROS, which in turn promotes oxidative damage to proteins, 
neuronal excitotoxicity and aggregation of α-synuclein into fibrils, eventually leading to neuronal 
death (285, 295).  
 
The mechanism by which the formation of α-synuclein aggregates induces the death of 
dopaminergic neurons still needs to be elucidated. However, it has been shown that exposure 
to specific metals, in particular copper, might affect the aggregation behaviour of the protein. 
Paik et al. first demonstrated that copper was an effective enhancer of the self-oligomerisation 
of α-synuclein. The self-oligomers of this protein are thought to subsequently aggregate and 
form Lewy Body fibrils, although whether the fibrillar or the oligomeric forms of α-synuclein are 
the primary cause of toxicity in PD is still unknown (296). Copper has been shown to accelerate 
the formation of α-synuclein fibrils at physiological concentrations without modifying the 
structure of the protein aggregates. The α-synuclein protein is known to contain a high affinity 
copper (II)-binding site at the N-terminus and a low-affinity copper (II)-binding site at the C-
terminal domain (297). Copper (II)-α-synuclein complexes have been found to oxidise ascorbic 
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acid, dopamine and glutathione in vitro, leading to the generation of ROS and to the depletion of 
these cellular species (298).  
 
In addition to the ability of copper to accelerate α-synuclein aggregation and promote oxidative 
stress, several copper metabolism abnormalities have been detected in PD pathology. Whether 
these abnormalities are a consequence of the interaction of copper ions with α-synuclein is not 
known. Interestingly, it has recently been reported that brain areas most affected by α-synuclein 
pathology in PD (substantia nigra and locus coeruleum) display significantly reduced levels of 
copper and copper transporter Ctr1 (299). This is consistent with the marked increases in total 
iron content observed in these regions, probably due to decreased ceruloplasmin ferroxidase 
activity (194). Defective ceruloplasmin function might result from intracellular copper deficiency 
but might also arise from the oxidation of the enzyme leading to an enzymatic form that lacks 
ferroxidase activity. Olivieri and co-workers first suggested this possibility after detecting the 
presence of acidic isoforms of ceruloplasmin in the CSF of PD patients, resulting from the 
oxidation of the enzyme (300). Copper levels in the CSF have been found to be significantly 
higher in PD patients compared to healthy controls and this increase has been shown to 
correlate with disease severity and progression (301). On the other hand, plasma copper 
concentration is not considered a relevant marker of the pathology since only a modest 
decrease in plasma copper levels has been detected in PD patients (302).  
 
A great number of therapeutic strategies have been developed in order to improve the quality of 
life of individuals affected by PD, including the administration of dopamine precursors, 
dopamine agonists and even inhibitors that block the breakdown of dopamine. Although some 
of these therapies are effective at controlling PD symptoms, none of them are able to halt or 
reverse the progression of the disease (303). The copper (II) complex Cu-ATSM, which is 
currently under investigation as a potential treatment for ALS, is also being evaluated as an 
inhibitor of peroxynitrite-mediated nitrosative stress in PD. PD patients are particularly 
vulnerable to nitrosative stress since their levels of uric acid, a natural scavenger of 
peroxynitrite, have been found to be markedly reduced. Oral administration of Cu-ATSM has 
been shown to increase the degradation rate of peroxynitrite, reduce peroxynitrite-mediated 
nitrosative stress and α-synuclein aggregation and improve motor and cognitive performance in 
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hA53T α-synuclein-overexpressing transgenic mice and several MPTP and 6-OHDA lesion 
murine models of PD (304). Whether these promising preclinical results will translate into the 
clinical setting remains to be seen.  
 
Except for those cases with a clear-cut family history of genetic disease, the diagnosis of PD is 
still largely based on the identification of its clinical symptoms and the exclusion of other 
diagnoses. MRI can be used to identify structural abnormalities in the basal ganglia or the 
presence of iron deposits in the substantia nigra and is therefore able to exclude symptomatic 
parkinsonism caused by other pathologies. PET imaging of dopamine production and 
metabolism with 18F-DOPA and SPECT imaging of dopamine transporter density with 123I-FP-
CIT are useful tools to visualise dopaminergic neuron degeneration and monitor disease 
progression (305). The Cu-ATSM complex has also been evaluated as an imaging agent to 
delineate regionalised oxidative stress in PD, as with ALS. In a small clinical study, Ikawa et al. 
reported significantly higher 62Cu-ATSM striatum-to-cerebellum SUV ratios in PD patients 
compared to controls, which correlated moderately with disease progression (306). Donnelly 
and co-workers further examined the mechanism of cellular retention of Cu-ATSM in cultured 
cell models of PD-like electron transport chain impairment. This in vitro study demonstrated that 
the accumulation and dissociation of the copper complex was driven by the buildup of NADH 
resulting from impaired activity of the electron transport chain, thus suggesting that Cu-ATSM 
retention may be more indicative of mitochondrial dysfunction than oxidative stress (307).  
 
2.3.5 Prion diseases 
Prion diseases are a diverse group of transmissible neurodegenerative disorders which are 
thought to originate from changes in the conformation of endogenous PrP resulting in the 
formation of an infectious conformer of the protein (PrPSc). These conditions are very rare 
among humans and are mainly characterised by spongiform degeneration of the brain and 
spinal cord, formation of amyloid-like fibrils, neuronal loss and gliosis (285).  
 
PrP is a membrane-anchored protein predominantly expressed in the CNS with a high affinity 
for copper (II) ions. The mechanism underlying the conversion of PrP into its infectious form and 
the pathological effects of this transformation are poorly understood. The infectious form of PrP 
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is characterised by its insolubility, resistance to protease activity and lack of nucleic acid 
content, which makes its mode of transmission very intriguing. Once formed, PrPSc acts as a 
template for PrP conversion into additional PrPSc, thus promoting the accumulation of the PrPSc 
isoform in the CNS and its aggregation into amyloid-like fibrils. Much like in other 
neurodegenerative diseases associated with abnormal protein aggregation, the buildup of 
misfolded PrPSc in prion disease is thought to lead to enhanced production of ROS and 
neuronal degeneration (250).   
 
In addition to the neurotoxic effects associated with the misfolded form of PrP, the conversion of 
PrP into PrPSc also entails the loss of function of the native protein, although the exact 
physiological role of the latter still remains undefined. Several reports have linked PrP to normal 
brain copper metabolism and have suggested potential roles for the protein in the cellular 
uptake and buffering of copper ions and even as a copper-dependent antioxidant species (see 
section 2.2.5). The impact of the conversion of PrP into PrPSc on brain copper metabolism is 
poorly understood but abnormal brain copper levels have been observed in patients with prion 
disease. Wong and co-workers reported a 50 % decrease in copper content and a 10-fold 
increase in manganese levels in brain homogenate samples of patients suffering from sporadic 
Creutzfeldt-Jakob disease, the most prevalent form of prion disease in humans. These changes 
in trace metal concentrations in the brain were supported by increased manganese binding to 
PrP accompanied by severely reduced levels of copper-bound PrP. Furthermore, the SOD-like 
activity of the PrP fraction extracted from brain homogenates of prion disease patients was 
found to be markedly decreased, potentially due to reduced copper binding to PrP (308). Brown 
and co-workers examined the inverse correlation between brain levels of manganese and 
copper in prion disease in cultured neurons and demonstrated that manganese ions were able 
to displace copper from PrP, thus reducing its antioxidant activity and increasing its protease 
resistance (309). 
 
Although the previous studies seem to indicate that copper binding to PrP is associated with 
neuroprotective properties of the protein, some deleterious effects of the copper-PrP connection 
have also been reported. For example, incubation of PrP with copper in vitro has been found to 
produce an increase in the hydrophobicity and proteinase K resistance of the protein, which are 
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properties reminiscent of PrPSc (310). Copper is also thought to contribute to the aggregation of 
PrP, although a specific copper-induced proaggregatory effect has not been proved yet. Jobling 
and co-workers demonstrated that removal of copper (II) and zinc (II) ions from aqueous media 
inhibited the aggregation of human PrP in vitro (311). Copper chelation therapy with D-
Penicillamine has been shown to significantly delay the onset of prion disease in infected mice 
by specifically decreasing copper concentration in the brain and blood (312). Paradoxically, 
Hijazi et al. observed a significant delay in prion disease onset in hamsters infected with PrPSc 
after copper supplementation, and suggested that copper might promote the cellular 
internalisation of PrP, thus hindering the interaction of PrP with infectious PrPSc molecules 
(313). The latter contradiction exemplifies the complexity of the relationship between copper, 
PrP and prion disease, and highlights the importance of defining the physiological role of PrP in 
brain copper metabolism in order to better understand the role of copper in the pathophysiology 
of prion diseases.  
 
2.3.6 Huntington’s disease 
HD is another neurological disorder characterised by abnormal protein aggregation. This 
neurodegenerative disease of genetic origin is caused by the expansion of glutamine repeats 
within the N-terminus of the huntingtin protein, whose physiological function has not yet been 
determined. The misfolding and aggregation of the huntingtin protein is thought to promote 
oxidative stress, mitochondrial dysfunction and neuronal loss, particularly in the striatum and 
cerebral cortex. Patients suffering from this condition experience movement abnormalities, 
psychiatric symptoms and progressive cognitive impairment (314). 
 
Much like other neurodegenerative disorders, HD is also characterised by brain metal 
dyshomeostasis. High levels of iron and copper have been detected by inductively coupled 
plasma mass spectrometry (ICP-MS) in the basal ganglia of patients with HD (315). Fox and co-
workers suggested that elevated brain copper content might substantially contribute to pro-
oxidative and neurodegenerative processes in HD by modulating the structure of the huntingtin 
protein and inhibiting the activity of the copper-sensitive enzyme lactate dehydrogenase. This 
group demonstrated that copper (II) was able to interact with human huntingtin protein 
fragments in vitro and stimulate their aggregation. Moreover, it was found that lactate 
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dehydrogenase activity was severely reduced in the brains of HD mice although expression 
levels of the enzyme remained unchanged. Fox et al. suggested that excess copper, which has 
an inhibitory effect on lactate dehydrogenase in vitro, might also be responsible for the 
decreased activity of the enzyme in vivo, thus triggering progressive striatal degeneration (316). 
Xiao and co-workers further examined the influence of copper in HD severity by manipulating 
the levels of expression of several copper transporters in a Drosophila model of HD. Reduced 
expression levels of copper uptake transporters and dietary copper restriction were found to 
rescue the survival rate of HD flies and remarkably decrease the levels of oligomerised and 
aggregated huntingtin protein (314).  
 
These observations first supported the idea that the reduction of brain copper levels might 
substantially mitigate HD pathology. Nguyen et al. evaluated the effects of copper chelation 
therapy in a mouse model of HD with 5-chloro-7-iodo-8-hydroxyquinoline (Clioquinol, CQ; 
Figure 2.4.A), a copper (II)/ zinc (II) chelating agent designed to interrupt neurotoxic interactions 
between these metals and target proteins in the brain. CQ treatment was shown to inhibit brain 
accumulation of aggregated huntingtin in vivo and improve motor function, survival rate and 
overall health in HD mice (317). Another 8-hydroxyquinoline metal chelator, 5,7-dichloro-2-
[(dimethylamino)methyl]quinolin-8-ol (PBT2, Figure 2.4.B), demonstrated similar neuroprotective 
effects in both Drosophila and mouse models of HD (318). However, the clinical evaluation of 
PBT2 treatment only revealed a modest improvement in executive function but not in cognition 
in early-stage to mid-stage HD patients, and therefore this chelation approach is not likely to 
progress clinically (189). 
 




2.3.7 Niemann-Pick disease type C 
Niemann-Pick type C disease (NPC) is a genetically inherited neurodegenerative disorder 
characterised by disrupted intracellular trafficking of endocytosed cholesterol and subsequent 
accumulation of the latter and other lipids in lysosomes and late endosomal compartments. The 
majority of NPC cases arise from mutations in the gene encoding the NPC1 protein, while only 
a few cases involve mutations in the NPC2 gene. Little is known about the exact physiological 
roles of NPC1 and NPC2 but it is thought that these two proteins are crucial players in the 
intracellular transport and processing of cholesterol and other lipids. Loss of function of NPC1 
and/or NPC2 results in the accumulation of ganglioside lipids in the brain and lysosomal/late 
endosomal buildup of cholesterol and other lipid molecules (sphingomyelin, glycosphingolipids, 
sphingosine) in extraneural tissues, resulting in profound abnormalities in lipid metabolism. The 
clinical manifestations of NPC disease are extremely variable and range from systemic disease 
involving liver, spleen and/or lungs, to psychiatric symptoms. The main pathological hallmarks of 
the neurodegenerative component of NPC disease are distortion of neuron shape, formation of 
neurofibrillary tangles (NFTs), neuroinflammation, neuroaxonal dystrophy and death of 
cerebellar Purkinje cells. Nevertheless, how lipid storage abnormalities lead to these processes 
is not understood (319). 
 
In recent years, some preclinical and clinical studies have suggested that impaired lipid 
metabolism in NPC disease may be accompanied by disrupted metal homeostasis. Among 
other transition metal imbalances, copper levels in the liver, blood and CNS have been found to 
be altered in both NPC1 knockout mice and patients, despite occasional inconsistencies in the 
direction of these metal changes between species. Hepatic copper content has been shown to 
be increased in NPC1 knockout mice and human subjects (320-323). Elevated copper levels in 
the liver of NPC1 knockout mice have been linked to reduced hepatic iron content and 
enhanced gene expression of ceruloplasmin, MT-1 and transferrin, suggesting an increased 
efflux rate of iron from liver stores in NPC1 disease. Dietary copper restriction and copper 
chelation therapy have been found to minimise the symptoms of liver disease in this preclinical 
NPC1 model but have not been shown to improve significantly cognitive decline, suggesting 
that hepatic copper overload might only be a regional effect of NPC1 loss-of-function (322). 
High copper and low iron content in the liver of NPC1 knockout mice are consistent with 
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significantly increased copper levels as well as enhanced ceruloplasmin concentration in blood 
plasma (321, 324). Although plasma copper levels have not been found to be increased in 
NPC1 patients, the concentration of copper-metallated ceruloplasmin in blood has been shown 
to be higher compared to apoceruloplasmin levels. While no significant abnormalities in brain 
copper homeostasis have been detected so far in human NPC1 subjects, levels of transition 
metals in the CSF have been found to be remarkably reduced compared to those of healthy 
subjects. Paradoxically, holoceruloplasmin concentration in the CSF has been reported to be 
increased in NPC1 patients and to positively correlate with disease severity (321). 
 
The origin of these copper metabolism abnormalities as well as their impact on the severity and 
progression of NPC disease is poorly understood. It has been demonstrated through dietary 
manipulation in animal studies that abnormal cholesterol metabolism has an effect on copper 
homeostasis, although the precise mechanisms that interlink these pathways have yet to be 
elucidated (325). Alternatively, a direct role for NPC1 in normal copper metabolism could 
explain the impact of NPC1 loss-of-function on copper homeostasis in NPC disease. 
Yanagimoto et al. revealed that cholesterol transport inhibition and NPC1 knockdown in 
hepatocytes resulted in reduced holoceruloplasmin secretion to culture medium, suggesting a 
potential role for the NPC1 protein in the incorporation of late endosomal copper into 
ceruloplasmin (326, 327). 
 
2.3.8 Alzheimer’s disease 
AD is a progressive, fatal neurodegenerative disorder and the most widespread form of 
dementia in the elderly. AD patients initially exhibit symptoms such as short-term memory loss, 
communication problems, disorientation or mood swings, which in later stages of the disease 
degenerate into profound cognitive impairment and ultimately lead to death. The main 
pathological hallmarks of AD are neuroinflammation, neurotransmitter imbalance and the 
accumulation of Aβ plaques and NFTs in the CNS (328). 
 
The progressive formation and deposition of Aβ plaques in the brain is considered a key 
pathological event in the onset and progression of AD. These plaques are mainly composed of 
insoluble aggregated forms of Aβ, a 39-43-aminoacid peptide that results from the sequential 
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cleavage of endogenous APP, whose biological role remains to be established. APP can be 
proteolytically processed through the non-amyloidogenic α-/γ-secretase pathway, or 
sequentially cleaved by BACE1 and γ-secretase, resulting into the production of neurotoxic Aβ 
species (329). The molecular mechanisms that regulate the activity and access of these 
proteolytic enzymes to APP have not been deciphered yet, although risk factors such as 
cholesterol or apolipoprotein E e4 allele have been associated with the amyloidogenic 
processing of the protein (330). The most abundant Aβ species in human plasma and CSF is 
Aβ-40, whereas Aβ-42 is the primary component of the Aβ plaque deposits. In familial AD, 
mutations in the genes encoding APP and the presenilin 1 and 2 proteins, which are 
components of the γ-secretase enzymatic complex, trigger an increase in the production ratio of 
Aβ-42 to less aggregation-prone Aβ-40 (331).  
 
Insoluble Aβ deposits are easily identifiable structures in the AD brain but their contribution to 
neuronal degeneration and cognitive decline is still unclear. Soluble Aβ oligomers have 
alternatively been proposed as the primary molecular culprits behind AD since a direct 
correlation has been demonstrated between Aβ oligomer levels and several markers of disease 
severity in AD patients (332). In addition to the deposition of extracellular Aβ plaques and the 
presence of oligomeric Aβ pools in both intracellular and extracellular compartments, Aβ-42 
aggregates have also been reported to accumulate intraneuronally, prior to the formation of 
NFTs (333). In most AD cases, Aβ plaque deposits also form in the perivascular space of blood 
vessels in the brain and are considered a risk factor for cerebral infarction and white matter 
ischemic lesions (334). 
 
For many years, the accumulation of Aβ plaques in the brain has been regarded as the main 
contributor to AD pathology, and neuronal cell death, vascular damage, NFT formation and 
cognitive impairment have been considered direct effects of this deposition (335). However, 
further research is needed to elucidate the mode of action of these Aβ species, identify their 
cellular targets and link their molecular pathways to the prodromal stages of AD. Aβ plaque 
deposits are thought to first develop in the synaptic clefts of glutamatergic synapses of the 
hippocampus and cerebral cortex and have therefore been associated with the inhibition of 
long-term potentiation, a synaptic enhancement process that contributes to memory formation 
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(269). Snyder et al. suggested that the accumulation of Aβ species might contribute to synaptic 
dysfunction by inhibiting the expression of NMDA glutamate receptors and even promoting their 
endocytosis (336). Aβ plaque deposition has also been linked to the hyperphosphorylation of 
the microtubule-associated tau protein and subsequent formation of the so-called NFTs, 
another key pathological hallmark of AD. However, the nature of this connection remains 
unclear. By crossing different transgenic AD mouse strains it has been found that Aβ promotes 
tau hyperphosphorylation and aggregation but also that tau aggregates contribute to Aβ 
neurotoxicity (337, 338).  
 
The neurotoxic effects of Aβ constitute the basis for the most widespread theory to explain the 
pathogenesis of AD, “The Aβ Cascade Hypothesis”, which posits that Aβ plaque deposition is 
the event that triggers the onset of AD. Nevertheless, the validity of this hypothesis has been 
questioned in recent years and is presently a matter of debate. It has been widely argued that 
the self-aggregating properties of Aβ might not be enough to justify the deposition of Aβ plaques 
in certain areas of the brain. Aβ species are generally found at nanomolar concentrations in the 
brain parenchyma, CSF, brain interstitial fluid and blood plasma of healthy subjects. 
Considering that the distribution of Aβ as well as APP in the CNS is homogenous, it is not yet 
clear how focal deposits of Aβ plaques form in AD. Furthermore, it has been reported that, while 
the deposition of Aβ plaques in the brain is an age-dependent process, the production rate of 
Aβ by proteolytic cleavage of APP does not increase with age. This evidence, together with the 
lack of effective anti-Aβ therapies, supports the notion that additional biochemical processes 
might contribute to the toxicity associated with Aβ buildup in AD (339). 
 
Bush et al. first reported that exposure to zinc accelerated synthetic Aβ-40 aggregation and 
precipitation and increased the resistance of the peptide to proteolytic degradation (340). Post-
mortem analysis of human AD brain tissue revealed elevated concentrations of zinc (~1 mM), 
copper (~400 µM) and iron (~1 mM) associated with extracellular Aβ plaque deposits. Copper 
and zinc were found to be directly bound to Aβ plaques, whereas iron was found in the form of 
ferritin complexes, which are thought to participate in inflammatory processes associated with 
senile plaques (269, 341, 342). This abnormally high transition metal content in Aβ plaque 
deposits has been repeatedly linked in recent years to key pathological processes in AD, such 
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as protein aggregation, ROS production, impaired neurotransmission and even brain metal 
dyshomeostasis. Collectively, this evidence has been used to support the so-called “Metal 
hypothesis of AD”, which suggests that AD pathogenesis is driven primarily by the interaction of 
Aβ and other AD-related proteins (e.g. APP, BACE1) with specific biometals (339).  
 
2.3.8.1 Copper homeostasis in AD  
Reports on endogenous copper content in the human AD brain are variable and often 
contradictory. For example, Lovell et al. detected by micro particle-induced X-ray emission 
elevated concentrations of copper in the rim of Aβ plaques and plaque-free neuropil of the 
amygdala of AD patients (341). Nevertheless, copper levels in the amygdala and hippocampus 
of AD subjects as measured by ICP-MS were found to be significantly decreased (~ 50 %) when 
compared to non-dementia controls (343). Controversy also exists regarding the concentration 
of copper in biological fluids in AD. Pajonk and Kessler reported reduced levels of copper and 
copper carrier ceruloplasmin in blood plasma of mild-to-moderate AD patients compared to 
healthy individuals, which correlated with cognitive decline (344, 345). However, in other 
studies, the concentration of copper and ceruloplasmin in the serum of AD subjects was found 
to be significantly higher relative to control subjects (346, 347). On the other hand, copper levels 
in the CSF have been reported to be similar between AD patients and control subjects (348, 
349). 
 
Copper status in AD is also reflected by reported alterations in the activities of essential copper-
dependent enzymes. Decreased Cu/Zn SOD-1 activity was measured in the brains of APP-
overexpressing mice. Normal antioxidant activity in this preclinical model was restored via 
copper supplementation, which implies a putative intracellular copper deficiency associated with 
Aβ plaque pathology (257). In support of this notion, the activities of cuproenzymes CCO and 
DβH were also found to be significantly reduced in brain regions affected by Aβ plaque 
deposition (e.g. cerebral cortex, hippocampus) in AD subjects, probably leading to impaired 
energy metabolism and neurotransmitter synthesis in those regions (86, 350). 
 
Aβ plaques have been frequently described as metal sinks due to their remarkable ability to 
sequester metal ions. It has been shown that iron, copper and zinc are enriched in extracellular 
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Aβ plaque deposits and that the Aβ peptide has high and low affinity copper and zinc binding 
sites on its structure (351). Considering that the mobilisation of metal ions across the BBB is 
tightly regulated, it has been suggested that the interactions of copper and zinc ions with Aβ 
could be responsible for the disruption of brain metal homeostasis in AD.  
 
The coordination chemistry of copper (II) ions to truncated Aβ peptides (Aβ-16, Aβ-28) and 
native Aβ oligomers (Aβ-40, Aβ-42) has been extensively investigated via nuclear magnetic 
resonance (NMR) and electron paramagnetic resonance (EPR). The coordination environment 
for copper (II) when bound to Aβ is still unclear but a distorted square planar geometry with a 
3N1O coordination mode has been proposed for the copper (II) coordination site on Aβ in 
solution (Figure 2.5.A) and a binuclear model involving a bridging histidyl ligand has been 
suggested as the copper (II) coordination mode in Aβ aggregates (Figure 2.5.B) (352). It has not 
yet been determined whether Aβ is also capable of binding copper (I) ions. Considering that the 
redox behaviour of copper when bound to Aβ aggregates has been linked to ROS generation, 
the coordination of copper (I) to Aβ plaques seems quite probable (351).  
 
Figure 2.5: Proposed models for the coordination of copper (II) on Aβ species. Copper (II) coordination 





APP is also capable of binding copper ions with high affinity. This protein possesses a copper 
(I) binding site in its N-terminus and a second coordination site for copper (II) acquired after 
proteolytic cleavage by BACE1 (353). Growing evidence indicates that APP is not only capable 
of binding copper ions but that it also plays a critical role in brain copper homeostasis. Research 
conducted on APP-knockout transgenic mice revealed high concentrations of copper in the 
cerebral cortex and liver, while APP overexpression in transgenic mouse models of AD resulted 
in significantly decreased brain copper levels (257, 258, 354). This evidence seems to indicate 
that APP might function as an efflux transporter for copper in the CNS.  
 
Another key player in AD pathology capable of binding copper is BACE1. The cytoplasmic 
domain of this enzyme has been shown to bind a single copper (I) ion with high affinity. 
Additionally, BACE1 has been reported to be able to interact with CCS, thus interfering with the 
delivery of copper from CCS to apo-Cu/Zn SOD-1. Angeletti et al. demonstrated that 
overexpression of BACE1 in cultured cells led to the downregulation of Cu/Zn SOD-1 activity 
due to direct competition between BACE1 and apo-Cu/Zn SOD-1 for CCS. This competitive 
effect could further weaken the antioxidant defences of brain cells in AD, leading to enhanced 
vulnerability of the brain to oxidative stress (248).   
 
Copper has also been reported to interact with the tau protein in vitro, resulting in the formation 
of redox-active complexes capable of pro-oxidant or antioxidant behaviour depending on the 
redox status of the cell (355). Despite the ability of copper to increase the aggregation rate of 
tau in vitro, the presence of copper in NFTs has not yet been confirmed, and therefore its 
potential contribution to the aggregation behaviour and neurotoxicity of hyperphosphorylated tau 
is still under investigation (356). 
 
2.3.8.2 Copper-induced synaptic toxicity in AD  
As previously mentioned, the formation of Aβ plaque deposits in AD initially occurs at the 
synaptic clefts of glutamatergic synapses in the cerebral cortex and hippocampus, where 
elevated concentrations of both copper and zinc ions have been detected. Zinc (II) ions are 
transferred by transporter ZnT3 into synaptic vesicles, from where they are released along with 
glutamate into the synaptic cleft during neurotransmission. The role of zinc in neurotransmission 
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still has to be defined but it has been suggested that this transition metal could act as a 
neurotransmitter and/or modulator of the activity of glutamate receptors (269). Schlief et al. 
demonstrated the existence of a correlation between the activation of NMDA receptors and 
increased post-synaptic trafficking of copper transporter ATP7A towards the synaptic cleft and 
subsequent copper release in cultured hippocampal neurons. It has been suggested that copper 
may act as an electron acceptor in the S-nitrosylation of NMDA receptors in the presence of 
nitric oxide, thus modulating the activity of NMDA receptors and minimising neuronal 
excitotoxicity (216). 
 
Considering that Aβ is also released into the synaptic cleft of glutamatergic synapses during 
neurotransmission, it has been suggested that potential interactions of the peptide with copper 
and zinc ions could be responsible for abnormal Aβ aggregation and ROS production in those 
brain regions (Figure 2.6). The binding of copper and zinc ions to the brain-specific MT-3 
protein, which is released into the synaptic cleft by neighbouring astrocytes, is thought to reduce 
Aβ aggregation and cross-linking and oxidative stress. However, this protein has been found to 
be downregulated in the AD brain (357).   
 
Figure 2.6: Copper/zinc-induced synaptic toxicity. During neurotransmission, zinc (II) ions are released 
along with glutamate from the presynaptic terminal of glutamatergic synapses into the synaptic cleft by 
transporter ZnT3. Aβ is also released during glutamatergic excitation into the synaptic cleft. Copper (II) 
ions are released from the post-synaptic terminal into the synaptic space by ATP7A as a response to the 
activation of NMDA receptors. The interaction of Aβ with copper (II) and zinc (II) ions leads to increased Aβ 
aggregation and oxidative stress. Metallothionein-3 is capable of minimising Aβ-metal interactions at the 




2.3.8.3 Copper-induced oxidative stress in AD  
Copper-induced oxidative stress is a characteristic pathological process occurring in many 
neurodegenerative diseases, including AD, as a result of brain copper dyshomeostasis. The Aβ 
peptide has been shown to be capable of binding copper (II) ions with high affinity and to utilise 
their redox cycling properties to produce ROS in vitro. Copper (II)-Aβ complexes are able to 
produce hydrogen peroxide via reduction of copper (II) to copper (I) and double electron transfer 
to molecular oxygen. The electron source responsible for the initial reduction of Aβ-bound 
copper (II) has not been identified yet but it has been suggested that electrons could be 
generated from Aβ side-chain oxidation, which in turn might enhance Aβ aggregation. Opazo et 
al. suggested that cholesterol, catecholamines (e.g. dopamine, noradrenaline, adrenaline) and 
vitamin C could act as electron donors to reconstitute the copper (II)-Aβ complex. Hydrogen 
peroxide is able to diffuse across cell membranes and oxidise different cellular components but 
can also react with copper (I)-Aβ complexes and form hydroxyl radicals, which can cause 
further oxidative damage (269, 358). Moreover, it has been shown that the presence of Aβ can 
modulate the concentration of glutathione, an essential component of the antioxidant defence 
machinery of the cell. White and co-workers demonstrated that pretreatment of cultured 
neurons with fibrillary Aβ fragments depleted cellular glutathione, resulting in increased copper 
toxicity and oxidative stress (359). 
 
2.3.8.4   Therapeutic approaches based on copper supplementation  
Multiple lines of evidence support the idea that brain copper homeostasis is disrupted in AD as 
a result of the interaction of copper ions with key molecular players in AD pathology (e.g. Aβ, 
APP, BACE1, tau). In particular, the accumulation of copper in extracellular Aβ plaque deposits 
has been proposed to result in a marked decrease in intracellular copper bioavailability leading 
to reduced activity of essential copper-dependent enzymes (339, 360, 361). 
 
In recent years, a great number of therapeutic approaches that seek to restore this putative 
brain copper deficit in AD have been developed. Bayer et al. examined the effects of increasing 
copper bioavailability in APP23 transgenic mice treated with copper-supplemented drinking 
water. Dietary copper treatment was shown to restore intracellular copper levels and Cu/Zn 
SOD-1 enzymatic activity in the brains of APP23 mice, as well as significantly decrease soluble 
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Aβ-40 and Aβ-42 levels, although this effect was only observed in male mice (257). Manso and 
co-workers treated three different groups of APP/PS1 transgenic AD mice with copper-
supplemented water, cholesterol-rich food or a combination of both in order to assess the effect 
of these parameters on Aβ burden and cognitive decline. All three different treatments caused a 
significant decrease in Aβ plaque burden in transgenic mice when compared to controls, but the 
combination of copper and cholesterol supplementation had the most dramatic impact (362). 
However, these findings are inconsistent with those reported by Sparks et al., who revealed that 
treatment of cholesterol-fed rabbits with copper-supplemented water promoted Aβ plaque 
accumulation in the hippocampus and temporal lobe and induced learning deficits relative to 
untreated controls (363). This discrepancy in the effects of copper supplementation may arise 
from differences in the administered copper doses but may also be due to the phenotypic 
variability existing between the different AD models.  
 
White and co-workers revealed that treatment with copper (II)/zinc (II)-CQ complexes induced a 
dramatic decrease in secreted levels of Aβ-40 and Aβ-42 in APP-overexpressing chinese 
hamster ovary cells (CHO) and neuroblastoma cells compared to non-treated controls. This 
group demonstrated that this reduction of Aβ burden resulted from copper (II) and zinc (II)-
mediated upregulation of matrix metalloproteinase (MMP) enzymatic activity. Copper (II)/zinc 
(II)-CQ complexes were found to induce the activation of the phosphoinositol 3-kinase (PI3K) 
enzyme as well as the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase 
3 (GSK3). Treatment of cultured APP-overexpressing cells with these metal complexes was 
shown to also trigger the activation of c-Jun N-terminal kinases (JNKs) and extracellular-signal-
regulated kinases (ERKs). The activation of all these molecular pathways ultimately led to the 
upregulation of MMPs and the subsequent degradation of Aβ aggregates (364).  
 
Despite these promising initial results, CQ shows only moderate copper (II) binding affinities 
(Kd= 10-10 M) and consequently the resulting complexes might offer moderate control over 
cellular uptake and intracellular metal release. In addition to this, White et al. failed to clarify 
some key aspects of the mechanism of action of CQ complexes since it remained uncertain 
whether copper-mediated upregulation of MMP activity required the release of the metal ion 
from the complex or whether the complex remained intact instead.  
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In an attempt to find suitable alternatives to CQ, Donnelly and co-workers investigated the 
effects of a series of Cu-BTSC complexes on Aβ burden in cultured APP-overexpressing CHO 
cells (Figure 2.7). The structural tunability of these metal complexes, which enables the 
modification of some of their physicochemical properties (e.g. redox potential, lipophilicity), 
allows subtle control over their uptake and metal release within specific cell microenvironments 
(see Chapter I, section 1.4.2.4). Treatment of APP-CHO cells with Cu-GTSM (Fig. 2.7.A) and 
Cu-ATSM (Figure 2.7.B) resulted in 216- and 177-fold increases in cellular copper levels 
respectively compared with untreated controls. Moreover, Cu-GTSM and its derivatives copper 
(II) glyoxal-bis(N4-ethyl-3-thiosemicarbazone) (Cu-GTSE, Figure 2.7.C) and copper (II) glyoxal-
bis(N4-phenyl-3-thiosemicarbazone) (Cu-GTSP, Figure 2.7.D) induced 15, 16 and 38 % 
decreases in secreted monomeric Aβ-40 levels respectively, while treatment of APP-CHO cells 
with Cu-ATSM had no effect on Aβ burden. Donnelly et al. suggested that the lack of impact of 
Cu-ATSM on Aβ turnover could be due to the higher thermodynamic stability and resistance to 
bioreduction and dissociation of the complex compared to Cu-GTSM and its derivatives, thus 
supporting the idea that copper-mediated Aβ proteolytic degradation requires the intracellular 
dissociation of the complex (142). This group also demonstrated that treatment of APP-CHO 
cells with Cu-GTSM triggered the phosphorylation of the Akt, JNK and GSK3 kinases and 
subsequent upregulation of MMP activity, resulting in dose-dependent reduction in the levels of 




                               (A)                                                                         (B) 
 
 
                                      
                              (C)                                                                           (D) 
Figure 2.7: Structures of Cu-GTSM (A), Cu-ATSM (B), Cu-GTSE (C) and Cu-GTSP (D). 
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Crouch et al. investigated further the effect of increasing copper bioavailability in the brain by 
treatment with Cu-GTSM and Cu-ATSM in vivo. Oral supplementation of Cu-GTSM resulted in a 
reduction of the levels of neurotoxic Aβ trimers and inhibition of GSK3β and tau 
hyperphosphorylation in 6-month-old APP/PS1 transgenic mice when compared to sham-
treated controls. Moreover, Cu-GTSM-supplemented AD mice also showed restored cognitive 
performance in the Y-maze test to the level of healthy animals. Conversely, Cu-ATSM 
supplementation in APP/PS1 transgenic mice produced no significant effect on Aβ burden, 
GSK3β activity or cognitive performance (366).  
 
Despite these promising preclinical results, the restoration of brain copper levels via copper (II)-
orotate-dihydrate supplementation had no effect on cognition in patients with mild AD (367). 
This discrepancy in the effects of copper supplementation may be due to different copper (II) 
complexes used or differences in copper metabolism between species, but may also be the 
result of the disconnection between AD animal models and human AD. 
  
2.3.8.5   Therapeutic approaches based on copper redistribution  
With the purpose of preventing neurotoxic copper-Aβ interactions and restoring brain copper 
homeostasis in AD, the ability of several copper (II)-chelating agents (e.g. EDTA, DTPA) to 
sequester copper ions from plaques and redistribute them into cells has been investigated. 
However, despite the ability of some of these chelators to extract copper from cerebral Aβ 
plaque deposits, their clinical application presents major drawbacks, such as limited BBB 
permeability and cell permeability or poor metal ion specificity, which may lead to excessive 
removal of essential biometals (368).  
 
The efficacy of several clinically approved metal-chelating drugs (e.g. Desferrioxiamine B, 
Deferiprone, D-Penicillamine) in attenuating neurotoxic copper-Aβ interactions has also been 
investigated. Clinical evaluation of these traditional chelators as therapeutic agents for AD 
treatment has produced mixed results so far. Treatment of AD patients with D-Penicillamine for 
6 months produced no effects on cognition but led to a moderate decrease in the levels of 
oxidative stress markers in serum (369). Conversely, daily intramuscular administration of 
Desferrioxiamine for 2 years resulted in a reduction in the rate of decline of daily living skills in 
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AD patients, demonstrating the potential of this drug to modestly delay the clinical progression 
of dementia (370). However, Desferrioxiamine is a non-specific metal chelator capable of 
binding copper, zinc, iron and aluminium and, as a result, this type of treatment could 
progressively lead to systemic metal depletion (339). 
 
The failure of traditional copper chelators to halt AD progression led to the notion that more 
sophisticated copper chelators were required to prevent copper-induced neurotoxicity in AD. In 
1997, Bush and co-workers first introduced the concept of metal-protein attenuation compounds 
(MPACs). These “smart” chelating agents are characterised by BBB-permeability, low molecular 
weight and nanomolar affinity for copper (II) and zinc (II) ions, which facilitates the sequestration 
of these metals from the low-affinity metal binding sites of Aβ (339).  
 
The copper (II)/zinc (II) chelator CQ was initially established as the gold-standard of this 
generation of “smart” chelating agents. Cherny et al. reported a 49 % reduction in brain Aβ 
accumulation in 21-month-old APP2576 transgenic mice orally treated with CQ (30 mg/kg/day) 
for a 9-week period when compared with sham-fed transgenic controls. Furthermore, a 
significant improvement in general health, body weight parameters and behaviour in CQ-treated 
APP2576 mice was observed, highlighting the therapeutic potential of CQ-like drugs for the 
treatment of AD. Interestingly, a significant increase in copper (19 %) and zinc (13 %) levels in 
brain homogenate samples of CQ-treated transgenic AD mice was also detected. Cherny and 
co-workers suggested that this increment in brain copper and zinc content could result from CQ-
mediated redistribution of the metals from Aβ plaque deposits to copper/zinc-deficient brain 
regions (371).  
 
These results supported the idea that the mechanism of action of CQ was much more complex 
than originally estimated (Figure 2.8). Treiber et al. subsequently reported that addition of CQ to 
cultured yeast cells dramatically increased intracellular copper levels, thus revealing the ability 
of CQ to alter copper distribution and stimulate intracellular copper uptake (256). Furthermore, 
treatment with copper/zinc-CQ complexes was shown to activate specific cell signalling 
pathways that in turn triggered the proteolytic degradation of Aβ plaques as well as the 




Figure 2.8: Proposed mechanisms of action for CQ and Cu-GTSM (364, 365). 
 
Despite these encouraging preclinical results, CQ treatment was found to produce significant 
clinical impact only on advanced AD cases. Reduced Aβ-42 plasma levels and enhanced 
plasma zinc concentration were observed in CQ-treated severe AD patients when compared 
with placebo-treated controls (372). Additional clinical studies on CQ treatment have not been 
performed due to the production of a carcinogenic impurity during drug manufacture (339).  
 
In recent years, PBT2 has become the leading MPAC alternative to CQ for the treatment of AD 
and other neurodegenerative disorders associated with brain copper dyshomeostasis. This 8-
hydroxyquinoline derivative presents several advantages over CQ, such as greater solubility 
and BBB penetration as well as straight-forward synthesis and purification. Moreover, Adlard et 
al. demonstrated that PBT2 also outperforms CQ as a copper (II)/zinc (II) ionophore. PBT2 was 
found to be able to promote copper and zinc intracellular uptake, thus reducing copper-induced 
hydrogen peroxide production and increasing the solubilisation of insoluble Aβ aggregates in 
vitro. In addition, PBT2 treatment resulted in marked decreases in soluble Aβ concentration, 
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plaque burden, synaptotoxicity marker levels and tau phosphorylation in two different mouse 
models of AD (APP/PS1 and Tg2576), resulting in marked behavioural improvement and rapid 
restoration of cognitive deficits (373).  
 
Nevertheless, clinical assessment of PBT2 as a therapeutic agent for the treatment of AD has 
failed to yield satisfactory results. Drug safety evaluation initially revealed that 12-week PBT2 
treatment (250 mg) induced a significant decrease in the levels of Aβ-42 in the CSF of patients 
with prodromal AD and produced significant improvements in two measures of executive 
function (374, 375). Despite these promising results, larger-scale testing of PBT2 in patients 
with mild AD did not show a significant reduction in brain levels of Aβ plaques or lead to a 
significant improvement in brain metabolic activity, cognition or function (376). The failure of 
MPAC therapies to improve the symptoms of human AD and halt disease progression reflects 
the discrepancies between current AD animal models and human AD as well as the critical gaps 
in knowledge of the pathophysiology of the disease and the role of copper in 
neurodegeneration.  
 
2.3.8.6 Cu-BTSCs for the delineation of brain copper trafficking in AD 
The complexity of AD pathology and the common symptoms existing between AD and other 
neurodegenerative diseases (e.g. frontotemporal dementia, vascular dementia, PD) complicate 
considerably the accurate diagnosis of this disorder. At present, absolute diagnosis of AD relies 
only on histological staining of Aβ plaque deposits and NFTs in post-mortem brain tissue. There 
are currently no reliable diagnostic biomarkers or techniques that can be used to detect AD 
before the onset of full dementia and monitor disease progression and response to treatment.                         
Neuropsychological testing remains the most frequently used tool in AD diagnosis since it 
allows the assessment of multiple cognitive domains (memory, language, perceptual skills, 
attention, orientation, problem-solving and functional and constructive abilities) (377). However, 
the interpretation of these tests is considered rather subjective and does not differentiate 
between AD and other forms of dementia nor detect early onset AD. In recent years, the use of 
imaging in various modalities (MRI, PET and SPECT) has provided the possibility of measuring 
in an objective and reliable manner disease markers that are indicative of specific pathological 
processes associated with AD. In particular, over the last decade, efforts have been focused on 
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the development of imaging agents capable of targeting Aβ plaque deposits in vivo. Although 
these agents can be used to effectively map Aβ plaque deposits in the brain, they only provide 
information on a particular feature of AD pathology, whose predictive value as a marker of 
disease progression and severity still remains unclear.  
 
Given the multifactorial nature of AD pathophysiology, the delineation of a biomarker that is 
affected by multiple pathological features of the disease could provide useful insight into the 
severity and progression of AD as well as valuable information for assessing prognosis and 
response to therapy. In this regard, brain copper trafficking is considered an attractive target 
since copper has been shown to interact with multiple molecular entities involved in AD 
pathology (e.g. Aβ, APP, BACE1, tau) and is known to contribute to several pathological 
processes that enhance AD severity (e.g. oxidative stress, abnormal protein aggregation, 
synaptic toxicity).  
 
The use of Cu-BTSC complexes as therapeutic agents for the treatment of AD illustrates the 
ability of these compounds to release their copper payload into cells selectively or non-
selectively, depending on their physicochemical properties. Cu-BTSC complexes Cu-ATSM and 
Cu-GTSM have both been shown to be capable of crossing the BBB in vivo and increasing 
intracellular copper bioavailability, but the higher susceptibility of Cu-GTSM to intracellular 
bioreduction and metal release has been found to enable the delivery of higher quantities of 
copper into the brain when compared with Cu-ATSM (366). Fodero-Tavoletti and co-workers 
first assessed the ability of these complexes to delineate brain copper trafficking in AD by PET 
in APP/PS1 transgenic mice. Ex vivo biodistribution data revealed almost a 2-fold greater 
uptake of 64Cu-GTSM in the brains of 9-12-month-old APP/PS1 mice (3.0 ± 0.25 %ID/g) when 
compared to age-matched controls (1.58 ± 0.14 %ID/g) at 1 h post-injection of the tracer. 
Conversely, no significant differences in brain 64Cu-ATSM concentration were observed 
between APP/PS1 and controls, which is consistent with the lower susceptibility of the complex 
to intracellular bioreduction and metal release. Furthermore, immunohistochemistry and in vitro 
autoradiography showed that 64Cu-GTSM accumulation in post-mortem human AD brain tissue 
did not co-localise with Aβ plaque deposits, demonstrating that 64Cu signal in brain tissue was 
not the consequence of 64Cu-GTSM or 64Cu binding to Aβ plaques (155). Although preliminary, 
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these results warrant further investigation and demonstrate the potential of 64Cu-GTSM-PET as 




Figure 2.9: MicroPET/CT images (sagittal, axial and coronal planes) of APP/PS1 trangenic mice injected 
with 64Cu-GTSM and 64Cu-ATSM at 30 min post-injection of the tracer. Reproduced with permission from 
(155). 
 
2.4 CONCLUDING REMARKS 
 
Copper is a fundamental bioelement for the normal development and function of the CNS. As a 
cofactor of both systemic and brain-specific enzymes and modulator of synaptic transmission 
and other cell signalling pathways, copper participates in many physiological processes that are 
essential for the maintenance of neurological health and function. However, due to the low 
antioxidant capacity of the brain, copper content in the CNS needs to be tightly regulated in 
order to minimise copper-induced production of ROS. Although significant progress has been 
made in identifying the molecular entities that regulate brain copper trafficking and distribution, 
many aspects of these homeostatic mechanisms remain to be elucidated. Little is known about 
the specific copper transport mechanisms of the different types of brain cells as well as the 
function and interactions of these cell types in brain copper homeostasis. The role of several 
copper-binding proteins associated with neurodegenerative diseases (e.g. PrP, NPC1, APP) in 
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normal copper metabolism also needs to be defined in order to better understand the origin and 
effect of copper imbalance in these disorders. 
 
The deleterious effects of brain copper deficiency and overload on CNS function are illustrated 
by the inherited Menkes and Wilson’s disorders, which result from mutations in the genes 
encoding copper transporters ATP7A and ATP7B, respectively. In recent years, brain copper 
imbalance has also been associated with other neurological diseases, including ALS, PD and 
AD. In addition to the dysregulation of copper-dependent signalling and enzymatic activity, brain 
copper dyshomeostasis is thought to contribute to common pathological features of these 
neurodegenerative conditions, such as abnormal protein aggregation and oxidative stress. 
However, it should be pointed out that the enhancement of these pathological processes is not 
an exclusive effect of brain copper imbalance since other trace metal abnormalities have also 
been reported in most of these disorders. A better knowledge of the interrelationships between 
copper and other transition metals in the brain, particularly iron and zinc, is required in order to 
understand the consequences of their dysregulation to CNS function as well as their specific 
contribution to neurodegeneration. 
 
Whether abnormal copper homeostasis is a cause or a consequence of neurological disease or 
merely a result of aging that enhances the severity of neurodegeneration is currently not known. 
The potential of trace metal abnormalities as disease markers needs to be investigated in order 
to determine whether they could provide meaningful information on disease severity and 
progression. The use of brain copper dyshomeostasis as a disease marker could be particularly 
informative for multifaceted neurodegenerative diseases such as AD, which ideally require 
biomarkers that are perturbed by several pathological factors. In AD, copper has been shown to 
interact with various molecular players of the pathology (e.g. Aβ, APP, BACE1, tau) and is 
thought to contribute to pathological processes such as Aβ and tau peptide aggregation, 
oxidative stress or synaptic toxicity. Brain copper dyshomeostasis could therefore be a much 
more useful marker to characterise the status and progression of AD than single molecular 




The growing availability of high-resolution PET systems and copper radionuclides encourages 
the use of copper radiotracers, in particular the BBB-permeable 64Cu-GTSM complex, to 
measure brain copper fluxes in vivo in real-time with PET. 64Cu-PET offers the unique 
opportunity to study brain copper trafficking in disease models and humans to determine its 
predictive value as a disease marker in several neurological disorders and further characterise 
the role of copper in neurodegeneration. 64Cu-PET imaging of copper trafficking could 
additionally be used as a tool to monitor the effect of copper-modulating therapies on copper 
biodistribution in diseases associated with copper dyshomeostasis, and even elucidate the 




















3. Chapter 3- PET imaging of brain copper trafficking in a 





The aim of this chapter is to investigate brain copper trafficking in a mouse model of AD by 
64Cu-GTSM-PET in order to detect and characterise potential metabolic abnormalities that might 




3.2.1 Diagnosis of AD 
AD is the most common form of dementia in the elderly. Its prevalence in an ageing global 
population is rapidly increasing, creating a major socio-economic burden. There is no 
satisfactory method for its early diagnosis and no effective treatment to halt or delay cognitive 
decline experienced by patients. The disease is mainly characterised by neuronal cell death, 
neurotransmitter imbalance, neuroinflammation and the deposition in the brain of two types of 
abnormal protein aggregates, namely NFTs and Aβ plaques (see section 2.3.8, Chapter II). At 
present, absolute diagnosis of AD is only possible via post-mortem histological identification of 
characteristic hallmarks of the pathology (e.g. Aβ plaque deposits, NFTs, microglia activation), 
while clinical diagnosis relies mostly on the neuropsychological assessment of the subject.  
 
Complementary diagnostic techniques to cognitive testing that have potential for routine clinical 
use include PET imaging of reduced regional brain glucose metabolism with 18F-FDG, CSF 
analysis, structural MRI, blood oxygen level–dependent (BOLD) functional MRI and PET 
imaging of Aβ plaques (378). Among these tests, 18F-FDG-PET has been shown to detect AD in 
human subjects with the highest sensitivity (~93 %) and specificity (~ 76 %) (379). Furthermore, 
18F-FDG-PET has been reported to be able to differentiate accurately AD from frontotemporal 
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dementia, and even mild cognitive impairment (MCI) cases from healthy elderly subjects when 
combined with executive function tests (380, 381). However, brain 18F-FDG uptake is a non-
specific indicator of cerebral glucose metabolism, which may be altered due to non-AD 
pathological processes, and consequently cannot be used as an independent diagnostic marker 
of AD pathology (378). 
 
The CSF is a valuable source of disease markers for several CNS disorders since its 
composition reflects the biochemical changes occurring in the brain. AD subjects have been 
reported to exhibit markedly increased CSF levels of total and phosphorylated tau, and 
significantly reduced levels of Aβ-42 when compared to controls (382). The combined analysis 
of CSF total and phosphorylated tau, and Aβ-42 has been found to differentiate AD sufferers 
from healthy individuals with high sensitivity and specificity (~80-90 %), particularly at early 
stages of the disorder. Nevertheless, the large overlap in pathology between AD and other 
types of dementia (e.g. vascular dementia, dementia with Lewy bodies) along with the presence 
of the latter AD biomarkers in the CSF of cognitively normal elderly individuals, limit the 
accuracy of CSF analysis as a diagnostic test. Moreover, CSF analysis involves invasive lumbar 
puncture procedures, which often cause discomfort to patients (383). 
 
Structural MRI is an effective imaging methodology to measure the degree of cerebral atrophy 
in AD, particularly in regions such as the hippocampus or the entorhinal cortex, in which tissue 
loss occurs before cognitive symptoms begin. Cerebral atrophy has been shown to correlate 
very closely with cognitive decline and therefore shows promise as a diagnostic marker of AD 
progression. However, brain structural measures on their own are not capable of detecting AD 
at the MCI stage and do not produce sufficiently specific spatial patterns to distinguish between 
AD and other types of dementia (384). 
 
The clinical utility of BOLD functional MRI methods has also been increasingly investigated in 
recent years. These diagnostic tests offer an indirect measure of neuronal activity inferred from 
changes in MRI signal caused by variations in blood flow, blood volume and blood 
oxyhemoglobin/deoxyhemoglobin ratio. Aberrant task-related BOLD MRI signal has been 
detected in regions exhibiting high Aβ plaque deposition and is therefore considered a 
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promising marker to assess the effects of anti-Aβ therapies in clinical trials. Nonetheless, BOLD 
functional MRI is logistically challenging when testing cognitively impaired subjects and has 
been reported to yield variable results across individuals, which hampers its clinical application 
(378). A wide range of MRI techniques capable of characterising other functional markers of AD 
(e.g. cerebral perfusion, axonal transportation, integrity of fibre tracts, N-acetylaspartate and 
glutamate levels) are currently in preclinical development (385).  
 
Molecular imaging offers unique potential to characterise and measure disease-specific 
molecular markers capable of accurately monitoring disease progression and response to 
treatment in vivo and in a non-invasive manner. To date, the most popular application of 
molecular imaging in AD is the delineation of Aβ plaque burden by PET or MRI. The majority of 
PET-based diagnostic approaches in AD are based on the development of radioligands capable 
of crossing the BBB and binding specifically to Aβ plaques. In 2004, Klunk and co-workers 
developed 2-(4'-[11C]methylaminophenyl)-6-hydroxybenzothiazole (Pittsburgh Compound B 
[11C-PIB]; Figure 3.1.A), a 11C-radiolabelled derivative of the fluorescent Aβ dye thioflavin T 
capable of binding to fibrillar Aβ with high affinity and specificity (386). Brain uptake of 11C-PIB 
in AD subjects was found to be greater compared to healthy elderly individuals and to correlate 
with regional glucose hypometabolism, reduced levels of Aβ-42 in the CSF and degree of 
cerebral atrophy (as measured by structural MRI) (387-389). However, although brain 
accumulation of 11C-PIB showed a positive correlation with the rate of memory decline in MCI 
and prodromal AD subjects, it did not correlate with the rate of memory impairment at later 
stages of the disease. Another drawback of brain amyloid imaging using 11C-PIB is the fact that 
the tracer shows moderate non-specific white matter binding, which together with age-
dependent accumulation of Aβ plaques in the brains of some healthy individuals might 
contribute to false-positive results (390).    
 
The ability of 11C-PIB to delineate Aβ plaque deposition encouraged the development of other 
Aβ-targeting agents using longer lived PET radioisotopes, such as fluorine-18 (t1/2= 109.8 min). 
Among these, the 18F-labelled radioligands 2-[3-[18F]Fluoro-4-(methylamino)phenyl]-1,3-
benzothiazol-6-ol (18F-Flutemetamol), trans-4-(N-methly-amino)-4″-(2-(2-(2-[18F]Fluoro-
ethoxy)ethoxy)-ethoxy) stilbene) (18F-Florbetaben) and trans-4-(2-(6-(2-(2-(2-[18F]Fluoro-
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ethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzeneamine)  (18F-Florbetapir) (Figure 
3.1.B/C/D) are currently the most promising candidates for clinical use. Although these probes 
have been shown to be able to accurately map cerebral Aβ plaque load, they exhibit greater 
non-specific white matter binding and lower average cortical uptake than 11C-PIB, which hinders 
the interpretation of their PET scans (390).  
 
Figure 3.1: Chemical structures of 11C-PIB (A), 18F-Flutemetamol (B), 18F-Florbetaben (C) and 18F-
Florbetapir (D). 
 
Because of its superior spatial resolution compared to PET, MRI has also been applied to 
delineate cerebral Aβ plaque load in AD. Several non-contrast MRI protocols have been shown 
to be capable of detecting thalamic, cortical and hippocampal plaques in different transgenic 
mouse models of AD. However, MRI detection of Aβ plaques without contrast agents has been 
found to be subject to the accumulation of iron and calcium within plaques, which is a feature of 
Aβ plaque deposits at late stages of the disease but not at the prodromal phase. In order to 
overcome this limitation, a large number of targeted contrast agents aimed at enhancing MRI 
image contrast and improving the detection of Aβ plaque deposits have been developed and 
are currently under preclinical evaluation (385).  
 
Although most of these molecular imaging approaches provide a reliable assessment of 
cerebral Aβ plaque burden, clinical data indicate that imageable A plaque load alone is not an 
adequate diagnostic marker for AD. Cerebral Aβ plaque load displays only a weak correlation 
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with cognitive impairment, suggesting that other pathological factors influence disease 
progression (391). Moreover, many cognitively normal subjects with high A burden (as 
detected by PET) did not subsequently develop AD, and there is much interest in developing 
PET radiotracers for a wider range of molecular features of the disorder (328, 392, 393). 
Several PET radiotracers targeting tau pathology and neuroinflammatory processes have been 
recently developed but the relevance of these markers for the diagnosis and assessment of AD 
still remains to be determined (394). 
 
In recent years, there has been growing evidence associating changes in trafficking and 
distribution of trace metals within the brain, including copper, with the onset and progression of 
AD (see section 2.3.8.1, Chapter II) (269, 271). Whether this association is a cause or 
consequence of the pathology is unknown and the nature of the changes is poorly understood. 
Copper has been found to interact with key components of AD pathology (e.g. Aβ, APP, 
BACE1, tau) and, as a result, is thought to contribute to abnormal protein aggregation, synaptic 
toxicity and oxidative stress (248, 353, 395-397). A plaques have been described as “sinks” of 
iron, zinc and copper ions, which have been shown to enhance Aβ aggregation and 
neurotoxicity (341, 351, 398, 399). It has been suggested that the association of copper with Aβ 
aggregates and other molecular entities involved in AD might also lead to decreased 
intracellular copper bioavailability and reduced activity of copper-dependent enzymes in the 
brain (86, 400, 401).  
 
This “metal hypothesis of AD” is the basis of the development of treatments aimed at minimising 
copper-induced neurotoxicity and restoring brain copper homeostasis (339, 361). Studies in AD 
animal models demonstrated reduced Aβ burden, increased intracellular copper levels and 
improved cognitive function following administration of copper (II) chelators (e.g. CQ, PBT2) 
capable of stripping away copper ions from Aβ plaque deposits and redistributing them into cells 
(256, 364, 372, 375). A recent investigation showed that treatment with Cu-GTSM - a Cu-BTSC 
complex that delivers copper into cells and releases it bioreductively - enhanced cognitive 
performance in APP/PS1 transgenic AD mice by triggering neuroprotective mechanisms that 
inhibited GSK3β and decreased phosphorylated tau and Aβ trimer levels (365, 366). Hence, 
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understanding the role of copper homeostasis in AD pathology may be critical to develop both 
novel diagnostics and therapeutics.  
 
A PET radiotracer able to measure brain copper trafficking in vivo could be a valuable tool to 
investigate changes in copper metabolism in brain and determine the potential of copper 
dyshomeostasis as an early diagnostic marker for AD and a useful complement to other 
imaging biomarkers. The availability of positron-emitting copper isotopes (60Cu, 61Cu, 62Cu, 
64Cu) raises the possibility to study the trafficking of copper to, from and within brain, not only in 
animal models but also in humans, by imaging with PET over a period of hours and repeatedly 
during the lifetime of the subject. Intravenous injection of 64Cu in the form of ionic copper (II) 
salts leads to delivery of radiotracer to the brain via native copper transport processes in 
quantities that are insufficient for meaningful imaging (153, 154). However, by exploiting the 
ability of uncharged lipophilic copper (II) complexes, such as Cu-GTSM, to penetrate the BBB 
and release their copper payload non-selectively into cells, the intracellular copper pool can be 
supplemented with tracer quantities of 64Cu sufficient to allow imaging of its subsequent 
trafficking (Figure 3.2) (144, 149, 166). A preliminary study by Fodero-Tavoletti and co-workers 
showed that when 64Cu-labelled Cu-GTSM was administered intravenously, brain uptake of 
64Cu as measured by ex vivo gamma-counting was found to be significantly greater in APP/PS1 
mice than in their age-matched wild-type counterparts at 60 min post-injection of the tracer 
(155). 
 
Figure 3.2: Chemical structure of Cu-GTSM and proposed uptake mechanism. 
     
Following up on the work by Fodero-Tavoletti et al., in this chapter we explore brain copper 
trafficking in AD by 64Cu-GTSM-PET in the TAS10 x TPM (TASTPM) transgenic mouse model 
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of AD-like pathology. The visualisation, mapping and monitoring of 64Cu trafficking in this model 
of AD will provide valuable information to determine the potential of imaging brain copper 
trafficking as a diagnostic marker for AD.  
 
3.2.2 The TASTPM mouse model of AD 
Animal models have played a crucial role over the years in improving our understanding of AD 
pathology. The use of AD animal models has allowed the dissection of disease-related 
pathways, the study of interactions between pathological markers (e.g. Aβ and tau) and the in 
vivo evaluation of new treatment options. Since the etiology of sporadic AD remains unknown, 
the generation of most AD animal models has been based on the use of genetic mutations 
associated with familial AD (e.g. APP, Presenilin-1, BACE1, tau). Although these transgenic 
models are capable of mimicking certain features of AD, an animal model that recapitulates all 
aspects of the human condition has not been developed yet. The lack of concordance between 
AD-like pathology in preclinical models and human disease, along with the metabolic 
differences between humans and preclinical species, contribute to discrepancies between the 
results obtained in the preclinical evaluation of potential therapeutic agents and the outcome of 
clinical trials. More sophisticated transgenic models are therefore necessary in order to improve 
the translation of new treatment options from animal models to clinical practice. Regardless, the 
existing animal models of AD remain useful tools for studying specific pathological features of 
the disorder (402, 403). 
 
Since copper has been reported to interact with several components of the Aβ cascade (e.g. 
APP, BACE1, Aβ), we have chosen to investigate 64Cu trafficking in a transgenic mouse model 
of AD-like Aβ plaque pathology. Double-transgenic TASTPM mice overexpress the 
hAPP695swe (TAS10) and presenilin-1 M146V (TPM) mutations, which lead to early-onset 
cerebral Aβ plaque deposition and cognitive deficits. Both transgenes are driven by the murine 
Thy-1 promoter. Howlett et al. reported that Aβ plaque deposition in the brains of TASTPM mice 
was first apparent by 3 months, preceding the onset of cognitive impairment at 6 months of age. 
Cerebral Aβ plaque load was found to increase with age and to be greater in females than 
males. In addition to cerebral Aβ plaque deposition, TASTPM mice have been shown to exhibit 
neuronal loss and inflammatory pathology, although not to the same level as human AD. Like 
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other APP transgenic lines, the TASTPM mouse model does not develop NFTs, even though 
hyperphosphorylated tau immunoreactivity can be observed by 4 months of age (404, 405). 
 
In the present study, TASTPM mice have been imaged at 6-8 and 13-15 months of age. We 
have chosen the 6-8-month range as an early clinical disease phase, since cognitive 
impairment in TASTPM mice becomes apparent at that age, while the 13-15-month-old group 
represents a moderate-to-severe stage of the disorder. Imaging experiments were initially 
conducted in female TASTPM mice since these have been shown to develop more severe Aβ 
plaque pathology than males. However, female TASTPM mice were soon replaced by their 
male counterparts due to high mortality rates. 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Chemistry 
All reagents were purchased from Sigma-Aldrich, Alfa Aesar, Interlink Scientific Services and 
VWR International Ltd. and were used without further purification, unless otherwise stated. NMR 
spectra were recorded on a Bruker Ultrashield 400WB PLUS 9.4 T spectrometer (1H NMR at 
400 MHz). All chemical shifts were referenced to residual solvent peaks and are quoted in ppm 
relative to tetramethylsilane. High-performance liquid chromatography (HPLC) was performed 
using an Agilent Technologies 1200 series unit with an Eclipse XDB-C18 column (4.6 x 150 mm, 
5 μm) and UV/VIS detection at 254 nm and water + 0.1 % (v/v) trifluoroacetic acid (TFA) (A) / 
acetonitrile + 0.1 % (v/v) TFA (B) gradient system (0 min: 95 % A / 5 % B; 15 min: 5 % A / 95 % 
B; 20 min: 5 % A / 95 % B; 25 min: 95 % A / 5 % B; 30 min: 95 % A / 5 % B). Mass spectra were 
recorded on an Agilent Technologies 6520 Accurate-Mass Q-TOF LC-MS mass spectrometer 
using the positive ion electrospray technique (ESI+-MS). Thin layer chromatography (TLC) was 
performed using MERCK 60 F254 silica gel TLC plates as the stationary phase and ethyl acetate 
as the mobile phase. 
 
Glyoxalbis(N4-methyl-3-thiosemicarbazone) (H2-GTSM) was synthesised following a previously 
reported procedure (142, 406). 4-Methyl-3-thiosemicarbazide (2.49 g, 23 mmol, 1) was 
dissolved at 50 °C in 50 mL of distilled water containing 5 % acetic acid (v/v). To this, 1.31 mL 
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of glyoxal solution (11.4 mmol, 2) were added dropwise. The reaction mixture was left to stir 
overnight at room temperature. The resulting white precipitate was collected by filtration and 
washed with distilled water (3 x 50 mL), ethanol (2 x 25 mL) and diethyl ether (25 mL) to yield 
the final product (2.5 g, 94 %, 3). IR νmax/cm-1: 3317, 3148, 3000, 2328, 1512, 1248, 1083, 914; 
1H NMR (400MHz, DMSO-d6) δ 2.965 (6H, d, 2 x NHCH3, 3JH-H = 4 Hz), 7.728 (2H, s, 2 x 
HC(=N)NHC(=S)), 8.505 (2H, q, 2 x C(=S)NHCH3 3JH-H = 4 Hz), 11.770 (2H, s, 2 x 
HC(=N)NHC(=S)); HPLC: Rt = 6.15 min. ESI+ MS: m/z for [C6H12N6S2 + H]+ = 233.0638 (calc.), 
233.0671 (found). TLC: Rf = 0.75. 
 
 
Figure 3.3: Synthesis of H2-GTSM (3) from 4-Methyl-3-thiosemicarbazide (1) and glyoxal (2). 
 
The Cu-GTSM complex was prepared following a previously reported protocol (142). The H2-
GTSM ligand (0.33 g, 1.4 mmol, 3) was dissolved in 1 M sodium hydroxide solution (25 mL). To 
this, an aqueous solution of copper (II) acetate (0.25 g, 1.4 mmol, 4) was slowly added, 
resulting in the formation of a brown precipitate. The reaction was left to stir overnight at room 
temperature. The solid was then retrieved by filtration and washed with distilled water (3 x 50 
mL) and cold methanol (50 mL) (0.28 g, yield= 68 %, 5). IR νmax/cm-1: 3307, 3000, 1747, 1533, 
1452, 1384, 1201, 863. HPLC: Rt = 5.57 min. ESI+ MS: m/z for [CuC6H10N6S2 + H]+= 293.9777 
(calc.), 293.9805 (found). 
 





64Cu was produced as previously reported on a CTI RDS 112 biomedical cyclotron at the 
Clinical PET Centre of St Thomas’ Hospital in the form of 64CuCl2 in 0.1 N HCl solution (4.8 
GBq/μg) (99). Radioactivity was measured using a Capintec CRC-25R dose calibrator. Radio-
TLC was performed on a LabLogic Flow-Count scanner (scan speed: 0.25 mm/s), using 
MERCK 60 F254 silica gel TLC plates as the stationary phase and ethyl acetate as the mobile 
phase.  
 
64CuCl2 (~300 MBq, pH 1) was neutralised to pH 6 with a 3 M solution of sodium acetate (Rf = 0, 
100 % radiochemical purity). 64Cu-GTSM (~90 % isolated radiochemical yield, ≥ 95 % 
radiochemical purity) was synthesised by reaction of the GTSM ligand with 64Cu-acetate (~300 
MBq) using a previously reported radiolabelling protocol (142). 64CuCl2 was initially buffered with 
3 M sodium acetate to pH 6. To this solution, 10 µL of a 1 mg/mL solution of GTSM in dimethyl 
sulfoxide (DMSO) were added. The reaction mixture was vortexed for 1 minute and allowed to 
stand at room temperature for 5-10 minutes. The resulting 64Cu-GTSM solution was then loaded 
onto a C18 cartridge (Sep-Pak C18 Plus Short Cartridge, 360 mg Sorbent, 55-105 µm particle 
size, Waters Ltd.), previously conditioned with ethanol and water. The sample was washed 
through with water (5 mL) and finally eluted in ethanol (2 mL). The initial 0.3 mL of ethanol was 
discarded, the following 1 mL fraction containing the purified 64Cu-GTSM complex, was 
collected and the remaining portion was discarded. Radio-TLC analysis of the radiolabelled 
complex was performed before and after purification (Rf  = 0.37; RCP≥ 95 %). For intravenous 
administration, 64Cu-GTSM was diluted in sterile 0.9 % saline solution (w/v) to <10 % of total 
injected volume (< 200 μL). 
 
3.3.3 Animals 
All animal experiments were performed in accordance with the Animals (Scientific Procedures) 
Act, 1986 and approved by the local ethics committee. Mice were fed ad libitum with regular 
animal feed (Rat and Mouse No.1 Maintenance, SDS, UK). 
 
Double-mutant TASTPM mice on a C57BL/6J background were bred in-house from mice 
provided by GlaxoSmithKline (GSK), and genotyped to confirm the presence of the TAS and 
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TPM mutant transgenes. C57BL/6J wild-type mice were obtained from Charles River 
Laboratories International, Inc. Both TASTPM and C57BL/6J mice were kept under the same 
housing conditions (21°C, 50 % humidity).  
 
3.3.4 Genotyping 
DNA was extracted from ear tissue samples from TASTPM mice in the following manner. Ear 
tissue samples were initially incubated in 30 µL of polymerase chain reaction (PCR) lysis buffer, 
consisting of 2 µL of a 20 mg/mL proteinase K aqueous solution and 950 µL of lysis buffer (3.60 
mL of 10x GB buffer, 0.72 mL of 25 % [v/v] Triton X-100, 0.36 mL of β-mercaptoethanol and 
31.32 mL of water; 10x GB buffer: 4.47 mL of 1.5 M Tris-HCl pH 8.8, 1.66 mL of 1 M (NH4)2SO4, 
0.67 mL of 1 M MgSO4 and 3.20 mL of water). The mixture was subsequently incubated in a 
thermo-shaker (PHMT Grant-bio) at 55 °C for 1 h and at 95 °C for 5 minutes. The resulting 
sample was then vortexed for 1 minute at 2500 g (Eppendorf centrifuge 5424R) and stored at -
20°C. 
 
Multiplex PCR was performed using an Agilent Technologies SureCycler 8800 unit. Each PCR 
reaction mixture contained 2 µL of DNA template, 12.5 µL of QIAGEN multiplex PCR mastermix 
(Taq DNA polymerase, deoxynucleotide triphosphates and MgCl2 in a KCl/(NH4)2SO4 buffer), 
10.4 µL of water, 0.05 µL of TAS or TPM 5’→3’ primer and 0.05 µL of TAS or TPM 3’→5’ primer 
(TAS 5’→3’: CAG CTG GTT GAC CTG TAG CTT T; TPM 5’→3’: CAG CTG GTT GAC CTG 
TAG CTT T; TAS 3’→5’: GTG TGC CAG TGA AGA TGA; TPM 3’→5’: ATG CTT GGC GCC 
ATA TTT CAA TG). Amplification reactions consisted of an initial denaturation period (10 
minutes at 95 °C), followed by 9 cycles (95 °C for 15 seconds, 68 °C for 15 seconds and 72 °C 
for 30 seconds) and 25 cycles (95 °C for 15 seconds, 58 °C for 15 seconds and 72 °C for 30 
seconds). 5 µL of 6 X orange DNA loading dye (Thermo Fisher Scientific Inc.) were 
subsequently added to each PCR reaction mixture. The samples were then subjected to 
electrophoresis in 1.2 % agarose gel in TAE buffer (Tris, CH3COOH and EDTA) containing 0.01 
% (v/v) of SYBR safe DNA stain (Life Technologies-Invitrogen). Quick-Load 2-Log DNA ladder 
(0.1-10.0 kb, New England Biolabs Inc.) was used as a molecular weight marker. Amplified PCR 




Figure 3.5: Gel electrophoresis illustrating the presence of the TAS and TPM mutant transgenes. 
 
3.3.5 Immunohistochemistry 
The extent of Aβ plaque deposition in the TASTPM mouse model was characterised following a 
previously reported immunohistochemistry protocol (404). Brain hemispheres of male and 
female TASTPM mice (6-8 and 13-15 months old) were immersed in 4 % (w/v) 
paraformaldehyde in 0.1 M phosphate buffered saline (pH 7.4) for 72 h. Brain tissue was then 
processed into paraffin wax (through sequential immersion in ethanol and xylene) and sectioned 
in the sagittal plane (6 μM). For Aβ-40 and Aβ-42 immunostaining, sections were dewaxed in 
xylene, rehydrated through a series of graded alcohols (100 %, 90 %, 70 % industrial 
methylated spirits, v/v), washed with distilled water, treated with 98 % (v/v) formic acid for 15 
min to increase Aβ antigenicity and incubated in 0.3 % (v/v) hydrogen peroxide in phosphate-
buffered saline (PBS) for 30 min to quench endogenous peroxidase activity. Brain slices were 
then incubated overnight at 4°C with monoclonal mouse antibodies to Aβ-42 (20G10, 1:10000, 
GlaxoSmithKline Pharmaceuticals R&D, UK) and Aβ-40 (11C5, 1:1000, GlaxoSmithKline 
Pharmaceuticals R&D, UK) in primary buffer (0.3 % [v/v] Triton X-100, 2 % [v/v] bovine serum 
albumin and 0.01 % [v/v] sodium azide in PBS). After incubation, brain sections were washed  
and incubated with biotinylated anti-mouse IgG (1:500, Vector Laboratories) in secondary buffer 
(0.3 % [v/v] Triton X-100 in PBS) for 45 min at 4°C. Tissue slices were then washed and 
incubated with the avidin-biotin complex (ABC Peroxidase Standard Staining Kit, Thermo Fisher 
Scientific Inc.) for 1 h at room temperature. For colour development, brain slices were incubated 
with the 3,3’-diaminobenzidine (DAB) reagent (DAB Substrate kit, Vector Laboratories) and 
counterstained with Mayer’s hematoxylin (Sigma Aldrich). Finally, tissue sections were 
dehydrated and  mounted with DPX new mounting medium (Merck Millipore). Images of 
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immunostained slices were acquired using a light microscope (DM6000B; Leica Microsystems 
Ltd., Bucks, UK). 
 
3.3.6 Serum stability 
The stability of 64Cu-GTSM in serum was assessed following a previously reported method 
(146). 64Cu-GTSM (0.5 MBq in saline)  was incubated in 500 μL of fresh human serum at 37°C  
and 250 rpm. At selected time-points (1, 15, 30, 45, 60, 90, 120 min and 24 h), the amount of 
intact complex was determined in triplicate by radio-TLC.  
 
3.3.7 Solvent extraction 
6-8-month-old TASTPM mice and age-matched controls were injected with 64Cu-GTSM (~20 
MBq) and sacrificed at 30 min and 24 h post-injection (n = 2/group/time point). Brains were 
explanted and homogenised in 500 μL of ice-cold PBS. 1 mL of n-octanol was subsequently 
added to the brain homogenate and the mixture was incubated at 0°C for 30 min under stirring. 
Samples were then centrifuged at 14000 g for 15 min at 4°C. The organic layer was separated 
from the aqueous phase (which contained denatured proteins and cell debris) and the two 
fractions were subsequently gamma-counted. The octanol-extractable fraction was analysed via 
radio-TLC to determine the presence of intact 64Cu-GTSM complex. 
 
3.3.8 In vivo blood sampling 
Following intravenous 64Cu-GTSM administration to wildtype mice (6-8 months old, n=4), blood 
samples (~10 μL) were withdrawn from the jugular vein at 1, 2, 5, 10, 15, 20, 30, and 60 min 
post-injection. Blood aliquots were subsequently weighed and gamma-counted. Time-activity 
curves were constructed to determine the blood half-life of the tracer. 
 
3.3.9 PET/CT imaging 
Imaging experiments were conducted using a nanoScan® PET/CT (Mediso Medical Imaging 
Systems, Budapest, Hungary) (407). Dynamic PET/CT imaging was conducted in female 
TASTPM mice and C57BL/6J wild-type controls at 6-8 months of age (n=3). Mice were 
anaesthetised by isoflurane inhalation (3 % [v/v], Vet Tech Solutions Ltd.), cannulated via lateral 
tail vein on the scanning bed, injected with 64Cu-GTSM (10 MBq, ≤200 µL) and imaged by PET 
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for 4 h (400-600 keV energy window; 5 ns coincidence window, 0.30 x 0.30 x 0.30 mm3 voxel 
size), followed by a CT scan (180 projections, 45 KVp, 0.25 x 0.25 x 0.21 mm3 voxel size). 
Longitudinal 64Cu-GTSM PET experiments were performed in 6-8- (n=4) and 13-15-month-old 
(n=3) male TASTPM mice and age-matched controls (n=6 and n=3, respectively). Animals were 
anaesthetised by isoflurane inhalation (3 %), injected with 64Cu-GTSM (35 MBq, ≤200 µL) via 
lateral tail vein and immediately placed on the scanning bed in a prone position. PET acquisition 
(400-600 keV energy window; 5 ns coincidence window, 0.30 x 0.30 x 0.30 mm3 voxel size) was 
started 1 min after tracer injection and continued for 30 min, followed by a CT scan (180 
projections, 45 KVp, 0.25 x 0.25 x 0.21 mm3 voxel size) for anatomical reference and 
attenuation correction. Anaesthesia was maintained at 2 % isoflurane throughout the duration of 
the scan. Animals were allowed to recover from anaesthesia and housed for 24 h. Urine and 
faeces were collected overnight. At 24 h post-injection of the tracer, mice were anaesthetised (3 
% isoflurane) and re-scanned for 1 h. Respiration rate and bed temperature were monitored 
throughout all scans.  
 
3.3.9.1 PET image analysis 
All PET/CT datasets were reconstructed using a novel Monte Carlo-based full 3D iterative 
algorithm called Tera-Tomo (Mediso Medical Imaging Systems, Budapest, Hungary) (408). To 
visualise small structures within the mouse brain, ‘fine’ reconstruction settings were used (8 
iterations, 6 subsets, 0.25 x 0.25 x 0.25 mm3 voxel size) for all PET datasets. Decay, dead-time, 
and intercrystal scatter corrections were applied as part of the reconstruction. Reconstructed CT 
images were used to derive an attenuation map for PET attenuation correction. Dynamic 0-4 h 
PET scans were reconstructed into 5-min (0-30 min) and 30-min (30-240 min) time bins. The 0-
30 min PET datasets were reconstructed into 5-min bins and binned images corresponding to 
25–30 min post-injection were used for ROI analysis. Static 24-25 h PET datasets were 
reconstructed into single bins representing the average radiotracer biodistribution during this 
time frame. All reconstructed datasets were analysed using VivoQuant 1.21 software (inviCRO, 
LLC, Boston, USA), which enables automatic co-registration of PET and CT images and 
delineation of regions of interest (ROIs) for quantification of activity in specific organs. When the 
initial automatic co-registration of PET and CT images was unsatisfactory, manual co-
registration functions were used to ensure accurate alignment of CT and PET images in all 
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planes. ROIs for different organs (e.g. brain) were defined in order to express 64Cu uptake in 
each organ as percentage of injected dose per milliliter (%ID/mL). The sum of activity (MBq) in 
the organ ROI was divided by the sum of activity (MBq) in the whole-body ROI (excluding tail) at 
the time of injection and the resulting percentage (%ID) was normalised by the volume of the 
organ ROI (%ID/mL). A mouse brain atlas NM/CT module (inviCRO, LLC) with 14 pre-defined 
regions was automatically co-registered to all PET datasets to enable measurement of global 
and regional brain uptake of 64Cu as %ID/mL.  
 
3.3.9.2 Texture analysis 
All PET/CT datasets were initially co-registered using VivoQuant 1.21 (InviCRO, LLC) and 
exported to in-house software implemented in MATLAB 2013b (The MathWorks, Inc.) capable 
of measuring first, second and high order heterogeneity parameters (409, 410). PET and CT 
image files were simultaneously imported in DICOM format and aligned. 3D ROIs were then 
manually drawn on the CT image file to separate the object of interest from the background. 
The same ROI was automatically overlaid on the PET scan in order to compute the properties 
of both modalities for the same region. First order parameters (mean, minimum/ maximum 
intensity, standard deviation, skewness, kurtosis, coefficient of variation, median, energy and 
entropy) measuring the distribution of voxel intensities were measured and statistically 
analysed. 
 
3.3.10 Ex vivo biodistribution 
   Mice were sacrificed by cervical dislocation immediately after imaging (25 h post-injection of 
64Cu-GTSM) and all major organs were explanted, weighed and gamma-counted (LKB Wallac 
1282). 64Cu uptake in each organ was expressed as %ID/g. The total injected dose was defined 
as the sum of all whole-body counts (excluding tail) and excreted activity (urine and faeces). 
 
3.3.11 Ex vivo brain autoradiography 
Brain tissue explanted from imaged mice was immersed in a 30 % (w/v) sucrose solution for ~6 
h and stored at -80°C overnight. Cryopreserved brains were then sectioned (10 µm) in the 
sagittal plane using a Bright 5040 cryotome. Tissue sections were thaw-mounted onto 
Superfrost PLUS glass microscope slides (Menzel-Glaser, Thermo Scientific) and allowed to dry 
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at room temperature. The slides were then exposed to a storage phosphor screen 
(PerkinElmer, Super Resolution, 12.5 x 25.2 cm) in a standard X-ray cassette for 15 h. The 
phosphor screen was then imaged using a Typhoon 8600 scanner (Molecular Dynamics) and 
images were analysed with OptiQuant 5.0 (PerkinElmer) and ImageJ (NIH). 
 
3.3.12 Congo red staining 
Following autoradiography, brain slices were stored at -80°C until decayed. For Congo red 
staining, frozen brain slices were fixed in 4 % (w/v) PFA for 45 min and subsequently washed 
with distilled water. Brain slices were then incubated in Congo red solution (0.5 % [w/v] Congo 
red dye [Sigma Aldrich] in 50 % [v/v] EtOH) for 15-20 min, rinsed with distilled water, and dipped 
(5-10 times) in alkaline alcohol solution (1 % [w/v] NaOH, 50 % [v/v] EtOH). Tissue slices were 
subsequently rinsed in tap water for 1 min and counterstained with Harris’ hematoxylin solution 
(Sigma Aldrich) for 10 s. Brain sections were then rinsed in tap water for 2 min and incubated in 
acid alcohol solution (1 mL 3M HCl in 200 mL 70 % [v/v] IMS) for 1 min. Finally, brain slices 
were incubated in 95 % (v/v) alcohol (3 min, 2 changes), 100 % alcohol (3 min, 2 changes) and 
Histo-Clear II solution (National Diagnostics, 1 min, 2 changes), and mounted with DPX new 
mounting medium (Merck Millipore). All cover-slipped slides were then evaluated under bright-
field microscopy using a light microscope (DM6000 B; Leica Microsystems Ltd., Bucks, UK).  
 
3.3.13 Statistical analysis 
All data are reported as mean ± SD. Statistical analysis was performed using GraphPad Prism 5 
(GraphPad Software Inc.). Two-way repeated measures ANOVA with post-hoc analyses using 
the Bonferroni multiple comparison correction was used to determine statistically significant 
differences between TASTPM mice and controls at different imaging time-points. A Student t-





In order to determine the extent of cerebral Aβ plaque deposition in male and female TASTPM 
mice at early (6-8 months old) and middle stages of the disease (13-15 months old), we stained 
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serial sections of TASTPM brain tissue with Aβ-40- and Aβ-42-specific antibodies. The Aβ-40 
and Aβ-42 isoforms are believed to be the primary components of Aβ plaque deposits, with Aβ-
42 being the most aggregation-prone of all Aβ species (411). As depicted in Figure 3.6, Aβ 
immunolabelling was associated with both dense-core plaques and the halo of diffuse Aβ 
species surrounding their cores.  
 
 
Figure 3.6: Photomicrographs of a sagittal section through the cerebral cortex (left) and hippocampus 
(right) of a 13-month-old female TASTPM mouse immunostained with an Aβ-42-specific antibody. The 
scale bars represent 100 m on the main figures and 10 m on the insets. 
 
As expected, both male and female TASTPM mice showed extensive Aβ-40 and Aβ-42 
immunoreactivity in the cerebral cortex, hippocampus and thalamus at 6 months of age (Figures 
3.7 and 3.8). In contrast, the cerebellum, caudate putamen and medulla exhibited the lowest 
concentrations of Aβ species. Aβ-40 load was found to be greater than that of Aβ-42 in both 
male and female TASTPM mice. Cerebral Aβ-40 and Aβ-42 levels were found to increase 
considerably between 6 and 13 months of age in both males and females. At both ages, female 
TASTPM mice exhibited higher Aβ-40 and Aβ-42 immunoreactivity than their male counterparts. 
These observations are consistent with those of Howlett et al., who reported a significant effect 





Figure 3.7: Immunohistochemical characterisation of cerebral Aβ-40/ Aβ-42 deposition in female TASTPM 
mice at 6 (left) and 13 (right) months of age. Photomicrographs depict areas of high Aβ plaque burden, 
namely the hippocampus, thalamus and cerebral cortex. The scale bars represent 200 μm. 
 
Figure 3.8:  Immunohistochemical characterisation of cerebral Aβ-40/ Aβ-42 deposition in male TASTPM 
mice at 6 (left) and 13 (right) months of age. Photomicrographs show Aβ plaque deposition in the 




3.4.2 Serum stability 
To evaluate the stability of 64Cu-GTSM in a biological milieu, the complex was incubated in 
fresh human plasma and monitored by radio-TLC at different time-points. Radio-TLC revealed 
that 64Cu-GTSM remained intact after 2 h of incubation in serum (Figure 3.9.C). At 24 h, over 90 
% of 64Cu radioactivity was still in the form of the complex, demonstrating the excellent serum 
stability of this tracer in vitro (Figure 3.9.D). 
 
Figure 3.9: Radio-TLC chromatograms of free 64Cu (A), 64Cu-GTSM (B), 64Cu-GTSM  after 2 h of 
incubation in human serum (C) and 64Cu-GTSM after 24 h of incubation in serum (D). Ethyl acetate was 
used as the mobile phase. 
 
3.4.3 Solvent extraction 
In order to assess the ability of 64Cu-GTSM to release 64Cu intracellularly within the brain, we 
determined the amount of intact complex in brain homogenates of TASTPM and wild-type mice 
(n = 2/group/time-point) injected with 64Cu-GTSM using a previously reported octanol-extraction 
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method (412). Gamma-counting of aqueous/protein-bound and octanol-extractable fractions 
revealed high water solubility and protein/cell debris binding of 64Cu activity, and little octanol 
extractable activity, at all time-points after tracer injection for both groups of mice. At 30 min 
post-administration of 64Cu-GTSM, less than 4 % of brain 64Cu radioactivity was associated with 
the octanol fraction. The partitioning of 64Cu activity did not change significantly with time, with 
less than 3 % of the radiocopper remaining in the octanol fraction at 24 h after injection (Table 
3.1). Radio-TLC of the octanol-extractable fractions showed that 64Cu radioactivity was no 
longer in the form of 64Cu-GTSM but instead behaved like ionic 64Cu. 
 
Table 3.1:  Distribution of 64Cu radioactivity in brain homogenates of mice injected with 64Cu-GTSM. 
 
  
Time post-injection (h) 
Percentage of 64Cu in aqueous/protein-
bound fraction 
           
0.5 96.19 ± 2.98 
24 97.18 ± 0.14 
  Data are mean (n = 4 mice per time point) ± SD. 
 
3.4.4 In vivo blood sampling 
After testing the ability of 64Cu-GTSM to deliver 64Cu into the brain, we evaluated the clearance 
rate of this tracer from blood by jugular vein blood sampling in wildtype mice. 64Cu-GTSM 
cleared rapidly from blood, following a monoexponential decay pattern with a half-life of 5.31  
2.03 min. 
 
Figure 3.10: Blood time-activity curves resulting from in vivo blood sampling in wildtype mice injected with 
64Cu-GTSM. Blood clearance of the tracer showed a monoexponential decay behaviour with an elimination 




3.4.5 PET/CT imaging 
PET/CT imaging of 64Cu trafficking with 64Cu-GTSM was initially performed in female TASTPM 
mice since these displayed a more severe Aβ plaque pathology than their male counterparts, as 
revealed by immunohistochemistry. Dynamic PET/CT imaging (0-4 h) of 6-8-month-old female 
TASTPM mice and age-matched controls revealed high 64Cu accumulation in the heart, lungs, 
liver, intestines, kidneys, spine and brain in both groups of animals. Time-activity curves 
showed that 64Cu-GTSM uptake in the brain was rapid, reaching a plateau within the first 10 
minutes after injection (Figure 3.11). Brain concentration of 64Cu was  found to be significantly 
greater in female TASTPM mice when compared to healthy controls at 30 min post-injection of 




Figure 3.11: PET/CT imaging of 64Cu trafficking in a female TASTPM mouse (6-8 months old) with 64Cu-
GTSM showing high 64Cu accumulation in the heart, lungs, liver, intestines, kidneys, spine and brain (A). 
Time-activity curves generated from dynamic PET images illustrating 64Cu concentration in organs of 
interest (B). Tracer uptake in the brain was rapid, peaking within 10 min after injection (C). 
 
 
Due to high mortality rates during experimental procedures and increased seizure incidence, 
female TASTPM mice were replaced by males in longitudinal PET/CT imaging experiments. In 
order to investigate whole-body copper fluxes in vivo in AD-like pathology at early and middle 
stages of the disease, 6-8- and 13-15-month-old male TASTPM mice (n=4 and n=3) were 
imaged with 64Cu-GTSM from 0-30 min and from 24-25 h after injection and compared to age-





Figure 3.12: Exemplar sagittal and coronal views of PET/CT MIPs of 6-8-month-old male wild-type 
controls (A) and age-matched TASTPM transgenic mice (B) at 30 min and 24 h post-administration of 
64Cu-GTSM. 64Cu-GTSM PET/CT scans showed high accumulation of 64Cu in the liver, lungs, heart, 
kidneys, intestines, spine and brain of both TASTPM mice and age-matched controls at 30 min post-
injection of the tracer. Kidney, lung and heart concentrations of 64Cu decreased substantially from 30 min 
to 24 h post-injection, whereas tracer uptake in the brain remained relatively constant over time in both 
groups. Concentration of 64Cu in brain appeared higher in TASTPM mice than in controls at both 30 min 
and 24 h post-injection of 64Cu-GTSM. Organs are indicated by arrows: B = brain; Sp = spine; H = heart; 
Lu = lungs; L = liver; K = kidneys; I = intestines. All MIPs were scaled to 0-1 %ID/mL (min) and 40 %ID/mL 
(max). 
 
Figure 3.13: Exemplar sagittal and coronal views of PET/CT MIPs of 13-15-month-old male wild-type 
controls (A) and age-matched TASTPM transgenic mice (B) at 30 min and 24 h post-administration of 
64Cu-GTSM. 64Cu radioactivity accumulated primarily in the liver, lungs, heart, kidneys, intestines, spine 
and brain of both TASTPM mice and age-matched controls at 30 min post-injection of the tracer. As 
previously observed in the 6-8-month-old mouse groups, 64Cu concentration decreased in kidney, lung and 
heart over time but remained relatively constant  in the brain. The concentration of 64Cu in brain was found 
to be higher in TASTPM mice compared to controls at both imaging-time-points, although the difference 
between groups seemed  less pronounced  than in the case of 6-8-month-old mice.  Organs are indicated 
by arrows: B = brain; Sp = spine; H = heart; Lu = lungs; L = liver; K = kidneys; I = intestines. All MIPs were 
scaled to 0-1 %ID/mL (min) and 40 %ID/mL (max). 
 
The general biodistribution of the tracer was similar for all animal groups. At 30 min after 
injection, 64Cu radioactivity accumulated primarily in the heart, lungs, liver, intestines, kidneys, 
spine and brain in both TASTPM and wild-type mice. After 24 h, a notable decrease in 64Cu 
activity was observed in the lungs, kidneys and heart, whereas 64Cu concentration in the brain 
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declined much more slowly, demonstrating greater 64Cu retention in brain tissue compared to 
other organs (2.04 ± 3.57 % decrease in brain %ID/mL vs. 67.51 ± 9.48, 47.25 ± 10.34 and 
50.76 ± 9.90 % decrease in lungs, kidneys and heart %ID/mL, in 6-8-month-old wildtypes). 
Hepatic 64Cu concentration remained relatively constant over time in all groups of animals, with 
a slight tendency to increase (Figure 3.14). Radioactivity concentration (expressed as %ID/mL) 
in brain decreased with age but was higher in TASTPM mice than in wildtype controls in both 
age groups. 
Figure 3.14: Time-activity curves extracted from PET image analysis showing 64Cu concentration 
(expressed as % ID/mL) over time in the heart, kidneys, liver, spine and brain of 6-8- (A) and 13-15-month-
old (C) male TASTPM mice and their respective age-matched controls (B and D, respectively). 
 
64Cu biokinetics within the CNS (brain and spine) were assessed using PET ROI analysis and 
compared between AD mice and healthy controls at both ages. Repeated measures ANOVA 
indicated significant effects of group (F1,8 = 10.41, p = 0.012), time (F1,8 = 36.04, p = 0.0003) 
and group by time interaction (F1,8 = 19.84, p = 0.0021) on brain 64Cu concentration in 6-8-
month-old TASTPM mice and age-matched controls. Post-hoc evaluation revealed that global 
average brain concentration of 64Cu was significantly higher in TASTPM transgenic mice than in 
wild-type controls at 30 min (7.83 ± 1.08 %ID/mL vs. 5.57 ± 0.70 %ID/mL, p<0.01) and 24 h 
(7.04 ± 0.94 %ID/mL vs. 5.46 ± 0.70 %ID/mL, p<0.05) post-injection of 64Cu-GTSM. After 24 h, 
a significant decrease in brain 64Cu concentration was found in TASTPM mice (-10.10 ± 2.23 %, 
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p<0.01) but not in age-matched controls (-2.04 ± 3.57 %, p>0.05). Statistical analysis also 
revealed significant effects of time (F1,8 = 30.68, p = 0.0005) and group (F1,8 = 12.23, p = 
0.0081) on spine 64Cu concentration, but the interaction between group and time was found to 
be non-significant (F1,8 = 4.35, p = 0.07). Post-hoc tests indicated significantly higher 64Cu 
concentration in the spinal cord of TASTPM mice as compared with controls at both 30 min 
(5.20 ± 0.67 %ID/mL vs. 3.73 ± 0.54 %ID/mL, p<0.01) and 24 h (4.65 ± 0.46 %ID/mL vs. 3.48 ± 
0.46 %ID/mL, p<0.05) post-injection of the tracer. Figure 3.15 shows mean brain and spinal 
cord concentrations of 64Cu in TASTPM mice and healthy controls at 30 min and 24 h post-
injection of 64Cu-GTSM, and the kinetic behaviour of the radiocopper in both tissues for each 
individual animal.  
 
Figure 3.15: In vivo brain (left) and spine (right) concentration of 64Cu, expressed as %ID/mL, in 6-8-
month-old TASTPM mice and age-matched controls as measured by PET ROI analysis. Time-activity 
curves illustrating clearance of 64Cu radioactivity over time for each individual mouse are shown at the top 
of the figure. TASTPM mice showed significantly higher concentration of 64Cu in the brain and spine at 30 
min and 24 h post-injection of 64Cu-GTSM and a faster 64Cu clearance rate from brain tissue compared to 
controls. Statistically significant differences from healthy controls are indicated by * (p<0.05) and ** 
(p<0.01). Data are mean (n = 4 for TASTPM mice; n = 6 for controls) ± SD. 
 
Two-way ANOVA analysis also revealed a significant effect of group (F1,4 = 16.25, p = 0.0157) 
on brain 64Cu concentration in 13-15-month-old male TASTPM mice and age-matched controls, 
but did not show significant effects of time (F1,4 = 1.230, p = 0.3296) and group by time 
interaction (F1,4 = 7.687, p = 0.0502). As observed for the 6-8 month-old age group, global 
concentration of 64Cu in the brain was significantly greater in 13-15-month-old TASTPM mice 
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than in age-matched controls at 30 min (6.11 ± 0.42 %ID/mL vs. 4.51 ± 0.42 %ID/mL, p<0.01) 
and 24 h (5.83 ± 0.25 %ID/mL vs. 4.63 ± 0.30 %ID/mL, p<0.05) post-injection of 64Cu-GTSM 
(Figure 3.16). Brain concentration of 64Cu increased slightly (2.96 ± 2.73 %) in the control group 
over 24 h, while it was found to decrease in TASTPM mice (-4.48 ± 2.59 %). However, this 
difference in 64Cu biokinetics between the two groups did not reach statistical significance. A 
significant effect of group (F1,4 = 34.48, p = 0.0042) was also observed on spine concentration 
of 64Cu in 13-15-month-old TASTPM mice and age-matched controls. Post-hoc evaluation 
showed that spinal cord concentration of 64Cu was significantly higher in the TASTPM group 
compared to controls at both 30 min (4.32 ± 0.32 %ID/mL vs. 2.98 ± 0.17 %ID/mL, p<0.001) 
and 24 h (4.09 ± 0.17 %ID/mL vs. 3.04 ± 0.21 %ID/mL, p<0.01) post-injection of 64Cu-GTSM. 
No significant effects of time (F1,4 = 0.7930, p = 0.4235) and interaction (F1,4 = 2.069, p = 
0.2237) on spinal cord 64Cu concentration in TASTPM mice and controls at 13-15 months of 
age were detected. 
 
Figure 3.16: In vivo brain (left) and spine (right) concentration of 64Cu, expressed as %ID/mL, in 13-15-
month-old TASTPM mice and age-matched controls as measured by PET ROI analysis. Time-activity 
curves illustrating clearance of 64Cu radioactivity over time for each individual mouse are shown at the top 
of the figure. TASTPM mice showed significantly higher concentration of 64Cu in the brain and spine at 30 
min and 24 h post-injection of 64Cu-GTSM. Statistically significant differences from healthy controls are 
indicated by * (p<0.05), ** (p<0.01) and *** (p<0.001). Data are mean (n=3/group) ± SD. 
 
Brain and spinal cord concentrations of 64Cu were found to decrease with age, particularly in the 
TASTPM group, but this trend did not reach statistical significance. However, a significant effect 
of group by time interaction (F1,5 = 7.510, p = 0.0408) on brain 64Cu concentration was detected 
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between 6-8- and 13-15-month-old TASTPM transgenic mice, indicating a modest variation in 
the clearance rate of 64Cu from brain tissue in the TASTPM group with age. No significant 
difference in 64Cu radioactivity clearance from the brain was found between 6-8- and 13-15-
month-old wildtype mice. 
 
3.4.5.1 Atlas-based image analysis of regional brain concentration of 64Cu 
 
Figure 3.17: Representative coronal and sagittal section PET/CT MIP images illustrating 64Cu distribution 
in the brain and spinal cord of 6-8-month-old C57BL/6J wild-type controls (A) and age-matched TASTPM 
mice (B) at 30 min (top) and 24 h (bottom) post-injection of 64Cu-GTSM. PET/CT scans revealed increased 
uptake and prolonged retention of 64Cu in the brains of TASTPM and wild-type mice, as well as 
heterogeneous distribution of the radiolabel at 30 min and 24 h post-injection of the tracer. All MIPs were 
scaled to 0-2 %ID/mL (min) and 12 %ID/mL (max). 
 
 
Figure 3.18: Representative coronal and sagittal section PET/CT MIP images showing 64Cu distribution in 
the brain and spinal cord of 13-15-month-old C57BL/6J wild-type controls (A) and age-matched TASTPM 
mice (B) at 30 min (top) and 24 h (bottom) post-injection of 64Cu-GTSM. All MIPs were scaled to 0-2 




As depicted in Figures 3.17 and 3.18, 64Cu-GTSM administration resulted in the heterogeneous 
distribution of 64Cu in the brains of both wildtype and TASTPM mice at all imaging time-points. 
On visual assessment, PET images showed both higher brain uptake and greater 
inhomogeneity, with more concentration of 64Cu hotspots, in the TASTPM AD model when 
compared to healthy controls. 
 
Figure 3.19: (A) 3D mouse brain atlas; (B) Regional brain distribution of 64Cu in 6-8-month-old TASTPM 
transgenic mice and age-matched controls at 30 min (top) and 24 h (bottom) post-injection of 64Cu-GTSM. 
Statistically significant differences from healthy controls are indicated by * (p<0.05), ** (p<0.01) and *** 
(p<0.001). Data are mean (n = 4 for TASTPM mice; n = 6 for controls) ± SD. 
 
In order to quantify 64Cu uptake heterogeneity in a functional context, brain PET images were 
analysed using a 3D mouse brain atlas. Statistical analysis revealed significant effects of group, 
region and group by region interaction on brain regional 64Cu accumulation in 6-8-month-old 
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TASTPM mice and age-matched controls at both 30 min (F1,8 = 12.68, p = 0.0074; F1,8 = 21.64, 
p<0.0001; F1,8 = 2.971, p=0.001) and 24 h (F1,8 = 7.701, p = 0.0241; F1,8 = 40.87, p<0.0001; F1,8 
= 11.69, p<0.0001) post-injection of the tracer. Post-hoc tests were used to identify brain 
regions of significantly different 64Cu concentration between these two groups. At 30 min post-
injection of the tracer, TASTPM mice showed significantly higher 64Cu concentration than 
controls in the medulla (p<0.05), cerebellum (p<0.01), midbrain (p<0.001), hippocampus 
(p<0.05), thalamus (p<0.01), hypothalamus (p<0.05), pallidum (p<0.05), olfactory bulb 
(p<0.001) and corpus callosum (p<0.05). The TASTPM group maintained significantly higher 
64Cu concentration than controls in the medulla (p<0.001), cerebellum (p<0.01), midbrain 
(p<0.05), hypothalamus (p<0.01) and olfactory bulb (p<0.05), as well as pons (p<0.05), at 24 h 
after injection of the tracer (Figure 3.19). Standard deviations of mean regional uptake values 
were noticeably larger for TASTPM mice when compared to controls, revealing a greater inter-
individual variability in the disease group.  
  
In a similar manner to the 6-8-month-old group, significant effects of group, region and 
interaction on brain regional 64Cu concentration were found in 13-15-month-old TASTPM mice 
and age-matched controls at 30 min (F1,8 = 14.86, p = 0.0182; F1,8 = 20.69, p<0.0001; F1,8 = 
4.835, p<0.0001) and 24 h (F1,8 = 19.24, p = 0.0118; F1,8 = 13.80, p<0.0001; F1,8 = 4.446, 
p<0.0001) post-injection of 64Cu-GTSM. Post-hoc evaluation revealed significantly greater 
concentrations of 64Cu in the cerebellum (p<0.001), midbrain (p<0.001), pons (p<0.05), 
thalamus (p<0.05), hypothalamus (p<0.01), pallidum (p<0.05), olfactory bulb (p<0.001), corpus 
callosum (p<0.05) and ventricles (p<0.05) of TASTPM mice compared to controls at 30 min 
post-administration of the tracer. After 24 h, 13-15-month-old TASTPM mice exhibited 
significantly higher 64Cu concentrations than controls in the cerebellum (p<0.001), midbrain 
(p<0.001), thalamus (p<0.01), olfactory bulb (p<0.001), corpus callosum (p<0.01) and ventricles 




Figure 3.20: Atlas-based quantification of brain regional 64Cu accumulation in 13-15-month-old TASTPM 
mice and age-matched controls. Statistically significant differences between groups are indicated by * 
(p<0.05), ** (p<0.01) and *** (p<0.001). Data are mean (n=3/group) ± SD. 
 
Additionally, statistical analysis detected significant differences in brain regional 64Cu 
concentration between the different age groups of mice. Ventricular uptake was found to be 
significantly higher in wildtype mice at 6-8 months of age when compared to the 13-15-month-
old group at both 30 min (p<0.05) and 24 h (p<0.05) post-injection of 64Cu-GTSM. Contrarily, 6-
8 month-old TASTPM mice exhibited significantly greater 64Cu uptake than their older 
counterparts in the medulla at 24 h after injection (p<0.05). 
 
3.4.5.2 Texture analysis 
Because the regional distribution of the tracer within the brain is at or beyond the resolution 
limits of the PET/CT scanner, the heterogeneity in the distribution of 64Cu within the brain will 
have been underestimated by atlas-based quantification due to the partial volume effect. For 
this reason, PET brain signal heterogeneity was alternatively quantified using texture analysis, 
which does not rely on the use of predefined structural templates and instead focuses on the 
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study of the spatial interrelationships of the image voxels. First-order parameters (mean, 
minimum/maximum, median, range, percentiles, standard deviation, skewness, kurtosis, 
coefficient of variation, energy and entropy), describing global texture features of tracer uptake 
that relate to the inhomogeneity of voxel intensity distribution within a predefined whole-brain 
ROI, were measured (Figure 3.21). 
 
 
Figure 3.21: (A) Brain ROI drawn in a CT image and applied to a PET image of a 13-15-month-old 
TASTPM mouse at 24 h post-injection of the tracer for texture analysis; (B) 3D brain ROI; (C) Histogram 
showing the distribution of radioactivity concentration voxel values (in units Bq/mL) within brain ROI. 
 
Two-way repeated measures ANOVA revealed significant differences between 6-8-month-old 
TASTPM transgenic mice and age-matched wildtype controls in standard deviation (p<0.05), 
skewness (p<0.01), kurtosis (p<0.01), coefficient of variation (p<0.01), entropy (p<0.01) and 
energy (p<0.05) (Table 3.2). The TASTPM group showed increased standard deviation and 
coefficient of variation compared to controls, demonstrating a higher spread and non-uniformity 
in voxel intensity values. Furthermore, TASTPM brain images had higher entropy (measure of 
spatial randomness) than those of wild-type mice, revealing an increased level of disorder in 
voxel intensity distribution. The energy (measure of uniformity) of TASTPM brain images was 
lower compared to that of control datasets, suggesting a broader histogram and spread of voxel 
intensity values. The TASTPM group also showed a lower kurtosis (kurtosis < 3) than controls, 
which is indicative of a voxel intensity distribution less clustered around the mean and more 
spread, when compared to the control group, which tended more towards a normal distribution 
(kurtosis~ 3). Skewness (a measure of asymmetry and deviation from a normal distribution) was 
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found to be more negative for controls than for TASTPM mice, indicating a greater spread for 
voxel intensity values lower than the median than for those higher than the median in wild-type 
datasets. All measures of central tendency of the datasets (mean, median, maximum, minimum, 
range and percentiles) were found to be higher for the TASTPM group than for wild-type mice, 
which is indicative of increased tracer uptake in the brains of TASTPM mice compared to 
controls. 
 
Table 3.2: Texture features of brain PET images of 6-8-month-old TASTPM mice and age-matched 
controls at 30 min and 24 h post-injection of 64Cu-GTSM. 
 
 
Statistically significant group, time and group by time interaction effects are indicated by * (p<0.05), ** 
(p<0.01) and *** (p<0.001). Data are mean (n = 4 for TASTPM mice; n = 6 for controls) ± SD. 
 
Although no significant effects of group and interaction on first-order texture parameters were 
detected in 13-15-month-old TASTPM mice and age-matched controls, similar trends to those 
of the younger age groups were observed. TASTPM transgenic mice exhibited higher central 
tendency measures as a result of their greater brain 64Cu uptake relative to controls. TASTPM 
datasets also showed higher standard deviation and entropy, and lower energy than wildtype 
controls, demonstrating a higher spread and non-uniformity in the distribution of voxel intensity 
values. Voxel intensity values in the TASTPM group tended towards a highly peaked, heavy-
tailed distribution (kurtosis > 3), while the control group was closer to a normal distribution 
150 
 
behaviour (kurtosis ~ 3). The skewness value was positive for both groups and slightly higher at 
both imaging time-points for wildtypes, revealing a higher spread for voxel intensity values 
greater than the median than for those lower than the median in this group. However, in this age 
range, standard deviations of texture parameters were considerably larger for the TASTPM 
group compared to controls, and therefore a larger number of datasets is required to determine 
the relevance of these trends in image heterogeneity. 
 
Table 3.3: Texture features of brain PET images of 13-15-month-old TASTPM mice and age-matched 
controls at 30 min and 24 h post-injection of 64Cu-GTSM. 
 
 
Statistically significant group, time and group by time interaction effects are indicated by * (p<0.05), ** 
(p<0.01) and *** (p<0.001). Data are mean (n=3/group) ± SD. 
 
3.4.6 Ex vivo biodistribution 
Following PET/CT imaging, the ex vivo biodistribution of 64Cu at 24 h post-injection of 64Cu-
GTSM was evaluated via gamma-counting of explanted organs in all groups of mice (Figures 
3.22 and 3.23). As expected from the PET images, high accumulation of 64Cu was observed in 
the lungs, heart, liver, kidneys, intestines and brain in both TASTPM and wildtype controls at 
both ages.  
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Figure 3.22: Tissue biodistribution of 64Cu in 6-8-month-old TASTPM mice and age-matched controls at 
24 h post-injection of 64Cu-GTSM. Statistically significant differences from controls are indicated by * 
(p<0.05). Data are mean (n = 4 for TASTPM mice; n = 6 for controls) ± SD. 
 
 
Figure 3.23: Tissue biodistribution of 64Cu in 13-15-month-old TASTPM mice and age-matched controls at 
24 h post-injection of 64Cu-GTSM. Statistically significant differences from controls are indicated by ** 
(p<0.01) and *** (p<0.001). Data are mean (n=3/group) ± SD. 
 
Two-way repeated measures ANOVA revealed significant effects of organ (F1,8 = 121.4, 
p<0.0001) and organ by group interaction (F1,8 = 2.06, p = 0.023) on 64Cu ex vivo biodistribution 
in 6-8-month-old TASTPM transgenic mice and age-matched controls but did not show a 
significant overall group effect (F1,8 = 0.057, p = 0.82). Only lung tracer uptake was found to be 
significantly different by post-hoc analysis between the two groups (p<0.05), with TASTPM mice 
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exhibiting a higher mean concentration of 64Cu than controls (21.30 ± 5.39 %ID/g vs. 17.54 ± 
1.22 %ID/g).  
 
Statistical analysis also demonstrated significant effects of organ (F1,4 = 85.24, p<0.0001) and 
interaction (F1,4 = 3.688, p=0.0002) and a non-significant group effect (F1,4 = 6.200, p=0.0675) 
on 64Cu ex vivo concentration in 13-15-month-old TASTPM mice and healthy controls. Post-hoc 
evaluation revealed significantly higher 64Cu concentrations in the liver (15.30 ± 0.42 %ID/g vs. 
10.13 ± 3.08 %ID/g, p<0.01) and lungs (20.42 ± 5.41 %ID/g vs. 13.82 ± 1.50 %ID/g, p<0.001) of 
13-15-month-old TASTPM mice when compared to age-matched controls. These significant 
differences were found to result from an age-dependent decrease in liver (p<0.001) and lung 
(p<0.01) uptake of 64Cu in wildtype mice between 6-8 and 13-15 months of age. No significant 
age effects were measured in TASTPM transgenic mice. 
 
Gamma-counting results revealed a small increase in global brain uptake of 64Cu in TASTPM 
mice compared to controls at both ages, which did not reach statistical significance by the tests 
employed. The brain %ID/g values determined by ex vivo organ counting showed a strong 
correlation (R2 = 0.6891) with whole-brain 64Cu uptake measured by PET expressed as %ID/mL, 
with two outliers included (Figure 3.24).  
 
 
Figure 3.24: Comparison of brain uptake of 64Cu as measured by PET imaging and by ex vivo gamma-
counting at 24 h post-injection of 64Cu-GTSM in 6-8-/13-15-month-old TASTPM transgenic mice and 




Ex vivo gamma-counting also confirmed hepatobiliary excretion as the main route of elimination 
of the radiocopper from the body (~ 90 % of excreted 64Cu radioactivity in faeces).  
 
3.4.7 Ex vivo brain autoradiography 
To evaluate further the heterogeneity in the brain distribution of 64Cu visualised by PET, sagittal 
brain slices of TASTPM and control mice sacrificed 24 h after 64Cu-GTSM injection were imaged 
by phosphor imaging autoradiography. The results are summarised in Figure 3.25. Ex vivo 
autoradiographs confirmed the heterogeneity of 64Cu uptake within brain tissue in both animal 
groups and the presence of prominent radioactive hotspots in the medulla, cerebellum, 
midbrain, caudate putamen and olfactory bulb (Figure 3.25.A) in 6-8-month-old TASTPM mice. 
The highest accumulation of 64Cu in wildtype brain tissue was found in the caudate putamen 
and cerebellum. Visual inspection of representative digital autoradiographs showed increased 
tracer uptake and a higher degree of heterogeneity in brain 64Cu distribution in the disease 
model when compared to healthy controls (Figure 3.25.B). 
 
Figure 3.25: (A) Sagittal section of PET/CT MIP image of the head of a 6-8-month-old TASTPM mouse at 
24 h post-injection of 64Cu-GTSM (top) and ex vivo autoradiograph of representative sagittal brain section 
from the same animal (bottom). (B) Surface plots of brain autoradiographs from a 6-8-month-old TASTPM 
(left) and control (right) mice sacrificed 24 h after administration of 64Cu-GTSM. Ex vivo autoradiography 
confirmed the heterogeneous pattern of 64Cu accumulation in the brain suggested by PET imaging. Visual 
examination of autoradiographs showed higher and patchier brain uptake of 64Cu in TASTPM mice 
compared to healthy controls. CE = cerebellum; CP = caudate putamen; OB = olfactory bulb. 
 
3.4.8 Histology 
The extent of cerebral Aβ plaque deposition in the TASTPM AD mouse model was evaluated 
via Congo red staining of brain sections previously autoradiographed. As expected from 
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previous reports (Howlett et al., 2004; Howlett et al., 2008) and our own immunohistochemical 
studies, Congo red-stained Aβ plaque deposits were predominantly found in the hippocampus, 
cortex and thalamus in 6-8- and 13-15-month-old TASTPM transgenic mice. No Aβ deposits 
were detected in age-matched wildtype controls. To determine whether there was a relationship 
between brain regional distribution of 64Cu and Aβ plaque deposition in TASTPM mice, Congo 
red-stained brain slices and their respective autoradiographs were inspected visually. Figures 
3.26 and 3.27 show exemplar brain slices of TASTPM mice at 6-8 and 13-15 months of age 
imaged by autoradiography and subsequently stained with Congo red. Although 64Cu was taken 
up by all brain regions, visual assessment of the paired images revealed that the areas 
predominantly affected by Aβ plaque load (red-orange stain; hippocampus, thalamus and 
cerebral cortex) did not correspond to the regions with the most prominent radioactive hotspots, 
as depicted by autoradiography (olfactory bulb, medulla, cerebellum, midbrain and caudate 
putamen), suggesting that other metabolic/pathological factors besides Aβ plaque deposition 
influence brain regional 64Cu accumulation.    
 
Figure 3.26: (A) Photomicrograph of a Congo red-stained sagittal brain section from a 6-8-month old 
TASTPM mouse (top) and corresponding autoradiograph at 24 h post-injection of 64Cu-GTSM (bottom). 
(B) Magnified views of representative brain regions shown in Figure 3.26.A. 64Cu was found to accumulate 
in the whole brain, including plaque-rich regions (red-orange stain; hippocampus, thalamus and cerebral 
cortex). However, the most prominent 64Cu hotspots were observed in areas with low plaque density 
(olfactory bulb, medulla, cerebellum, midbrain and caudate putamen), suggesting the influence of 
additional factors other than Aβ plaque deposition on brain regional 64Cu accumulation. From top left to 
bottom right: ME = medulla; CE = cerebellum; M = midbrain; C1 = cerebral cortex; H = hippocampus; TH = 
thalamus; CP = caudate putamen; LV = lateral ventricle; C2 = cerebral cortex; ON = anterior olfactory 





Figure 3.27: (A). Photomicrograph of sagittal brain section from a 13-15-month old TASTPM mouse (top) 
and corresponding brain autoradiograph (bottom) at 24 h post-injection of 64Cu-GTSM (B) Magnified views 
of representative brain regions shown in Figure 3.27.A. As observed in 6-8-month-old TASTPM mice, 64Cu 
accumulated most prominently within brain regions with low Aβ plaque load (olfactory bulb, medulla, 
cerebellum, midbrain and caudate putamen) at 24 h post-injection of 64Cu-GTSM. From top left to bottom 
right: ME = medulla; CE = cerebellum; M = midbrain; C1 = cerebral cortex; H = hippocampus; TH = 
thalamus; CP = caudate putamen; LV = lateral ventricle; C2 = cerebral cortex; ON = anterior olfactory 




Non-invasive monitoring of brain copper trafficking in vivo by PET could provide unique insight 
into the role of copper metabolism in AD biology, and may have potential as a diagnostic marker 
of disease progression and response to therapy, particularly in the context of metal chelation 
treatments. In this study, we aimed to explore brain copper trafficking in TASTPM transgenic 
mice at early and middle stages of AD-like pathology by PET imaging using the Cu-BTSC 
complex 64Cu-GTSM. 
 
The chosen route of administration of 64Cu-GTSM was intravenous injection, which does not 
mimic the gastrointestinal uptake and biodistribution of endogenous copper but ensures rapid 
delivery of the radiotracer into the brain. In order to confirm the ability of the tracer to release 
radiocopper intracellularly within the brain, we used solvent extraction to measure the amount of 
intact 64Cu-GTSM complex present in brain homogenates of mice injected with the tracer, at 
different time-points after injection (30 min, 24 h). The results revealed that less than 4 % of 
64Cu radioactivity was associated with the octanol-extractable fraction already at 30 min post-
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injection, consistent with the proposed cellular uptake and non-selective bioreductive trapping of 
64Cu-GTSM (142, 150, 365). The low 64Cu radioactivity present in the octanol-extractable 
fraction, and the lack of 64Cu-GTSM complex detectable by radio-TLC of that fraction, indicated 
that 64Cu-GTSM was almost completely dissociated by 30 min. Alongside our in vivo blood 
sampling  and dynamic PET/CT imaging experiments, which revealed short blood half-life and 
remarkably high and rapid uptake of the tracer into the brain, the results obtained are consistent 
with a process in which the lipophilic nature of the 64Cu-GTSM complex facilitates its passage 
across the BBB and into cells, where it dissociates, releasing 64Cu intracellularly, as previously 
suggested for this compound (413). This mechanism is the basis for the selection of 64Cu-GTSM 
as a vehicle for the intracellular delivery of imageable amounts of 64Cu into the brain. The use of 
radioactive copper salts, which enter the brain via active transport mechanisms, would mimic 
brain copper metabolism much more closely but would not allow the delivery of sufficient 
radiocopper to study copper trafficking processes within the CNS, as shown in previous studies 
(179). The speciation of the 64Cu radiolabel of 64Cu-GTSM in the intracellular copper pool has 
not been elucidated but it probably follows the same metabolic pathways as endogenous 
copper.  
 
As well as efficient delivery of 64Cu into the brain, 64Cu-GTSM-PET imaging also demonstrated 
that clearance of radiocopper from the brain is considerably slower than that of most other 
tissues (e.g. heart, kidneys). The biological significance of this observation is not yet clear but it 
could be due to brain tissue showing greater active sequestration of copper ions driven by 
increased metabolic demands associated with regular brain function, or less active copper efflux 
mechanisms.  
 
PET/CT imaging of copper trafficking with 64Cu-GTSM revealed significantly increased brain and 
spine uptake of 64Cu in male TASTPM mice at both 6-8 and 13-15 months of age compared to 
age-matched controls at 30 min and 24 h post-injection of the tracer. Despite differences in the 
animal model, age ranges and methodology used, these results agree with those of Fodero-
Tavoletti et al., who reported that 64Cu uptake in the brain was nearly two-fold higher in 
APP/PS1 transgenic mice compared to healthy controls at 60 min post-injection of 64Cu-GTSM 
(155). However, enhanced brain uptake of 64Cu in TASTPM mice was found to be much less 
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marked (~1.3-fold increase in the 6-8-month-old group and ~1.4-fold increase in the 13-15-
month-old group) than that previously reported for the APP/PS1 model. This may be partially 
due to inherent differences in phenotype severity and disease progression between the two AD 
models. 
 
Unlike PET, the increase in 64Cu brain uptake in TASTPM mice compared to controls at 24 h 
post-injection of the tracer did not reach statistical significance when measured by ex vivo 
gamma-counting. Ex vivo organ counting is subject to greater opportunities for non-systematic 
error (e.g. cross contamination between tissues during dissection, weighing errors, incomplete 
explantation) that may account for this discrepancy. It should be also noted that the total 
injected dose used to quantify ex vivo biodistribution of 64Cu may have been underestimated 
due to activity loss during dissection and urine/faeces collection. These potential opportunities 
for error may explain why gamma-counting measurements did not show a stronger linear 
correlation with PET quantitative data (R2 = 0.6891). 
 
While 64Cu clearance from brain was found to be slower than that from other tissues in both 
TASTPM and wildtype mice, it was also observed that tracer washout was faster in TASTPM 
mice when compared to healthy controls (-10 % vs. -2 % at 6-8 months of age; -4.5 % vs +3 % 
at 13-15 months of age). Despite this faster 64Cu clearance rate, TASTPM mice still had 
significantly increased 64Cu concentration in the brain than controls both at 30 min and 24 h 
post-injection of 64Cu-GTSM. These differences in brain copper trafficking between the two 
groups may be explained by the combination of more active copper influx and efflux 
mechanisms in the TASTPM model, or by different patterns of copper bioavailability to these 
processes. The molecular mechanisms underlying the increased concentration of 64Cu in the 
brains of AD mice have yet to be deciphered but may be driven by the regulation of total brain 
copper levels in an effort to maintain brain copper homeostasis and/or enhance copper-
dependent antioxidant enzyme activity as a response to oxidative stress. Another possibility to 
consider is the existence of pathological alterations of cerebral vasculature in this AD model. No 
perturbations of BBB integrity and permeability have been reported for the TASTPM model but 
morphological and architectural alterations of cerebral vasculature caused by Aβ plaque 
pathology, as evidenced for APP23 transgenic mice, could result in abnormal regional blood 
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flow and affect global tracer uptake (414, 415).  On the other hand, faster brain clearance of 
64Cu in TASTPM transgenic mice may be caused by the overexpression of APP, which has 
been suggested to play a role in normal copper metabolism as an efflux transporter (256, 353, 
416).  
 
An age-dependent decrease in global 64Cu brain uptake was observed in both TASTPM and 
wildtype mice between 6-8 and 13-15 months of age. This could be due to reductions in 
cerebral blood flow associated with aging, but could also result from regulatory mechanisms of 
the CNS aimed at maintaining copper homeostasis at a constant level. The latter possibility was 
first suggested by Wang and co-workers after observing increased cerebral copper content and 
reduced active 67CuCl2 brain uptake in aging mice (196, 417).  
 
Both PET/CT imaging and ex vivo brain autoradiography demonstrated that the accumulation of 
64Cu within the brain at 30 min and 24 h after 64Cu-GTSM administration was heterogeneous. In 
an attempt to rationalise 64Cu brain signal heterogeneity, we measured 64Cu uptake in 14 
predefined brain regions using a 3D mouse brain atlas.  64Cu concentration was found to be 
higher in all brain regions in TASTPM mice  compared to controls, with differences between the 
two groups reaching statistical significance in specific areas at 30 min and 24 h post-injection of 
the tracer. Whether these differences in 64Cu regional brain uptake are a consequence of 
localised AD-like pathology or result from globally higher 64Cu accumulation in the brains of 
TASTPM mice is unknown. However, it should be noted that many of these brain regions are 
very small compared to the limited spatial resolution of the PET/CT scanner; this means that the 
heterogeneity in 64Cu concentration within the brain will have been underestimated by atlas-
based quantification due to the partial volume effect; combined with the lack of flexibility of 
segmentation boundaries and the potential for imperfect matching of the atlas regions onto the 
real brain regions, these results must be interpreted cautiously. 
 
In order to avoid overinterpreting regional variations in brain uptake of 64Cu as a result of these 
limitations, PET brain signal heterogeneity was alternatively measured by texture analysis. This 
type of analysis investigates the spatial interrelationships of the image voxels that reflect global 
and regional patterns of image heterogeneity, without an underlying biological or structural 
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model. Statistical analysis of first-order texture parameters revealed a higher spread, 
asymmetry and non-uniformity of the voxel intensity distribution in TASTPM brain images, 
indicating a greater degree of image heterogeneity in the disease model compared to controls. 
Nevertheless, larger sample sizes are needed in order to determine the significance of these 
trends in PET image heterogeneity, particularly in the 13-15-month old age group, in which 
standard deviation of texture parameters was found to be higher. While this type of image 
analysis does not offer insight into the biological interpretation of differences in brain uptake of 
64Cu between the two animal groups, it does offer a basis for parameterisation of imaging for 
clinical diagnostic purposes.  
 
The molecular mechanisms responsible for the increased heterogeneity of 64Cu distribution 
within the brain (evidenced both via atlas-based quantification and texture analysis) have yet to 
be elucidated. Brain copper metabolism is based on a complex network of uptake, trafficking 
and efflux processes and a delicate balance between “free” and protein-bound copper species. 
Whether higher 64Cu accumulation in certain regions results from endogenous metabolic 
demands of each brain region, enhanced regional BBB permeability and/or microvessel density, 
or localised AD-like pathology remains unknown. Metabolite analysis studies will be necessary 
to determine the fate of the 64Cu radiolabel and the biological significance of its heterogeneous 
distribution within brain tissue. 
 
The ability of Aβ plaques to bind copper has been extensively reported in the literature (418-
420). The sequestration of copper by extracellular Aβ plaque deposits is thought to contribute to 
brain copper dyshomeostasis in AD by reducing the intracellular bioavailability of copper ions 
(341, 398, 400, 421). In order to determine whether a correlation existed between the regional 
distribution of 64Cu in the brain and Aβ plaque deposition in 6-8- and 13-15-month-old TASTPM 
transgenic mice, brain tissue was imaged by autoradiography and subsequently stained with the 
Aβ-binding Congo red dye. We observed that, although 64Cu was taken up by the whole brain, 
the main radioactive hotspots (cerebellum, midbrain, caudate putamen, olfactory bulb) did not 
co-localise with the regions of highest Aβ plaque load (cerebral cortex, hippocampus, 
thalamus). This distribution pattern does not preclude the possibility that Aβ plaques serve as a 
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sink for copper ions, but highlights the influence of additional metabolic/pathological factors 




This study demonstrated that 64Cu-GTSM is a suitable vehicle for the efficient delivery of 64Cu 
into the brain, and revealed the potential for application of 64Cu-GTSM-PET to study changes in 
copper ion trafficking associated with various neurological disorders (e.g. AD, PD, ALS, HD). 
PET/CT imaging with 64Cu-GTSM showed statistically significant differences in 64Cu brain 
uptake and biokinetics between TASTPM transgenic mice at early and middle stages of the 
disease and age-matched controls. Furthermore, atlas-based PET quantification and texture 
analysis demonstrated substantial variations in regional brain concentration of 64Cu and PET 
image heterogeneity, respectively, between the two groups of mice. The present study provides 
an initial set of PET imaging parameters (global brain concentration of 64Cu; rate of clearance of 
64Cu from brain; degree of heterogeneity of brain 64Cu distribution) that could be evaluated in 
early human trials. These results support further evaluation of PET imaging of brain copper 
trafficking both as a tool to investigate alterations in copper trafficking that might have added 
value in the diagnosis of AD, and as a possible diagnostic biomarker to monitor disease 















4. Chapter 4- Imaging active copper trafficking in a mouse 





The aim of this chapter is to investigate active copper transport in the brain and whole-body in 
the TASTPM mouse model of AD by synchrotron radiation X-ray fluorescence (XRF) and 64Cu-
acetate-PET in order to identify potential copper metabolism abnormalities that may be 




For many years, radioactive copper salts have played a crucial role in the understanding of the 
physiology of copper metabolism in health and disease. The assessment of tissue radioactivity 
in small animals after radiocopper administration contributed to the early characterisation of 
copper absorption, distribution and excretion in living organisms (109, 422-425). The 
measurement of radiocopper accumulation in body fluids and tissues using nuclear scintillation 
systems was also performed in human subjects and used to identify copper metabolism 
abnormalities associated with genetic conditions, such as WD (426-430). However, the limited 
spatial resolution of nuclear scintillation cameras in the 1960s hindered temporarily the 
application of radioactive copper salts to investigate whole-body copper fluxes in vivo. 
 
With the advent of high-resolution PET scanners and increasing availability of copper 
radioisotopes, the feasibility of using radioactive copper salts as PET radiotracers for the real-
time assessment of active copper transport at the whole-body level in living organisms has been 
demonstrated. Bissig and co-workers first reported the use of a high-resolution PET system to 
image copper trafficking in a rat model of WD, although prolonged retention of orally 
administered radiocopper in the gastrointestinal tract did not allow the detection of abnormalities 
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in copper hepatic processing (431). Subsequent studies by Peng et al. demonstrated the utility 
of 64CuCl2-PET to characterise copper metabolism imbalance in an ATP7B knockout mouse 
model of WD (153, 179).  Peng and co-workers also used 64CuCl2 to visualise prostate cancer 
and hepatoma xenografts, and reported abnormally high accumulation of radiocopper in both 
tumour types compared to soft tissue (184, 185). 
 
With growing evidence supporting the existence of abnormalities in copper metabolism in many 
neurological disorders (e.g. AD, PD, HD, ALS), the application of radioactive copper salts as 
radiotracers offers great potential not only to study active copper transport in these diseases but 
also as a diagnostic tool to assess disease status and progression. To date, only Fodero-
Tavoletti and co-workers have used copper radioisotopes to image copper trafficking by PET in 
a mouse model of AD (155). However, their study focused on the evaluation of brain copper 
fluxes by using the BBB-permeable 64Cu-GTSM complex as a radiocopper delivery vehicle, and 
did not provide any information on active copper transport at the whole-body level. Although in 
AD research much focus has been on the dysregulation of copper homeostasis in the brain, 
serum copper levels have also been shown to be altered in AD, which could have an effect on 
copper trafficking at the level of the whole organism (349, 432). PET imaging of whole-body 
copper trafficking using radioactive copper salts would enable the identification and 
characterisation of metabolic abnormalities that might have added value for the diagnosis of AD 
and other neurological disorders. 
 
The potential of radioactive copper salts as PET radiotracers extends beyond the detection of 
copper metabolism abnormalities associated with disease. In the context of copper chelation 
therapies, radiocopper can be used to evaluate the mechanism of action of a particular copper 
chelating drug and even monitor response to treatment. Nomura et al. demonstrated the utility 
of 64CuCl2-PET to evaluate the copper trafficking efficacy of chelating agent disulfiram in a 
mouse model of MD (154). The development of copper chelating drugs (e.g. CQ, PBT2) aimed 
at restoring copper homeostasis in several pathological conditions (e.g. AD, HD, PD, brain 
cancer) encourages the application of PET imaging using ionic radiocopper as a tool for 




Hence, in this study we examine the potential of 64Cu-acetate-PET to evaluate the short-term 
dynamics of copper at the level of the whole organism in the TASTPM mouse model of AD, and 
assess the effects of CQ treatment on whole-body copper trafficking. In addition to monitoring 
whole-body copper trafficking in the acute time scale by PET, the endogenous distribution of 
copper in the brain resulting from prolonged active transport was imaged in AD transgenic mice 
by XRF. The characterisation of acute and chronic copper distribution at brain and whole-body 
levels in the TASTPM mouse model will allow the detection of potential trafficking abnormalities 
that can be used as diagnostic markers of the pathology.  
 
4.3 MATERIALS AND METHODS 
 
4.3.1 Radiochemistry 
All reagents were purchased from Sigma-Aldrich, Alfa Aesar, Interlink Scientific Services or 
VWR International Ltd. and were used without further purification, unless otherwise stated. 64Cu 
was produced as previously reported on a CTI RDS 112 biomedical cyclotron at the Clinical 
PET Centre of St Thomas’ Hospital in the form of 64CuCl2 in 0.1 N HCl solution (4.8 GBq/μg) 
(99). Radioactivity was measured using a Capintec CRC-25R dose calibrator. Radio-TLC was 
performed on a LabLogic Flow-Count scanner (scan speed: 0.25 mm/s), using MERCK 60 F254 
silica gel plates as the stationary phase and ethyl acetate as the mobile phase. 64Cu-acetate 
was prepared by buffering 64CuCl2 (~300 MBq) with a 3 M solution of sodium acetate to pH 6 
(Rf= 0, 100 % radiochemical purity) and administered in physiological saline. CQ doses (50 
mg/kg) were suspended in 4 % (w/v) (2-hydroxypropyl)-β-cyclodextrin for intraperitoneal 
administration (≤400 μL). Sham doses were made with 4 % (w/v) (2-hydroxypropyl)-β-
cyclodextrin (≤400 μL).  
 
4.3.2 Animals 
All animal experiments were performed in accordance with the Animals (Scientific Procedures) 
Act, 1986 and approved by the local ethics committee. Animals were kept in standard BSU 




Double-mutant TASTPM mice on a C57BL/6J background were bred in-house from mice 
provided by GlaxoSmithKline (GSK). Additional information on the TASTPM mouse model is 
included in Chapter III. C57BL/6J wildtype controls were obtained from Charles River 
Laboratories International, Inc.  
 
4.3.3 XRF 
Elemental copper maps of brain tissue sections from TASTPM and wildtype mice (4- and 8-
month age groups, n=3/group) were obtained using XRF. Animals were sacrificed by cervical 
dislocation and their brains removed and hemisected. All dissection instruments were previously 
wiped down with alcohol in order to avoid metal contamination of the tissue. Brain hemispheres 
were incubated in a 30 % (w/v) sucrose solution until they sank, and stored at -80°C overnight. 
Frozen left hemispheres were sectioned (40 μm) in the sagittal plane using a Bright 5040 
cryotome. Two representative brain slices were taken per animal (sections 109 and 129 in 
Paxinos and Franklin’s mouse brain atlas) (433). Tissue slices were placed on XRF film (4 μm 
thick, Ultralene®, SPEX SamplePrep, NJ, USA) and allowed to dry at room temperature.  
 
XRF was performed at the Diamond Light Source synchrotron facility (Harwell Science and 
Innovation Campus, Didcot, UK) by Dr Po-Wah So (Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London). Elemental copper maps were acquired at 100 μm 
spatial resolution using the I18-Microfocus Spectroscopy beamline. Fluorescence 
measurements were performed with the sample surface positioned at 45° with respect to the 
incoming X-ray beam in order to reduce the scatter contribution to the detected signal. 2D 
copper maps were quantified using ImageJ (NIH) software. Fixed-volume ROIs (12 mm2) were 
drawn on several brain regions of the elemental copper maps to compare mean pixel intensity 
values between control and TASTPM samples. 
 
4.3.4 In vivo blood sampling 
Following inhalation induction with isoflurane (2 % [v/v]) and surgical exposure of the left 
external jugular vein, C57BL/6J controls (n=3, 6-8 months old) were intravenously injected with 
64Cu-acetate via the lateral tail vein (5 MBq, ~100 µL). Blood samples (~10 μL) were withdrawn 
from the jugular vein at different time-points after injection (1, 2, 5, 10, 15, 20, 30, and 60 min 
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post-injection), and were subsequently weighed and gamma-counted. Time-activity curves were 
plotted to determine the blood half-life of the tracer. 
 
4.3.5 PET/CT imaging 
Imaging experiments were performed using a nanoScan® PET/CT (Mediso Medical Imaging 
Systems, Budapest, Hungary). 64Cu-acetate-PET was conducted in 6-8- (n=3) and 13-15-
month-old (n=3) male TASTPM transgenic mice and age-matched C57BL/6J controls (n=4 and 
n=3, respectively). Animals were anaesthetised by isoflurane inhalation (3 % [v/v], Vet Tech 
Solutions Ltd.) and injected with 64Cu-acetate (40 MBq, ≤200 µL) via lateral tail vein. 
Immediately after injection, mice were placed on the scan bed in the prone position and 
maintained under inhalation anaesthesia (2 % isoflurane). A 30-min PET scan was 
subsequently acquired (400-600 keV energy window; 5 ns coincidence window, 0.30 x 0.30 x 
0.30 mm3 voxel size), followed by a CT scan (180 projections, 45 KVp, 0.25 x 0.25 x 0.21 mm3 
voxel size). Animals were allowed to recover from anaesthesia and housed overnight. Mice 
were then scanned again at 24 h post-injection of the tracer for 1 h. PET imaging of copper 
trafficking with 64Cu-acetate after CQ/sham treatment was performed in 2-month-old male 
C57BL/6J wildtype mice (n=2/treatment). Mice were intraperitoneally injected with CQ or sham 
doses (see section 4.3.1) and anaesthetised 30 min after injection. Animals were then injected 
with 64Cu-acetate via lateral tail vein and scanned by PET for 30 min (400-600 keV energy 
window; 5 ns coincidence window, 0.30 x 0.30 x 0.30 mm3 voxel size), followed by a CT scan 
(180 projections, 45 KVp, 0.25 x 0.25 x 0.21 mm3 voxel size). Mice were re-imaged at 24.5 h 
post-injection of the tracer for 30 min. Respiration rate and bed temperature were monitored 
throughout all scans. 
 
4.3.5.1 PET image analysis 
All PET/CT datasets were reconstructed using the Tera-Tomo 3D iterative algorithm (8 
iterations, 6 subsets, 0.25 x 0.25 x 0.25 mm3 voxel size). Decay, dead-time, and intercrystal 
scatter corrections were applied. A CT-derived attenuation map was used for PET attenuation 
compensation. The 0-30 min PET datasets were reconstructed into 5-min bins and binned 
images corresponding to 25–30 min post-injection were used for ROI analysis. Static 24-25 h 
and 24.5-25 h PET datasets were reconstructed into single bins representing the average 
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radiotracer biodistribution during each time frame. All reconstructed datasets were analysed 
using VivoQuant 1.21 software (InviCRO, LLC). Software-driven PET/CT co-registration was 
applied and corrected using manual reorientation functions when inaccurate. To measure 64Cu 
concentration in the spine, heart, liver and kidneys, fixed-volume ROIs (~15 mm3) were 
delineated within each organ. The sum of activity (MBq) within each organ ROI was divided by 
the sum of the whole-body ID (excluding tail) and normalised by the volume of the ROI to yield 
%ID/mL.  
 
To quantify global and regional brain concentration of 64Cu,  a mouse brain atlas NM/CT module 
(inviCRO, LLC) was automatically overlaid onto all PET/CT datasets. Atlas-based 
measurements of 64Cu brain concentration were expressed as %ID/mL. Ventricular uptake of 
64Cu was alternatively measured by drawing a fixed-volume ROI (0.3125 mm3) within the lateral 
ventricles. The mean and maximum concentration of activity per voxel in the ventricle ROI were 
divided by the ID normalised by the weight of the mouse to give mean and maximum 
standardised uptake values (SUVmean and SUVmax), respectively. 
 
4.3.6 Ex vivo biodistribution 
After imaging, animals were sacrificed by cervical dislocation immediately and all major organs 
were explanted, weighed and gamma-counted (LKB Wallac 1282). The activity in the urine and 
faeces collected from the recovery cages was also measured. 64Cu concentration in each organ 
was expressed as %ID/g. The total ID was defined as the sum of all whole-body counts 
(excluding tail) and excreted activity (urine and faeces). 
 
4.3.7 Ex vivo brain autoradiography and histology 
Brain tissue removed from imaged mice was incubated in a 30 % (w/v) sucrose solution until it 
sank and stored at -80°C overnight. Cryopreserved brains were sectioned (10 µm) in the sagittal 
plane using a Bright 5040 cryotome. Tissue sections were thaw-mounted onto Superfrost PLUS 
glass microscope slides (Menzel-Glaser, Thermo Scientific) and allowed to dry at room 
temperature. The slides were then exposed to a storage phosphor screen (PerkinElmer, Super 
Resolution, 12.5 x 25.2 cm) in a standard X-ray cassette for 15 h. The phosphor screen was 
167 
 
then imaged using a Typhoon 8600 scanner (Molecular Dynamics) and images were analysed 
with OptiQuant 5.0 (PerkinElmer) and ImageJ (NIH). 
 
Following autoradiography, brain slices were stored at -80°C. After decay, the sections were 
stained with hematoxylin for visualisation of tissue morphology. Frozen brain slices were fixed in 
4 % (w/v) PFA for 45 min and washed with distilled water. Subsequently, tissue sections were 
immersed in Harris’ hematoxylin (Sigma Aldrich) for 15 s. Brain slices were then washed with 
tap water for 2 min, followed by a rinse in acid alcohol solution (1 mL 3M HCl in 200 mL 70 % 
IMS [v/v]) for 1 min. Finally, brain slices were incubated in 95 % (v/v) alcohol (3 min, 2 changes) 
and 100 % alcohol (3 min, 2 changes) for dehydration, cleared in Histo-Clear II solution 
(National Diagnostics; 2 changes, 3 min) and mounted with DPX mounting medium (Merck 
Millipore). All cover-slipped slides were examined under bright-field microscopy using a light 
microscope (DM6000 B; Leica Microsystems Ltd., Bucks, UK). 
 
4.3.8 Statistical analysis 
All data are reported as mean ± SD. Statistical analysis was performed using GraphPad Prism 5 
(GraphPad Software Inc.). Two-way repeated measures ANOVA with post-hoc analyses using 
the Bonferroni multiple comparison correction was used to determine statistically significant 
differences between TASTPM mice and controls at different imaging time-points. Student t-test 





To examine the distribution of endogenous copper in the brains of TASTPM transgenic mice 
and wildtype controls, elemental copper maps from representative brain sections were 
generated by XRF. We initially aimed to perform XRF analysis on brain sections of 6-8- and 13-
15-month-old TASTPM mice and age-matched controls, but the lack of availability of aged AD 
mice did not allow copper distribution to be evaluated in the latter age group. Instead, copper 
mapping was conducted on brain sections of 4-month-old TASTPM and wildtype mice in order 
to assess the effect of disease progression and aging on brain copper distribution.  
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Slices 109 and 129 from the Paxinos and Franklin’s mouse brain atlas were used as reference 
points for the sectioning. Figure 4.1 depicts representative photomicrographs of the 109 and 
129 sagittal brain sections stained with acetylcholinesterase, showing the main brain structures 
present at each level. 
 
 
Figure 4.1: Photomicrographs of the 129 (top) and 109 (bottom) sagittal brain sections from the Paxinos 
and Franklin’s mouse brain atlas stained with acetylcholinesterase. Left-hand side illustrations depict the 
location of the brain slice with respect to the bregma (129: 3.36 mm; 109: 0.96 mm) (433). C = cerebral 
cortex; PC = piriform cortex; H = hippocampus; EC = entorrhinal cortex; CE = cerebellum; OB = olfactory 
bulb; CP = caudate putamen; F = fimbria of the hippocampus; TH = thalamus; HT = hypothalamus; M = 
midbrain; P = pons; ME = medulla. 
 
Representative brain sections of 4- and 8-month-old TASTPM transgenic mice and age-
matched controls were scanned by synchrotron-based XRF to produce quantitative elemental 
copper maps. Visual inspection of the XRF maps revealed that copper distribution in the 
selected brain sections was heterogeneous in all groups, with particularly high copper levels 








Figure 4.2: Elemental copper maps from sagittal brain sections 129 (left) and 109 (right) of 4-month-old 
TASTPM mice and age-matched controls acquired by synchrotron-based XRF. On visual assessment, 
copper accumulation seemed to be particularly prominent in the areas surrounding the lateral and fourth 
ventricles (fimbria of the hippocampus, caudate putamen and cerebellum). C = cerebral cortex; PC = 
piriform cortex; H = hippocampus; EC = entorrhinal cortex; CE = cerebellum; OB = olfactory bulb; CP = 
caudate putamen; F = fimbria of the hippocampus; TH = thalamus; HT = hypothalamus; M = midbrain; P = 
pons; ME = medulla. 
 
Figure 4.3: Elemental copper maps from sagittal brain sections 129 (left) and 109 (right) of 8-month-old 
TASTPM mice and age-matched controls acquired by synchrotron-based XRF. As observed in the 4-
month-old mouse groups, copper accumulated primarily in periventricular regions in both TASTPM and 
control mice. C = cerebral cortex; PC = piriform cortex; H = hippocampus; EC = entorrhinal cortex; CE = 
cerebellum; OB = olfactory bulb; CP = caudate putamen; F = fimbria of the hippocampus; TH = thalamus; 
HT = hypothalamus; M = midbrain; P = pons; ME = medulla. 
 
Fixed-volume ROIs were drawn within the main brain regions in each section and mean pixel 
intensity values were compared between AD and control samples. Repeated measures ANOVA 
indicated significant effects of region (F1,4 = 4.699, p = 0.0053) and group by region interaction 
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(F1,4 = 3.322, p = 0.0240) on mean copper signal intensity in section 129 of 4-month-old 
TASTPM and control groups (Figure 4.4). Post-hoc evaluation revealed that copper levels in the 
hippocampus were significantly higher in 4-month-old TASTPM transgenic mice compared to 
age-matched controls (8.96 ± 4.37 vs 3.15 ± 0.75, p<0.05). In section 109, significant effects of 
region (F1,4 = 14.68, p<0.0001) and interaction (F1,4 = 3.347, p = 0.0014) were also detected. 
XRF quantification of mean copper signal intensity in section 109 did not indicate a significant 
difference in hippocampal copper levels between 4-month-old TASTPM mice and age-matched 
controls, but showed a two-fold higher accumulation of copper in the caudate putamen of the 
wildtype group when compared to AD mice (18.48 ± 8.44 vs 9.07 ± 1.12, p<0.001).  
 
Figure 4.4: Quantification of elemental copper maps from brain sections 129 (top) and 109 (bottom) of 4-
month-old TASTPM mice and age-matched controls. XRF analysis revealed statistically significant 
differences in mean copper signal intensity between the groups in the hippocampus (p<0.05) and caudate 
putamen (p<0.001). Statistically significant differences are indicated by * (p<0.05) and *** (p<0.001). Data 
are mean (n =3/group) ± SD.    
 
Statistical analysis also revealed significant effects of region (129: F1,4 = 6.901, p = 0.0007; 109: 
F1,4 = 15.19, p<0.0001) and group by region interaction (129: F1,4 = 4.377, p = 0.0075; 109: F1,4 
= 11.42, p<0.0001) on mean pixel intensity values in sections 129 and 109 of 8-month-old 
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TASTPM transgenic mice and wildtype controls (Figure 4.5). Post-hoc tests indicated almost 
four-fold higher levels of copper in the cerebellum of TASTPM mice when compared to controls 
(15.47 ± 8.49 vs 4.31 ± 2.87, p<0.01) in section 129. Quantification of section 109 also showed 
significantly higher mean copper signal intensity in the cerebellum of 8-month-old TASTPM mice 
relative to controls (30.92 ± 8.07 vs 14.30 ± 0.79, p<0.01), as well as a nearly seven-fold greater 
accumulation of copper in the thalamus of AD mice (30.06 ± 6.61 vs 4.57 ± 1.18, p<0.001). In 
addition, post-hoc evaluation revealed significantly higher mean copper signal intensity in the 
caudate putamen of 8-month-old wildtype controls compared to age-matched TASTPM mice 
(34.58 ± 18.80 vs 6.11 ± 2.01, p<0.001), in the same manner as for the 4-month-old mouse 
groups.  
 
Figure 4.5: Quantification of elemental copper maps from brain sections 129 (top) and 109 (bottom) of 8-
month-old TASTPM mice and age-matched controls. XRF analysis indicated statistically significant 
differences in mean copper signal intensity between the groups in the cerebellum (p<0.01), thalamus 
(p<0.001) and caudate putamen (p<0.001). Statistically significant differences are indicated by ** (p<0.01) 
and *** (p<0.001). Data are mean (n = 3/group) ± SD.    
 
Additional ROIs were drawn around the periventricular areas of section 109 without following 
specific anatomical boundaries and mean pixel intensity values were compared between AD 
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and wildtype groups. No significant differences in mean copper signal intensity were found 
between the groups within the region surrounding the lateral ventricles, but TASTPM transgenic 
mice were found to exhibit significantly higher copper levels than controls in the area 
surrounding the fourth ventricle, at the junction between the pons, midbrain and cerebellum, at 
both 4 (11.79 ± 0.78 vs 8.41 ± 1.94, p<0.05) and 8 (24.65 ± 1.80 vs 12.65 ± 2.44, p<0.01) 
months of age. Global copper content in each slice was found to be slightly higher for the 
TASTPM group compared to age-matched controls at both ages. 
 
The effects of aging and disease progression on the distribution of endogenous copper within 
the brain were also evaluated by comparing mean copper signal intensity values between the 
different age groups (Figure 4.6). An age-dependent increase of copper signal was observed in 
the maps of both TASTPM and control mice, although this effect did not reach statistical 
significance. For wildtype controls, copper levels in the caudate putamen were found to 
increase significantly from 4 to 8 months of age (18.48 ± 8.44 vs 34.58 ± 18.80, p<0.01). 
Conversely, TASTPM transgenic mice showed age-dependent increases of mean copper signal 
intensity in the thalamus (3.57 ± 0.15 vs 30.06 ± 6.61, p<0.001) and cerebellum (14.83 ± 2.05 




Figure 4.6: The effect of aging on brain copper distribution in TASTPM transgenic mice and wildtype 
controls as shown by XRF. Significant differences in copper levels between the 4- and 8-month-old age 
groups were found in the caudate putamen (p<0.01) in wildtype mice, and in the thalamus and cerebellum 
in the AD group. Statistically significant differences are indicated by ** (p<0.01) and *** (p<0.001). Data are 
mean (n =3/group) ± SD.    
 
4.4.2 In vivo blood sampling 
To evaluate the in vivo behaviour of 64Cu-acetate in blood, blood samples were collected from 
the left external jugular vein of wildtype mice injected with the tracer at different time-points after 
injection. Blood aliquots were subsequently gamma-counted and time-activity curves were 
constructed to determine the blood half-life of the tracer. 64Cu-acetate was found to follow a 
biexponential clearance pattern, with a fast half-life  of 1.28  0.47 min and a slow half-life of 




Figure 4.7: Blood time-activity curves resulting from in vivo blood sampling in wildtype mice injected with 
64Cu-acetate. Blood clearance of 64Cu-acetate followed a biexponential behaviour, with a fast elimination 
half-time of 1.28  0.47 min and a slow half-life of 9.75  3.50 min. 
 
 
4.4.3 Measurement of whole-body copper trafficking in AD by 64Cu-acetate-PET 
 
4.4.3.1 PET/CT imaging  
After investigating the short-term dynamics of copper fluxes within the CNS in AD-like pathology 
with 64Cu-GTSM (see Chapter III), we evaluated copper trafficking at the level of the whole 
organism in the TASTPM mouse model by 64Cu-acetate-PET. The fate of intravenously 
administered radiocopper was monitored longitudinally by PET in 6-8- and 13-15- month-old 
male TASTPM mice and age-matched controls. 
 
At 30 min post-injection of the tracer, 64Cu radioactivity was found to accumulate predominantly 
in the liver of both 6-8-month-old TASTPM and wildtype mice (Figure 4.8). PET imaging also 
revealed high 64Cu signal in the intestines and kidneys in both animal groups. Unlike 64Cu-
GTSM, 64Cu-acetate was not taken up avidly by the lungs, heart and brain. The biodistribution 
of the radiocopper exhibited little change from 30 min to 24 h post-injection of the tracer, with 
most 64Cu radioactivity concentrating in the liver, kidneys and intestines. On visual assessment, 
the TASTPM group appeared to exhibit higher intestinal 64Cu concentration than controls at 30 
min post-injection of 64Cu-acetate. No obvious differences in 64Cu biodistribution were observed 




Figure 4.8: Exemplar sagittal and coronal views of PET/CT MIPs of 6-8-month-old male wild-type controls 
(A) and age-matched TASTPM transgenic mice (B) at 30 min and 24 h post-administration of 64Cu-
acetate. 64Cu-acetate PET/CT scans showed high accumulation of radiocopper in the liver, kidneys and 
intestines of both TASTPM mice and age-matched controls at 30 min and 24 h post-injection of the tracer. 
High 64Cu signal in the rectum at late imaging time-points seems to indicate that radiocopper was mainly 
excreted in the faeces. Organs are indicated by arrows: B = brain; H = heart; Lu = lungs; L = liver; K = 
kidneys; I = intestines; R = rectum. All MIPs were scaled to 0-1 %ID/mL (min) and 40 %ID/mL (max). 
 
The general biodistribution of the tracer was similar for the 13-15-month-old TASTPM and 
wildtype groups (Figure 4.9). 64Cu-acetate PET/CT scans showed high accumulation of 64Cu in 
the liver, and to a lesser extent, in the intestines and kidneys in both TASTPM transgenic mice 
and wildtype controls. After 24 h, 64Cu concentration decreased in all three organs in both 
animal groups. In a similar manner as observed in the younger age group, 13-15-month-old 
TASTPM mice seemed to accumulate a higher concentration of radiocopper in the intestines at 
30 min post-injection of the tracer than age-matched controls. Radiocopper appeared to be 
mainly excreted in the faeces, as evidenced by significant accumulation of 64Cu radioactivity in 
the rectum at 24 h post-injection of the tracer in both TASTPM and control mice. 
Figure 4.9: Exemplar sagittal and coronal views of PET/CT MIPs of 13-15-month-old male wild-type 
controls (A) and age-matched TASTPM transgenic mice (B) at 30 min and 24 h post-administration of 
64Cu-acetate. Radiocopper accumulated primarily in the liver, intestines and kidneys in both animal groups 
at 30 min and 24 h post-administration of the tracer. Radiocopper appeared to be excreted in the faeces, 
as evidenced by significant accumulation of 64Cu in the rectum at 24 h post-injection of the tracer. Organs 
are indicated by arrows: B = brain; H = heart; Lu = lungs; L = liver; K = kidneys; I = intestines; R = rectum. 
All MIPs were scaled to 0-1 %ID/mL (min) and 40 %ID/mL (max). 
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The biokinetics of intravenously injected radiocopper were evaluated by PET ROI analysis and 
compared between TASTPM transgenic mice and healthy controls. Figure 4.10 shows time-
activity curves for the main organs of interest (heart, kidneys, liver, spine and brain) illustrating 
clearance of 64Cu radioactivity over time in 6-8-month-old TASTPM mice and age-matched 
controls. As expected, the liver exhibited the highest accumulation of 64Cu in both animal 
groups. 64Cu radioactivity was found to decrease over time in the liver, kidneys and heart of 
both TASTPM and wildtype mice, although 64Cu clearance in these organs was more 
pronounced in the AD group (21.97 ± 15.51 vs 15.99 ± 15.95 % decrease in liver %ID/mL; 60.10 
± 4.17 vs 36.27 ± 8.91 % decrease in heart %ID/mL; 35.15 ± 8.70 vs 12.73 ± 20.71 % decrease 
in kidneys %ID/mL). 64Cu uptake in the CNS was low in both TASTPM transgenic mice and 
healthy controls. Brain 64Cu concentration showed a tendency to decrease over time in the AD 
group, while it slightly increased in wildtype controls (9.13 ± 1.28 % decrease vs 2.36 ± 5.63 % 
increase in brain %ID/mL). 64Cu radioactivity cleared from the spine over time in both groups, 
although more markedly for TASTPM mice than controls (28.54 ± 2.65 vs 16.54 ± 4.83 % 
decrease in spine %ID/mL). 
 
Figure 4.10: Time-activity curves extracted from PET image analysis showing 64Cu concentration 
(expressed as %ID/mL) over time in the heart, kidneys, liver, spine and brain of 6-8-month-old male (A) 
TASTPM mice and age-matched C57BL/6J controls (B). PET ROI analysis revealed that clearance of 64Cu 
radioactivity from organs of interest was more marked in TASTPM mice than controls. Data are mean (n=3 
for TASTPM, n=4 for wildtype controls) ± SEM. 
 
Repeated measures ANOVA demonstrated significant effects of time (F1,5 = 59.04, p = 0.0006) 
and group by time interaction (F1,5 = 10.78, p = 0.0219) on heart 64Cu concentration in 6-8-
month-old TASTPM mice and age-matched controls. Post-hoc tests revealed that 64Cu 
concentration in the heart was significantly higher in the AD group relative to controls at 30 min 
after injection of 64Cu-acetate (5.25 ± 1.39 %ID/mL vs. 3.49 ± 0.51 %ID/mL, p<0.05). Contrarily, 
no significant differences in liver and kidney 64Cu concentration were found between the two 
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groups at any imaging time-point. Although no significant effects of time and group were 
measured, statistical analysis indicated a significant effect of group by time interaction (F1,5 = 
12.18, p = 0.0175) on brain 64Cu concentration in 6-8-month-old TASTPM and wildtype controls, 
possibly associated with the faster rate of 64Cu clearance exhibited by the AD group when 
compared to controls. Repeated measures ANOVA also showed a significant interaction effect 
(F1,5 = 12.26, p = 0.0173) on spinal cord 64Cu concentration, as well as significant effects of 
group (F1,5 = 9.849, p = 0.0257) and time (F1,5 = 76.63, p = 0.0003) in 6-8-month-old TASTPM 
and age-matched controls. Post-hoc evaluation demonstrated significantly higher 64Cu 
concentration in the spine of TASTPM transgenic mice compared to wildtype controls (1.53 ± 
0.17 %ID/mL vs. 1.14 ± 0.15 %ID/mL, p<0.01) at 30 min after injection of the tracer.  
 
PET ROI analysis revealed similar 64Cu biokinetics between the 6-8- and 13-15-month-old 
TASTPM and wildtype groups (Figure 4.11). The liver exhibited the highest 64Cu concentration 
among all organs in both 13-15-month-old TASTPM mice and age-matched controls. 64Cu 
concentration in the liver, kidneys and heart decreased over time in both animal groups, 
although the decline rate was more pronounced for AD mice when compared to healthy controls 
(32.55 ± 7.84 vs 18.67 ± 17.95 % decrease in liver %ID/mL; 58.37 ± 5.38 vs 34.64 ± 11.74 % 
decrease in heart %ID/mL; 28.59 ± 4.16 vs 14.83 ± 1.00 % decrease in kidneys %ID/mL). In this 
age range, brain 64Cu concentration increased slightly over time for both TASTPM and control 
mice (2.26 ± 4.29 and 1.54 ± 5.58 % increase in %ID/mL, respectively). 64Cu radioactivity in the 
spinal cord decreased from 30 min to 24 h post-injection in both 13-15-month-old TASTPM and 
age-matched controls but, in this case, 64Cu clearance rate was faster for the control group 
when compared to AD mice (25.27 ± 3.16 vs 13.38 ± 5.01 % decrease in %ID/mL). 
 
Figure 4.11: Time-activity curves extracted from PET image analysis showing 64Cu concentration 
(expressed as %ID/mL) over time in the heart, kidneys, liver, spine and brain of 13-15-month-old male (A) 
TASTPM mice and age-matched wildtype controls (B). Data are mean (n=3/group) ± SEM. 
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Statistical analysis did not reveal significant effects of group, time or group by time interaction 
on 64Cu concentration in the heart, brain and spinal cord in 13-15-month-old TASTPM 
transgenic mice and age-matched controls. Instead, repeated measures ANOVA indicated 
significant effects of time (F1,4 = 14.81, p = 0.0183) and group (F1,4 = 11.34, p = 0.0281) on 
hepatic 64Cu concentration in this age range. Post-hoc tests demonstrated that 13-15-month-old 
TASTPM transgenic mice exhibited a significantly higher concentration of 64Cu in the liver than 
their wildtype counterparts at 30 min post-injection of 64Cu-acetate (24.17 ± 2.89 %ID/mL vs. 
17.90 ± 2.76 %ID/mL, p<0.05). Significant effects of time (F1,4 = 80.80, p = 0.0008) and 
interaction (F1,4 = 10.82, p = 0.0302) were also observed on renal 64Cu concentration, although 
no significant differences in specific patterns were detected by post-hoc evaluation.  
 
The effect of age on 64Cu biodistribution was also evaluated in all TASTPM and wildtype age 
groups. A significant effect of age (F1,5 = 8.908, p = 0.0306) on hepatic 64Cu concentration was 
found in wildtype controls resulting from a reduction in 64Cu accumulation from 6-8 to 13-15 
months of age at both 30 min and 24 h post-injection. Moreover, statistical analysis revealed 
significant effects of age (F1,4 = 15.73, p = 0.0166), time (F1,4 = 87.27, p = 0.0007) and age by 
time interaction (F1,4 = 22.06, p = 0.0093) on spinal cord 64Cu concentration in the TASTPM 
groups. Post-hoc tests showed that 64Cu concentration in the spine was significantly greater in 
6-8-month-old TASTPM transgenic mice than in their older counterparts at 30 min post-injection 
of 64Cu-acetate (1.53 ± 0.17 %ID/mL vs. 1.07 ± 0.03 %ID/mL, p<0.01). The concentration of 
64Cu in the brain was found to decrease from 6-8 to 13-15 months of age in both animal groups, 
although this trend did not reach the level of statistical significance. 
 
Unlike 64Cu-GTSM, 64Cu-acetate is not able to cross the BBB by passive diffusion and relies on 
active transport mechanisms to enter the brain. Because of this, very little 64Cu radioactivity 
(~0.5-1 %ID/mL) was measured in the brains of both TASTPM and wildtype mice by PET at the 
chosen imaging time-points. While 64Cu-GTSM released 64Cu in all brain regions, 64Cu-acetate 
was found to concentrate mostly around the CSF spaces. Figure 4.12 depicts the distribution of 
64Cu in the brain of a 13-15-month-old control mouse injected with 64Cu-acetate at both 30 min 
and 24 h post-injection. On visual assessment, 64Cu radioactivity appeared to accumulate 
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focally in the right and left lateral ventricles and fourth ventricle, and seemed to decrease 
slightly over time. 
 
Figure 4.12: Representative sagittal and axial section PET/CT MIP images illustrating 64Cu distribution in 
the brain of a 13-15-month-old C57BL/6J wild-type control at 30 min and 24 h post-injection of 64Cu-
acetate. PET/CT scans revealed that most 64Cu radioactivity was concentrated in or near the ventricular 
system.  
 
In order to measure the concentration of 64Cu in the ventricles and other brain regions over 
time, we applied a 3D mouse brain atlas module to all PET/CT datasets. The ventricles and, to 
a lesser extent, the hypothalamus, exhibited the highest concentration of 64Cu among all brain 
regions in 6-8-month-old TASTPM mice and age-matched controls at 30 min and 24 h post-
administration of the tracer (Figure 4.13). Statistical analysis indicated significant effects of 
region and group by region interaction on brain regional accumulation of 64Cu in 6-8-month-old 
TASTPM and control mice at both 30 min (region: F1,5 = 18.16, p<0.0001; interaction: F1,5 = 
2.222, p=0.0180) and 24 h (region: F1,5 = 35.60, p<0.0001; interaction: F1,5 = 3.045, p=0.0015) 
post-injection. However, no specific significant differences in brain regional 64Cu concentration 




Figure 4.13: Brain regional concentration of 64Cu in 6-8-month-old TASTPM mice and age-matched 
controls injected with 64Cu-acetate at 30 min (top) and 24 h (bottom) after injection, as measured by atlas-
based quantification. Data are mean (n=3 for TASTPM, n=4 for wildtype controls) ± SD. 
 
Atlas-based quantification showed lower 64Cu concentration in all brain areas and a more 
homogeneous 64Cu distribution pattern in aged TASTPM mice and controls compared to the 6-
8-month-old mouse groups (Figure 4.14). The ventricles remained the region with the highest 
64Cu concentration in both groups at all imaging time-points. Repeated measures ANOVA 
indicated significant effects of region (F1,4 = 12.68, p<0.0001) and group by region interaction 
(F1,4 = 2.092, p = 0.0306) on regional concentration of 64Cu in the brain in 13-15-month-old 
TASTPM mice and age-matched controls at 30 min post-injection of 64Cu-acetate. Post-hoc 
tests did not demonstrate any specific statistically significant differences in brain 64Cu 
distribution between the two groups. No significant effects of group or interaction on brain 
regional concentration of 64Cu were measured in the 13-15-month-old TASTPM and wildtype 




Figure 4.14: Brain regional concentration of 64Cu in 13-15-month-old TASTPM mice and age-matched 
controls injected with 64Cu-acetate at 30 min (top) and 24 h (bottom) after injection, as measured by atlas-
based quantification. Data are mean (n=3/group) ± SD. 
 
Statistical comparison of brain 64Cu distribution among the different age groups revealed 
significant effects of region (F1,5 = 14.44, p<0.0001) and group by region interaction (F1,5 = 
2.096, p = 0.0261) in wildtype controls from 6-8 to 13-15 months of age. Post-hoc evaluation 
indicated significantly higher ventricular concentration of 64Cu in 6-8-month-old controls 
compared to their older counterparts at 30 min post-injection of 64Cu-acetate (1.39 ± 0.30 
%ID/mL vs. 1.01 ± 0.34 %ID/mL, p<0.05). 
 
However, atlas-based quantification of ventricular 64Cu concentration may provide inaccurate 
results due to the partial volume effect associated with the small size of the region and potential 
for imperfect matching of the atlas template onto the real ventricular system. For this reason, 
ventricular 64Cu concentration was alternatively measured by drawing a fixed-volume ROI within 




Figure 4.15 shows the ventricular SUVmean and SUVmax values for 6-8-month-old TASTPM and 
wildtype groups at 30 min and 24 h post-injection of 64Cu-acetate. Average SUVmax and SUVmean 
values were found to be generally higher in the wildtype group when compared to AD mice at 
30 min post-injection of 64Cu-acetate, although this trend did not reach statistical significance. 
This was consistent with atlas-based quantification, which also revealed increased early uptake 
of 64Cu in the ventricles of 6-8-month-old C57BL/6J controls compared to age-matched 
TASTPM mice. The SUV parameters were found to increase over time in both groups, but with 
a more pronounced trend in AD mice (SUVmax: 74.48 ± 19.16 vs 3.15 ± 34.97 % increase; 
SUVmean: 51.07 ± 22.13 vs 7.73 ± 22.14 % increase). This was also in agreement with the atlas-
based measurements (35.58 ± 14.86 % increase in %ID/mL in TASTPM vs 11.75 ± 32.67 % 
increase in %ID/mL in controls). A large interindividual variability in 64Cu biokinetics was 
observed in both TASTPM and wildtype groups. 
 
Figure 4.15: Ventricular 64Cu concentration in 6-8-month-old TASTPM transgenic mice and age-matched 
controls at 30 min and 24 h post-injection of 64Cu-acetate, expressed as SUVmax (top) and SUVmean 
(bottom). Time-activity curves have been plotted for each individual mouse.  
 
 
Similar results were obtained for the older TASTPM and wildtype groups (Figure 4.16). Higher 
ventricular SUVmean and SUVmax values were measured for 13-15-month-old controls compared 
to age-matched TASTPM mice at both 30 min and 24 h post-injection. Two-way ANOVA 
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analysis revealed a significant effect of group (F1,4 = 10.99, p = 0.0295) on ventricular SUVmean 
in aged TASTPM and wildtype mice. Post-hoc evaluation indicated significantly greater SUVmean 
values in the ventricles of 13-15-month-old C57BL/6J controls compared to TASTPM transgenic 
mice at all time-points after injection (30 min: 0.90 ± 0.14 vs. 0.49 ± 0.04 %ID/mL, p<0.05; 24 h: 
0.97 ± 0.15 vs. 0.58 ± 0.14 %ID/mL, p<0.05). Ventricular SUVmean and SUVmax values were 
found to increase over time for both groups but more markedly for TASTPM mice (SUVmax: 
45.94 ± 8.38 vs 4.89 ± 10.76 % increase; SUVmean: 17.34 ± 22.94 vs 7.96 ± 4.14 % increase), in 
the same manner as for their younger counterparts. No significant differences in 64Cu ventricular 
uptake expressed as SUV were detected between the different age groups of TASTPM  and 
wildtype mice. 
 
Figure 4.16: Ventricular 64Cu concentration in 13-15-month-old TASTPM transgenic mice and age-
matched controls at 30 min and 24 h post-injection of 64Cu-acetate, expressed as SUVmax (top) and 
SUVmean (bottom). Time-activity curves have been plotted for each individual mouse.  
 
 
4.4.3.2 Ex vivo biodistribution 
After imaging, all animals were sacrificed and the biodistribution of 64Cu was assessed via 
gamma-counting of explanted organs. Figure 4.17 depicts 64Cu accumulation in organs and 
tissues of interest of both 6-8- and 13-15-month-old TASTPM and control mice at 24 h post-




Figure 4.17: Tissue biodistribution of 64Cu in 6-8- (A) and 13-15-month-old (B) TASTPM mice and age-
matched controls at 24 h post-injection of 64Cu-acetate. Statistically significant differences are indicated by 
*** (p<0.001). Data are mean (n=3/group) ± SD. 
 
 
Gamma-counting of explanted organs revealed a similar biodistribution pattern for the 6-8- and 
13-15-month-old TASTPM and wildtype groups. Similar to PET, gamma-counting showed that 
64Cu radioactivity was predominantly concentrated in the liver and, to a lesser extent, in the 
intestines and kidneys. High 64Cu accumulation was also observed in the stomach and lungs.  
Statistical analysis did not reveal any significant differences in ex vivo tissue biodistribution of 
64Cu between 6-8-month-old TASTPM transgenic mice and age-matched controls at 24 h post-
injection of the tracer. However, two-way repeated measures ANOVA indicated significant 
effects of organ (F1,4 = 253.4, p<0.0001) and group by organ interaction (F1,4 = 6.281, p<0.0001) 
on 64Cu concentration in the older TASTPM and wildtype groups. Post-hoc tests demonstrated 
significantly higher ex vivo accumulation of 64Cu in the stomach (5.12 ± 0.78 %ID/mL vs. 2.58 ± 
0.53 %ID/mL, p<0.001) and large intestine (8.65 ± 0.96 %ID/mL vs. 5.52 ± 0.65 %ID/mL, 




Age-dependent differences in 64Cu ex vivo biodistribution were found between 6-8- and 13-15-
mont-old TASTPM and control groups. Statistical analysis revealed significant effects of organ 
(F1,4 = 284.6, p<0.0001) and group by organ interaction (F1,4 = 3.956, p = 0.0001) in 6-8- and 
13-15-month-old TASTPM transgenic mice on ex vivo concentration of 64Cu. TASTPM 
transgenic mice at 6-8 months of age exhibited significantly higher 64Cu accumulation in the 
large intestines (7.46 ± 1.43 %ID/mL vs. 5.52 ± 0.65 %ID/mL, p<0.01) and liver (17.47 ± 0.78 
%ID/mL vs. 14.26 ± 0.66 %ID/mL, p<0.001) than their older counterparts. Significant effects of 
organ (F1,4 = 66.41, p<0.0001) and interaction (F1,4 = 2.875, p = 0.0026) on 64Cu ex vivo tissue 
biodistribution were also measured in the 6-8- and 13-15-month-old control groups. Hepatic 
64Cu concentration was found to be significantly greater in younger wildtype mice relative to 
aged controls (20.57 ± 5.79 %ID/mL vs. 13.35 ± 0.80 %ID/mL, p<0.001). 
 
Similar to PET, gamma-counting revealed an age-dependent decrease in 64Cu brain 
concentration in both TASTPM and control mice, although this trend did not reach statistical 
significance by the tests employed. Ex vivo measurements of 64Cu concentration in the brain 
were found to correlate poorly (R2 = 0.3102) with brain %ID/mL values at 24 h post-injection 
determined by PET ROI analysis.  
 
 
Figure 4.18: Comparison of brain uptake of 64Cu as measured by PET imaging and by ex vivo gamma-
counting at 24 h post-injection of 64Cu-acetate in 6-8-/13-15-month-old TASTPM transgenic mice and age-
matched controls. All TASTPM (n = 6) and wildtype (n = 6) mice were included in the correlation. 
 
 
4.4.3.3 Ex vivo brain autoradiography and histology 
In order to characterise further the distribution of 64Cu in the brain resulting from 64Cu-acetate 
administration, sections of brain tissue of TASTPM and wildtype mice sacrificed at 24 h post-
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injection of the tracer were imaged by phosphor imaging autoradiography. Ex vivo brain 
autoradiography revealed a very similar 64Cu distribution pattern in brain tissue for both 
TASTPM transgenic mice and healthy controls. As depicted in Figure 4.19, 64Cu radioactivity 
accumulated predominantly in the area surrounding the lateral ventricles and, to a lesser extent, 
around the fourth ventricle and hypothalamus. This is consistent with the distribution pattern 
revealed by atlas-based quantification of the PET/CT datasets, which identified the ventricles 
and hypothalamus as the brain regions with the highest 64Cu concentration at 24 h post-
injection of 64Cu-acetate in vivo. 
 
Figure 4.19: Ex vivo brain autoradiographs and corresponding surface plots from representative sagittal 
brain sections of 6-8-month-old wildtype (left) and TASTPM (right) mice sacrificed at 24 h post-injection of 
64Cu-acetate. Ex vivo autoradiography revealed a similar pattern of 64Cu accumulation in the brain for both 
control and AD mice, with main radioactive hotspots situated near the lateral and fourth ventricles and 
hypothalamus. LV = lateral ventricle; FV = fourth ventricle; HT = hypothalamus. 
 
 
Following radioactive decay, brain slices were stained with hematoxylin dye in order to provide 
an anatomical reference to their corresponding autoradiographs. Figure 4.20 shows an 
exemplar sagittal brain slice of a 6-8-month-old control mouse imaged by autoradiography and 
subsequently stained with hematoxylin. Atlas-guided identification of brain structures in 
histological photomicrographs and comparison of histology and autoradiography images 
confirmed the close association between 64Cu hotspots and the ventricular system. 64Cu 
radioactivity was found to accumulate in and around the lateral and fourth ventricles as well as 
in the lateral hypothalamic area. The main radioactive peak in the autoradiographic maps 
resulted from high accumulation of radiocopper in the lateral ventricles but also in the fimbria of 
the hippocampus. Previous characterisation of cerebral Aβ plaque load in the TASTPM mouse 
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model (see Chapter III, section 3.4.1) revealed that the areas showing high 64Cu signal in the 
64Cu-acetate autoradiographs were traditionally not affected by Aβ plaque pathology. 
 
 
Figure 4.20: (A) Photomicrograph of sagittal brain section stained with hematoxylin from a 6-8-month old 
wildtype mouse (top) and corresponding brain autoradiograph (bottom) at 24 h post-injection of 64Cu-
acetate; (B) Magnified view of the area surrounding the lateral ventricle in hematoxylin-stained brain 
section; (C) Magnified view of the lateral ventricle area in representative sagittal brain slice stained with 
hematoxylin and Congo red dye from a 6-8-month old TASTPM mouse. 64Cu radioactivity predominantly 
accumulated in the lateral ventricle and fimbria of the hippocampus and, to a lesser extent, in the fourth 
ventricle and lateral hypothalamic area. None of these regions showed congophilic Aβ plaque deposits 
(red-orange stain). LV = lateral ventricle; F = fimbria of the hippocampus. 
 
 
4.4.4 Imaging the effects of CQ on copper biodistribution with 64Cu-acetate-PET 
4.4.4.1 PET/CT imaging  
To gain insight into the mode of action of copper-zinc chelator CQ, we examined its effect on 
short-term copper trafficking in 2-month-old wildtype mice with 64Cu-acetate-PET. Animals 
(n=2/treatment group) were intravenously injected with 64Cu-acetate and imaged at 0-30 min 
and 24-24.5 h post-injection of the tracer 30 min after CQ (50 mg/kg) or 4 % (w/v) (2-







Figure 4.21: Experimental protocol for PET/CT imaging of copper trafficking with 64Cu-acetate in 
Clioquinol- and sham-treated mice. Mice were intraperitoneally injected with CQ or saline 30 min before 
64Cu-acetate administration. PET/CT scans were performed at 0-30 min and 24-24.5 h post-injection of the 
tracer. After imaging, animals were sacrificed and ex vivo biodistribution of 64Cu was assessed via gamma-
counting of explanted organs. 
 
The uptake and efflux of 64Cu in selected organs of CQ- and sham-treated mice are shown in 
Figure 4.22. 64Cu radioactivity accumulated predominantly in the liver and, to a lesser extent, in 
the kidneys and intestines in both treatment groups. 64Cu concentration as measured by PET 
ROI analysis decreased over time in the heart, spine, kidneys and liver in both CQ- and sham-
treated mice. 64Cu clearance rates from spine (20.22 ± 9.07 % decrease in %ID/mL in CQ-
treated mice vs. 5.01 ± 11.51 % decrease in %ID/mL in sham-treated mice) and kidneys (7.65 ± 
25.43 % decrease in %ID/mL in CQ-treated mice vs. 45.78 ± 17.90 % decrease in %ID/mL in 
sham-treated mice) from 30 min to 24 h post-injection of the tracer were markedly different 
between the two treatment groups.  
Figure 4.22: Exemplar sagittal view of the PET/CT MIP of a 2-month-old wildtype mouse pretreated with 
CQ at 30 min post-injection of 64Cu-acetate (A). Time-activity curves extracted from PET ROI analysis 
showing 64Cu concentration (expressed as %ID/mL) over time in the heart, kidneys, liver, spine and brain 
of CQ- (B) and sham-treated (C) C57BL6/J controls injected with 64Cu-acetate. Data are mean 




CQ-treated mice exhibited a higher concentration of 64Cu in the heart (30 min: 5.79 ± 0.89 
%ID/mL vs. 3.84  ± 0.17 %ID/mL; 24 h: 3.60 ± 1.03 %ID/mL vs. 2.76 ± 0.47 %ID/mL), spine (30 
min: 1.66 ± 0.22 %ID/mL vs. 1.10  ± 0.007 %ID/mL; 24 h: 1.31 ± 0.04 %ID/mL vs. 1.04 ± 0.18 
%ID/mL) and liver (30 min: 32.28 ± 2.20 %ID/mL vs. 30.21  ± 2.78 %ID/mL; 24 h: 23.31 ± 2.98 
%ID/mL vs. 20.01 ± 3.47 %ID/mL) when compared to their sham-treated counterparts at both 
30 min and 24 h post-injection of the tracer. The CQ group also showed greater accumulation of 
64Cu in the brain than sham-treated mice at all imaging time-points (30 min: 0.85 ± 0.11 %ID/mL 
vs. 0.71 ± 0.08 %ID/mL; 24 h: 0.90 ± 0.10 %ID/mL vs. 0.66 ± 0.07 %ID/mL). While 64Cu 
radioactivity in the brain decreased slightly over time in sham-treated mice (6.12 ± 0.60 % 
decrease in %ID/mL), a small increase in 64Cu concentration was measured between 30 min 
and 24 h post-injection of the tracer in the brains of CQ-treated controls (7.42 ± 18.34 % 
increase in %ID/mL). However, larger sample sizes are required to confirm these trends. 
 
Atlas-based quantification of PET/CT datasets demonstrated globally higher 64Cu concentration 
in all predefined brain regions in the CQ treatment group compared to sham-treated mice at 
both 30 min and 24 h post-injection of 64Cu-acetate (Figure 4.23). The ventricles exhibited the 







Figure 4.23: Brain regional concentration of 64Cu in CQ- and sham-treated wildtype mice injected with 
64Cu-acetate at 30 min (top) and 24 h (bottom) after injection, as measured by atlas-based quantification. 
Data are mean (n=2/treatment group) ± SD. 
 
 
Ventricular SUVmean and SUVmax values were determined for CQ and sham treatment groups in 
order to provide a measurement alternative to atlas-based quantification (Figure 4.24). PET ROI 
analysis revealed similar ventricular SUVmean and SUVmax values for CQ- and sham-treated 
wildtype mice at 30 min post-injection of the tracer. After 24 h, 64Cu concentration in the 
ventricles increased in both treatment groups, although more markedly for sham-treated mice 
(SUVmax: 190.06 ± 67.43 % vs. 76.52 ± 18.21 % increase in %ID/mL; SUVmean: 84.83 ± 15.91 % 





Figure 4.24: Ventricular 64Cu concentration in CQ- and sham-treated C57BL/6J controls at 30 min and 24 
h post-injection of 64Cu-acetate, expressed as SUVmax (top) and SUVmean (bottom). Time-activity curves 
have been plotted for each individual mouse.  
 
4.4.4.2 Gamma-counting 
The ex vivo biodistribution of 64Cu in CQ- and sham-treated wildtype mice at 24 h post-injection 
of 64Cu-acetate was evaluated via gamma-counting of explanted organs (Figure 4.25). 64Cu 
biodistribution as measured by gamma-counting was found to be very similar for both treatment 
groups, with most 64Cu radioactivity accumulating in the liver, intestines, kidneys and lungs. 
Similar to PET, gamma-counting revealed higher 64Cu concentration in the heart (3.58 ± 0.07 
%ID/mL vs. 2.84 ± 0.21 %ID/mL), liver (19.99 ± 2.99 %ID/mL vs. 16.98 ± 1.77 %ID/mL) and 
brain (0.53 ± 0.05 %ID/mL vs. 0.35 ± 0.001 %ID/mL) of CQ-treated wildtype mice compared to 




Figure 4.25: Tissue biodistribution of 64Cu in CQ- and sham-treated C57BL/6J controls at 24 h post-





The evaluation of whole-body copper trafficking by PET imaging may shed new light into the 
pathophysiology of many neurological disorders that have been associated with copper 
metabolism imbalance, including AD. The feasibility of 64Cu-GTSM-PET as a useful tool to 
investigate copper fluxes within the CNS was demonstrated in the third chapter of this 
dissertation. The ability of 64Cu-GTSM to bypass the BBB and release its 64Cu payload non-
selectively into cells allows the delivery of radiocopper into the brain in sufficient amounts for the 
visualisation of brain copper trafficking. However, while 64Cu-GTSM-PET is useful to study the 
short-term dynamics of copper within the CNS, it does not provide any information on the long-
term accumulation of endogenous copper within the brain or the active routes of entry for 
copper into the CNS. In this chapter, we examined the endogenous distribution of actively 
transported dietary copper within the brain in the TASTPM mouse model of AD by XRF. 
Furthermore, we investigated acute active copper transport at the whole-body level in TASTPM 
transgenic mice at early and middle stages (6-8 and 13-15 months of age) of AD-like pathology 
by PET imaging with radioactive copper salt 64Cu-acetate. The potential of 64Cu-acetate-PET as 
a tool to assess the effects of copper chelation therapies was also evaluated in a very 




64Cu-GTSM-PET did not reveal an obvious association between regional accumulation of 64Cu 
in the brain on a short-term time scale and cerebral Aβ plaque deposition in the TASTPM 
mouse model (see chapter III, section 3.4.8). However, the accumulation of copper ions in Aβ 
plaque-rich areas may occur more prominently over the lifetime of the animal. In order to 
investigate the regional distribution pattern of endogenous copper within the brain in AD-like 
pathology, 2D elemental copper maps from representative brain sections of TASTPM 
transgenic mice were generated by XRF and compared to those of age-matched healthy 
controls. Despite not being able to distinguish between oxidation states or chemical forms, XRF 
is an excellent tool to study the distribution of metals in tissue since it allows global mapping of 
multiple metals on the same sample (193). Although we initially intended to use the same age 
groups for XRF elemental analysis as those used in our 64Cu-GTSM-PET imaging experiments 
(6-8 and 13-15 months of age), brain copper maps were finally generated for 4- and 8-month-
old TASTPM transgenic mice and age-matched controls due to lack of availability of AD mice in 
the 13-15-month-old range. The addition of a 4-month-old age group allowed quantitative 
assessment of the effect of age and disease progression on brain copper distribution. 
 
XRF mapping revealed prominent accumulation of endogenous copper around the CSF spaces 
and comparatively low copper concentration within the brain parenchyma in all groups. This 
brain copper distribution pattern had been previously observed in 2- and 7-month-old C57BL/6J 
wildtype mice by laser ablation inductively coupled plasma mass spectrometry (196). The focal 
accumulation of copper around the ventricular system underlines the importance of the BCSFB 
in brain copper metabolism, even though its exact role is not completely understood. Although 
the BBB has been proposed as the main route of entry for copper ions into the brain, the 
BCSFB is also thought to play a crucial role in copper transport to and from the CNS. In view of 
both the nutrient and secretory capacity of the CSF and the ability of the choroid plexus to 
sequester copper ions, the BCSFB has been suggested as the main barrier for the regulation of 
brain copper homeostasis (219, 434). In the ventricular system, high copper concentrations 
have been measured in the CSF and choroid plexus but also in the subventricular zone of the 
lateral ventricles, a region known to play a key role in the process of adult neurogenesis (435, 
436). Fu and co-workers reported elevated copper levels and high MT expression in the 
subventricular zone in young, adult and old rats compared to other brain regions. The choroid 
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plexus was also found to accumulate high levels of copper but exhibited higher levels of 
expression of copper transporters (Ctr1, DMT1 and ATP7A) than storage proteins. Fu et al. 
observed that age-related increase of copper content in these regions was inversely associated 
with the expression of neurogenesis markers, which might indicate a regulatory role for copper 
in adult neurogenesis. The individual contribution of the subventricular zone, choroid plexus and 
CSF to the XRF copper signal is unknown (436). 
 
Quantification of the XRF elemental copper maps revealed increased copper levels in brain 
sections from the TASTPM group when compared to controls, along with an age-dependent rise 
in brain copper content in both groups. This is consistent with the results of a previous study by 
Wang et al., who reported elevated copper accumulation in the brains of APP/V717I transgenic 
AD mice and an increase in brain copper concentration with aging (437). Brain copper buildup 
may result in increased vulnerability of the brain to oxidative stress and enhance, as a result, 
the neurodegenerative phenotype in these AD models.  
 
Despite previous evidence of elevated copper levels in human Aβ plaque deposits, our XRF 
results revealed an ambiguous association between plaque-rich areas and brain regional 
accumulation of endogenous copper in the TASTPM mouse model (341, 398). TASTPM 
transgenic mice exhibited significantly higher copper concentration than controls in the thalamus 
at 8 months of age but not in the cerebral cortex or hippocampus, which are other regions 
traditionally affected by Aβ plaque pathology. This could be due to a decrease in the metal 
binding capacity of TASTPM Aβ plaques when compared to human plaque deposits, which was 
evidenced in another mouse model of AD-like Aβ plaque deposition (PSAPP) (438). XRF 
mapping of brain copper distribution in older TASTPM transgenic mice may reveal whether 
there is a more obvious relationship between regional copper accumulation and Aβ plaque 
deposition at later stages of the disease. 
 
ROI analysis of XRF elemental copper maps demonstrated significantly higher copper content 
in the cerebellum of 8-month-old TASTPM transgenic mice when compared to age-matched 
controls and increased levels of copper in the caudate putamen of wildtype mice at 4 and 8 
months of age relative to their respective TASTPM counterparts. The effects of aging on brain 
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copper distribution were also different between control and AD groups. While wildtype mice 
showed an age-dependent increase in copper concentration in the caudate putamen, TASTPM 
groups exhibited a buildup of copper levels in the thalamus and cerebellum from 4 to 8 months 
of age. The origin of these differences in brain regional copper content is unknown. In contrast 
to the global understanding of brain copper metabolism, very little is known about brain regional 
copper metabolism, cell-specific copper handling systems or interrelationships between trace 
metals in the different brain areas. XRF offers the possibility of mapping several trace metals on 
the same sample, which would allow a better characterisation of these abnormalities in brain 
regional copper distribution. For example, reduced copper content in the caudate putamen of 
AD mice could be associated with a buildup in iron levels in the same region, which has been 
detected in AD subjects by MRI (439, 440). However, it should be noted that the differences in 
brain copper distribution reported here result from the quantification of only two XRF copper 
maps per age group and therefore additional brain sections need to be added to the analysis to 
confirm their significance.  
 
After examining the brain distribution pattern of endogenous copper resulting from prolonged 
active copper transport in AD-like pathology, we evaluated the short-term dynamics of active 
copper trafficking at the level of the whole organism in the TASTPM model by 64Cu-acetate-
PET. Radioactive copper salts have only been used so far to image whole-body copper 
trafficking in copper metabolism genetic disorders (e.g. WD, MD) but may hold promise for 
identifying metabolic abnormalities in other pathological conditions associated with copper 
dyshomeostasis (e.g. AD, HD, PD, ALS, NPC), particularly in the context of copper chelation 
therapies. Although in AD research much focus has been on the disruption of copper 
homeostasis in the brain, increased serum copper levels have also been reported in AD, which 
could have an effect on the short-term dynamics of whole-body copper trafficking (349, 432). 
The availability of 64Cu-PET offers the possibility to study the trafficking of intravenously or orally 
administered radiocopper in disease models as well as the dynamics of specific copper 





In the present study, the chosen route of administration of the tracer was intravenous injection. 
Although this route does not mimic gastrointestinal absorption of dietary copper, it improves the 
resorption rate of the radiocopper when compared to oral administration, allowing the 
assessment of 64Cu biokinetics in extraintestinal organs. Nevertheless, PET imaging 
experiments using orally administered radiocopper should also be performed to determine 
whether there are any abnormalities in the gastrointestinal absorption and biodistribution of 
dietary copper associated with AD pathology. 
 
Blood clearance of 64Cu-acetate as measured by in vivo blood sampling was found to follow a 
biexponential pattern, which probably reflects an initial wave of radiocopper uptake into organs 
(mainly the liver, intestines and kidneys), followed by efflux of copper back into the circulation 
and transfer to other organs. As expected, 64Cu-acetate-PET revealed high accumulation of 
64Cu in the liver, intestines and kidneys of TASTPM and wildtype mice and comparatively low 
radiocopper uptake in the rest of organs at all imaging time-points. High 64Cu signal in the 
rectum at late imaging time-points suggested that radiocopper was mostly excreted in the 
faeces. At 6-8 months of age, AD mice showed significantly increased 64Cu concentration in the 
heart and spine when compared to controls at 30 min post-injection of 64Cu-acetate. However, 
these differences were not detected between 13-15-month-old TASTPM and age-matched 
controls. Instead, aged TASTPM mice were found to exhibit significantly higher hepatic 64Cu 
levels than wildtype controls at 30 min post-injection of the tracer. It should be noted that the 
reported differences in whole-body copper trafficking are significant but subtle and therefore a 
larger sample size is required to verify these trends in TASTPM and control mice. Higher 
accumulation of 64Cu in the spine, heart and liver of TASTPM transgenic mice at early imaging 
time-points may arise from more active copper influx mechanisms driven by increased 
metabolic demands associated with the disease or a different profile (biokinetics, speciation) of 
the tracer in blood. PET ROI analysis also revealed a faster clearance rate of 64Cu radioactivity 
from 30 min to 24 h post-injection from the liver, heart, kidneys and spine in TASTPM transgenic 
mice when compared to controls, which may be due to more active copper efflux mechanisms in 




Unlike 64Cu-GTSM, 64Cu-acetate is taken up by the brain via active copper transport 
mechanisms. Although this uptake route does not allow the delivery of radiocopper into the 
brain in sufficient quantities to monitor brain copper trafficking longitudinally, it mimics the entry 
mechanism of plasma copper into the brain. While 64Cu-GTSM released radiocopper in all brain 
regions, 64Cu-acetate was found to accumulate focally within and around the ventricular system, 
similar to the distribution pattern observed in the XRF copper maps. Whether the ventricular 
signal of the 64Cu-acetate PET scans reflects copper influx, efflux or regulatory processes is not 
known. The limited spatial resolution of the PET/CT scanner does not allow the distinction 
between the CSF, the choroid plexus and the areas contiguous to the ventricles (e.g. fimbria of 
the hippocampus, subventricular zone of the lateral ventricles) and therefore these images are 
difficult to quantify and interpret.  
 
PET image analysis and ex vivo counting revealed no significant differences in global brain 64Cu 
concentration between TASTPM transgenic mice and wildtype controls at either age. However, 
despite showing similar group effects, PET and gamma-counting measurements were found to 
exhibit a poor correlation (R2 = 0.3102). This discrepancy is probably due to the overestimation 
of brain 64Cu concentration as measured by PET due to the spillover of activity from high-uptake 
neighbouring regions (mainly neck) into the brain ROI. In addition, gamma-counting 
measurements might have been subject to cross contamination between tissues, weighing 
errors, incomplete explantation or activity loss during dissection. Both PET and gamma-
counting demonstrated an age-dependent decrease in brain 64Cu concentration in both 
TASTPM transgenic mice and controls. These findings are consistent with those of Wang and 
co-workers, who reported an age-related reduction of brain 67CuCl2 uptake in C57BL/6J wildtype 
mice (196). This age-dependent decrease in active brain 64Cu uptake may be driven by a 
regulatory mechanism aiming to compensate the increase in brain endogenous copper content 
measured in aged TASTPM and control mice by XRF. 
 
To assess the regional distribution of 64Cu in the brains of TASTPM and wildtype mice over 
time, we initially applied a 3D mouse brain atlas template to all the 64Cu-acetate-PET datasets. 
Atlas-based quantification did not indicate any significant differences in brain regional 64Cu 
accumulation between AD mice and controls at either age. As expected, the ventricles showed 
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the highest 64Cu concentration among all brain regions in both TASTPM and control mice at all 
imaging time-points. Nevertheless, atlas-based quantification may yield inaccurate 
measurements of the ventricular 64Cu concentration due to the partial volume effect associated 
with the small size of the ventricles and the potential for imperfect matching of the template onto 
the real brain region. Hence, SUVmean and SUVmax values were also measured within the lateral 
ventricles to provide an alternative estimate of the accumulation of 64Cu in the ventricles. 
Although these SUV parameters may also be affected by the partial volume effect, they produce 
a more reliable measurement of the concentration of 64Cu in the ventricles since they do not 
entail the (potentially highly inaccurate) delineation of an ROI around the boundaries of the 
ventricular system. Interestingly, wildtype mice exhibited higher average ventricular SUVmean 
and SUVmax values than their TASTPM counterparts at both ages, although this difference only 
reached statistical significance between the 13-15-month-old groups.  SUV quantification also 
demonstrated a time-dependent increase in 64Cu radioactivity in the ventricles of both TASTPM 
and control mice at both 6-8 and 13-15 months of age, which was more prominent in the AD 
groups. The interpretation of these results is rather complex since the limited spatial resolution 
of the PET scanner does not allow the measurement of 64Cu concentration within specific 
subregions of the ventricular system (CSF, choroid plexus, fimbria of the hippocampus, 
subventricular zone of the lateral ventricles). C57BL6/J controls may exhibit a greater 
accumulation of 64Cu in the ventricles due to a higher rate of active copper transport from the 
blood into the choroid plexus or to a greater concentration of radiocopper in blood at early time-
points than TASTPM transgenic mice. On the other hand, AD mice may show a more 
pronounced time-dependent increase in ventricular 64Cu levels due to a leakier epithelium, 
increased demand for copper or different 64Cu blood biokinetics than controls. It should be 
noted that the BCSFB could be also acting as a CSF-to-blood efflux system for copper ions 
and/or as a copper metabolism regulatory site, and therefore the ventricular 64Cu signal may 
also reflect these processes. However, these results should not be overinterpreted since a high 
interindividual variability was observed in SUV quantification and consequently a larger sample 
size is needed to confirm the reported trends.  
 
The potential of 64Cu-acetate-PET as a tool to evaluate the effects of copper-zinc chelator CQ 
on copper biodistribution in vivo was also preliminarily investigated. In recent years, a number of 
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copper chelating agents (e.g. CQ, PBT2) aimed at minimising neurotoxic Aβ-copper interactions 
and correcting copper dyshomeostasis in the AD brain have been developed. Although some of 
these chelators have shown therapeutic effects in mouse models of AD, their mechanism of 
action remains to be fully characterised (441, 442). CQ has been reported to sequester copper 
from Aβ plaque deposits and transport it into cells, thus decreasing Aβ toxicity and restoring 
intracellular copper levels in the brain (371). Furthermore, it has also been shown that the 
intracellular release of copper ions from CQ complexes promotes the degradation of Aβ plaque 
deposits through the upregulation of MMP activity (364).  
 
64Cu-acetate-PET offers the possibility to visualise and quantify the effects of chelation 
therapies on whole-body copper dynamics in vivo. To date, the application of PET for the 
assessment of response to copper chelation treatments has only been reported in a study by 
Nomura et al., in which PET imaging with 64CuCl2 was used to demonstrate the efficacy of 
disulfiram for brain copper transport in a mouse model of MD (154).  In this study, we present 
the results of a preliminary experiment to evaluate the effects of CQ pretreatment on the short-
term dynamics of 64Cu in wildtype mice. The dose (50 mg/kg) and administration route used in 
this experiment had been previously reported in the literature (443). The 30 min gap between 
CQ administration and 64Cu-acetate injection was chosen based on previous studies reporting 
peak concentrations of CQ in the plasma and brain being reached at 15 and 60 min after 
intraperitoneal administration of the drug, respectively (444).   
 
Both PET imaging and ex vivo gamma-counting revealed higher concentrations of 64Cu in the 
liver, heart, spine and brain of mice pretreated with CQ when compared to the sham group. 
Increased 64Cu accumulation in these organs in CQ-treated mice might result from the formation 
of the hydrophobic 64Cu-CQ complex in blood, which in turn might move across biological 
membranes by non-saturable diffusion mechanisms at a much faster rate than active transport. 
Nevertheless, it should be noted that the differences in 64Cu concentration observed between 
CQ- and sham-treated mice were relatively subtle and therefore a larger sample size is needed 
to confirm the significance of these trends. The low amount of radiocopper delivered by 64Cu-
acetate into the brain did not allow the visualisation of the effect of CQ treatment on brain 
copper trafficking and therefore this experiment should be repeated using 64Cu-GTSM as a 
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delivery vehicle. Furthermore, additional experiments using different doses, administration 
routes and/or treatment times need to be conducted to fully evaluate the impact of CQ treatment 





The characterisation of active copper transport at brain and whole-body levels is key to identify 
copper metabolism abnormalities associated with inherited and acquired neurological disorders. 
In this study, we have shown the utility of XRF and 64Cu-acetate-PET as tools to investigate 
brain and whole-body copper distribution resulting from acute and chronic active copper 
transport processes in a mouse model of AD-like pathology. Significant differences in brain 
regional distribution of endogenous copper were measured by XRF between TASTPM 
transgenic mice and wildtype controls. Our results showed an ambiguous association between 
brain regional copper accumulation as determined by XRF and cerebral Aβ plaque deposition, 
which supports the idea that the dysregulation of brain copper metabolism in AD extends 
beyond Aβ plaque pathology. PET/CT imaging using 64Cu-acetate revealed subtle differences in 
acute whole-body 64Cu trafficking between TASTPM transgenic mice at early and middle stages 
of the disease and age-matched controls, which need to be further examined in order to 
determine their importance in the pathophysiology of the disorder. The present study also 
demonstrated the potential of 64Cu-acetate-PET to evaluate the effects of copper chelating 
agent CQ on whole-body copper trafficking. In the context of copper chelation therapies, 64Cu-
acetate-PET could be used not only to shed some light into the mechanism of action of copper 
chelating drugs but also to monitor response to treatment in several disorders linked to copper 








5. Chapter 5- PET imaging of copper trafficking in a mouse 




The purpose of this study is to examine the short-term dynamics of copper, particularly within 
the CNS, in a mouse model of NPC1 disease by 64Cu-GTSM-PET, in order to delineate 





NPC1 disease is a rare lipid storage disorder predominantly caused by mutations in the gene 
encoding the NPC1 protein. Loss-of-function of this protein leads to the intracellular 
accumulation of cholesterol and other lipids in late endosomes and lysosomes. As a result of 
abnormal lipid storage, patients suffering from NPC1 disease show liver and spleen 
enlargement and progressive CNS degeneration, leading to the development of cognitive 
deficits and motor impairment (319). Additionally, NPC1 disease patients have been shown to 
develop AD-like neurofibrillary pathology, which also contributes to the neurodegenerative 
process (445, 446). 
 
Analysis of NPC1 function has suggested that this protein may play a role in the regulation of 
lysosomal transport of endocytosed lipid cargo or function to transport lipophilic molecules, 
except cholesterol, out of endosomal/lysosomal compartments (447, 448). However, it remains 
to be clarified what the exact role of NPC1 is and how loss-of-function of this protein induces the 
pathological features characteristic of the disorder (e.g liver dysfunction, neurodegeneration). 
While the metabolism of several lipids, including cholesterol, sphingomyelin, glycosphingolipids, 
phospholipids and lysobisphosphatidic acid, has been reported to be disrupted in the liver and 
spleen of NPC1 disease patients, glycosphingolipids have been found to be the predominant 
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storage material in the brain (449). These two lipid storage patterns and their distinctly different 
pathological effects suggest multiple functional roles for the NPC1 protein in the body. 
 
The fact that systemic and neurological disease processes follow independent courses along 
with the broad phenotypic variability of NPC1 disease hamper the development of successful 
treatment options for this disorder. To date, no curative therapy exists for NPC1 disease and the 
management of the disorder remains largely symptomatic (450). Treatment with miglustat, an 
inhibitor of glycosphingolipid biosynthesis, was shown to improve or stabilise several markers, 
mostly neurological, of disease severity in NPC1 patients, but was not able to halt or reverse 
disease progression (451). 
 
Due to its extreme clinical heterogeneity and variable age of presentation, accurate diagnosis of 
NPC1 disease is often challenging. Although the disease can be detected via molecular genetic 
testing, there are currently no reliable independent diagnostic markers to assess disease 
severity and progression and monitor response to treatment. For many years, the primary 
diagnostic test for NPC1 disease has been invasive skin biopsy followed by biochemical testing 
of intracellular accumulation of exogenously derived LDL-cholesterol in cultured fibroblasts 
(452). Nevertheless, this diagnostic approach is complex, time-consuming and costly and may 
not be effective to detect NPC1 cell lines presenting only minor abnormalities (319). 
 
Both in vitro and in vivo studies have demonstrated that abnormal lipid metabolism in NPC1 
disease is accompanied by oxidative stress (453-457). As a consequence of oxidative stress, 
plasma and tissue levels of cholesterol oxidation products have been found to be increased in 
NPC1 knockout mice (457). Porter and co-workers revealed that elevation of plasma oxysterol 
levels correlated with the age of disease onset and disease severity in human subjects. This 
study additionally showed that concentration of cholesterol oxidation products in blood plasma 
decreased in a feline model of NPC1 disease in response to the administration of cholesterol 
modulator 2-hydroxypropyl-β-cyclodextrin, demonstrating the potential usefulness of this marker 
for monitoring response to treatment (458). However, although measurement of oxysterols in 
plasma is a cheap, rapid and highly sensitive diagnostic method, it cannot differentiate between 
NPC1 disease and other subtypes of Niemann-Pick disease (e.g. Niemann-Pick disease type 
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A/B, acid sphingomyelinase-deficient Niemann-Pick disease), thus requiring additional testing to 
confirm the diagnosis (459, 460).  
 
The source of oxidative stress in NPC1 disease remains unknown. It is thought that 
mitochondrial function is disrupted in NPC1 disease, which may lead to ATP deficiency and 
increased production of ROS. Furthermore, it has been suggested that alterations in the 
activities of several antioxidant systems (e.g. peroxisomal catalase, vitamin E, glutathione 
peroxidase 1) may be responsible for the buildup of ROS in plasma and tissues of NPC1 
patients. Finally, it has been hypothesised that dysregulation of metal homeostasis in NPC1 
disease may enhance ROS production and accelerate neurodegeneration (461). 
 
Growing evidence suggests that the metabolism of several transition metals, including copper, 
is disrupted in NPC1 disease (321-324, 462-465). Among other transition metal imbalances, 
copper content in the liver and blood has been found to be altered in both NPC1 deficient mice 
and human subjects (323, 324, 465). The origin of these metabolic abnormalities is not 
understood. The NPC1 protein may play a direct role in normal copper metabolism since it has 
been shown to mediate the incorporation of endosomal copper into ceruloplasmin in cultured 
hepatocytes (326, 327). However, copper imbalance in NPC1 disease may merely be a 
consequence of aberrant cholesterol storage since copper and cholesterol metabolic pathways 
have been shown to be interconnected (325).  
 
Although copper dyshomeostasis is thought to contribute to neurodegeneration in NPC1 
disease through the production of ROS, copper metabolism abnormalities in the CNS have not 
been fully characterised. Reports on CNS copper content in NPC1 disease are few and often 
contradictory. Whole-brain copper levels have not been measured in human brain tissue but 
were found to be decreased in NPC1 knockout mice compared to healthy controls (321). 
Copper content in the cerebellum, which is the brain structure most affected by 
neurodegeneration in NPC1 disease, was shown to be reduced or unchanged in NPC1 
knockout mice relative to age-matched controls (321, 324). CSF copper levels were found to be 




A better characterisation of copper metabolism imbalance in NPC1 disease, particularly within 
the CNS, is needed to understand its impact on disease severity and progression and evaluate 
its potential as a diagnostic marker of the disorder. Hence, in the present study, we have 
investigated the short-term dynamics of copper in a mouse model of NPC1 disease by 64Cu-
GTSM-PET in order to delineate potential metabolic abnormalities associated with the disorder. 
By exploiting the ability of 64Cu-GTSM to cross the BBB and release its copper payload non-
selectively into cells, we were able visualise and quantify radiocopper trafficking in vivo both at 
CNS and whole-body level. To our knowledge, this is the first report evaluating the real-time 
dynamics of copper in NPC1-like pathology in vivo by noninvasive imaging. 
 
5.2.1 The BALB/cNctr-Npc1m1N/J mouse model of NPC1 disease 
In the present study, in vivo copper trafficking was investigated by PET in the BALB/cNctr-
Npc1m1N/J mouse model of NPC1 disease. This mouse model is commonly used since is fully 
characterised and displays an early-onset, severe form of NPC1 disease, with lifespan limited to 
12-14 weeks (49). Loss of NPC1 function in this model is caused by a spontaneous mutation 
arising from the insertion of a retrotransposon-like sequence in the NPC1 gene, resulting in a 
premature stop codon and protein truncation (466).  
 
NPC1 knockout mice exhibit intracellular accumulation of cholesterol and glycosphingolipids, 
leading to hepatosplenomegaly and liver dysfunction (467-469). Similar to NPC1 patients, 
NPC1 deficient mice also develop progressive neurodegeneration, characterised by cerebral 
atrophy, demyelination of the corpus callosum, and degeneration of cerebellar Purkinje cells. As 
a result, NPC1 mutant mice show a staggering gait, action tremors, reduced exploratory 
behaviour and impaired learning and memory capacity (470). However, NPC1 knockout mice 
are not able to reproduce all the features of human NPC1 pathology. In contrast to the 
widespread occurrence of neurofibrillary tangles in patients with NPC1 disease, neurofibrillary 
pathology has not been detected in NPC1 deficient mice (471). NPC1-/- mouse models are also 
not able to reproduce the high phenotypic variability characteristic of human disease (319). 
Regarding metal homeostasis, it should be noted that Hung et al. reported discrepancies in the 
direction of trace metal abnormalities between patients with NPC1 disease and NPC1-/- 
transgenic mice, which probably reflect species-specific differences in metal metabolism. 
205 
 
Therefore, following preclinical evaluation, copper trafficking should also be evaluated in NPC1 
patients in order to assess the status of copper metabolism in human NPC1 disease (321). 
 
In this study, NPC1 knockout mice and their wildtype littermates have been imaged at 6 and 9 
weeks of age. The 6-week-old age group was chosen as representative of the presymptomatic 
stage of the disease, since symptoms in this NPC1 model usually start at about 7 weeks of age, 
while 9-week-old mice were designated as the symptomatic group (49).   
 
5.3 MATERIALS AND METHODS 
 
5.3.1 Radiochemistry 
All reagents were purchased from Sigma-Aldrich, Alfa Aesar, Interlink Scientific Services or 
VWR International Ltd. and were used without further purification, unless otherwise stated. 64Cu 
was produced as previously reported on a CTI RDS 112 biomedical cyclotron at the Clinical 
PET Centre of St Thomas’ Hospital in the form of 64CuCl2 in 0.1 N HCl solution (4.8 GBq/μg) 
(99). Radioactivity was measured using a Capintec CRC-25R dose calibrator. Radio-TLC was 
performed on a LabLogic Flow-Count scanner (scan speed: 0.25 mm/s), using MERCK 60 F254 
silica gel plates as the stationary phase and ethyl acetate as the mobile phase.  
 
H2GTSM was synthesised following a previously reported procedure (142, 406). 64Cu-GTSM 
(~90 % isolated radiochemical yield, ≥ 95 % radiochemical purity) was prepared by reaction of 
the H2GTSM ligand with 64Cu-acetate (~100 MBq) using a previously reported radiolabelling 
protocol. Full experimental details for the synthesis of H2GTSM and 64Cu-GTSM are included in 
the third chapter of this dissertation (sections 3.31 and 3.3.2). For intravenous administration, 




All animal experiments were performed in accordance with the Animals (Scientific Procedures) 
Act, 1986 and approved by the local ethics committee. Animals were kept in standard BSU 
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conditions (21°C, 50 % humidity) and fed ad libitum with regular animal feed (PicoLab Rodent 
Diet 20 EXT IRR, LabDiet ®, US).  
 
BALB/cNctr-Npc1m1N/J transgenic mice (The Jackson Laboratory, Charles River, UK) were 
maintained by heterozygote sibling matings and genotyped as previously described (466). 
Animals were bred at the Department of Pharmacology of the University of Oxford and 
transferred to the Rayne Institute two weeks before the experiment. Food intake, natural 
behaviour and animal body weight were monitored weekly.  
 
5.3.3 PET/CT imaging 
Imaging experiments were performed using a nanoScan® PET/CT (Mediso Medical Imaging 
Systems, Budapest, Hungary). 64Cu-GTSM-PET was performed in 6- and 9-week-old female 
NPC1-/- transgenic mice and age-matched wildtype controls (n=3/group). All animals were 
anaesthetised by isoflurane inhalation (3 % [v/v], Vet Tech Solutions Ltd.) and injected with 
64Cu-GTSM (~15-20 MBq, ≤200 µL) via lateral tail vein. Immediately after injection, mice were 
placed on the scan bed in the prone position and imaged for 30 min by PET/CT (PET: 400-600 
keV energy window; 5 ns coincidence window, 0.30 x 0.30 x 0.30 mm3 voxel size; CT: 180 
projections, 45 KVp, 0.25 x 0.25 x 0.21 mm3 voxel size). After imaging, mice were allowed to 
recover and housed overnight. At 15 h post-injection of 64Cu-GTSM, animals were re-scanned 
for 30 min. Anaesthesia was maintained at 2 % isoflurane throughout the duration of the scans. 
Respiration rate and bed temperature were monitored during image acquisition. 
 
5.3.3.1 PET image analysis 
All PET/CT datasets were reconstructed using 3D iterative algorithms (8 iterations, 6 subsets, 
0.25 x 0.25 x 0.25 mm3 voxel size) (408). Decay, dead-time, intercrystal scatter and CT-derived 
attenuation corrections were applied as part of the reconstruction. The 0-30 min PET datasets 
were reconstructed into 5-min bins and binned images corresponding to 25–30 min post-
injection were used for ROI analysis. Static 15-15.5 h PET datasets were reconstructed into 
single bins representing the average radiotracer biodistribution during this time frame. All 
reconstructed datasets were quantified using VivoQuant 1.21 software (inviCRO, LLC, Boston, 
USA). PET and CT images were automatically co-registered and fixed-volume 3D ROIs (~15 
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mm3) were drawn to determine %ID/mL of 64Cu in organs of interest. A mouse brain atlas 
NM/CT module (inviCRO, LLC) was automatically co-registered to all PET/CT datasets and 
used to measure global and regional concentration of 64Cu in the brain. 
 
5.3.4 Ex vivo biodistribution 
After imaging (15.5 h post-injection of 64Cu-GTSM), all mice were culled and dissected. Organs 
of interest were explanted, weighed and gamma-counted (LKB Wallac 1282) to measure 64Cu 
concentration in each organ as %ID/g. The sum of whole-body counts (excluding tail) and 
excreted activity (urine and faeces) was considered as the total ID. 
 
5.3.5 Ex vivo brain autoradiography  
After dissection, brain tissue was cryopreserved in 30 % (w/v) sucrose solution for ~6 h and 
stored at -80°C overnight. Sagittal brain sections were then cut at 10 µm using a Bright 5040 
cryotome and thaw-mounted onto Superfrost PLUS glass microscope slides (Menzel-Glaser, 
Thermo Scientific). Subsequently, tissue slices were exposed to a storage phosphor screen 
(PerkinElmer, Super Resolution, 12.5 x 25.2 cm) for 15 h. Finally, the plate was scanned using 
a Typhoon 8600 scanner (Molecular Dynamics) and the resulting autoradiographs were 
analysed with OptiQuant 5.0 (PerkinElmer) and ImageJ (NIH). 
 
5.3.6 Statistical analysis 
All data are reported as mean ± SD. Statistical analysis was performed using GraphPad Prism 5 
(GraphPad Software Inc.). Two-way repeated measures ANOVA with post-hoc analyses using 
the Bonferroni multiple comparison correction was used to determine statistically significant 





5.4.1 PET/CT imaging 
In order to investigate short-term copper trafficking in NPC1 disease, particularly at the CNS 
level, NPC1-/- transgenic mice at 6 and 9 weeks of age and age-matched controls were 
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intravenously injected with 64Cu-GTSM and imaged from 0-30 min and from 15-15.5 h post-
injection. Figure 5.1 depicts the in vivo biodistribution of 64Cu in 6-week-old NPC1 knockout 
mice and wildtype controls at 30 min and 15 h after injection. On visual assessment, 64Cu 
radioactivity seemed to accumulate predominantly in the lungs and heart and to a lesser extent 
in the liver, intestines, kidneys and brain in both animal groups at 30 min post-injection of the 
tracer. 64Cu accumulation in the lungs at 30 min after injection seemed remarkably higher for 
wildtype controls when compared to NPC1-/- transgenic mice. After 15 h, 64Cu radioactivity 
appeared to wash out from the heart, lungs and kidneys and to increase in the liver and 
intestines in both NPC1-/- transgenic mice and wildtype controls. Brain 64Cu uptake seemed to 
remain relatively constant over time in both groups.   
 
 
Figure 5.1: Exemplar sagittal and coronal views of PET/CT MIPs of 6-week-old female wildtype controls 
(A) and age-matched NPC1-/- transgenic mice (B) at 30 min and 15 h post-injection of 64Cu-GTSM. PET 
imaging revealed high accumulation of 64Cu radioactivity in the heart, lungs, liver, kidneys, intestines and 
brain at 30 min after injection of the tracer in all mice. While 64Cu accumulation decreased in the heart, 
lungs and kidneys over time, the concentration of radiocopper in the liver and intestines increased. Brain 
uptake of 64Cu remained relatively constant over time in both animal groups. Organs are indicated by 
arrows: B = brain; Sp = spine; H = heart; Lu = lungs; L = liver; K = kidneys; I = intestines. All MIPs were 
scaled to 0-1 %ID/mL (min) and 40 %ID/mL (max). 
 
The in vivo biodistribution of 64Cu in 9-week-old NPC1 knockout mice and age-matched controls 
at 30 min and 15 h post-injection of 64Cu-GTSM was very similar to that of their younger 
counterparts (Figure 5.2). Based on visual inspection of PET/CT images, 64Cu radioactivity 
accumulated mainly in the heart, lungs, liver, kidneys intestines and brain at 30 min post-
injection of the tracer. At 15 h after injection, 64Cu concentration decreased in the heart, lungs 
and kidneys and increased in the liver and intestines. Intestinal 64Cu uptake at late imaging 
time-points appeared to be greater in NPC1 knockout mice than in wildtype controls. 64Cu 
accumulation in the brain remained relatively constant over time in both animal groups but 





Figure 5.2: Exemplar sagittal and coronal views of PET/CT MIPs of 9-week-old female wildtype controls 
(A) and age-matched NPC1-/- transgenic mice (B) at 30 min and 15 h post-injection of 64Cu-GTSM. Similar 
to the 6-week-old mouse groups, 9-week-old NPC1-/-and control mice showed high concentration of 64Cu 
in the heart, lungs, liver, kidneys, intestines and brain at 30 min after injection. From 30 min to 15 h post-
injection of 64Cu-GTSM, 64Cu radioactivity decreased in the heart, lungs and kidneys and increased in the 
liver and intestines. The concentration of 64Cu in the brain appeared to be higher for NPC1 knockout mice 
at both imaging time-points when compared to their wildtype littermates. Organs are indicated by arrows: B 
= brain; Sp = spine; H = heart; Lu = lungs; L = liver; K = kidneys; I = intestines. All MIPs were scaled to 0-1 
%ID/mL (min) and 40 %ID/mL (max). 
 
64Cu biokinetics in the CNS (brain and spine) and other organs of interest (e.g. heart, liver) were 
quantified in all groups by PET ROI analysis (Figure 5.3). As expected, 64Cu concentration was 
found to decrease markedly in the heart (NPC1-/-: 54.24 ± 12.34 % decrease in %ID/mL; 
wildtype: 49.71 ± 20.50 % decrease in %ID/mL) and increase in the liver (NPC1-/-: 64.07 ± 10.18 
% increase in %ID/mL; wildtype: 33 ± 22.44 % increase in %ID/mL) from 30 min to 15 h post-
injection of the tracer in both 6-week-old NPC1 knockout mice and age-matched controls. 
Furthermore, PET ROI analysis revealed that 64Cu concentration increased slightly in the brain 
(NPC1-/-: 1.71 ± 1.20 % increase in %ID/mL; wildtype: 1.42 ± 0.84 % increase in %ID/mL) and 
spine (NPC1-/-: 3.07 ± 3.87 % increase in %ID/mL; wildtype: 2.15 ± 6.31 % increase in %ID/mL) 
in both animal groups from 30 min to 15 h post-injection of the tracer. The concentration of 64Cu 
in the brain and spinal cord of NPC1 knockout mice was found to be slightly higher when 
compared to that of their wildtype littermates but this difference between the groups did not 





Figure 5.3: Time-activity curves extracted from PET ROI analysis depicting 64Cu concentration (expressed 
as %ID/mL) over time in the heart, liver, spine and brain of 6-week-old NPC1-/- (A) and age-matched 
wildtype controls (B). Data are mean (n=3/group) ± SEM. 
 
 
PET quantification demonstrated that the in vivo biokinetics of 64Cu in the 9-week-old NPC1-/- 
and control groups were similar to those of their younger counterparts (Figure 5.4). A decrease 
in cardiac 64Cu concentration was measured from 30 min to 15 h post-injection of 64Cu-GTSM in 
both NPC1-/- transgenic mice (48.38 ± 10.81 % decrease in %ID/mL) and age-matched controls 
(52.56 ± 9.74 % decrease in %ID/mL). Hepatic 64Cu content was also found to increase over 
time in both animal groups (NPC1-/-: 69.42 ± 15.76 % increase in %ID/mL; wildtype: 69.77 ± 
6.19 % increase in %ID/mL). Nevertheless, contrary to younger mice, 9-week-old NPC1 
knockout mice and wildtype controls exhibited a decrease in spinal cord 64Cu concentration over 
time (NPC1-/-: 5.30 ± 2.95 % decrease in %ID/mL; wildtype: 3.95 ± 3.24 % decrease in 
%ID/mL). While 64Cu accumulation in the brains of NPC1-/- transgenic mice was found to 
decrease slightly from 30 min to 15 h post-injection of 64Cu-GTSM (0.38 ± 1.50 % decrease in 
%ID/mL), brain 64Cu concentration in age-matched controls was shown to increase from 30 min 
to 15 h post-injection of the tracer (2.47 ± 1.41 % increase in %ID/mL).  
 
Figure 5.4: Time-activity curves extracted from PET ROI analysis showing 64Cu concentration (expressed 
as %ID/mL) from 30 min to 15 h post-injection of 64Cu-GTSM in the heart, liver, spine and brain of 9-week-





Unlike in younger mice, significant differences in 64Cu biokinetics within the CNS were detected 
between 9-week-old NPC1 knockout mice and age-matched controls (Figure 5.5). 
 
Figure 5.5: In vivo brain (left) and spine (right) concentration of 64Cu (expressed as %ID/mL) in 6- (A) and 
9-week-old (B) NPC1 knockout mice and age-matched controls, as measured by PET ROI analysis. Time-
activity curves illustrating clearance of 64Cu radioactivity over time for each individual mouse are shown at 
the top of each bar chart. NPC1-/- transgenic mice exhibited significantly higher 64Cu concentration in the 
brain and spine at all imaging time-points than controls. Statistically significant differences from healthy 
controls are indicated by * (p<0.05) and ** (p<0.01). Data are mean (n=3/group) ± SD. 
 
Two-way ANOVA analysis demonstrated a significant group effect on brain 64Cu concentration 
in 9-week-old NPC1 knockout mice and wildtype controls (F1,4 = 13.54, p = 0.0212). Post-hoc 
tests indicated significantly higher 64Cu accumulation in the brains of NPC1-/- transgenic mice 
compared to their wildtype littermates at 30 min (10.92 ± 0.94 %ID/mL vs. 7.71 ± 0.64 %ID/mL, 
p<0.05) and 15 h (10.89 ± 1.10 %ID/mL vs. 7.89 ± 0.61 %ID/mL, p<0.05) post-administration of 
64Cu-GTSM. Statistical analysis also revealed significant effects of group (F1,4 = 26.46, p = 
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0.0068) and time (F1,4 = 10.15, p = 0.0334) on spine 64Cu concentration in 9-week-old NPC1-/- 
mice and wildtype controls. NPC1 knockout mice exhibited significantly higher 64Cu 
accumulation in the spinal cord than their wildtype littermates at all imaging time-points (30 min: 
8.35 ± 0.76 %ID/mL vs. 5.48 ± 0.40 %ID/mL, p<0.01; 15 h: 7.93 ± 1.02 %ID/mL vs. 5.25 ± 0.19 
%ID/mL, p<0.01 ).   
 
These significant differences in brain and spine 64Cu accumulation between the two animal 
groups result mainly from an age-dependent decrease in 64Cu concentration in these organs in 
wildtype mice. Two-way ANOVA analysis indicated significant effects of age on brain (F1,4 = 
8.256, p = 0.0453) and spine (F1,4 = 77.34, p = 0.0009) 64Cu concentration in 6- and 9-week-old 
wildtype controls. Post-hoc evaluation showed significantly higher 64Cu concentration in the 
brain (30 min: 10.11 ± 0.99 %ID/mL vs. 7.71 ± 0.64 %ID/mL, p<0.05; 15 h: 10.25 ± 0.99 
%ID/mL vs. 7.89 ± 0.61 %ID/mL, p<0.05 ) and spinal cord (30 min: 7.73 ± 0.25 %ID/mL vs. 5.48 
± 0.40 %ID/mL, p<0.001; 15 h: 7.90 ± 0.65 %ID/mL vs. 5.25 ± 0.19 %ID/mL, p<0.001 ) of 6-
week-old wildtype mice compared to their older counterparts at all imaging time-points. 
Although an age-dependent reduction in 64Cu concentration was also observed in NPC1 
knockout mice, this trend did not reach statistical significance. 
 
Figure 5.6: Representative coronal and sagittal section PET/CT MIP images illustrating 64Cu distribution in 
the brains of 6-week-old wildtype controls (A) and age-matched NPC1 knockout mice (B) at 30 min (top) 
and 15 h (bottom) post-injection of 64Cu-GTSM. Brain distribution of 64Cu appeared relatively homogenous 
at 30 min post-injection of the tracer but became slightly more heterogeneous over time in both animal 




Figure 5.7: Representative coronal and sagittal section PET/CT MIP images showing the distribution of 
64Cu in the brains of 9-week-old wildtype controls (A) and age-matched NPC1 knockout mice (B) at 30 min 
(top) and 15 h (bottom) post-injection of 64Cu-GTSM. NPC1 knockout mice exhibited higher brain 64Cu 
accumulation than their wildtype littermates at all imaging time-points. The heterogeneity of the brain 64Cu 
signal seemed to increase from 30 min to 15 h after injection in both mouse groups. All MIPs were scaled 
to 0-2 %ID/mL (min) and 20 %ID/mL (max). 
 
Figures 5.6 and 5.7 depict the distribution of 64Cu in the brains of 6- and 9-week-old NPC1-/- 
transgenic mice and age-matched controls at 30 min and 15 h post-injection of the tracer. Brain 
distribution of 64Cu appeared relatively homogeneous at 30 min after injection in both 6-week-
old NPC1-/- and wildtype mice but became slightly more heterogeneous over time in both 
groups. In the older mouse groups, 64Cu was taken up in all brain regions at 30 min post-
injection of the tracer but seemed to accumulate more prominently around the medulla. From 30 
min to 15 h post-injection, the heterogeneity of the brain PET signal appeared to increase in 
both 9-week-old NPC1 knockout mice and wildtype controls. 
 
Due to the low amount of activity injected and limited spatial resolution of the PET scanner, the 
visualisation of the regional accumulation of 64Cu in the brains of NPC1-/- transgenic mice and 
wildtype controls proved difficult. To evaluate the distribution of 64Cu in the brain in a functional 
context, our PET/CT datasets were analysed using a 3D mouse brain atlas. Two-way ANOVA 
analysis demonstrated only a significant effect of interaction (F1,4 = 3.841, p = 0.0002) on brain 
regional concentration of 64Cu in 6-week-old NPC1 knockout mice and age-matched controls at 
30 min post-injection of the tracer, but did not reveal any significant differences in 64Cu 
accumulation in specific regions between the groups at either imaging time-point (Figure 5.8). 
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The concentration of 64Cu in all brain regions was found to be generally higher in NPC1-/- 
transgenic mice compared to age-matched controls at both 30 min and 15 h post-injection of 
64Cu-GTSM. The thalamus and midbrain were found to accumulate more radiocopper than the 
rest of brain regions in both animal groups. 
 
Figure 5.8: Regional brain distribution of 64Cu in 6-week-old NPC1-/- transgenic mice and age-matched 
controls at 30 min (top) and 15 h (bottom) post-injection of 64Cu-GTSM. No significant differences in brain 
regional 64Cu concentration between the two groups were detected. Data are mean (n = 3/group) ± SD. 
 
Significant effects of group, region and group-by-region interaction on brain regional 
accumulation of 64Cu were measured in 9-week-old NPC1 knockout mice and age-matched 
controls at both 30 min (group: F1,4 = 16.38, p = 0.0155; region: F1,4 = 32.91, p<0.0001; 
interaction: F1,4 = 3.840, p = 0.0002) and 15 h (group: F1,4 = 15.17, p = 0.0176; region: F1,4 = 
41.48, p<0.0001; interaction: F1,4 = 5.274, p<0.0001) post-injection of the tracer. Contrary to the 
findings in younger mice, post-hoc evaluation revealed significant differences in 64Cu 
concentration in specific brain regions between the two animal groups at both imaging time-
points (Figure 5.9). At 30 min after injection, NPC1 knockout mice exhibited significantly greater 
64Cu levels than their wildtype littermates in the medulla (p<0.05), cerebellum (p<0.05), midbrain 
(p<0.001), pons (p<0.01), hippocampus (p<0.05), thalamus (p<0.001), hypothalamus (p<0.01), 
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striatum (p<0.01), pallidum (p<0.01), olfactory bulb (p<0.05), corpus callosum (p<0.01), white 
matter (p<0.01) and ventricles (p<0.01). The NPC1-/- group showed significantly higher 64Cu 
concentration than controls in the medulla (p<0.01), midbrain (p<0.001), pons (p<0.01), 
hippocampus (p<0.05), thalamus (p<0.001), hypothalamus (p<0.001), striatum (p<0.01), 
pallidum (p<0.01), corpus callosum (p<0.05), white matter (p<0.01) and ventricles (p<0.05) at 
15 h post-injection of 64Cu-GTSM. 
  
Figure 5.9: Regional brain distribution of 64Cu in 9-week-old NPC1-/- transgenic mice and age-matched 
controls at 30 min (top) and 15 h (bottom) post-injection of 64Cu-GTSM. Statistically significant differences 
from healthy controls are indicated by * (p<0.05), ** (p<0.01) and *** (p<0.001). Data are mean (n = 
3/group) ± SD. 
 
Moreover, two-way ANOVA analysis demonstrated significant effects of age (F1,4 = 8.323, p = 
0.0448), region (F1,4 = 33.15, p<0.0001) and interaction (F1,4 = 2.599, p = 0.0074) on brain 
regional concentration of 64Cu in wildtype mice at 30 min post-injection of the tracer. Post-hoc 
tests indicated significantly higher 64Cu accumulation in the medulla (p<0.01), midbrain (0<0.05) 
and pons (p<0.05) of 6-week-old controls when compared to their older counterparts. Significant 
effects of age (F1,4 = 8.277, p = 0.0451) and region (F1,4 = 20.23, p<0.0001) on brain regional 
64Cu uptake were also detected in the wildtype groups at late imaging time-points. At 15 h after 
injection of 64Cu-GTSM, a significant reduction in 64Cu concentration was measured in the 
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midbrain (p<0.05), thalamus (p<0.05) and white matter (p<0.05) of 9-week-old wildtype mice 
relative to young controls. On the other hand, no significant differences in brain regional 64Cu 
accumulation as measured by atlas-based quantification were detected between 6- and 9-week-
old NPC1-/- knockout mice. 
 
5.4.2 Ex vivo biodistribution 
At the end of the imaging process, the biodistribution of 64Cu in NPC1 knockout mice and 
wildtype controls was evaluated via ex vivo gamma-counting of explanted organs. In this study, 
ex vivo tissue counting was only performed in 9-week-old NPC1 knockout mice and wildtype 
controls since their younger counterparts were kept alive for a follow-up imaging session, which 
could not be conducted in the end due to lack of 64CuCl2 supply.   
 
Figure 5.10 illustrates the ex vivo biodistribution of 64Cu in 9-week-old NPC1 knockout mice and 
age-matched controls at 15 h post-injection of 64Cu-GTSM. 64Cu radioactivity was found to 
accumulate predominantly in the lungs, liver and intestines and to a lesser extent in the heart 
and brain in both animal groups.  
 
Figure 5.10: Tissue biodistribution of 64Cu in 9-week-old NPC1-/- transgenic mice and age-matched 
controls at 15 h post-injection of 64Cu-GTSM. Statistically significant differences from controls are indicated 
by * (p<0.05) and ** (p<0.01). Data are mean (n = 3/group) ± SD. 
 
Interestingly, statistical analysis demonstrated significantly greater 64Cu concentration in the 
blood of 9-week-old NPC1 knockout mice compared to age-matched wildtype controls (2.25 ± 
0.10 %ID/mL vs. 1.38 ± 0.11 %ID/mL, p<0.01). The NPC1-/- group also showed significantly 
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higher 64Cu concentration in urine than their wildtype littermates (1.29 ± 0.2 %ID/mL vs. 0.64 ± 
0.10 %ID/mL, p<0.05). Furthermore, the concentration of 64Cu in the brain was found to be 
significantly higher in NPC1-/- transgenic mice relative to age-matched controls (11.86 ± 1.69 
%ID/mL vs. 7.03 ± 1 %ID/mL, p<0.05), which was consistent with our PET quantification results. 
Brain 64Cu %ID/g values measured by ex vivo counting exhibited a strong correlation (R2 = 
0.7461) with whole-brain 64Cu concentration estimated by PET ROI analysis (Figure 5.11).  
 
Figure 5.11: Comparison of whole-brain 64Cu concentration values as measured by PET ROI analysis and 
ex vivo gamma-counting at 15 h post-injection of 64Cu-GTSM in 9-week-old NPC1-/- transgenic mice and 
age-matched controls. A strong correlation was found between the two parameters (R2 = 0.7461). All 
NPC1-/- (n = 3) and wildtype (n = 3) mice were included in the correlation. 
 
5.4.3 Ex vivo brain autoradiography 
In order to generate high-resolution maps of the distribution of 64Cu within brain tissue, sagittal 
brain sections of NPC1 knockout mice and wildtype controls sacrificed at 15 h post-injection of 
64Cu-GTSM were imaged by phosphor imaging autoradiography. Similar to gamma-counting, ex 
vivo autoradiography could only be performed in 9-week-old NPC1-/- transgenic mice and age-
matched controls since 6-week-old mice were kept alive for a follow-up imaging study.  
 
Figure 5.12 shows the regional distribution of 64Cu in representative sagittal brain slices of 
NPC1 knockout mice and wildtype controls at 15 h after injection of the tracer as measured by 
autoradiography. Ex vivo autoradiographs reflect globally higher accumulation of 64Cu in the 
brains of 9-week-old NPC1 knockout mice compared to age-matched controls, depicted also by 
PET imaging. The most prominent radioactive hotspots in the NPC1-/- brain autoradiographs 
were found in the midbrain, thalamus, pons, cerebellum and medulla, consistent with the results 
of atlas-based PET quantification. The distribution of 64Cu in wildtype brain tissue was found to 
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be more homogeneous compared to that in the  NPC1-/- group, although distinct accumulation 
of 64Cu in the thalamic area could also be observed.     
 
Figure 5.12: Ex vivo autoradiographs from representative sagittal brain sections of 9-week-old NPC1-/- 
(top) and control (bottom) mice sacrificed at 15 h post-injection of 64Cu-GTSM. Ex vivo autoradiography 
demonstrated higher brain 64Cu accumulation and more prominent 64Cu hotspots in NPC1 knockout mice 
compared to controls. The main radioactive hotspots in the NPC1-/- brain autoradiographs were located in 
the thalamus, midbrain, cerebellum, medulla and pons areas. TH = thalamus; M = midbrain; ME = medulla; 




Growing evidence has suggested that the metabolism of several trace metals, including copper, 
is altered in NPC1 disease (321-324, 463-465). The characterisation of trace metal 
abnormalities in NPC1 disease is essential to understand their impact on the severity and 
progression of the disorder and to determine whether they provide any added diagnostic value 
to the existing NPC1 biomarkers. Hence, in this study, we have studied in vivo copper trafficking 
in a mouse model of NPC1 disease at presymptomatic and symptomatic stages of the disorder 
by 64Cu-GTSM-PET in order to identify any measurable alterations that may be associated with 
the pathology.  
 
In the present study, we have focused on the delineation of copper trafficking within the CNS 
since transition metal imbalance has been linked to enhanced oxidative stress in NPC1 disease 
and is therefore thought to contribute heavily to the neurodegenerative process characteristic of 
this disorder (320, 324, 458). For this reason, we used the Cu-BTSC complex 64Cu-GTSM as a 
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vehicle to deliver radioactive copper into the CNS and subsequently monitor its trafficking. The 
efficacy of 64Cu-GTSM to transport radiocopper into the brain was demonstrated in the third 
chapter of this dissertation. Nevertheless, additional studies should be performed using ionic 
radiocopper in order to investigate active transport of dietary copper salts at the whole-body 
level in NPC1 disease.  
 
The chosen route for 64Cu-GTSM administration was tail vein injection, which bypasses the 
absorption phase of endogenous copper metabolism but facilitates the rapid deposition of 
radiocopper within the CNS. However, the fate of orally administered radiocopper should also 
be evaluated by PET in future studies in order to detect any potential abnormalities in the 
gastrointestinal absorption of copper that might be associated with NPC1 disease. 
 
As expected from a previous study (see Chapter III), 64Cu-GTSM rapidly released radiocopper 
in all major organs after injection, including heart, lungs, liver, intestines, kidneys and brain. At 
15 h post-injection of the tracer, 64Cu radioactivity was found to decrease in the heart, lungs and 
kidneys, and to accumulate in the liver and intestines, probably reflecting the excretion of 
radiocopper via the biliary system. Despite previous studies reporting increased copper content 
in the liver of NPC1 deficient mice compared to control animals, no significant differences in 
hepatic 64Cu concentration were found between NPC1 and wildtype groups at either 6 or 9 
weeks of age (320-322). This discrepancy might be explained on the basis of differences 
between long-term and short-term copper biodistribution in this mouse model of NPC1 disease. 
Increased copper levels in the liver of NPC1 knockout mice might result from prolonged 
accumulation of dietary copper in this organ, and might therefore not be measurable by PET, 
due to its limited temporal range. 
 
As previously observed (see Chapter III), both brain and spine showed surprisingly high 
radiocopper sequestration capacities. Slow clearance of 64Cu radioactivity from brain and spinal 
cord compared to other tissues might be caused by a particularly high metabolic demand for 




PET image analysis revealed no significant differences in whole-brain and spine 64Cu 
concentration between presymptomatic NPC1 knockout mice and age-matched controls. 
Conversely, at 9 weeks of age, NPC1-/- transgenic mice exhibited significantly higher 64Cu 
concentration than wildtype controls at both 30 min and 15 h post-injection of 64Cu-GTSM. 
Interestingly, these differences in brain and spine 64Cu concentration between the two animal 
groups were found to result from an age-dependent decrease in 64Cu concentration in these 
organs in wildtype mice. Due to the low statistical power of this study, these results need to be 
interpreted cautiously. The exact role of the NPC1 protein in copper metabolism has not yet 
been defined and consequently the impact of its deletion on brain copper trafficking is unknown. 
Yanagimoto et al. demonstrated that NPC1 mediated copper transport from late endosomes to 
the secretory compartment for its subsequent incorporation into ceruloplasmin in cultured 
hepatocytes (326, 327). A potential role for NPC1 in the metallation and secretion of 
ceruloplasmin was further supported by Arguello et al., who reported higher copper and lower 
iron content along with increased ceruloplasmin, MT-1 and transferrin receptor gene expression 
in the liver of NPC1 deficient mice compared to controls (322). However, the lack of benefit of 
chelation therapy on neurological function in NPC1 knockout mice together with reduced 
cerebral copper content in this model seem to suggest a different role for the NPC1 protein in 
brain copper metabolism (321). In this context, increased brain 64Cu retention in symptomatic 
NPC1-/- transgenic mice could also be driven by a regulatory mechanism aiming to compensate 
for the low cerebral copper levels previously reported for this model in an effort to restore 
copper-dependent antioxidant enzyme activity as a response to oxidative stress (321). 
 
Atlas-based quantification revealed no significant differences in brain regional 64Cu 
concentration between 6-week-old NPC1 deficient mice and wildtype controls but did show 
significantly increased 64Cu accumulation in multiple brain regions in symptomatic NPC1 
knockout mice compared to age-matched controls. Whether these differences in brain regional 
64Cu concentration are a result of localised NPC1 disease or globally higher 64Cu accumulation 
in the NPC1 model is not known. Considering the limitations of atlas-based quantification (e.g 
partial volume effect, imperfect matching between atlas regions and brain structures), these 
results should be considered orientative rather than definitive. Enhanced brain regional 64Cu 
concentration in symptomatic NPC1 knockout mice might arise from an increased metabolic 
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demand for copper in these regions associated with the disease, higher regional BBB 
permeability or increased blood vessel density in this model.  
 
Similar to PET quantification, ex vivo brain autoradiography demonstrated globally higher 
accumulation of 64Cu in the brains of 9-week-old NPC1 deficient mice compared to age-
matched controls. Prominent 64Cu hotspots were observed in the midbrain, thalamus, medulla, 
cerebellum and pons regions in the NPC1-/- brain autoradiographs, which was also consistent 
with our PET imaging results. The molecular mechanisms driving the accumulation of 
radiocopper in these regions remain to be elucidated. The cerebellum and brainstem structures 
(medulla, pons and midbrain) are the regions most affected by neurodegeneration in NPC1 
disease (472). Neuronal loss and oxidative damage have also been documented in the 
thalamus of NPC1-/- transgenic mice (455, 471). Consequently, increased accumulation of 64Cu 
in these regions might be driven by a regulatory mechanism aiming to enhance their antioxidant 
capacity to counteract oxidative stress. Alternatively, higher 64Cu uptake could be highlighting a 
potential copper deficiency in these brain regions caused by increased intracellular cholesterol 
accumulation, since an inverse relationship between copper and cholesterol concentrations has 
been reported in animal studies (473-476). Reduced copper content has been measured in the 
cerebellum of NPC1 deficient mice but copper levels in the remaining brain regions have not 
been reported yet (321). 
 
After imaging, the ex vivo biodistribution of 64Cu in symptomatic NPC1 deficient mice and age-
matched controls at 15 h post-injection of 64Cu-GTSM was evaluated via gamma-counting of 
explanted organs. NPC1 knockout mice were found to exhibit significantly higher 64Cu 
concentration in blood than their wildtype littermates. These results are in agreement with 
previous research revealing increased copper content in blood plasma in 7-week-old NPC1-/- 
transgenic mice compared to healthy controls (321, 324). It should be noted that elevated blood 
64Cu concentration might contribute to some extent to enhanced accumulation of 64Cu in the 
brain and spinal cord of NPC1-/- transgenic mice. Elevation of plasma copper in symptomatic 
NPC1 knockout mice (7 weeks old) has been associated with an increase in copper-bound 
holoceruloplasmin levels and ceruloplasmin oxidase activity, which might indicate a higher rate 
of synthesis/secretion of this protein in this NPC1 model (321, 324). Additional studies need to 
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be performed to determine whether plasma 64Cu is inserted into ceruloplasmin or bound to other 
plasma proteins (e.g. albumin, transcuprein), whether increased blood 64Cu concentration in 
NPC1 knockout mice can be detected at earlier time-points after injection of the tracer and 
stages of the disease, and whether this increase can also be measured in human NPC1 
subjects. The relationship between blood copper concentration and disease severity and 
progression also needs to be evaluated in order to determine the potential of this parameter as 




This study has further demonstrated the potential of 64Cu-GTSM-PET as a tool to identify 
alterations in copper metabolism associated with disease processes, particularly within the 
CNS. The characterisation of copper metabolism abnormalities in NPC1 disease is essential to 
understand their effect on certain pathological features of the disorder, such as oxidative stress, 
which is a major contributor to neurodegeneration. In this study, PET imaging has been used for 
the first time to evaluate the real-time dynamics of copper trafficking in a mouse model of NPC1 
disease in order to identify potential metabolic abnormalities that might have added value in the 
diagnosis of the disorder. 64Cu-GTSM-PET revealed significantly increased 64Cu concentration 
in the brain and spine of symptomatic NPC1 deficient mice compared to healthy controls at both 
30 min and 15 h post-injection of the tracer. Furthermore, atlas-based PET quantification 
indicated significant differences in brain regional 64Cu accumulation between these two groups 
of mice. Symptomatic NPC1 knockout mice were additionally found to exhibit significantly higher 
64Cu concentration in blood than their wildtype littermates at late time-points after injection. 
Despite the low statistical power of this study, the origin of these metabolic abnormalities along 
with their relationship with disease severity and progression merit further investigation. Due to 
the inability of NPC1 mouse models to mimic the phenotypic variabiliaty of human NPC1 
disease, PET imaging of copper trafficking should additionally be performed in human subjects 
in order to delineate any potential abnormalities that could be used to assess the status of the 




6. Chapter 6- Asymmetrical copper bis(thiosemicarbazone) 




In this chapter, we aimed to synthesise and characterise a series of new asymmetrical Cu-
BTSCs for potential use in molecular imaging applications, including the measurement of 
copper trafficking processes. The redox potential and lipophilicity of these complexes were 




Cu-BTSCs are a versatile family of copper (II) complexes with a wide range of pharmacological 
properties, including antineoplastic, antimicrobial and neuroprotective activities (288, 477-479). 
The most attractive feature of these complexes is that their biological behaviour can be tuned by 
structural modification of their ligand scaffold. For example, the addition of alkyl groups to the 
diimine backbone of the ligand has been reported to decrease the redox potential of the 
resulting copper complexes, making them less susceptible to bioreduction and metal-ligand 
dissociation. On the other hand, alkylation of the terminal amine groups of the ligand has been 
shown to increase the lipophilicity of the complexes, subsequently influencing their cell 
permeability, plasma protein binding and biokinetics (142, 166).  
 
The tunability of the physicochemical properties of Cu-BTSCs via ligand structure modification 
offers the possibility to control the conditions under which these complexes undergo 
bioreduction and metal-ligand dissociation for a variety of diagnostic imaging applications. This 
was exploited in the third chapter of this dissertation to provide a BBB-permeable complex 
capable of releasing its copper payload nonselectively into cells by bioreduction (Cu-GTSM). 
The feasibility of using Cu-BTSC complexes as molecular imaging agents was first 
demonstrated by Green et al., who unveiled the potential of Cu-PTSM to delineate regional 
blood flow. This complex, with only one alkyl group on its backbone, has a relatively high redox 
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potential and is therefore prone to bioreduction and metal release in all cellular environments. 
The intracellular reduction and metal-ligand dissociation of Cu-PTSM have been found to be so 
rapid that the uptake of the tracer is thought to be almost entirely dependent on blood flow. 
Green and co-workers reported rapid blood clearance and high brain and heart accumulation of 
67Cu-PTSM as well as an excellent correlation between tracer uptake and regional blood flow 
(assessed using [125I] iodoantipyrine) in a gerbil stroke model, demonstrating the potential utility 
of Cu-PTSM-PET for the assessment of cerebral and myocardial perfusion (168). Cu-PTSM has 
shown promise in identifying perfusion abnormalities in a small clinical study performed on 
patients with occlusive coronary artery disease, and remains so far the Cu-BTSC gold-standard 
for imaging regional blood flow (174). 
 
The effect of backbone alkylation on bioreduction and metal-ligand dissociation has also been 
exploited to develop Cu-BTSC radiotracers capable of releasing their copper payload selectively 
into hypoxic cells. This is the case of the prototype hypoxia-selective complex Cu-ATSM, which 
differs from Cu-PTSM only by an additional backbone methyl group. Due to its lower Cu (II/I) 
reduction potential, bioreduction of Cu-ATSM is harder compared to that of Cu-PTSM and the 
complex is able to diffuse out of the cell under normoxic conditions before reduction and 
dissociation occur. However, the complex gets trapped by bioreduction in more reducing 
environments, providing a means for delineating and quantifying hypoxia within tissues. The 
hypoxia selectivity of Cu-ATSM has been repeatedly demonstrated both in vitro and in vivo and 
the tracer has been shown to be useful in depicting hypoxic tissue and predicting response to 
therapy in a small number of cancer clinical trials (89, 142, 147, 158, 159, 166). 
 
Nevertheless, despite initial promise, both Cu-PTSM- and Cu-ATSM-PET suffer from major 
drawbacks that significantly hamper their clinical use. Cu-PTSM has been found to exhibit 
significant interspecies variability in the strength of its binding to serum albumin, which results in 
the underestimation of regional blood flow in humans (175, 412). On the other hand, the cellular 
uptake of Cu-ATSM has been shown to be hypoxia-selective only in certain types of tumours, 
which seems to suggest that other factors besides tissue hypoxia might contribute to the 
retention mechanism of this tracer in vivo (160). Furthermore, the in vivo stability of Cu-ATSM 
has been found to be poor, as evidenced by the similar biodistribution profiles obtained for 64Cu-
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ATSM and 64Cu-acetate in tumour-bearing mice at early and late imaging time-points (480). 
Finally, although Cu-ATSM may be suitable to delineate tumour hypoxia, its hypoxia-selective 
threshold has been shown to be too low to identify hypoxically compromised but salvageable 
myocardium underlying chronic cardiovascular disease (481). 
 
Because to these limitations as well as the possibility to use Cu-BTSCs for new imaging 
applications (e.g. imaging of copper trafficking/ cerebral oxidative stress), there is growing 
interest in developing new Cu-BTSC radiotracers with improved imaging properties for clinical 
use. For this reason, in collaboration with the University of Kent (Dr Oliver C. Brown and Prof 
Michael Went), we have synthesised and characterised a library of new asymmetrical Cu-BTSC 
complexes with a variety of alkylation patterns. Asymmetrical BTSC ligands, although harder to 
synthesise and purify, offer greater structural diversity than symmetrical BTSCs and therefore 
may facilitate the fine-tuning of the physicochemical properties of the Cu-BTSC complexes 
needed for specific imaging applications (482). The measurement of the redox potential and 
lipophilicity of the new Cu-BTSC complexes was included as part of their characterisation as 
these two properties are the most influential in determining their biodistribution and selectivity, 
and the most tunable by regional alkylation. However, it should be noted that additional 
physicochemical parameters (acid dissociation coefficient [pKa], dissociation constant [Kd]) need 
to be determined in order to fully define the biological behaviour of the new Cu-BTSC 
complexes as well as their potential as molecular imaging agents. 
 




6.3.1.1 General directions 
All reagents were purchased from Sigma-Aldrich, Alfa Aesar, Interlink Scientific Services and 
VWR International Ltd. and were used without further purification, unless otherwise stated. NMR 
spectra were recorded on a Bruker Ultrashield 400WB PLUS 9.4 T spectrometer (1H NMR at 
400 MHz). All chemical shifts were referenced to residual solvent peaks and are quoted in ppm 
relative to tetramethylsilane. High-performance liquid chromatography (HPLC) was performed 
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using an Agilent Technologies 1200 series unit with a C18 column and UV/VIS detection at 254 
nm and a gradient mobile phase consisting of water + 0.1 % (v/v) trifluoroacetic acid (TFA) (A) 
and acetonitrile + 0.1 % (v/v) TFA (B) (0 min: 95% A / 5% B; 15 min: 5% A / 95% B; 20 min: 5% 
A / 95% B; 25 min: 95% A / 5% B; 30 min: 95% A / 5% B). Mass spectra were recorded on an 
Agilent Technologies 6520 Accurate-Mass Q-TOF LC-MS mass spectrometer using the positive 
ion electrospray technique (ESI+ MS). Thin layer chromatography (TLC) was performed using 
MERCK 60 F254 silica gel TLC plates as the stationary phase and ethyl acetate as the mobile 
phase.  
 
6.3.1.2 Synthesis of BTSC ligands 
 











































































































































Symmetric BTSC ligands (1, 2, 10 and 11) were synthesised using a common protocol, 
exemplified by the method for the preparation of glyoxalbis(N4-methyl-3-thiosemicarbazone) (1) 
described in the third chapter of this dissertation (see section 3.3.1) (142, 406). 1: IR max/cm-1: 
3317, 3148, 3000, 2328, 1512, 1248, 1083, 914; 1H NMR (400 MHz, DMSO-d6) /ppm 2.965 
(6H, d, 2 x NHCH3, 3JH-H = 4 Hz), 7.728 (2H, s, 2 x H(C=)NNHC(=S)), 8.505 (2H, q, 2 x 
C(=S)NHCH3 3JH-H = 4 Hz), 11.770 (2H, s, 2 x H(C=)NNHC(=S)); HPLC: Rt = 6.15 min. ESI+ MS: 
m/z for [C6H12N6S2 + H]+ = 233.0638 (calc.), 233.0671 (found). 2: IR νmax/cm-1: 3370, 3133, 






















































































































































































































































CH2CH3, 3JH-H = 4 Hz), 3.540 (4H, m, 2 x NHCH2CH3, 3JH-H = 4 Hz),  7.730 (2H, s, 2 x 
H(C=)NNHC(=S)), 8.545 (2H, t, 2 x C(=S)NHCH2CH3 3JH-H = 4 Hz), 11.720 (2H, s, 2 x 
H(C=)NNHC(=S)); HPLC: Rt = 7.59 min. 10: IR νmax/cm-1: 3359, 3243, 2953,1543, 1489, 1224, 
1130, 1074, 817, 554. 1H NMR (400MHz, DMSO-d6) /ppm: 2.21 (6H, s, 2 x CH3(C=)NNH), 3.03 
(6H, d, 2 x CH3NH, 3JH-H = 4 Hz), 8.37 (2H, m, 2 x CH3NH, 3JH-H = 4 Hz), 10.21 (2H, s, 
H(C=)NNHC(=S)). HPLC: Rt = 8.46 min; ESI+ MS: m/z for [C8H16N6S2 + H+ ]+= 261.0951 (calc.), 
261.0900 (found). 11: 1H NMR (400MHz, DMSO-d6) /ppm: 1.14 (6H, t, 2 x CH2CH3, 3JH-H = 4 
Hz), 2.21 (6H, s, 2 x CH3(C=)NNH)), 3.59 (4H, m, 2 x CH3CH2NH, 3JH-H = 4 Hz), 8.42 (2H, t, 2 x 
C(=S)NHCH2CH3, 3JH-H = 4 Hz), 10.15 (2H, s, 2 x H(C=)NNHC(=S)); ESI+ MS: m/z for 
[C10H20N6S2 + H+ ]+ = 289.1264 (calc.), 289.1248 (found).  
 
Asymmetric BTSC ligands 12 and 13 were prepared using a previously reported procedure, 
illustrated by the following method for the synthesis of diacetyl-2-(4-N-methyl-3-
thiosemicarbazone)-3-(3-N-amino-3-thiosemicarbazone) (12, Figure 6.1) (484). 2,3-butanedione 
(5.26 mL, 60 mmols) was dissolved in 100 mL of cold distilled water (0 °C) in a conical flask. 
Five drops of concentrated HCl (97 %) were added to the reaction mixture, followed by 4-
methyl-3-thiosemicarbazide (3.45 g, 32.8 mmol). After stirring for 1 hour, the resulting 
suspension was filtered and the residue rinsed with water (3 x 100 mL), ethanol (3 x 50 mL) and 
diethyl ether (3 x 10 mL) and recrystallised from warm ethanol to afford pure mono-substituted-
3-thiosemicarbazone intermediate (2.4 g, 43 %). Subsequently, this intermediate (0.80 g, 4.62 
mmols) was added over 2 h in portions to a solution of thiosemicarbazide in methanol (0.44 g, 
4.82 mmol) previously acidified with concentrated HCl. The reaction mixture was heated under 
reflux (~65 °C) for 5 h, during which a whitish suspension formed. After cooling down to room 
temperature, the solution was filtered under vacuum and the precipitate washed with ethanol (3 
x 50 mL) and diethyl ether (3 x 10 mL). The resulting solid was then recrystallised from warm 
DMSO/water (50:50) to yield pure 12 (0.90 g, 79 %). 12: IR max/cm-1: 3416, 3223, 3154, 1554, 
1490, 1239, 1082, 826, 566; 1H NMR (400 MHz, DMSO-d6) /ppm: 2.17 (3H, s, 
CH3(C=)NNH(C=S)(NH2)), 2.21 (3H, s, CH3(C=)NNH(C=S)NHCH3)), 3.03 (3H, d, CH3NHC(=S), 
3JH-H = 4 Hz), 7.85 (2H, s, NH(C=S)NH2), 8.39 (1H, m, C(=S)NHCH3, 3JH-H = 4 Hz), 10.18 (1H, s, 
((C=)NNH(C=S)NH2), 10.23 (1H, s, ((C=)NNH(C=S)NHCH3); HPLC: Rt = 6.48 min. 13: IR 
max/cm-1: 3361, 3242, 1487, 1243, 1131, 1072, 551; 1H NMR (400MHz, DMSO-d6) /ppm: 2.15 
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(3H, s, CH3(C=)NNH(C=S)N(CH3)2), 2.20 (3H, s, CH3(C=)NNH(C=S)NHCH3), 2.21 (6H, s, 
CH3(C=)NNH(C=S)N(CH3)2), 3.03 (3H, d, CH3(C=)NNH(C=S)NHCH3, 3JH-H = 4 Hz), 8.39 (1H, m, 
CH3(C=)NNH(C=S)NHCH3, 3JH-H = 4 Hz), 9.53 (1H, s, CH3(C=)NNH(C=S)N(CH3)2), 10.24 (1H, 
s, CH3(C=)NNH(C=S)NHCH3). HPLC: Rt = 8.06 min.   
 
Figure 6.1: Synthesis of diacetyl-2-(4-N-methyl-3-thiosemicarbazone)-3-(3-N-amino-3-thiosemicarbazone) 
(12, E) from diacetyl-2-(4-N-methyl-3-thiosemicarbazone) (C) and thiosemicarbazide (D). C was prepared 
by reaction of an excess of 2,3-butanedione (A) and 4-methyl-3-thiosemicarbazide (B) (484). 
 
BTSC ligands 3, 4, 5, 6, 7, 8, 9, 14, 15, 16, 17, 18, 19 and 20 were synthesised by Dr Oliver C. 
Brown (School of Physical Sciences, University of Kent) and sent to King’s College London for 
characterisation of the physicochemical properties of their corresponding copper (II) complexes. 
15 was prepared following the synthetic approach for symmetric BTSC ligands by Gingras et al. 
previously described (406). Asymmetrical ligands 14, 16, 17, 18, 19 and 20 were prepared via 
the previously reported non-protected diketone strategy used for the synthesis of 12 (484). On 
the other hand, asymmetric ligands 3, 4, 5, 6, 7, 8 and 9 were synthesised using a protocol by 
Lim and co-workers based on the use of an acetal as a protecting group in order to ensure that 
only one carbonyl group of the diketone reactant condenses with the first thiosemicarbazide 
(Figure 6.2) (482). After this first step, the acetal group is cleaved with a mild Lewis acid (e.g. 
lithium tetrafluoroborate) and the deprotected intermediate reacts with a dissimilar 
thiosemicarbazide to afford the desired asymmetric BTSC ligand. Characterisation data for all 





Figure 6.2: Synthesis of pyruvaldehyde-2-(4-N-methyl-3-thiosemicarbazone)-3-(3-N-dimethyl-3-
thiosemicarbazone) (3, F) following a previously reported protocol by Lim et al.(482). Pyruvic aldehyde 
dimethyl acetal (A) first reacts with 4-methyl-3-thiosemicarbazide (B) to yield pyruvaldehyde dimethyl 
acetal 2-(4-N-methyl-3-thiosemicarbazone) (C). Subsequently, C is deprotected with lithium 
tetrafluoroborate (LiBF4) to give pyruvaldehyde 2-(4-N-methyl-3-thiosemicarbazone) (D), which is finally 
condensed with 4,4-dimethyl-3-thiosemicarbazide (E) to afford F. 
 
6.3.1.3 Synthesis of Cu-BTSC complexes 
 




























































































All copper (II) complexes were synthesised using a common procedure, exemplified by the 









































































































































































































































































































3.3.1) (142). Cu(1): HPLC: Rt = 5.57 min; ESI+ MS: m/z for [CuC6H10N6S2 + H]+= 293.9777 
(calc.), 293.9805 (found); TLC: Rf = 0.36. Cu(2): HPLC: Rt = 8.14 min; ESI+ MS: m/z for 
[CuC8H14N6S2 + H]+ = 322.0090 (calc.), 322.0093 (found); TLC: Rf = 0.58. Cu(3): ESI+ MS: m/z 
for [CuC8H14N6S2 + H]+ = 322.0090 (calc.), 322.0093 (found); TLC: Rf = 0.38. Cu(4): HPLC: Rt = 
7.51 min; ESI+ MS: m/z for [CuC8H14N6S2 + H]+ = 322.0090 (calc.), 322.0098 (found); Cu(5): 
HPLC: Rt = 12.11 min; ESI+ MS: m/z for [CuC13H16N6S2 + H]+ = 384.0247 (calc.), 384.0247 
(found); TLC: Rf = 0.52. Cu(6): HPLC: Rt = 13.51 min; ESI+ MS: m/z for [CuC12H14N6S2 + H]+ = 
370.0090 (calc.), 370.0093 (found); TLC: Rf = 0.54. Cu(7): HPLC: Rt = 10.37 min; ESI+ MS: m/z 
for [CuC12H14N6S2 + H]+ = 370.0090 (calc.), 370.0095 (found); TLC: Rf = 0.41. Cu(8): ESI+ MS: 
m/z for [CuC9H16N6S2 + H]+ = 336.0247 (calc.), 336.0255 (found); TLC: Rf = 0.34. Cu(9): ESI+ 
MS: m/z for [CuC13H16N6S2 + H]+ = 384.0247 (calc.), 384.0247 (found); TLC: Rf = 0.59. Cu(10): 
HPLC: Rt = 7.36 min; ESI+ MS: m/z for [CuC8H14N6S2 + H]+ = 322.0090 (calc.), 322.0101 
(found); TLC: Rf = 0.52. Cu(11): ESI+ MS: m/z for [CuC10H18N6S2 + H]+ = 350.0403 (calc.), 
350.0957 (found); TLC: Rf = 0.55. Cu(12): HPLC: Rt = 6.03 min; ESI+ MS: m/z for [CuC7H12N6S2 
+ H]+ = 307.9934 (calc.), 307.9935 (found); TLC: Rf = 0.39. Cu(13): HPLC: Rt = 9.54 min; ESI+ 
MS: m/z for [CuC9H16N6S2 + H]+ = 336.0247 (calc.), 336.0249; TLC: Rf = 0.42. Cu(14): HPLC: Rt 
= 8.12 min; ESI+ MS: m/z for [CuC8H14N6S2 + H]+ = 322.0090 (calc.), 322.0085 (found). Cu(15): 
HPLC: Rt = 5.27 min; ESI+ MS: m/z for [CuC7H12N6S2 + H]+ = 307.9934 (calc.), 307.9934 
(found); TLC: Rf = 0.40. Cu(16): HPLC: Rt = 7.05 min; ESI+ MS: m/z for [CuC8H14N6S2 + H]+ = 
322.0090 (calc.), 322.0080 (found); TLC: Rf = 0.53. Cu(17): HPLC: Rt = 7.52 min; ESI+ MS: m/z 
for [CuC9H16N6S2 + H]+ = 336.0247 (calc.), 336.0248 (found); TLC: Rf = 0.54. Cu(18): HPLC: Rt 
= 8.07 min; ESI+ MS: m/z for [CuC9H16N6S2 + H]+ = 336.0247 (calc.), 336.0287 (found); TLC: Rf 
= 0.47. Cu(19): HPLC: Rt = 6.49 min; ESI+ MS: m/z for [CuC8H14N6S2 + H]+ = 322.0090 (calc.), 
322.0093 (found); TLC: Rf = 0.53. Cu(20): HPLC: Rt = 9.02 min; ESI+ MS: m/z for [CuC9H16N6S2 
+ H]+ = 336.0247 (calc.), 336.0247 (found); TLC: Rf = 0.57. 
 
6.3.2 Electrochemistry 
All cyclic voltammograms were recorded using a μAUTOLAB potentiostat (Metrohm Autolab B. 
V., Netherlands) and General Purpose Electrochemical System (GPES) acquisition and 
analysis software. Cyclic voltammetry measurements were performed at a scan rate of 0.1 V/s 
under an inert atmosphere of argon using a glassy carbon working electrode, a silver wire 
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pseudo-reference electrode and a platinum auxiliary electrode. All experiments were carried out 
in anhydrous deoxygenated DMSO (5 mL) using tetrabutylammonium hexafluorophosphate (0.1 
M, Sigma Aldrich) as a support electrolyte and a Cu-BTSC concentration of 0.5 mM. Ferrocene 
(Sigma Aldrich) was used as an internal reference and all potentials were referenced to the 
ferrocene/ferrocenium couple. The Cu(II)/Cu(I) and Cu(II)/Cu(III) potentials were calculated as 
the midpoint between the reduction and oxidation peaks. All electrochemical experiments were 
performed under the supervision of Dr Katherine Holt (Department of Chemistry, University 
College London). 
 
6.3.3 HPLC determination of lipophilicity 
Log P values of new Cu-BTSC complexes were estimated by reversed-phase HPLC using an 
Eclipse XDB-C18 column (4.6 x 150 mm, 5 μm) as the stationary phase and an isocratic mobile 
phase consisting of water + 0.1 % (v/v) TFA (60 %) and acetonitrile + 0.1 % (v/v) TFA (40 %). A 
number of Cu-BTSC complexes of known logP values (Cu(10), Cu(11), Cu(21), Cu(22) and 
Cu(23), determined by octanol-water extraction) were chromatographed by HPLC and the 
logarithms of their retention factors (logKs) plotted against their literature logP values to 
construct a calibration curve (Table 6.3) (143). LogK values were calculated using the equation 
logK = log(tr-to/to), where tr is the retention time of the complex and to is the retention time of the 
solvent front (DMSO) (486). The calibration equation was then used to calculate the logP values 
of the new Cu-BTSC complexes using their experimental retention factors. Complexes Cu(21), 
Cu(22) and Cu(23) were synthesised and characterised by Dr Maxwell G. Handley (Department 




















All symmetric BTSC ligands (1, 2, 10, 11 and 15) were prepared following a previously reported 
procedure by Gingras et al. and obtained in high yield and purity (>95 %) (406). Conversely, the 
synthesis of asymmetric BTSC ligands via protected (3, 4, 5, 6, 7, 8 and 9) and unprotected (12, 
14, 16, 17, 18, 19 and 20) diketone methods proved to be more challenging, often resulting in 
low reaction yields and mixtures of isomers and undesired by-products. Moreover, asymmetrical 
BTSCs were difficult to isolate and purify due to their low solubility in common solvents, which 
limited the amount of pure ligand that could be used for characterisation (485). 
 
All Cu-BTSC complexes were easily synthesised and purified  following a previously reported 

















































































































consistent with the proposed formulations and HPLC analysis revealed no significant impurities 
(<5 %) in the final product. 
 
6.4.2 Electrochemistry 
Table 6.4 shows the electrochemical reduction and oxidation potentials of complexes Cu(1)-
Cu(20) as measured by cyclic voltammetry. Cyclic voltammograms were acquired in a three-
electrode configuration using a glassy carbon electrode as the working electrode, a platinum 
wire as the auxiliary electrode and a silver wire as the reference electrode. To be able to 
compare electrochemical potentials for different Cu-BTSC complexes, ferrocene was used as 
an internal standard. 
 
Table 6.4: Half-wave potentials (E1/2) and peak separations (ΔEp) of Cu(1)-Cu(20) complexes in 
anhydrous DMSO at 298 K normalised with respect to ferrocene. All measurements were performed at 0.1 










































































































































a Half-wave potentials were calculated by averaging the anodic and cathodic peak potentials: E1/2 = (Epa + 
Epc)/2. b Peak separations are given by ΔEp = |Epa - Epc|. 
 
All Cu-BTSC complexes underwent reversible or nearly reversible one-electron Cu(II/I) 
reductions, as exemplified by the voltammogram of complex Cu(17) (Figure 6.3). The 
magnitudes of the anodic and cathodic current peaks were found to be approximately equal, 
demonstrating chemical reversibility for the Cu(II/I) couple. The behaviour of the Cu(III/II) redox 
couple was only found to be reversible for Cu-BTSC complexes with two alkyl groups at the 
diimine backbone (except for Cu(14) and Cu(16)), while CuBTSCs with less than two alkyl 
substituents showed reduced peak current for the return potential scan (Cu(1), Cu(2), Cu(3), 
Cu(4) and Cu(8)), or were not oxidisable within the potential range studied (Cu(5), Cu(6), Cu(7) 
























































































































Figure 6.3: Cyclic voltammogram of Cu(17) in anhydrous DMSO at 0.1 V/s scan rate. A silver wire served 
as pseudo-reference electrode and ferrocene was used as an internal standard. i/A = current in amperes 
E/V (Fc+/Fc) = applied potential in volts versus ferrocene/ferrocenium couple.  
 
Anodic to cathodic peak separations ranged from 51 to 93 mV for the Cu(II/I) redox processes 
and from 66 to 131 mV for the Cu(III/II) couple (except Cu(1), 170 mV), similar to the peak 
separation range for the reversible one-electron oxidation of the ferrocene/ferrocinium couple 
under the same experimental conditions (79-145 mV). Cyclic voltammograms of all Cu-BTSC 
complexes are included in the appendix of this chapter. 
 
As expected, a correlation was found between the alkylation pattern of the ligand backbone and 
the Cu(II/I) redox potential, although less pronounced than previously reported (142) (Figure 
6.4). Alkylation of the diimine backbone of the ligand appeared to lower the half-wave potential 
of the Cu(II/I) couple. Half-wave potentials for Cu-BTSC complexes with zero (Cu(1) and Cu(2)) 
and one alkyl substituent (Cu(3)-Cu(9)) on the backbone were found to be relatively similar, 
ranging from -0.96 to -1.06 and from -0.93 to -1.08 V respectively. Complexes with two methyl 
groups at Q1 and Q2 (Cu(10)-Cu(14)) had E1/2 Cu(II/I) potentials in the range of -1.05 to -1.13 V, 
while CuBTSCs with ethyl and methyl substituents on the ligand backbone (Cu(15)-Cu(20)) had 





















Figure 6.4: Effect of ligand backbone alkylation on E1/2 Cu(II/I) potential of Cu-BTSC complexes. Half-
wave potential values for Cu-BTSCs were found to decrease with increasing number of backbone alkyl 
groups. 
 
6.4.3 HPLC determination of lipophilicity 
Due to the lack of availability of 64Cu at the time of these experiments, reversed-phase HPLC 
was used to estimate the lipophilicity of the newly synthesised Cu-BTSC complexes as an 
alternative to octanol-water partitioning. Lipophilicity assessment by reversed-phase HPLC 
assumes a linear relationship between the logarithm of the retention factor of the compound 
(logK) and its logP. Thus, a number of reference Cu-BTSC complexes (Cu(10), Cu(11), Cu(21), 
Cu(22) and Cu(23)) were chromatographed and their experimental logK values correlated 
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Figure 6.5: Correlation between the literature logP values of Cu(10), Cu(11), Cu(21), Cu(22) and Cu(23) 
and their experimental logKs measured by HPLC. A C18 column was used as the stationary phase and a 
water + 0.1 % (v/v) TFA (60 %) / acetonitrile + 0.1 % (v/v) TFA (40 %) isocratic system as the mobile 
phase.  
 
The calibration equation was then applied to calculate the logPs of the new Cu-BTSC 
complexes using their experimental logK values. The logP values obtained for complexes 
Cu(1)-Cu(20) are summarised in Table 6.5. 
 
Table 6.5: LogP values for complexes Cu(1)-Cu(20) estimated by reversed-phase HPLC. 
 
























































































































As expected, higher logP values correlated with greater molecular weight, with complexes 
having phenyl groups in their structure being the most lipophilic. Alkylation of both the diimine 
backbone and pendant amino arms contributed to enhancing the lipophilicity of Cu-BTSCs.  
 
Figure 6.6 shows the total E1/2 Cu(II/I) potential and lipophilicity range covered by the new 
library of Cu-BTSC complexes. This plot demonstrates that Cu(3), Cu(5) and Cu(6), although 
more lipophilic, have an electrochemical behaviour similar to that of Cu(1) (Cu-GTSM). On the 










































































































































































lipophilicity characteristics as hypoxia-selective Cu(10) (Cu-ATSM) and Cu(11) (Cu-ATSE). 
Cu(12) is considerably less lipohilic than the previous complexes but its E1/2 Cu(II/I) potential lies 
within the same range, similarly to Cu(15). Complexes Cu(2), Cu(4), Cu(7)-(9) and Cu(13) have 
redox potentials intermediate between those of the two previous groups of complexes and 
variable lipophilicity.  
 
 
Figure 6.6: Scatter plot showing the relationship between E1/2 Cu(II/I) potential and logP values of Cu-
BTSCs Cu(1)-Cu(20). Purple: no backbone alkyl groups; red: one backbone alkyl group; green: two 




The sensitivity of the biodistribution properties of Cu-BTSC radiopharmaceuticals to the 
structural modification of their ligand scaffold has favoured their adaptability to a diverse range 
of imaging applications. It has been shown that Cu-BTSC complexes with two alkyl substituents 
at the diimine backbone are bioreduced and irreversibly trapped only under reductive cellular 
environments, which facilitates their use as hypoxia imaging agents. Conversely, Cu-BTSCs 
with less than two alkyl groups on their backbone tend to be taken up by all cells and thus hold 
potential for imaging blood flow or copper trafficking processes. For many years, symmetrical 
complexes Cu-ATSM and Cu-PTSM, which differ from one another only by one backbone alkyl 































perfusion, respectively (147, 158, 170, 488). However, despite much promise, these tracers 
remain prototypes since some of their imaging characteristics (e.g. in vivo stability, plasma 
protein binding, hypoxia sensitivity, liver and kidney uptake) are far from optimal (143, 175, 480, 
489). Hence, there is great interest in developing alternative Cu-BTSC radiotracers with 
improved imaging characteristics for clinical use. Despite the ease of synthesis of symmetrical 
BTSCs, asymmetrical ligands offer greater structural diversity, which allows the fine-tuning of 
the physicochemical properties of the final Cu-BTSC complexes, facilitating the optimisation of 
their biodistribution and pharmacokinetics for specific imaging applications. In collaboration with 
the University of Kent (Dr Oliver C. Brown and Prof Michael Went), we have synthesised an 
extended library of asymmetric Cu-BTSCs with a variety of ligand alkylation patterns, and 
determined their redox potential and lipohilicity values. Although the measurement of these two 
parameters is not sufficient for predicting the biological behaviour of these complexes, it is an 
important step in their characterisation and a useful indicator of their imaging potential.  
 
A strong correlation has been repeatedly reported between the Cu(II/I) redox potential of Cu-
BTSCs and their hypoxia selectivity. Symmetrical Cu-BTSC complexes with two backbone alkyl 
substituents and reduction potentials lower than -0.5 V have been found to be selectively 
retained in cultured cells under hypoxic conditions, whereas that Cu-BTSCs with less than two 
alkyl groups on their backbone and higher redox potentials have been shown to be irreversibly 
trapped within cells under both normoxia and hypoxia (142, 166). These observations support 
the idea that hypoxia selectivity in Cu-BTSCs is a function of redox potential, which in turn has 
been shown to be strikingly dependent on the backbone alkylation pattern of these complexes. 
However, it should be noted that redox potential is probably not the only factor controlling 
hypoxia-selective targeting, as evidenced by the variations in the degree of hypoxia selectivity 
observed in Cu-BTSCs exhibiting similar redox behaviour (483).  
 
In this study, the electrochemical behaviour of Cu-BTSCs was investigated by cyclic 
voltammetry using a three-electrode system (glassy carbon, silver and platinum electrodes), 
tetrabutylammonium hexafluorophosphate as a support electrolyte and ferrocene as an internal 
standard. Due to the low solubility of Cu-BTSCs in water, all electrochemical measurements 
were carried out in DMSO, despite the fact that this solvent has the ability to coordinate to 
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copper (II) centres. As previously reported for symmetrical Cu-BTSC complexes, the addition of 
alkyl groups to the diimine backbone of the complexes generally resulted in the lowering of their 
Cu(II/I) reduction potential (142). Asymmetrical Cu-BTSCs with two alkyl substituents on the 
diimine backbone (Cu(10)-Cu(20)) were found to exhibit lower redox potentials than complexes 
with zero or one backbone alkyl groups (Cu(1)-Cu(9)). Blower and co-workers suggested that 
this structural effect on the redox behaviour of Cu-BTSCs might arise from the lengthening of 
the backbone C-C bond on alkylation, which might allow the copper ion to fit better into the 
ligand cavity, thus enhancing the stability of the complex and decreasing the susceptibility to 
reduction of Cu (II) to Cu (I) (145). It has been suggested that increased C-C bond length upon 
alkylation might result from either steric repulsion between the backbone alkyl groups or 
overlapping between the lowest energy unoccupied molecular orbital and the alkyl C-H bonds 
(144, 145).  
 
Compared to previously reported literature values, the Cu(II/I) reduction potentials of standard 
symmetrical Cu-BTSCs were found to be considerably lower in this study (Cu(1): -0.43 vs -0.96 
V;  Cu(10): -0.59 vs -1.12 V; Cu(15): -0.59 vs -1.16 V) (142). This could be due to the use of a 
pseudo-reference electrode (silver wire) instead of a true reference electrode (e.g Ag/AgCl).  
Pseudo-reference electrodes are often used in non-aqueous electrochemistry in place of true 
reference systems to avoid the formation of liquid junction potentials between aqueous and 
nonaqueous medium and prevent leakage of reference electrolyte from the electrode into the 
cell, which could affect the electrochemical processes occurring in the analyte solution. The 
main disadvantage of pseudo-reference systems is the lack of thermodynamic equilibrium 
between the electrode and the electrolyte because of the absence of common ionic species in 
the two adjacent phases. Nevertheless, this type of electrode can be calibrated by adding a 
reference redox system (e.g. ferrocene) into the electrolyte after the experiment and measuring 
its potential (490). Despite variation among studies in reduction potential values, the shift in 
redox potential per alkyl group was found to be roughly the same. 
 
Although the number of alkyl groups on the ligand backbone (Q1, Q2) is thought to be the main 
structural determinant of the redox behaviour of Cu-BTSCs, the spread of redox potential values 
observed within each backbone group seems to suggest that the alkylation pattern of the 
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pendant amino arms also influences the reduction potential of asymmetrical Cu-BTSC 
complexes (142). Despite having a less significant impact than backbone alkylation, the number 
of alkyl substituents at the terminal amino positions of the ligand may affect the susceptibility of 
Cu-BTSCs to bioreduction as well as the stability of the resulting Cu (I) complexes by either 
steric or electronic effects. Asymmetrical Cu-BTSCs with zero and one alkyl groups on their 
diimine backbone were found to exhibit higher variability in Cu (II/I) reduction potential values 
(0.13 V spread) when compared to complexes with two alkyl substituents (0.05 V spread).  
 
All asymmetrical Cu-BTSC complexes showed reversible or nearly reversible one-electron 
Cu(II/I) reductions, in which the peak currents for the cathodic and anodic processes were found 
to be approximately equal. On the other hand, the electrochemical behaviour of the Cu(III/II) 
redox couple was only found to be reversible for Cu-BTSCs with two alkyl groups on their 
diimine backbone, with the exception of Cu(14) and Cu(16), which showed loss of peak current 
on the reverse scan. Complexes Cu(1), Cu(2), Cu(3), Cu(4) and Cu(8), with zero or one 
backbone alkyl substituents, exhibited reduced peak current for the return Cu(III/II) reduction 
process, suggesting partial dissociation upon oxidation. Interestingly, the cathodic current peak 
was not observed in the cyclic voltammograms of Cu-BTSCs with one backbone alkyl 
substituent and a phenyl group in their structure (Cu(5), Cu(6), Cu(7) and Cu(9)), which may 
indicate that these complexes undergo an irreversible decomposition reaction following 
oxidation.  
 
Based on the proposed structure-activity relationship for Cu-BTSCs, the hypoxia-targeting 
ability of backbone-alkylated complexes Cu(12), Cu(14) and Cu(16)-Cu(20) should be 
investigated, since the Cu(II/I) reduction potentials of these (-1.12, -1.13, -1.13, -1.14,  -1.11, -
1.13 and -1.10 V) fall within the same range as those of Cu(10) (Cu-ATSM, -1.12 V), Cu(11) (-
1.13 V) and Cu(15) (-1.16 V), which have previously shown hypoxia selectivity in vitro (142, 
143, 146). On the other hand, Cu(3), Cu(5) and Cu(6) (-1.01, -0.97 and -0.93 V), although 
considerably more lipophilic, showed similar Cu(II/I) reduction potential values as non-selective 
Cu(1) (Cu-GTSM, -0.96 V), and therefore might hold potential as imaging agents for the 
visualisation of copper trafficking processes at brain or whole-body level. Cu(2), Cu(4), Cu(7)-
Cu(9) and Cu(13) have moderate lipophilicities, which may promote rapid diffusion of the 
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complexes into tissues, and E1/2 Cu(II/I) potential values intermediate between those of the two 
previous groups of Cu-BTSCs (-1.06, -1.08, -1.04, -1.05, -1.06 and -1.05 V), which may 
facilitate non-selective copper release into cells. These complexes should be therefore 
evaluated for perfusion imaging applications. However, it should be noted that the trapping 
mechanism of Cu-BTSCs is complex and relies on other parameters besides redox potential, 
such as the pKa and Kd of Cu(I)-BTSC complexes (144, 491). Lipophilicity is thought to 
considerably influence the hypoxia selectivity of Cu-BTSCs in vivo. Handley et al. recently 
demonstrated that Cu(15) (Cu-CTS), a Cu-BTSC complex with similar redox behaviour and 
lower lipophilicity than hypoxia-selective Cu(10) (Cu-ATSM), delivered a better hypoxic-to-
normoxic contrast than the latter (17:1 vs. 8:1) in the Langendorff isolated perfused heart 
system. It is therefore important to also assess these properties to fully define the potential of 
these Cu-BTSC radiotracers as hypoxia, copper trafficking or blood flow imaging agents.   
 
Lipophilicity is a critical parameter for Cu-BTSC radiotracers since it has a strong influence on 
membrane permeability, plasma protein binding and kinetic behaviour. Lipophilicity is often 
expressed as a the logarithm of the partition coefficient (logP) of a compound between two 
immiscible phases at equilibrium, an octanol layer and an aqueous buffer. This lipophilicity 
index can be measured by several methods, including the “shake-flask” test, potentiometric 
titration and reversed-phase chromatography (486). Although the “shake-flask” method remains 
the reference procedure for assessing the lipophilicity of radiopharmaceuticals, it is time-
consuming, sensitive to impurities and requires the use of radioactivity. Due to the limited 
availability of 64Cu, we determined the logP values of the new asymmetrical Cu-BTSC 
complexes by reversed-phase HPLC using the linear regression equation between the logK 
values of reference Cu-BTSC complexes and their experimental logPs, measured by the 
“shake-flask” method. Reversed-phase HPLC is an easy, rapid and reproducible method to 
quantify the logP values of a library of compounds. Since HPLC-based lipophilicity measures do 
not rely on the partitioning of the analyte between two phases, they are not affected by the 
presence of impurities and do not require the use of radioactive material.  
 
In this study, we measured the retention factors of new asymmetrical Cu-BTSC complexes by 
reversed-phase HPLC using a C18 column as the stationary phase and an isocratic 
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water/acetonitrile gradient as the mobile phase. Although this method is rapid and reproducible, 
it also has some disadvantages. For example, HPLC silica-based stationary phases do not 
mimic biological membranes and are therefore not able to provide information about the 
membrane permeability and plasma protein binding of a compound. For this reason, the use of 
biomimetic stationary phases (e.g. immobilised artificial membrane system, human serum 
albumin column) should be considered in future work (492, 493). Another drawback is that only 
a single mobile phase composition (60 % water/ 40 % acetonitrile) was used in this study, which 
does not allow the extrapolation of the logK values to elution with 100 % water (486, 494). 
However, despite these limitations, this method is a useful tool to estimate the lipophilicity of a 
library of radiotracers without radioactivity.  
 
As previously reported for symmetrical Cu-BTSCs, a correlation was found between the 
molecular weight of asymmetrical Cu-BTSC complexes and their logP values (142). Increased 
alkylation of both the diimine backbone and pendant amino arms resulted in enhanced 
lipophilicity of the complexes. Regarding tracer biokinetics, it is expected that Cu-BTSCs with 
high logPs (e.g. Cu(5), Cu(9), Cu(13)) will show slower tissue clearance and higher non-specific 
binding than less lipophilic complexes (e.g. Cu(2), Cu(12)), as exemplified by the differences in 
kinetic profiling found between Cu(10) (Cu-ATSM) and Cu(15) (Cu-CTS) (143). However, 
further research is needed to characterise the pharmacokinetic profile of these new complexes 
in vivo and additional parameters (e.g. pKa, Kd) need to be determined to elucidate their utility 




In an attempt to develop new Cu-BTSC radiotracers with improved imaging characteristics for a 
range of diagnostic applications, we synthesised fourteen asymmetrical Cu-BTSC complexes 
with a variety of alkylation patterns. The electrochemical behaviour and lipophilicity of these 
complexes were investigated by cyclic voltammetry and reversed-phase HPLC, respectively. 
Our results showed a correlation between the Cu(II/I) half-wave potential of Cu-BTSCs and the 
number of alkyl groups on their ligand backbone (Q1, Q2), which supports the notion that the 
redox behaviour of these complexes can be tuned by ligand scaffold modification. Our 
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electrochemical measurements revealed that a number of Cu-BTSCs (Cu(12), Cu(14), Cu(16)-
Cu(20)) had Cu(II/I) reduction potentials within the range that could potentially confer hypoxia 
selectivity. The hypoxia-targeting ability of these complexes should be therefore examined in 
vitro and in vivo in future experiments. On the other hand, Cu(3), Cu(5) and Cu(6) showed a 
similar redox behavior to that of non-selective Cu-GTSM and may hold promise as imaging 
agents for the visualisation of copper trafficking processes at brain or whole-body level. 
Although many other parameters (e.g. pKa, Kd, plasma protein binding) need to be determined to 
fully delineate the biological behaviour and pharmacokinetics of these complexes, the 
measurement of their redox potential and lipophilicity is an essential step in their 























The primary aim of this thesis was to evaluate the utility of 64Cu-PET as a tool to detect changes 
in copper trafficking associated with the pathophysiology of copper–related neurological 
disorders. In the last decade, a large number of studies have reported the existence of  
alterations in the levels of copper and other trace metals in a wide spectrum of 
neurodegenerative diseases (e.g. AD, PD, ALS, HD, NPC1). Although aberrant copper 
homeostasis has been shown to enhance the severity of neurodegeneration by contributing to 
common pathological processes such as protein aggregation or ROS production, copper 
metabolism abnormalities remain relatively poorly characterised in these disorders. The work 
presented in this thesis contributes towards this area of research by providing quantitative and 
longitudinal measurements of short-term copper trafficking in animal models of AD and NPC1 
disease. Preclinical assessment of copper trafficking by PET allowed the identification of 
alterations in radiocopper distribution and biokinetics that may have added value for the 
diagnosis, prognosis and treatment of these conditions. 
 
In this study, copper trafficking processes were investigated using two different radioactive 
copper tracers, the Cu-BTSC complex 64Cu-GTSM and the uncomplexed 64Cu-acetate salt. 
While 64Cu-acetate was used to visualise the uptake of copper into tissues via active transport 
mechanisms, 64Cu-GTSM was chosen as a vehicle to deliver radiocopper into the CNS to 
enable the measurement of copper retention, efflux and redistribution within the brain and spinal 
cord. The Cu-GTSM complex has been repeatedly shown to release its copper payload non-
selectively into cells through a putative bioreductive mechanism (142, 150, 365, 366, 495). 
However, the ability of this complex to cross the BBB by passive diffusion and deliver 
radiocopper into the brain in imageable quantities had only been previously demonstrated by 
Fodero-Tavoletti et al., who used 64Cu-GTSM to assess brain 64Cu uptake in the APP/PS1 
mouse model of AD at early time-points post-injection of the tracer (155). Our PET quantification 
results revealed that 64Cu-GTSM uptake into the brain was remarkably high (~5 %ID/mL in 
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wildtype mice) and rapid, reaching a plateau 10 min after injection. The tracer was found to 
clear rapidly from blood (t1/2 ~ 5 min) and release most of its radiocopper cargo (>95 %) into 
brain cells within 30 min post-injection. These characteristics make 64Cu-GTSM an ideal 
radiotracer for detecting alterations in copper transport and distribution within the CNS as well 
as variations in early tracer uptake due to disease-related blood flow changes. 
 
64Cu-GTSM-PET was used to investigate copper trafficking processes within the CNS in the 
TASTPM mouse model of AD plaque pathology at early and moderate-to-severe stages of the 
disease (6-8 and 13-15 months of age, respectively). PET ROI analysis revealed significantly 
increased brain and spine 64Cu concentration in 6-8- (brain: 1.3-fold; spine: 1.4-fold) and 13-15-
month-old TASTPM transgenic mice (brain: 1.4-fold; spine: 1.4-fold) compared to wildtype 
controls at 30 min and 24 h post-injection of the tracer. These results are in accordance with 
those by Fodero-Tavoletti and co-workers, who also reported significantly higher brain 64Cu 
uptake in the APP/PS1 model of AD compared to the control group at 1 h post-injection of 64Cu-
GTSM. The molecular mechanism underlying increased brain 64Cu accumulation in these AD 
models remains to be elucidated but may be driven by disease-related alterations in cerebral 
vasculature or enhanced physiological demand for copper in response to brain copper 
dyshomeostasis.   
 
In addition to showing higher brain 64Cu accumulation, TASTPM transgenic mice were also 
found to exhibit faster 64Cu clearance from brain tissue than healthy controls from 30 min to 24 
h post-injection of the tracer. This difference in the washout rate of 64Cu may arise from APP 
overexpression in the TASTPM model since this protein is thought to act as an efflux transporter 
for copper ions in the brain (256, 353, 416). Interestingly, although AD mice showed faster 64Cu 
clearance from the brain than wildtype controls, the rate of radiocopper efflux from brain tissue 
over 24 h was found to be remarkably slower when compared to that of other organs in both 
animal groups. This finding had not been previously reported and may reflect a greater copper 
sequestration capacity of the brain driven by increased metabolic demands or the presence of 




TASTPM transgenic mice and their wildtype counterparts showed differences not only in global 
64Cu concentration and biokinetics in the CNS but also at regional brain level. Both PET imaging 
and ex vivo brain autoradiography revealed that the distribution of 64Cu within brain tissue was 
heterogeneous in TASTPM and control mice injected with 64Cu-GTSM at both early and late 
time-points post-injection of the tracer. In order to assess the heterogeneity of the PET brain 
signal in a functional context, we initially chose to measure the concentration of 64Cu in several 
brain regions using a 3D mouse brain atlas. This approach enabled quantitative mapping of 
brain regional 64Cu uptake in all PET scans, and demonstrated significantly greater radiocopper 
concentration in some brain regions of TASTPM transgenic mice at both early and moderate-to-
severe stages of the disease compared to age-matched controls. Whether these regional 
differences in 64Cu concentration result from globally higher brain 64Cu uptake in the TASTPM 
model or truly reflect functional metabolic changes associated with AD-like pathology remains 
unknown. Nevertheless, it is important to note that the accuracy of the quantification of small 
structures in PET images may be hampered by the limited spatial resolution of the PET imaging 
system, which can cause spill-in and spill-out of activity to and from neighbouring regions. 
 
 In order to minimise the quantitative bias introduced by the partial volume effect, we 
alternatively assessed the heterogeneity of the PET brain signal by texture analysis. This 
method does not rely on the use of a structural template and provides information on the spatial 
distribution of voxel intensities within a ROI, rather than mean parameter values. Although the 
pathophysiological interpretation of image texture remains unclear, the application of this type of 
analysis in our study allowed the detection of changes in the textural features of the 64Cu-
GTSM-PET images caused by alterations in brain radiocopper distribution potentially associated 
with AD-like pathology. Our results revealed a higher degree of image heterogeneity in the 
TASTPM scans compared to the images of the control group, although the differences in texture 
properties only reached significance between the 6-8-month-old groups. Taken together, our 
findings support the evaluation of PET image heterogeneity, global brain and spine 64Cu 
concentration and rate of clearance of radiocopper from brain tissue in early clinical studies. 
 
Another key finding from our 64Cu-GTSM work is the ambiguous relationship observed between 
brain regional 64Cu accumulation and Aβ plaque deposition in the TASTPM mouse model. The 
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ability of human Aβ plaque deposits to accumulate copper and other trace metals has served as 
a major pillar of the “metal hypothesis of AD”, which suggests that the interaction between Aβ 
plaque aggregates and metal ions leads to enhanced Aβ neurotoxicity and reduced intracellular 
metal bioavailability in the brain (339, 341, 360, 398). While radiocopper was found to 
accumulate in the entire brain (including plaque-rich areas), ex vivo autoradiography of 
TASTPM brain tissue showed that the main  64Cu hotspots (cerebellum, midbrain, olfactory bulb 
and caudate putamen) did not coincide with the regions containing the highest Aβ plaque load 
(cerebral cortex, thalamus and hippocampus) as depicted by Congo red staining. The 
quantification of XRF brain elemental copper maps from 8-month-old TASTPM transgenic mice 
also did not show a clear association between the regional distribution of endogenous copper in 
the brain and cerebral Aβ plaque deposition in this AD model. TASTPM transgenic mice 
exhibited significantly greater copper concentration than controls in the thalamus but not in 
other plaque-rich regions such as the cerebral cortex or hippocampus. These results may 
indicate a lower metal binding capacity of TASTPM Aβ plaques compared to human plaque 
deposits but may also highlight the contribution of other metabolic/pathological factors (besides 
Aβ plaque deposition) to copper dyshomeostasis in the AD brain. 
 
XRF mapping  of representative brain sections from TASTPM and control mice also showed 
that endogenous copper accumulated mostly around the CSF spaces in both animal groups. 
Similarly, PET imaging of active copper trafficking with 64Cu-acetate evidenced focal 
accumulation of radiocopper in the ventricular areas of the brain and comparatively low uptake 
in the brain parenchyma in both TASTPM transgenic mice and wildtype controls. This 
distribution pattern for endogenous copper and actively transported radiocopper had been 
previously reported by Wang et al. in C57BL6/J wildtype mice and underlines the importance of 
the BCSFB in brain copper metabolism (196). Unfortunately, the limited resolution of both XRF 
and PET imaging did not allow the assessment of the individual contribution of the CSF, choroid 
plexus and periventricular areas to the global ventricular signal. ROI-based analysis of 64Cu-
acetate-PET images interestingly showed greater mean ventricular SUVmean and SUVmax values 
for 6-8- and 13-15-month-old wildtype controls compared to age-matched TASTPM mice at 30 
min and 24 h post-injection of the tracer. SUV quantification also revealed a time-dependent 
increase in ventricular SUVmean and SUVmax values in both animal groups, which was 
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considerably more prominent in AD mice. These results, however, are difficult to interpret since 
the BCSFB is thought to act as a major regulatory site to maintain copper homeostasis in the 
brain and therefore the ventricular 64Cu signal likely reflects a combination of copper influx, 
efflux and storage processes (196, 219, 496). Furthermore, it should be noted that a high 
interindividual variability was observed in both TASTPM and control groups and thus a larger 
sample size is necessary to confirm the reported trends.  
 
64Cu-acetate-PET was also used to examine the short-term dynamics of active copper 
trafficking in TASTPM transgenic mice at early and moderate-to-severe stages of the disease 
(6-8 and 13-15-months of age, respectively) and age-matched controls at the whole-body level. 
Our PET quantification results revealed subtle but significant differences in 64Cu concentration 
and/or clearance between AD mice and healthy controls in various organs (liver, heart, kidneys 
and spine). These variations in active copper trafficking had not been previously identified in 
preclinical AD models or human patients and therefore deserve further investigation, if 
confirmed with a larger sample size.  
 
In this study, we also aimed to evaluate the utility of 64Cu-acetate-PET to assess the effect of 
chelation therapies on whole-body copper trafficking. Considering the evaluation of copper 
chelating agents as potential treatment options for neurological disorders (e.g. AD, HD, MD), 
64Cu-acetate-PET may prove to be a useful tool to characterise the mechanism of action of 
these drugs and even monitor response to therapy. In a preliminary experiment, we investigated 
the effect of BBB-permeable copper/zinc chelator CQ (50 mg/kg) on the biodistribution of 64Cu 
in wildtype mice. Wildtype mice pretreated with CQ were found to exhibit increased 64Cu 
concentration in the liver, heart, spine and brain when compared to mice receiving the sham 
treatment. This effect may arise from the formation of the lipophilic 64Cu-CQ complex in blood, 
which may diffuse across biological membranes at a much faster rate than radiocopper 
mobilised by active transport mechanisms. However, the limited availability of 64Cu did not allow 
the evaluation of the effect of different experimental conditions (CQ dose, administration route, 
radioactive copper tracer, treatment time, animal model) on 64Cu trafficking and therefore further 




The potential of 64Cu-GTSM-PET as a tool to detect alterations in brain copper trafficking 
associated with disease was not only evaluated in a transgenic mouse strain of AD but also in a 
mouse model of NPC1 disease, a rare lipid storage disorder predominantly caused by 
mutations in the gene encoding the NPC1 protein. Although endogenous copper levels have 
been previously measured in preclinical NPC1 models, this is the first report on real-time in vivo 
copper trafficking in NPC1 knockout mice at presymptomatic and symptomatic stages of the 
disorder (6 and 9 weeks of age, respectively) (321, 324). PET image analysis revealed 
significantly increased 64Cu concentration in the brain and spine of symptomatic NPC1 knockout 
mice compared to age-matched controls at both 30 min and 15 h post-injection of 64Cu-GTSM 
(brain: 1.4-fold; spine: 1.5-fold). This difference in brain 64Cu concentration may arise from a 
regulatory mechanism aiming to compensate for the low brain endogenous copper content 
previously reported for NPC1 knockout mice, the disruption of a specific function of the NPC1 
protein in brain copper trafficking or blood flow alterations associated with the disease (321). 
Interestingly, symptomatic NPC1 deficient mice were also found to exhibit significantly greater 
blood 64Cu concentration than their wildtype littermates at late time-points post-injection of the 
tracer. This finding is consistent with previous reports that demonstrated an elevation in plasma 
copper content in symptomatic NPC1-/- transgenic mice, as well as increased copper-bound 
holoceruloplasmin levels and ceruloplasmin oxidase activity (321, 324). Although a larger 
sample size is required to confirm these trends, the differences in copper trafficking reported in 
this thesis merit further investigation in order to determine their diagnostic value and relation to 
the progression and severity of NPC1 disease. 
 
In the last chapter of this thesis, we reported on the synthesis and characterisation of fourteen 
new asymmetrical Cu-BTSC complexes for potential use in molecular imaging applications, 
including the delineation of copper trafficking processes. Although symmetrical Cu-BTSC 
complexes, like Cu-GTSM, are easier to synthesise and able to display distinct biological 
behaviours for a variety of imaging applications, asymmetrical Cu-BTSCs offer greater structural 
diversity and therefore the possibility of further refining the imaging characteristics of these 
radiotracers (e.g. in vivo stability, plasma protein binding, hypoxia sensitivity) for potential 
clinical use. In collaboration with the University of Kent (Dr Oliver C. Brown and Prof Michael 
Went), we synthesised a library of asymmetric Cu-BTSC complexes with a variety of ligand 
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alkylation patterns, and determined their redox potential and lipophilicity. Our cyclic voltammetry 
results showed a correlation between the Cu(II/I) half-wave potential of Cu-BTSCs and the 
number of alkyl groups on their ligand backbone, in agreement with previous observations by 
Dearling et al (142). Nevertheless, the spread of redox potential values observed within each 
backbone group seems to indicate that the alkylation pattern of the pendant amino arms also 
affects the reduction potential of Cu-BTSCs, which supports the idea that asymmetrical BTSC 
ligands enable fine-tuning of the physicochemical properties of these complexes. The new Cu-
BTSC complexes exhibited a wide range of logP values as a result of the varying alkylation 
patterns of the diimine backbone and thiosemicarbazide arms of the ligand scaffold. Although 
the measurement of the redox potential and lipophilicity of these asymmetrical Cu-BTSC 
complexes is an essential first step in their characterisation, further work is needed to determine 
their biological behaviour and pharmacokinetics in vivo and thus their potential for specific 
imaging applications. 
 
7.2 FUTURE WORK 
 
While this thesis has demonstrated the potential of 64Cu-PET as a tool to identify copper 
trafficking abnormalities associated with neurological disorders, many opportunities for 
extending the scope of this research remain. First and foremost, we believe that a case for a 
clinical study to test the utility of this approach in human subjects has been made by the results 
presented. Our study revealed a series of copper trafficking alterations imageable by PET in 
mouse models of AD and NPC1 disease that may have added value in the diagnosis of these 
conditions. However, although the preclinical models of AD and NPC1 disease used in this 
study were able to mimic specific features of human pathology, the best “model” to investigate 
the diagnostic value of  measuring copper trafficking is human disease itself, since (i) no animal 
model closely reflects all aspects of the natural history and pathophysiology of human AD/ 
NPC1 disease, and (ii) species differences in copper metabolism exist between mice and 
humans. Hence, a clinical study should be planned to evaluate the potential of copper trafficking 
as a diagnostic marker of AD/NPC1 disease, and determine its relationship with disease 




In addition to this and directly following on from the work presented in this thesis, our 
suggestions for the future are as follows: 
 
 Continuation of the AD project 
The work presented in this thesis described the biodistribution and trafficking kinetics of 
intravenously administered radiocopper in a mouse model of AD-like Aβ plaque pathology at 
brain and whole-body level. Nevertheless, since endogenous copper enters the body ultimately 
via the diet, a similar study should also be performed in mice after oral administration of 64Cu. 
This will enable the assessment of in vivo copper trafficking via natural routes in AD-like 
pathology and the detection of potential abnormalities in intestinal copper absorption associated 
with the disease. It is expected that only a small amount of orally administered radiocopper will 
be taken up by the brain within the time-scale of the experiment, which may not be 
quantitatively imageable by PET. However, this experiment will provide necessary information to 
understand the pathways of distribution of copper via normal biological routes in this model of 
AD-like disease. 
 
Although the intravenous administration route facilitated rapid delivery of radioactive copper into 
tissues, it did not allow the evaluation of the dynamics of specific plasma copper-binding 
proteins in AD-like pathology. Since copper is expected to reach tissues predominantly via 
ceruloplasmin, in vivo imaging of 64Cu-ceruloplasmin by PET in the TASTPM model would allow 
the identification of potential alterations in this pathway that may affect the delivery of copper 
ions into organs. The long half-life of 64Cu offers the possibility of isolating 64Cu-ceruloplasmin 
from plasma or liver tissue of mice orally treated with radioactive copper, and injecting it 
intravenously into other mice  to monitor its trafficking and tissue uptake in vivo. 
 
Having identified quantitative global changes in radiocopper uptake, biokinetics and distribution, 
an important issue to address in the future is the fate of the administered radiocopper at the 
molecular level. Answering this question will provide crucial information to better characterise 
the copper trafficking abnormalities measured in this study and understand their link to AD-like 
pathology. Gel electrophoresis and size-exclusion chromatography of tissue samples (e.g. 
plasma, CSF, brain region homogenates) from mice injected with radioactive copper can be 
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performed to gain further information on the speciation of the radiocopper in TASTPM and 
control mouse groups. To achieve a better quantification of the abundance of copper-binding 
species in tissue samples from TASTPM and control mice, speciation analysis could 
alternatively be conducted by size-exclusion chromatography coupled to ICP-MS. This 
technique could be performed in biological samples from mice injected with isotopically enriched 
65Cu-GTSM, thus eliminating the need for 64Cu radioactivity.  
 
Despite the inability of current AD animal models to mimic human pathology, they remain useful 
tools for studying specific pathological features of the disease (e.g. Aβ plaque deposition, 
neurofibrillary tangle formation, neuroinflammation, neuronal loss). Since the nature of the 
copper/tau protein interactions is currently poorly understood, it would also be interesting to 
evaluate copper trafficking by PET in a model of AD-like tau pathology (e.g. PS19, THY-Tau22) 
in order to determine the effect of cerebral neurofibrillary tangle accumulation on the distribution 
and biokinetics of copper in the brain (497, 498). 
 
 Continuation of the NPC1 and CQ projects 
Although the data reported in this thesis demonstrated significant copper trafficking 
abnormalities in NPC1 knockout mice and provided some insight into the mode of action of 
copper/zinc chelator CQ,  a continuation of both of these preclinical projects is warranted. This 
is to supply currently missing data (e.g. ex vivo biodistribution and brain autoradiography in 6-
week-old NPC1-/- mice and controls) and increase the number of animals per group to confirm 
the trends observed in these studies.  
 
Additional experiments to provide the missing data for the 6-week-old NPC1-/- and wildtype 
groups are currently being performed by a postdoctoral researcher in the Imaging Chemistry 
and Biology department under the supervision of Prof. Philip Blower. Considering the two-fold 
difference in blood 64Cu concentration detected between 9-week-old NPC1 knockout mice and 
age-matched controls, emphasis should also be placed on investigating the speciation of 64Cu 
in blood by size-exclusion chromatography and SDS-PAGE, in order to identify metabolic 




Due to lack of availability of 64Cu, the sample size used in our preliminary CQ study was too 
small for statistical analysis. Therefore, in order to validate the reported trends, it is necessary to 
perform this experiment in a larger sample of mice. Furthermore, since only one set of 
experimental conditions was used, different doses, chelator administration routes, treatment 
times and even radioactive copper tracers should be tested in order to fully evaluate the impact 
of CQ treatment on copper biodistribution. 
 
 Continuation of the Cu-BTSC library project 
In this thesis, we reported the synthesis of a new library of asymmetrical Cu-BTSCs and the 
measurement of their redox potential and lipophilicity. This work was only the first step in the 
characterisation of these complexes as potential PET imaging agents. In order to assess the 
pharmacokinetics and normoxia or hypoxia selectivity of the new Cu-BTSC complexes, our 
library will be screened in the triple γ-detector system for isolated perfused hearts developed in 
the Imaging Chemistry and Biology department. This ex vivo model enables the measurement 
of real-time rates of tracer delivery, cardiac uptake and washout under normoxic and hypoxic 
conditions. After determining their pharmacokinetics and hypoxia selectivity, the most promising 
tracer candidates for specific imaging applications (e.g. hypoxia delineation, blood flow 
assessment, imaging of copper trafficking) will be evaluated in vivo. PET imaging, ex vivo 
biodistribution and in vivo stability studies will be performed in wildtype mice and appropiate 











8. Appendix- Asymmetrical Cu-BTSC complexes for PET: 
synthesis and characterisation 
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